CA2417195A1 - G-protein coupled receptors - Google Patents
G-protein coupled receptors Download PDFInfo
- Publication number
- CA2417195A1 CA2417195A1 CA002417195A CA2417195A CA2417195A1 CA 2417195 A1 CA2417195 A1 CA 2417195A1 CA 002417195 A CA002417195 A CA 002417195A CA 2417195 A CA2417195 A CA 2417195A CA 2417195 A1 CA2417195 A1 CA 2417195A1
- Authority
- CA
- Canada
- Prior art keywords
- polynucleotide
- polypeptide
- seq
- gcrec
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title abstract description 337
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title abstract description 335
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 319
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 319
- 239000002157 polynucleotide Substances 0.000 claims abstract description 319
- 230000014509 gene expression Effects 0.000 claims abstract description 133
- 239000005557 antagonist Substances 0.000 claims abstract description 23
- 239000000556 agonist Substances 0.000 claims abstract description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 252
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 237
- 229920001184 polypeptide Polymers 0.000 claims description 230
- 238000000034 method Methods 0.000 claims description 192
- 210000004027 cell Anatomy 0.000 claims description 155
- 239000012634 fragment Substances 0.000 claims description 134
- 150000001875 compounds Chemical class 0.000 claims description 117
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 108
- 239000000523 sample Substances 0.000 claims description 94
- 150000007523 nucleic acids Chemical class 0.000 claims description 77
- 238000009396 hybridization Methods 0.000 claims description 71
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 61
- 238000012360 testing method Methods 0.000 claims description 60
- 239000002773 nucleotide Substances 0.000 claims description 58
- 125000003729 nucleotide group Chemical group 0.000 claims description 58
- 230000000694 effects Effects 0.000 claims description 57
- 102000039446 nucleic acids Human genes 0.000 claims description 41
- 108020004707 nucleic acids Proteins 0.000 claims description 41
- 230000000295 complement effect Effects 0.000 claims description 37
- 230000027455 binding Effects 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 35
- 239000012472 biological sample Substances 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 28
- 238000012216 screening Methods 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 230000002163 immunogen Effects 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 18
- 231100000419 toxicity Toxicity 0.000 claims description 12
- 230000001988 toxicity Effects 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 230000009870 specific binding Effects 0.000 claims description 8
- 230000009261 transgenic effect Effects 0.000 claims description 8
- 238000012408 PCR amplification Methods 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 230000002018 overexpression Effects 0.000 claims description 2
- 230000005875 antibody response Effects 0.000 claims 2
- 210000000628 antibody-producing cell Anatomy 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 39
- 108020003175 receptors Proteins 0.000 abstract description 39
- 239000013604 expression vector Substances 0.000 abstract description 19
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 abstract description 2
- 102000052301 human GNAZ Human genes 0.000 abstract description 2
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 175
- 102000004169 proteins and genes Human genes 0.000 description 102
- 235000018102 proteins Nutrition 0.000 description 91
- 239000002299 complementary DNA Substances 0.000 description 86
- 108020004414 DNA Proteins 0.000 description 67
- 239000013598 vector Substances 0.000 description 65
- 238000002869 basic local alignment search tool Methods 0.000 description 51
- 108091028043 Nucleic acid sequence Proteins 0.000 description 47
- 210000001519 tissue Anatomy 0.000 description 47
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 45
- 238000004458 analytical method Methods 0.000 description 45
- 239000013615 primer Substances 0.000 description 40
- 108091034117 Oligonucleotide Proteins 0.000 description 35
- 208000035475 disorder Diseases 0.000 description 35
- 241000282414 Homo sapiens Species 0.000 description 32
- 238000003752 polymerase chain reaction Methods 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 31
- 239000013612 plasmid Substances 0.000 description 28
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 27
- 150000001413 amino acids Chemical class 0.000 description 27
- 238000003556 assay Methods 0.000 description 24
- 238000004422 calculation algorithm Methods 0.000 description 24
- 238000005516 engineering process Methods 0.000 description 22
- 238000002493 microarray Methods 0.000 description 22
- 230000002068 genetic effect Effects 0.000 description 21
- 238000000746 purification Methods 0.000 description 19
- 238000012163 sequencing technique Methods 0.000 description 19
- 238000006467 substitution reaction Methods 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 17
- 238000013518 transcription Methods 0.000 description 17
- 230000035897 transcription Effects 0.000 description 17
- 108020004635 Complementary DNA Proteins 0.000 description 16
- 230000000875 corresponding effect Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 230000000692 anti-sense effect Effects 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 108020001507 fusion proteins Proteins 0.000 description 14
- 102000037865 fusion proteins Human genes 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 238000013519 translation Methods 0.000 description 13
- 230000014616 translation Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 108700024394 Exon Proteins 0.000 description 12
- 125000000539 amino acid group Chemical group 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 12
- 241001430294 unidentified retrovirus Species 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 10
- 108090000820 Rhodopsin Proteins 0.000 description 10
- 241000700584 Simplexvirus Species 0.000 description 10
- 230000003321 amplification Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000000170 cell membrane Anatomy 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000001415 gene therapy Methods 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 102000015636 Oligopeptides Human genes 0.000 description 9
- 108010038807 Oligopeptides Proteins 0.000 description 9
- 102000004330 Rhodopsin Human genes 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- -1 antibodies Proteins 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 210000000349 chromosome Anatomy 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- 238000002864 sequence alignment Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 241000701161 unidentified adenovirus Species 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 8
- 241000710929 Alphavirus Species 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 230000002759 chromosomal effect Effects 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 238000013507 mapping Methods 0.000 description 8
- 208000030159 metabolic disease Diseases 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 241001529453 unidentified herpesvirus Species 0.000 description 8
- 108090000994 Catalytic RNA Proteins 0.000 description 7
- 102000053642 Catalytic RNA Human genes 0.000 description 7
- 108010070675 Glutathione transferase Proteins 0.000 description 7
- 102000005720 Glutathione transferase Human genes 0.000 description 7
- 208000001132 Osteoporosis Diseases 0.000 description 7
- 102000003982 Parathyroid hormone Human genes 0.000 description 7
- 108090000445 Parathyroid hormone Proteins 0.000 description 7
- 108010026552 Proteome Proteins 0.000 description 7
- 108091034057 RNA (poly(A)) Proteins 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 208000036142 Viral infection Diseases 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 229960001319 parathyroid hormone Drugs 0.000 description 7
- 239000000199 parathyroid hormone Substances 0.000 description 7
- 239000002987 primer (paints) Substances 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 108091092562 ribozyme Proteins 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 231100000167 toxic agent Toxicity 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 201000006549 dyspepsia Diseases 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000000926 neurological effect Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 102000009410 Chemokine receptor Human genes 0.000 description 5
- 108050000299 Chemokine receptor Proteins 0.000 description 5
- 108091035707 Consensus sequence Proteins 0.000 description 5
- 238000001712 DNA sequencing Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 108050002069 Olfactory receptors Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 241000701447 unidentified baculovirus Species 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 102100036465 Autoimmune regulator Human genes 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108091060211 Expressed sequence tag Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 4
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 4
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000012547 Olfactory receptors Human genes 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 206010033645 Pancreatitis Diseases 0.000 description 4
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 241000714474 Rous sarcoma virus Species 0.000 description 4
- 102100037505 Secretin Human genes 0.000 description 4
- 108010086019 Secretin Proteins 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 201000001352 cholecystitis Diseases 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 201000001981 dermatomyositis Diseases 0.000 description 4
- 206010014665 endocarditis Diseases 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 210000000688 human artificial chromosome Anatomy 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 206010028417 myasthenia gravis Diseases 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 208000005987 polymyositis Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 208000012672 seasonal affective disease Diseases 0.000 description 4
- 229960002101 secretin Drugs 0.000 description 4
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 201000005060 thrombophlebitis Diseases 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108060003345 Adrenergic Receptor Proteins 0.000 description 3
- 102000017910 Adrenergic receptor Human genes 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 241001635598 Enicostema Species 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 3
- 108010002724 Pheromone Receptors Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
- 241000710961 Semliki Forest virus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100036407 Thioredoxin Human genes 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 241000723873 Tobacco mosaic virus Species 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
- 102000004136 Vasopressin Receptors Human genes 0.000 description 3
- 108090000643 Vasopressin Receptors Proteins 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 102100038344 Vomeronasal type-1 receptor 2 Human genes 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 229940095074 cyclic amp Drugs 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 208000010643 digestive system disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 229940049906 glutamate Drugs 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000813 peptide hormone Substances 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000002427 pheromone receptor Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 108060008226 thioredoxin Proteins 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000008791 toxic response Effects 0.000 description 3
- 230000002110 toxicologic effect Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 102000027257 transmembrane receptors Human genes 0.000 description 3
- 108091008578 transmembrane receptors Proteins 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 description 2
- 208000007887 Alphavirus Infections Diseases 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 2
- 241000712891 Arenavirus Species 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010003226 Arteriovenous fistula Diseases 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 2
- 208000012219 Autonomic Nervous System disease Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 206010004552 Bicuspid aortic valve Diseases 0.000 description 2
- 208000015163 Biliary Tract disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000004020 Brain Abscess Diseases 0.000 description 2
- 208000007257 Budd-Chiari syndrome Diseases 0.000 description 2
- 206010006811 Bursitis Diseases 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
- 206010008635 Cholestasis Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- 208000019736 Cranial nerve disease Diseases 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 208000012239 Developmental disease Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005872 Diffuse Esophageal Spasm Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 206010062608 Endocarditis noninfective Diseases 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 241000701867 Enterobacteria phage T7 Species 0.000 description 2
- 206010058838 Enterocolitis infectious Diseases 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 206010015226 Erythema nodosum Diseases 0.000 description 2
- 206010015251 Erythroblastosis foetalis Diseases 0.000 description 2
- 208000007217 Esophageal Stenosis Diseases 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 206010061846 Extradural abscess Diseases 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 101800002068 Galanin Proteins 0.000 description 2
- 102000011392 Galanin receptor Human genes 0.000 description 2
- 108050001605 Galanin receptor Proteins 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000036495 Gastritis atrophic Diseases 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 2
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010061201 Helminthic infection Diseases 0.000 description 2
- 208000018565 Hemochromatosis Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010019713 Hepatic vein thrombosis Diseases 0.000 description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- 206010021518 Impaired gastric emptying Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 206010062062 Large intestinal obstruction Diseases 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 208000024369 Libman-Sacks endocarditis Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 206010026712 Mallory-Weiss syndrome Diseases 0.000 description 2
- 206010027202 Meningitis bacterial Diseases 0.000 description 2
- 206010027260 Meningitis viral Diseases 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 206010068836 Metabolic myopathy Diseases 0.000 description 2
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000003926 Myelitis Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 206010028643 Myopathy endocrine Diseases 0.000 description 2
- 208000023137 Myotoxicity Diseases 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010030184 Oesophageal spasm Diseases 0.000 description 2
- 206010030194 Oesophageal stenosis Diseases 0.000 description 2
- 241000713112 Orthobunyavirus Species 0.000 description 2
- 208000027099 Paranoid disease Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 201000004602 Peliosis Hepatis Diseases 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 206010058989 Portal vein occlusion Diseases 0.000 description 2
- 201000009454 Portal vein thrombosis Diseases 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 206010036774 Proctitis Diseases 0.000 description 2
- 206010036783 Proctitis ulcerative Diseases 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 206010037075 Protozoal infections Diseases 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 208000003782 Raynaud disease Diseases 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 208000033464 Reiter syndrome Diseases 0.000 description 2
- 241000702263 Reovirus sp. Species 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 201000007981 Reye syndrome Diseases 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 102100028927 Secretin receptor Human genes 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 206010049416 Short-bowel syndrome Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 102100022831 Somatoliberin Human genes 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- 208000029033 Spinal Cord disease Diseases 0.000 description 2
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 2
- 201000000002 Subdural Empyema Diseases 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 206010046996 Varicose vein Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 208000012346 Venoocclusive disease Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 201000011032 Werner Syndrome Diseases 0.000 description 2
- 208000027207 Whipple disease Diseases 0.000 description 2
- 208000018839 Wilson disease Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 206010002906 aortic stenosis Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 201000009904 bacterial meningitis Diseases 0.000 description 2
- 208000018300 basal ganglia disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 208000021654 bicuspid aortic valve disease Diseases 0.000 description 2
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 2
- 230000008236 biological pathway Effects 0.000 description 2
- 210000000625 blastula Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 208000005761 carcinoid heart disease Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 206010007776 catatonia Diseases 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 230000007870 cholestasis Effects 0.000 description 2
- 231100000359 cholestasis Toxicity 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 230000006552 constitutive activation Effects 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 208000002296 eclampsia Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000002616 endonucleolytic effect Effects 0.000 description 2
- 208000037902 enteropathy Diseases 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 201000000165 epidural abscess Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 201000005619 esophageal carcinoma Diseases 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 201000006061 fatal familial insomnia Diseases 0.000 description 2
- 208000001031 fetal erythroblastosis Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 208000001288 gastroparesis Diseases 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000018578 heart valve disease Diseases 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- 206010019680 hepatic infarction Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 201000011200 hepatorenal syndrome Diseases 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 208000036796 hyperbilirubinemia Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000015210 hypertensive heart disease Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000027139 infectious colitis Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 201000007119 infective endocarditis Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 208000003243 intestinal obstruction Diseases 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 206010023497 kuru Diseases 0.000 description 2
- 102000035110 latrophilin Human genes 0.000 description 2
- 108091005543 latrophilin Proteins 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 231100001023 lymphopenia Toxicity 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 201000007261 marantic endocarditis Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000002988 nephrogenic effect Effects 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 208000018360 neuromuscular disease Diseases 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 208000016135 nonbacterial thrombotic endocarditis Diseases 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 208000008494 pericarditis Diseases 0.000 description 2
- 208000029308 periodic paralysis Diseases 0.000 description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 208000024981 pyrosis Diseases 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 206010061928 radiculitis Diseases 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 208000004124 rheumatic heart disease Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 108700027603 secretin receptor Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 208000009999 tuberous sclerosis Diseases 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 208000027185 varicose disease Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 201000011531 vascular cancer Diseases 0.000 description 2
- 206010055031 vascular neoplasm Diseases 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- 201000010044 viral meningitis Diseases 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- ZPZDIFSPRVHGIF-UHFFFAOYSA-N 3-aminopropylsilicon Chemical compound NCCC[Si] ZPZDIFSPRVHGIF-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 108010089414 Anaphylatoxins Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical class OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100152433 Caenorhabditis elegans tat-1 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
- 241000173351 Camvirus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 239000005496 Chlorsulfuron Substances 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010008674 Cholinergic syndrome Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000168726 Dictyostelium discoideum Species 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- LLQPHQFNMLZJMP-UHFFFAOYSA-N Fentrazamide Chemical compound N1=NN(C=2C(=CC=CC=2)Cl)C(=O)N1C(=O)N(CC)C1CCCCC1 LLQPHQFNMLZJMP-UHFFFAOYSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091008885 GPCRs class E Proteins 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- SAEBUDRWKUXLOM-ACZMJKKPSA-N Glu-Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O SAEBUDRWKUXLOM-ACZMJKKPSA-N 0.000 description 1
- QXDXIXFSFHUYAX-MNXVOIDGSA-N Glu-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O QXDXIXFSFHUYAX-MNXVOIDGSA-N 0.000 description 1
- CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
- 206010072079 Glucocorticoid deficiency Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- WZOGEMJIZBNFBK-CIUDSAMLSA-N His-Asp-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O WZOGEMJIZBNFBK-CIUDSAMLSA-N 0.000 description 1
- SDTPKSOWFXBACN-GUBZILKMSA-N His-Glu-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O SDTPKSOWFXBACN-GUBZILKMSA-N 0.000 description 1
- YADRBUZBKHHDAO-XPUUQOCRSA-N His-Gly-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C)C(O)=O YADRBUZBKHHDAO-XPUUQOCRSA-N 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 101000777564 Homo sapiens C-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000583199 Homo sapiens Prokineticin receptor 1 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 1
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- USXAYNCLFSUSBA-MGHWNKPDSA-N Ile-Phe-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N USXAYNCLFSUSBA-MGHWNKPDSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108700005090 Lethal Genes Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108010062166 Lys-Asn-Asp Proteins 0.000 description 1
- BYPMOIFBQPEWOH-CIUDSAMLSA-N Lys-Asn-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N BYPMOIFBQPEWOH-CIUDSAMLSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 241000288145 Meleagris Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100333728 Mus musculus Ercc8 gene Proteins 0.000 description 1
- 101100018717 Mus musculus Il1rl1 gene Proteins 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 102000010175 Opsin Human genes 0.000 description 1
- 108050001704 Opsin Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 241001483952 Peach chlorotic mottle virus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 241000881705 Porcine endogenous retrovirus Species 0.000 description 1
- 102100030364 Prokineticin receptor 1 Human genes 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 101710097451 Putative G-protein coupled receptor Proteins 0.000 description 1
- 102100039117 Putative vomeronasal receptor-like protein 4 Human genes 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 101150006985 STE2 gene Proteins 0.000 description 1
- 101100204213 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) STE3 gene Proteins 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VQBLHWSPVYYZTB-DCAQKATOSA-N Ser-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N VQBLHWSPVYYZTB-DCAQKATOSA-N 0.000 description 1
- CDVFZMOFNJPUDD-ACZMJKKPSA-N Ser-Gln-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CDVFZMOFNJPUDD-ACZMJKKPSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 101000783611 Takifugu rubripes 5-hydroxytryptamine receptor 1D Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- SWSUXOKZKQRADK-FDARSICLSA-N Trp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N SWSUXOKZKQRADK-FDARSICLSA-N 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- KWKJGBHDYJOVCR-SRVKXCTJSA-N Tyr-Ser-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O KWKJGBHDYJOVCR-SRVKXCTJSA-N 0.000 description 1
- AFWXOGHZEKARFH-ACRUOGEOSA-N Tyr-Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=C(O)C=C1 AFWXOGHZEKARFH-ACRUOGEOSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
- LZRWTJSPTJSWDN-FKBYEOEOSA-N Val-Trp-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)N LZRWTJSPTJSWDN-FKBYEOEOSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 108700029631 X-Linked Genes Proteins 0.000 description 1
- 208000028247 X-linked inheritance Diseases 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 108010045245 alpha-latrotoxin receptor Proteins 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010040856 glutamyl-cysteinyl-alanine Proteins 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 108091005708 gustatory receptors Proteins 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000001551 hemic and immune system Anatomy 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 101150113423 hisD gene Proteins 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000043450 human CCR1 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 101710130522 mRNA export factor Proteins 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 210000001517 olfactory receptor neuron Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000006155 precocious puberty Diseases 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001548 stomatognathic system Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 101150081616 trpB gene Proteins 0.000 description 1
- 101150111232 trpB-1 gene Proteins 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
- QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
Abstract
The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonist, and antagonist. The invention also provides mehtods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.
Description
G-PROTEIN COUPLED RECEPTORS
TECHNICAL FIELD
This invention relates to nucleic acid and amino acid sequences of G-pxotein coupled receptors and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmunelinflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.
l0 BACKGROUND OF THE INVENTION
Signal transduction is the general process by which cells respond to extracellular signals.
Signal transduction across the plasma membrane begins with the binding of a signal molecule, e.g., a hormone, neurotransmitter, or growth factor, to a cell membrane receptor. The receptor, thus activated, triggers an intracellular biochemical cascade that ends with the activation of an intracellular target molecule, such as a transcription factor. This process of signal transduction regulates all types of cell functions including cell proliferation, differentiation, and gene transcription. The G-protein coupled receptors (GPCRs), encoded by one of the largest families of genes yet identified, play a central role in the transduction of extracellular signals across the plasma membrane. GPCRs have a proven history of being successful therapeutic targets.
GPCRs are integral membrane proteins characterized by the presence of seven hydrophobic transmembrane domains which together form a bundle of antiparallel alpha (a) helices. GPCRs range in size from under 400 to over 1000 amino acids (Strosberg, A.D. (I99I) Eur.
J. Biochem. 196:1-10;
Coughlin, S.R. (1994) Curr. Opin. Cell Biol. 6:191-197). The amino-terminus of a GPCR is extracellular, is of variable length, and is often glycosylated. The carboxy-terminus is cytoplasmic and generally phosphorylated. Extracellular loops alternate with intracellular loops and link the transmembrane domains. Cysteine disulfide bridges linking the second and third extracellular loops may interact with agonists and antagonists. The most conserved domains of GPCRs are the transmembrane domains and the first two cytoplasmic loops. The transmembxane domains account, in part, for structural and functional features of the receptor. In most cases, the bundle of a helices forms a ligand-binding pocket. The extracellular N-terminal segment, or one or more of the three extracellular loops, may also participate in ligand binding. Ligand binding activates the receptor by inducing a conformational change in intracellular portions of the receptor. In turn, the large, third intracellular Ioop of the activated receptor interacts with a heterotrimeric guanine nucleotide binding (G) protein complex which mediates further intracellular signaling activities, including the activation of second messengers such as cyclic AMP (cAMP), phospholipase C, and inositol triphosphate, and the interaction of the activated GPCR with ion channel proteins. (See, e.g., Watson, S. and S.
Arkinstall (1994) The G protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 2-6; Bolander, F.F. (1994) Molecular Endocrinolo~y, Academic Press, San Diego CA, pp. 162-176;
Baldwin, J.M. (1994) Curr. Opin. Cell Biol. 6:180-190.) GPCRs include receptors for sensory signal mediators (e.g., light and olfactory stimulatory molecules); adenosine, y-aminobutyric acid (GABA), hepatocyte growth factor, melanocortins, neuropeptide Y, opioid peptides, opsins, somatostatin, tachykinins, vasoactive intestinal polypeptide family, and vasopressin; biogenic amines (e.g., dopamine, epinephrine and norepinephrine, histamine, glutamate (metabotropic effect), acetylcholine (muscarinic effect), and serotonin); chemokines; lipid IO mediators of inflammation (e.g., prostaglandins and prostanoids, platelet activating factor, and leukotrienes); and peptide hormones (e.g., bombesin, bradykinin, calcitonin, CSa anaphylatoxin, endothelin, follicle-stimulating hormone (FSH), gonadotropic-releasing hormone (GnRH), neurokinin, and thyrotropin-releasing hormone (TRIT), and oxytocin). GPCRs which act as receptors for stimuli that have yet to be identified are known as orphan receptors.
The diversity of the GPCR family is further increased by alternative splicing.
Many GPCR
genes contain introns, and there are currently over 30 such receptors for which splice variants have been identified. The largest number of variations are at the protein C-terminus. N-terminal and cytoplasmic loop variants are also frequent, while variants in the extracellular loops or transmembrane domains are less common. Some receptors have more than one site at which variance can occur. The splicing variants appear to be functionally distinct, based upon observed differences in distribution, signaling, coupling, regulation, and ligand binding profiles (I~ilpatrick, G.J. et al.
(1999) Trends Pharmacol. Sci. 20:294-301).
GPCRs can be divided into three major subfamilies: the rhodopsin-like, secretin-like, and metabotropic glutamate receptor subfamilies. Members of these GPCR subfamilies share similar functions and the characteristic seven transmembrane structure, but have divergent amino acid sequences. The largest family consists of the rhodopsin-like GPCRs, which transmit diverse extracellular signals including hormones, neurotransmitters, and light.
Rhodopsin is a photosensitive GPCR found in animal retinas. In vertebrates, rhodopsin molecules are embedded in membranous stacks found in photoreceptor (rod) cells. Each rhodopsin molecule responds to a photon of light by triggering a decrease in cGMP levels which leads to the closure of plasma membrane sodium channels. In this manner, a visual signal is converted to a neural impulse.
Other rhodopsin-like GPCRs are directly involved in responding to neurotransmitters. These GPCRs include the receptors for adrenaline (adrenergic receptors), acetylcholine (muscarinic receptors), adenosine, galanin, and glutamate (N-methyl-D-aspartate/NMDA receptors). (Reviewed in Watson, S. and S. Arkinstall (1994) The G-Protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 7-9, 19-22, 32-35, 130-131, 214-216, 221-222; Habert-Ortoli, E. et al. (1994) Proc. Natl.
Acad. Sci. USA
91:9780-9783.) The galanin receptors mediate the activity of the neuroendocrine peptide galanin, which inhibits secretion of insulin, acetylcholine, serotonin and noradrenaline, and stimulates prolactin and growth hormone release. Galanin receptors are involved in feeding disorders, pain, depression, and Alzheimer's disease (Kask, K. et al. (1997) Life Sci. 60:1523-1533). Other nervous system rhodopsin-like GPCRs include a growing family of receptors for lysophosphatidic acid and other lysophospholipids, which appear to have roles in development and neuropathology (Chum J. et al.
(1999) CeII Biochem. Biophys. 30:213-242).
The largest subfamily of GPCRs, the olfactory receptors, axe also members of the rhodopsin-like GPCR family. These receptors function by transducing odorant signals.
Numerous distinct olfactory receptors are required to distinguish different odors. Each olfactory sensory neuron expxesses only one type of olfactory receptor, and distinct spatial zones of neurons expressing distinct receptors are found in nasal passages. For example, the RAlc receptor which was isolated from a rat brain library, has been shown to be limited in expression to very distinct regions of the brain and a defined zone of the olfactory epithelium (Raining, K. et al. (1998) Receptors Channels 6:141-151).
However, the expression of olfactory-like receptors is not confined to olfactory tissues. For example, three rat genes encoding olfactory-like receptors having typical GPCR
characteristics showed expression patterns not only in taste and olfactory tissue, but also in male reproductive tissue (Thomas, M.B. et al. (1996) Gene 178:1-5).
Members of the secretin-like GPCR subfamily have as their ligands peptide hormones such as secretin, calcitonin, glucagon, growth hormone-releasing hormone, parathyroid hormone, and vasoactive intestinal peptide. For example, the secretin receptor responds to secretin, a peptide hormone that stimulates the secretion of enzymes and ions in the pancreas and small intestine (Watson, su ra, pp. 278-283). Secretin receptors are about 450 amino acids in length and are found in the plasma membrane of gastrointestinal cells. Binding of secretin to its receptor stimulates the production of cAMP.
Examples of secretin-like GPCRs implicated in inflammation and the immune response include the EGF module-containing, mucin-like hormone receptor (Emrl) and CD97 receptor proteins. These GPCRs are members of the recently characterized EGF-TM7 receptors subfamily.
These seven transmembrane hormone receptors exist as heterodimers in vivo and contain between three and seven potential calcium-binding EGF-like motifs. CD97,is predominantly expressed in leukocytes and is markedly upregulated on activated B and T cells (McKnight, A.J. and S. Gordon (1998) J. Leukoc. Biol. 63:271-280).
The third GPCR subfamily is the metabotropic glutamate receptor family.
Glutamate is the major excitatory neurotransmitter in the central nervous system. The metabotropic glutamate receptors modulate the activity of intracellular effectors, and are involved in long-term potentiation (Watson, supra, p.130). The Ca2+-sensing receptor, which senses changes in the extracellular concentration of calcium ions, has a large extracellular domain including clusters of acidic amino acids which may be involved in calcium binding. The metabotropic glutamate receptor family also includes pheromone receptors, the GABAB receptors, and the taste receptors.
Other subfamilies of GPCRs include two groups of chemoreceptor genes found in the nematodes Caenorhabditis ele_gans and Caenorhabditis bri~~sae, which are distantly related to the mammalian olfactory receptor genes. The yeast pheromone receptors STE2 and STE3, involved in the response to mating factors on the cell membrane, have their own seven-transmembrane signature, as do the CAMP receptors from the slime mold Dictyostelium discoideum, which are thought to regulate the aggregation of individual cells and control the expression of numerous developmentally-regulated genes.
GPCR mutations, which may cause loss of function or constitutive activation, have been associated with numerous human diseases (Coughlin, supra). For instance, retinitis pigmentosa may arise from mutations in the rhodopsin gene. Furthermore, somatic activating mutations in the thyrotropin receptor have been reported to cause hyperfunctioning thyroid adenomas, suggesting that certain GPCRs susceptible to constitutive activation may behave as protooncogenes (Parma, J. et al.
(1993) Nature 365:649-651). GPCR receptors for the following ligands also contain mutations associated with human disease: lutenizing hormone (precocious puberty);
vasopressin VZ (X-linked nephrogenic diabetes); glucagon (diabetes and hypertension); calcium (hyperparathyroidism, hypocalcuria, hypercalceniia); parathyroid hormone (short limbed dwarfism);
(33 adrenoceptor (obesity, non-insulin-dependent diabetes mellitus); growth hormone releasing hormone (dwa~sm);
and adrenocorticotropin (glucocorticoid deficiency) (Wilson, S. et al. (1998) Br. J. Pharmocol.
125:1387-1392; Stadel, J.M. et al. (1997) Trends Pharmacol. Sci. 18:430-437).
GPCRs are also involved in depression, schizophrenia, sleeplessness, hypertension, anxiety, stress, renal failure, and several cardiovascular disorders (Horn, F. and G. Vriend (1998) J. Mol. Med.
76:464-468).
In addition, within the past 20 years several hundred new drugs have been recognized that are directed towards activating or inhibiting GPCRs. The therapeutic targets of these drugs span a wide range of diseases and disorders, including cardiovascular, gastrointestinal, and central nervous system disorders as well as cancer, osteoporosis and endometriosis (Wilson, s-unra;
Stadel, supra). For example, the dopamine agonist L-dopa is used to treat Parkinson's disease, while a dopamine antagonist is used to treat schizophrenia and the early stages of Huntington's disease. Agonists and antagonists of adrenoceptors have been used for the treatment of asthma, high blood pressure, other cardiovascular disorders, and anxiety; muscarinic agonists are used in the treatment of glaucoma and tachycardia; serotonin 5HT1D antagonists are used against migraine; and histamine Hl antagonists are used against allergic and anaphylactic reactions, hay fever, itching, and motion sickness (Horn, supra).
Recent research suggests potential future therapeutic uses for GPCRs in the treatment of metabolic disorders including diabetes, obesity, and osteoporosis. For example, mutant V2 vasopressin receptors causing nephrogenic diabetes could be functionally rescued in vitro by co-expression of a C-terminal V2 receptor peptide spanning the region containing the mutations. This result suggests a possible novel strategy for disease treatment (Schoneberg, T. et al. (1996) EMBO J.
15:1283-1291). Mutations in melanocortin-4. receptor (MC4R) are implicated in human weight regulation and obesity. As with the vasopressin V2 receptor mutants, these MC4R mutants are defective in trafficking to the plasma membrane (Ho, G. and R.G. MacKenzie (1999) J. Biol. Chem.
274:35816-35822), and thus might be treated with a similar strategy. The type 1 receptor for parathyroid hormone (PTH) is a GPCR that mediates the PTH-dependent regulation of calcium homeostasis in the bloodstream. Study of PTH/receptor interactions may enable the development of novel PTH receptor ligands for the treatment of osteoporosis (Mannstadt, M. et aI. (I999) Am. J.
Physiol. 277:F665-F675).
The chemokine receptor group of GPCRs have potential therapeutic utility in inflammation and infectious disease. (For review, see Locati, M. and P.M. Murphy (1999) Annu. Rev. Med.
50:425-440.) Chemokines are small polypeptides that act as intracellular signals in the regulation of leukocyte trafficking, hematopoiesis, and angiogenesis. Targeted disruption of various chemokine receptors in mice indicates that these receptors play roles in pathologic inflammation and in autoimmune disorders such as multiple sclerosis. Chemokine receptors are also exploited by infectious agents, including herpesviruses and the human immunodeficiency virus (HIV-1) to facilitate infection. A truncated version of chemokine receptor CCRS, which acts as a coreceptor for infection of T-cells by HIV-1, results in resistance to AIDS, suggesting that CCRS antagonists could be useful in preventing the development of AmS.
The discovery of new G-protein coupled receptors, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.
SUMMARY OF THE INVENTION
The invention features purified polypeptides, G-protein coupled receptors, referred to collectively as "GCREC" and individually as "GCREC-l," "GCREC-2," "GCREC-3,"
"GCREC-4,"
"GCREC-5," "GCREC-6," "GCREC-7," "GCREC-8," "GCREC-9," "GCREC-10," "GCREC-11,"
"GCREC-12," "GCREC-13," "GCREC-14," "GCREC-15," "GCREC-16," "GCREC-17," "GCREC-18," and "GCREC-19." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring annino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ
ID NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m N0:1-19.
In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ )D NO:1-19.
The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ
ll~ NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19.
In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-19. Tn another alternative, the polynucleotide is selected from the group consisting of SEQ m NO:20-38.
Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ )D NO:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: l-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.
The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ m N0:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ m N0:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m N0:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.
Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ m N0:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ll~ NO:1-19.
The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ 1D N0:20-38, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ m N0:20-38, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d).
In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.
Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ m N0:20-38, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ m N0:20-38, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA
equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.
The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ll7 N0:20-38, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ m N0:20-38, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d).
The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring, amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ m NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ m NO:1-19. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition.
The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ m N0:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ m NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:l-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: l-19. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional GCR.EC, comprising administering to a patient in need of such treatment the composition.
Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ 117 NO:1-19. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample.
In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional GCREC, comprising administering to a patient in need of such treatment the composition.
The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ m NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.
The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID
N0:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.
The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID N0:20-38, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.
The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ
ID N0:20-38, ii) a polynucleotide comprising a naturally occurnng polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID N0:20-38, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID
NO:20-38, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ >D N0:20-38, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv).
Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
BRIEF DESCRIPTION OF THE TABLES
Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.
Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.
Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.
Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.
Table 5 shows the representative cDNA library for polynucleotides of the invention.
Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.
Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.
DESCRIPTION OF THE INVENTION
Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
It must be noted that as used herein and in the appended claims, the singular forms "a," "an,"
and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs.
Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
DEFINITIONS
"GCREC" refers to the amino acid sequences of substantially purified GCREC
obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.
The term "agonist" refers to a molecule which intensifies or mimics the biological activity of GCREC. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by directly interacting with GCREC or by acting on components of the biological pathway in which GCREC
participates.
An "allelic variant" is an alternative form of the gene encoding GCREC.
Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.
Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
"Altered" nucleic acid sequences encoding GCREC include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as GCREC or a polypeptide with at least one functional characteristic of GCREC. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding GCREC, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GCREC. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GCREC. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of GCREC is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine.
Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.
The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.
"Amplification" xelates to the production of additional copies of a nucleic acid sequence.
Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.
The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of GCREC. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by directly interacting with GCREC or by acting on components of the biological pathway in which GCREC participates.
The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')z, and Fv fragments, which are capable of binding an epitopic determinant.
Antibodies that bind GCREC polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired.
Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.
The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.
The term "antisense" refers to any composition capable of base-pairing with the "sense"
(coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA;
RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the 3S designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.
The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "irnmunologically active" or "immunogenic"
refers to the capability of the natural, recombinant, or synthetic GCREC, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.
"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.
A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution.
Compositions comprising polynucleotide sequences encoding GCREC or fragments of GCREC may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCI), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).
"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL,-PCR
kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.
"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions.
The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.
Original Residue Conservative Substitution Ala Gly, Ser Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln, Glu Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile, Leu, Thr Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.
A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.
The term "derivative" refers to a chemically modified polynucleotide or polypeptide.
Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or innmunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.
A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.
"Differential expression" refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.
"Exon shuffling" refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.
A "fragment" is a unique portion of GCREC or the polynucleotide encoding GCREC
which is identical in sequence to but shorter in length than the parent sequence. A
fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A
fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule.
For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.
A fragment of SEQ >D N0:20-38 comprises a region of unique polynucleotide sequence that specifically identifies SEQ m N0:20-38, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ m N0:20-38 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ m N0:20-38 from related polynucleotide sequences. The precise length of a fragment of SEQ
m N0:20-38 and the region of SEQ m N0:20-38 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.
A fragment of SEQ m NO:1-19 is encoded by a fragment of SEQ ID N0:20-38. A
fragment of SEQ m N0:1-19 comprises a region of unique amino acid sequence that specifically identifies SEQ ID N0:1-19. For example, a fragment of SEQ ID NO:1-19 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ m NO:1-19.
The precise length of a fragment of SEQ m N0:1-19 and the region of SEQ m NO:1-19 to which the fragment ' corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.
A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A
"full length" polynucleotide sequence encodes a "full length" polypeptide sequence.
"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.
The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.
Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN
version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS
8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.
Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorF/bl2.html.
The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST
programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2Ø12 (April-21-2000) set at default parameters. Such default parameters may be, for example:
Matrix: BLOSUM62 Reward for match: 1 Penalty for mismatch: -2 Opera Gap: 5 and Extension Gap: 2 penalties Gap x drop-off.' SO
Expect: l0 Word Size: 11 Filter: on Percent identity ma.y be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.
Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.
The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions.
Such conservative substitutions, explained in more detail above, generally preserve the charge and-hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.
Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN
version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: I~tuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.
Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences"
tool Version 2Ø12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:
Matrix: BLOSUM62 Open Gap: 11 and Extension Gap: 1 pezzalties Gap x drop-off 50 Expect: 10 Word Size: 3 Filter: on Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.
"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in, size and which contain all of the elements required for chromosome replication, segregation and maintenance.
The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.
"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity.
Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing steps) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity.
Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1 % (w/v) SDS, and about 100 ~,g/ml sheared, denatured salmon sperm DNA.
Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T,~) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating Tm and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al.
(1989) Molecular Cloning: A Laboratory Manual, 2"d ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.
High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC
concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1 %.
Typically, blocking reagents are used to block non-specific hybridization.
Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 p,g/ml. Organic solvent, such as formamide at a concentration of about 35-50% vlv, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.
The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A
hybridization complex may be formed in solution (e.g., Cot or Rot analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).
The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amnno acid residues or nucleotides, respectively.
"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.
An "immunogenic fragment" is a polypeptide or oligopeptide fragment of GCREC
which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of GCREC which is useful in any of the antibody production methods disclosed herein or known in the art.
The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.
The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microanray.
The term "modulate" refers to a change in the activity of GCREC. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of GCREC.
The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.
"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.
"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition.
PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.
"Post-translational modification" of an GCREC may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of GCREC.
"Probe" refers to nucleic acid sequences encoding GCREC, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule.
Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.
"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).
Probes and primers as used in the present invention typically compxise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the, specification, including the tables, figures, and Sequence Listing, may be used.
Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloni~yA Laboratory Manual, 2°a ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biolo~y, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR
Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA.
PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).
Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR
primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases.
Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge LTI~) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.
A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence.
This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.
Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.
A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (LTTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.
"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes;
fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors;
magnetic particles; and other moieties known in the art.
An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.
The term "sample" is used in its broadest sense. A sample suspected of containing GCREC, nucleic acids encoding GCREC, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.
The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A
and the antibody will reduce the amount of labeled A that binds to the antibody.
The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60%a free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.
A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.
"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.
A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.
"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or vixal infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.
A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.
A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2Ø9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A
splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.
A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2Ø9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%
or greater sequence identity over a certain defined length of one of the polypeptides.
THE INVENTION
The invention is based on the discovery of new human G-protein coupled receptors (GCREC), the polynucleotides encoding GCREC, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections.
Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project 117). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide III) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ m NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.
Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog.
Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog.
Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ILK NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ~) for each polypeptide of the invention.
Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI]. Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.
Together, Tables 2 and 3 summarize the properties of each polypeptide of the invention, and these properties establish that the claimed polypeptides are G-protein coupled receptors. For example, SEQ ID NO:1 is 40% identical to Meleagris gallo~avo G protein-coupled P2Y nucleotide receptor (GenBank ID g2707256) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 4.0e-62, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ m NO: l also contains a rhodopsin family 7 transmembrane receptor domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and BLAST analyses provide further .
corroborative evidence that SEQ ll~ N0:1 is G-protein coupled receptor. SEQ ID
N0:2 was analyzed and annotated in a similar manner. These analyses indicate that SEQ ID N0:2 is a pheromone receptor (Dulac, C. and R. Axel (1995) Cell 83:195-206).
As a further example, SEQ ID N0:6 is 29% identical to human C-C chemokine receptor type 1 (GenBank ID g179985) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.6e-15, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID N0:6 also contains a 7 transmembrane receptor (rhodopsin family) domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and PROF1LESCAN analyses provide further corroborative evidence that SEQ ID NO:6 is a chemokine receptor.
As a further example, SEQ ID N0:9 is 95% identical to rat calcium-independent alpha-latrotoxin receptor (GenBank ID g3882981) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ )D NO:9 also contains a 7-transmembrane receptor (secretin family) domain and a latrophilin/CL-1-like GPS domain, as 2S determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLllVIPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID N0:9 is a latrophilin-related G-protein coupled receptor.
As a further example, SEQ ID N0:12 is 84% identical to Mus musculus G-protein coupled receptor GPR73 (GenBank ID g7248884) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 6.7e-166, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID
N0:12 also contains a 7 transmembrane receptor (rhodopsin family) domain as determined by searching for statistically significant matches in the hidden Markov model (I~VIM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMfS analysis reveals the presence of a rhodopsin-like GPCR supexfamily signature (See Table 3). Additional data from MOTIFS and PROFILESCAN
analyses provide further corroborative evidence that SEQ m N0:12 is a G-protein coupled receptor.
As a further example, SEQ ID N0:15 is 80% identical to rat serotonin receptor (GenBank ID
g310075) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 2.5e-152, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID N0:15 also contains a rhodopsin family receptor domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLI1VIPS, analyses provide further corroborative evidence that SEQ ID N0:15 is a G-protein coupled receptor.
As a further example, SEQ DJ N0:16 is 71% identical to mouse olfactory receptor E3 (GenBank ID g3983382) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.9e-88, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ m N0:16 also contains a rhodopsin family 7-transmembrane receptor domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOT1FS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID N0:16 is an olfactory G-protein coupled receptor.
As a further example, SEQ ID N0:17 is 83% identical to mouse olfactory G-protein coupled receptor G3 (GenBank ID g3983398) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is S.Oe-99, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ m N0:17 also contains a rhodopsin family 7-transmembrane receptor domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLM'S, MOT1FS, and PROF1LESCAN
analyses provide further corroborative evidence that SEQ ID NO:17 is an olfactory G-protein coupled receptor. SEQ
113 N0:2-5, SEQ ID N0:7-8, SEQ ID NO: IO-1 I, SEQ ID NO: I3-14, and SEQ TD
NO:I8-19 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ
ID NO: I-I9 are described in Table 7.
As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention.
Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID N0:20-38 or that distinguish between SEQ ID
N0:20-38 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA
sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5') and stop (3') positions of the cDNA and/or genomic sequences in column 5 relative to their respective full length sequences.
The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 7075196H1 is the identification number of an Incyte cDNA sequence, and BRAUTDR04 is the cDNA
library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., 71906055V1). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs (e.g., g900324) which contributed to the assembly of the full length polynucleotide sequences. In addition, the identification numbers in column 5 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, ITK) database (i.e., those sequences including the designation "ENST"). Alternatively, the identification numbers in column 5 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (i.
e., those sequences including the designation "NM" or "NT") or the NCBI RefSeq Protein Sequence Records (i.e., those sequences including the designation "NP"). Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, FL IiXXXI~X_NI 1Vz YYYYY_N3 1Vø represents a "stitched"
sequence in which ~XXXX is the identification number of the cluster of sequences to which the algorithm was applied, and YYYYY is the number of the prediction generated by the algorithm, and 2S N1,2,3...~ if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the identification numbers in column 5 may refer to assemblages of exons brought together by an "exon-stretching" algorithm. For example, FLXXX_gAAAAA_gBBBBB_1 IV is the identification number of a "stretched"
sequence, with XI~XXXX being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the "exon-stretching" algorithm was applied, gBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and N refernng to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the "exon-stretching" algorithm, a RefSeq identifier (denoted by "NM," "NP," or "NT") may be used in place of the GenBank identifier (i.e., gBBBBB).
Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V).
Prefix Type of analysis and/or examples of programs GNN, GFG,Exon prediction from genomic sequences using, for example, ENST GENSCAN (Stanford University, CA, USA) or FGENES
(Computer Genomics Group, The Sanger Centre, Cambridge, UK).
GBI Hand-edited analysis of genomic sequences.
FL Stitched or stretched genomic sequences (see Example V).
INCY Full length transcript and exon prediction from mapping of EST
sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.
In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.
Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.
The invention also encompasses GCREC variants. A preferred GCREC variant is one which has at least about 80°Io, or alternatively at least about 90%, or even at least about 95°Io amino acid sequence identity to the GCREC amino acid sequence, and which contains at least one functional or structural characteristic of GCREC.
The invention also encompasses polynucleotides which encode GCREC. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID N0:20-38, which encodes GCREC. The polynucleotide sequences of SEQ m N0:20-38, as presented in the Sequence Listing, embrace the equivalent RNA
sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.
The invention also encompasses a variant of a polynucleotide sequence encoding GCREC. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding GCREC. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID
N0:20-38 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:20-38. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of GCREC.
It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding GCREC, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurnng gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible colon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring GCREC, and all such variations are to be considered as being specifically disclosed.
Although nucleotide sequences which encode GCREC and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring GCREC
under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GCREC or its derivatives possessing a substantially different colon usage, e.g., inclusion of non-naturally occurring colons. Colons rnay be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular colons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GCREC and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.
The invention also encompasses production of DNA sequences which encode GCREC
and GCREC derivatives, or fragments thereof, entirely by synthetic chemistry.
After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GCREC or any fragment thereof.
Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ >l7 N0:20-38 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol.
152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."
Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the I~lenow fragment of DNA polymerise I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerise (Applied Biosystems), thermostable T7 polymerise (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerises and proofreading exonucleases such as those found in the ELONGASE
amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA
sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithW s which are well known in the art.
(See, e.g., Ausubel, F.M.
(1997) Short Protocols in Molecular Biolo~y, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biolo$y and Biotechnolo~y, Wiley VCH, New York NY, pp.
856-853.) The nucleic acid sequences encoding GCREC may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic.
2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (I988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA
fragments adjacent to known sequences in human and yeast artificial chromosome DNA.
(See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res.
19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFIIVDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids.the need to screen libraries and is useful in finding intronlexon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.
When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.
Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.
In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode GCREC may be cloned in recombinant DNA molecules that direct expression of GCREC, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express GCREC.
The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter GCREC-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA
shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.
The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat.
Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of GCREC, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial"
breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.
In. another embodiment, sequences encoding GCREC may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Sex. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser.
7:225-232.) Alternatively, GCREC itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques.
(See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Pro erties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems).
Additionally, the amino acid sequence of GCREC, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.
The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.) In order to express a biologically active GCREC, the nucleotide sequences encoding GCREC
or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding GCREC. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GCREC. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding GCREC and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used.
(See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.) Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GCREC and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et aI. (1989) Molecular Cloning; A
Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biolo~y, John Wiley & Sons, New York NY, ch. 9, 13, and 16.) A variety of expression vector/host systems may be utilized to contain and express sequences encoding GCREC. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra;
Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl.
Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technolo~y (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc.
Natl. Acad. Sci. USA
81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population.
(See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M.
et al. (1993) Proc.
Natl. Acad. Sci. USA 90(13):6340-6344; Butler, R.M. et al. (1985) Nature 317(6040):813-815;
McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, LM. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.
In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding GCREC. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding GCREC can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORTl plasmid (Life Technologies). Ligation of sequences encoding GCREC into the vector's multiple cloning site disrupts the lacZ gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M.
Schuster (1989) J. Biol.
Chem. 264:5503-5509.) When large quantities of GCREC are needed, e.g. for the production of antibodies, vectors which direct high level expression of GCREC may be used.
For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.
Yeast expression systems may be used for production of GCREC. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH
promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation.
(See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.) Plant systems may also be used for expression of GCREC. Transcription of sequences encoding GCREC may be driven by viral promoters, e.g., the 355 and 195 promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N.
(1987) EMBO J.
6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al.
(1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA
transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technoloay (1992) McGraw Hill, New York NY, pp. 191-196.) In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GCREC
may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses GCREC in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc.
Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.
Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J.
et al. (1997) Nat. Genet.
15:345-355.) For long term production of recombinant proteins in mammalian systems, stable expression of GCREC in cell lines is preferred. For example, sequences encoding GCREC can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector.
Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.
Any number of selection systems may be used to recover transformed cell lines.
These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in tk- and apr cells, respectively.
(See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, T. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dlafr confers resistance to methotrexate; neo confers resistance to the aminoglycosides neomycin and G-418; and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase;
respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., trpB and hisD, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc.
Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescentproteins (GFP; Clontech),13 glucuronidase and its substrate I3-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system.
(See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.) Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding GCREC is inserted within a marker gene sequence, transformed cells containing sequences encoding GCREC can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GCREC under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.
In general, host cells that contain the nucleic acid sequence encoding GCREC
and that express GCREC may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR
amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.
Immunological methods for detecting and measuring the expression of GCREC
using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked irrununosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GCREC is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS
Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. ( 1997) Current Protocols in Innnunolo~y, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) hnmunochemical Protocols, Humana Press, Totowa NJ.) A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GCREC
include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide.
Alternatively, the sequences encoding GCREC, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.
Host cells transformed with nucleotide sequences encoding GCREC may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GCREC may be designed to contain signal sequences which direct secretion of GCREC through a prokaryotic or eukaryotic cell membrane.
In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion.
Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity.
Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEI~293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.
In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GCR.EC may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric GCREC protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of GCREC
activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, c-myc, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the GCREC encoding sequence and the heterologous protein sequence, so that GCREC may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.
In a further embodiment of the invention, synthesis of radiolabeled GCREC may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These ystems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, 35S-methionine.
GCREC of the present invention or fragments thereof may be used to screen for compounds that specifically bind to GCREC. At least one and up to a plurality of test compounds may be screened for specific binding to GCREC. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.
In one embodiment, the compound thus identified is closely related to the natural ligand of GCREC, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunolo~y 1(2):
Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which GCREC
binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening fox these compounds involves producing appropriate cells which express GCREC, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing GCREC or cell membrane fractions which contain GCREC
are then contacted with a test compound and binding, stimulation, or inhibition of activity of either GCREC or the compound is analyzed.
An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable Iabel. For example, the assay may comprise the steps of combining at least one test compound with GCREC, either in solution or affixed to a solid support, and detecting the binding of GCREC to the compound.
Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compounds) may be free in solution or affixed to a solid support.
GCREC of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of GCREC. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for GCREC activity, wherein GCREC is combined. with at least one test compound, and the activity of GCREC in the presence of a test compound is compared with the activity of GCREC in the absence of the test compound. A change in the activity of GCREC in the presence of the test compound is indicative of a compound that modulates the activity of GCREC. Alternatively, a test compound is combined with an in vitro or cell-free system comprising GCREC under conditions suitable for GCREC activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of GCREC may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.
In another embodiment, polynucleotides encoding GCREC or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S.
Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo;
Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, I~.U.
et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.
Polynucleotides encoding GCREC may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al.
(1998) Science 282:1145-1147).
Polynucleotides encoding GCREC can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding GCREC is injected into animal ES cells, and the injected 15, sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease.
Alternatively, a mammal inbred to overexpress GCREC, e.g., by secreting GCREC
in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).
THERAPEUTICS
Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of GCREC and G-protein coupled receptors. In addition, the expression of GCREC
is closely associated with brain tissue, fetal brain tissue, colon polyps, diseased colon tissue, colon tumor tissue, diseased gallbladder tissue, heart tissue, diseased breast tissue, interleukin-5 stimulated eosinophils, tumor tissue, and reproductive tissues. Therefore, GCREC appears to play a role in cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections. In the treatment of disorders associated with increased GCREC
expression or activity, it is desirable to decrease the expression or activity of GCREC. In the treatment of disorders associated with decreased GCREC expression or activity, it is desirable to increase the expression or activity of GCREC.
Therefore, in one embodiment, GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, colon, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha 1-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmunelinflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and togavirus.
In another embodiment, a vector capable of expressing GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those described above.
In a further embodiment, a composition comprising a substantially purified GCREC in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC
including, but not limited to, those provided above.
In still another embodiment, an agonist which modulates the activity of GCREC
may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those listed above.
In a further embodiment, an antagonist of GCREC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCREC. Examples of such disorders include, but are not limited to, those cell proliferative, neurological, cardiovascular, IO gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections described above. In one aspect, an antibody which specifically binds GCREC may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express GCREC.
In an additional embodiment, a vector expressing the complement of the polynucleotide encoding GCREC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCREC including, but not limited to, those described above.
In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
An antagonist of GCREC may be produced using methods which are generally known in the are. In particular, purified GCREC may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GCREC.
Antibodies to GCREC may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.
For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with GCREC or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium~arvum are especially preferable.
It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to GCREC have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of GCREC amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.
Monoclonal antibodies to GCREC may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture.
These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D.
et al. (1985) J.
Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA
80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.) In addition, techniques developed for the production of "chimeric antibodies,"
such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Mornson, S.L. et al. (1984) Proc.
Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods laiown in the art, to produce GCREC-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.) Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl.
Acad. Sci. USA
86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.) Antibody fragments which contain specific binding sites for GCREC may also be generated.
For example, such fragments include, but are not limited to, F(ab')Z fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
(See, e.g., Huse, W.D.
et al. (1989) Science 246:1275-1281.) Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GCREC and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering GCREC epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).
Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for GCREC.
Affinity is expressed as an association constant, Ka, which is defined as the molar concentration of GCREC-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions.
The Ka determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple GCREC epitopes, represents the average affinity, or avidity, of the antibodies for GCREC. The Ka determined for a preparation of monoclonal antibodies, which are monospecific for a particular GCREC epitope, represents a true measure of affinity. High-affinity antibody preparations with Ka ranging from about 109 to 1012 Llmole are preferred for use in immunoassays in which the GCREC-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with Ka ranging from about 106 to 10' Llmole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of GCREC, preferably in active form, from the antibody (Catty, D. (1988) Antibodies.
Volume T: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A
Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).
The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibodylml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of GCREC-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, su~a, and Coligan et al. supra.) In another embodiment of the invention, the polynucleotides encoding GCREC, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding GCREC. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding GCREC. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.) In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (19.98) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) Blood 76:271; Ausubel, su ra; Uckert, W. and W. Walther (1994) Phaxmacol. Ther.
63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull.
51(1):217-225; Boado, R.J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morns, M.C. et al. (1997) Nucleic Acids Res.
25 ( 14):2730-2736.) In another embodiment of the invention, polynucleotides encoding GCREC may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cel175:207-216; Crystal, R.G. et al.
(1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX
deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, LM. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D.
(1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci.
USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falcipaxum and Trypanosoma cruzi). In the case where a genetic deficiency in GCREC expression or regulation causes disease, the expression of GCREC from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.
In a further embodiment of the invention, diseases or disorders caused by deficiencies in GCREC are treated by constructing mammalian expression vectors encoding GCREC
and introducing these vectors by mechanical means into GCREC-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev.
Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H.
Recipon (1998) Curr.
Opin. Biotechnol. 9:445-450).
Expression vectors that may be effective for the expression of GCREC include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA).
GCREC
may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or (3-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl.
Acad. Sci. USA 89:5547-5551; Gossen, M. et aI. (I995) Science 268:1766-1769;
Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-4.56), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND;
Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding GCREC from a normal individual.
Commercially available liposome transformation kits (e.g., the PERFECT LIPID
TRANSFECTION KIT, available from Invitxogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al.
(1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.
In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to GCREC expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding GCREC under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc.
Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al.
(1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol.
72:8463-8471; Zufferey, R.
et al. (1998) J. Virol. 72:9873-9880). U.5. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4+ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J.
Virol. 71:4707-4716;
Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).
In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding GCREC to cells which have one or more genetic abnormalities with respect to the expression of GCREC. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, LM. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.
In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding GCREC to target cells which have one or more genetic abnormalities with respect to the expression of GCREC. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing GCREC to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al.
(1999) Exp. Eye Res.
169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S.
Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.5. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol.
73:519-532 and Xu, H. et al.
(1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.
In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding GCREC to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol.
9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for GCREC into the alphavirus genome in place of the capsid-coding region results in the production of a large number of GCREC-coding RNAs and the synthesis of high levels of GCREC in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of GCREC into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction.
The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA
transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.
Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E.
and B.I. Carr, Molecular and Immunolo~ic Approaches, Futura Publishing, Mt.
Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.
Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage.
For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GCREC.
Specific ribozyme cleavage sites within any potential RNA target are initially identif ed by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable.
The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.
Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules.
These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis.
Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA
sequences encoding GCREC. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6.
Alternatively, these cDNA
constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.
RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.
An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding GCREC.
Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased GCREC expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding GCREC may be therapeutically useful, and in the treatment of disorders associated with decreased GCREC expression or activity, a compound which specifically promotes expression of the polynucleotide encoding GCREC may be therapeutically useful.
At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide;
and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding GCREC is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding GCREC are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding GCREC. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynueleotide can be carried out, for example, using a Schizosaccharom, ces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al.
(2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al.
(2000) Biochem. Biophys.
Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W.
et al. (2000) U.S.
Patent No. 6,022,691).
Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient.
Delivery by transfection, by liposorne injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat.
Biotechnol. 15:462-466.) Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.
An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and pxoteins.
Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of GCREC, antibodies to GCREC, and mimetics, agonists, antagonists, or inhibitors of GCREC.
The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.
Compositions for pulmonary administration may be prepared in liquid or dry powder form.
These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar xegion of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, . J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.
Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.
Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising GCREC or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, GCREC or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).
For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
A therapeutically effective dose refers to that amount of active ingredient, for example GCREC or fragments thereof, antibodies of GCREC, and agonists, antagonists or inhibitors of GCREC, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the EDSO (the dose therapeutically effective in 50% of the population) or LDso (the dose lethal to 50°7o of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LDSOlEDSO ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the EDSO
with little or no toxicity.
The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.
The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half life and clearance rate of the particular formulation.
Normal dosage amounts may vary from about O. l ,ug to 100,000 ,ug, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature arid generally available to practitioners in the art.
Those skilled in the axt will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.
DIAGNOSTICS
In another embodiment, antibodies which specifically bind GCREC may be used for the diagnosis of disorders characterized by expression of GCREC, or in assays to monitor patients being treated with GCREC or agonists, antagonists, or inhibitors of GCREC.
Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics.
Diagnostic assays for GCREC include methods which utilize the antibody and a label to detect GCREC in human body fluids or in extracts of cells or tissues. The antibodies ma.y be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.
A variety of protocols for measuring GCREC, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of GCREC expression.
Normal or standard values for GCREC expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, far example, human subjects, with antibodies to GCREC under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means.
Quantities of GCREC
expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.
In another embodiment of the invention, the polynucleotides encoding GCREC may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of GCREC
may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of GCREC, and to monitor regulation of GCREC levels during therapeutic intervention.
In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding GCREC or closely related molecules may be used to identify nucleic acid sequences which encode GCREC. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5'regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding GCREC, allelic variants, or related sequences.
Probes may also be used for the detection of related sequences, and may have at least 50%
sequence identity to any of the GCREC encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID
N0:20-38 or from genomic sequences including promoters, enhancers, and introns of the GCREC
gene.
Means for producing specific hybridization probes for DNAs encoding GCREC
include the cloning of polynucleotide sequences encoding GCREC or GCREC derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA
polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as 32P or 35S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.
Polynucleotide sequences encoding GCREC may be used for the diagnosis of disorders associated with expression of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, colon, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha 1-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmunelinflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and togavirus. The polynucleotide sequences encoding GCREC may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered GCREC' expression. Such qualitative or quantitative methods are well known in the art.
In a particular aspect, the nucleotide sequences encoding GCREC may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding GCREC may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding GCREC in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.
In order to provide a basis for the diagnosis of a disorder associated with expression of GCREC, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding GCREC, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder.
Deviation from standard values is used to establish the presence of a disorder.
Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject.
The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.
With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type rnay allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.
Additional diagnostic uses for oligonucleotides designed from the sequences encoding GCREC may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding GCREC, or a fragment of a polynucleotide complementary to the polynucleotide encoding GCREC, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.
In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC may be used to detect single nucleotide polymorphisms (SNPs).
SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like.
SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).
Methods which may also be used to quantify the expression of GCREC include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. hnmunol. Methods 159:235-244; Duplaa, C.
et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.
In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.
In another embodiment, GCREC, fragments of GCREC, or antibodies specific for GCREC
may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.
A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis,"
U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.
Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.
Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S.
and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families.
Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression~is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at http://www.niehs.nih.gov/oclnews/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.
In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.
Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type.
In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.
A proteomic profile may also be generated using antibodies specific for GCREC
to quantify the levels of GCREC expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem.
270:103-l I l; Mendoze, L.G. et al. (1999) Biotechniques 27:778-788).
Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.
Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.
In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.
In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A
difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.
Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al.
(1996) Proc. Natl. Acad. Sci.
USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application W095/251116;
Shalom D. et al.
(1995) PCT application W095/35505; Heller, R.A. et al. (1997) Proc. Natl.
Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed.
(1999) Oxford University Press, London, hereby expressly incorporated by reference.
In another embodiment of the invention, nucleic acid sequences encoding GCREC
may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence.
Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (PACs), bacterial artificial chromosomes (BACs), bacterial Pl constructions, or single chromosome cDNA libraries. (See, e.g., Harnngton, J.J.
et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134;
and Trask, B.J.
(1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl.
Acad. Sci. USA 83:7353-7357.) Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding GCREC on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.
In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps.
Often the placement of a gene on the chromosome of another mannmalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.
In another embodiment of the invention, GCREC, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between GC1ZEC and the agent being tested may be measured.
Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT
application W084/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with GCREC, or fragments thereof, and washed. Bound GCREC is then detected by methods well known in the art.
Purified GCREC
can also be coated directly onto plates for use in the aforementioned drug screening techniques.
Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.
In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GCREC specifically compete with a test compound for binding GCREC. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GCREC.
In additional embodiments, the nucleotide sequences which encode GCREC may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent.
The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 60/221,478, U.S. Ser. No. 60/223,268, U.S. Ser. No.
60/231,121, U.S. Ser.
No. 60/232,691, U.S. Ser. No. 60/235,146, U.S. Ser. No. 60/227,054, and U.S.
Ser. No. 60/232,243, are hereby expressly incorporated by reference.
EXAMPLES
I. Construction of cDNA Libraries Incyte cDNAs were derived from cDNA libraries described in the LlFESEQ GOLD
database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCI cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.
Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA
purity. In some eases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA
purification kit (Ambion, Austin TX).
In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA
libraries. Otherwise, cDNA was synthesized and cDNA libraries Were constructed with the UNIZAP
vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA
was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S 1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BIueMRF, or SOLR from Stratagene or DHSa, DH10B, or ElectroMAX
DHlOB from Life Technologies.
II. Isolation of cDNA Clones Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis.
Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Prornega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL
8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIA.GEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.
Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II
fluorescence scanner (Labsystems Oy, Helsinki, Finland).
III. Sequencing and Analysis Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows.
Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ.Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI
sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI
protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.
The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) Curr. Opin.
Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and I~VIMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences.
Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA
assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM.
Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).
Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.
Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, ,where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).
The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ
ID N0:20-38. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.
IV. Identification and Editing of Coding Sequences from Genomic DNA
Putative G-protein coupled receptors were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA
sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon.
The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode G-protein coupled receptors, the encoded polypeptides were analyzed by querying against PFAM models for G-protein coupled receptors.
Potential G-protein coupled receptors were also identified by homology to Incyte cDNA sequences that had been annotated as G-protein coupled receptors. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST
hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA
coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan predicted coding sequences.
V. Assembly of Genomic Sequence Data with cDNA Sequence Data "Stitched" Sequences Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA
sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences, to generate the longest possible sequence, as well as sequence variants.
Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.
"Stretched" Seguences Partial DNA sequences were extended to full length with an algorithm based on BLAST
analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST
analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example 1V. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog.
Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.
VI. Chromosomal Mapping of GCREC Encoding Polynucleotides The sequences which were used to assemble SEQ m N0:20-38 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ 1D N0:20-38 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Genethon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ LD NO:, to that map location.
Map locations are represented by ranges, or intervals, of human chromosomes.
The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM
distances are based on genetic markers mapped by Genethon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.
VII. Analysis of Polynucleotide Expression Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.) Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or L1FESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:
BLAST Score x Percent Identity 5 x minimum { length(Seq. 1), length(Seq. 2) }
The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP
(separated by gaps). If there is more than one HSP, then the pair with the highest BLAST
score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100%
identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50%
overlap at one end, or 79%
identity and 100% overlap.
Alternatively, polynucleotide sequences encoding GCREC are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA
sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue;
digestive system; embryonic structures; endocrine system; exocrine glands;
genitalia, female;
genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed;
or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding GCREC. cDNA sequences and cDNA
library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).
VIII. Extension of GCREC Encoding Polynucleotides Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.
Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.
High fidelity amplification was obtained by PCR using methods well known in the art. PCR
was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg2+, (NH4)ZS04, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec;
Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2:
94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min;
Step 5: Steps 2, 3, and 4 repeated 20 times;
Step 6: 68°C, 5 min; Step 7: storage at 4°C.
The concentration of DNA in each well was determined by dispensing 100 ~.l PICOGREEN
quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE
and 0.5 ~,l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II
(Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 ,u1 to 10 ~1 aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.
The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE
(Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LBl2x carb liquid media.
The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3:
60°C, 1 min; Step 4: 72°C, 2 min;
Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA
recoveries were reamplified using the same conditions as described above.
Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI
PRISM
BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5'regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.
IX. Labeling and Use of Individual Hybridization Probes Hybridization probes derived from SEQ ID N0:20-38 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 ,uCi of [y-3zP] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech).
An aliquot containing 10' counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases:
Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).
The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5%
sodium dodecyl sulfate.
Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.
X. Microarrays The linkage or synthesis of array elements upon a microaxray can be achieved utilizing photolithography, piezoelectric printing (ink jet printing, See, e.g., Baldeschweiler, supra.), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers.
Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, LTV, chemical, or mechanical bonding.
procedures. A typical array may be produced using available methods and machines well lalown to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalom D. et al. (1996) Genome Res. 6:639-645;
Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.) Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection.
After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element.
Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization.
The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.
Tissue or Cell Sample Preparation Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)~ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)+
RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/~,l oligo-(dT) primer (2lmer), 1X
first strand buffer, 0.03 units/~.1 RNase inhibitor, 500 ~,M dATP, 500 ~.M
dGTP, 500 ~,M dTTP, 40 ~,M dCTP, 40 ~,M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)''- RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)~ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37° C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH
Laboratories, Inc.
(CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mglml), 60 ml sodium acetate, and 300 ml of 100%
ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 p,1 5X SSC/0.2% SDS.
Microarra,~paration Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts.
PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert.
Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 ~.g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).
Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1 % SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4%
hydrofluoric acid (VWR
Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.
Array elements are applied to the coated glass substrate using a procedure described in US
Patent No. 5,807,522, incorporated herein by reference. 1 ~,l of the array element DNA, at an average concentration of 100 ng/~,1, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 n1 of array element sample per slide.
Microarrays are UV-crosslinked using a STRATALINI~ER UV-crosslinker (Stratagene).
Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water.
Non-specific binding sites are blocked by incubation of microarrays in 0.2%
casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°
C followed by washes in 0.2% SDS and distilled water as before.
Hybridization Hybridization reactions contain 9 ,u1 of sample mixture consisting of 0.2 ~,g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer.
The sample mixture is heated to 65° C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cmz coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 ,u1 of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45° C in a second wash buffer (0.1X
SSC), and dried.
Detection Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of CyS. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.
In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially.
Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT 81477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for CyS. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.
The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A
specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:.100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.
The output of the photomultiplier tube is digitized using a 12-bit RTI-835H
analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC
computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstallc (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.
A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).
XI. Complementary Polynucleotides Sequences complementary to the GCREC-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring GCREC.
Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of GCREC.
To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GCREC-encoding transcript.
XII. Expression of GCREC
Expression and purification of GCREC is achieved using bacterial or virus-based expression systems. For expression of GCREC in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA
transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3).
Antibiotic resistant bacteria express GCREC upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of GCREC in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Auto~raphica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding GCREC by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera fru~iperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases.
Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K.
et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al.
(1996) Hum. Gene Ther.
7:1937-1945.) In most expression systems, GCREC is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-~kilodalton enzyme from Schistosoma is onp icum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from GCREC at specifically engineered sites. FLAG, an F-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG
antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, su~a, ch. 10 and 16). Purified GCREC obtained by these methods can be used directly in the assays shown in Examples XVI,,XVII, and XVITI, where applicable.
XIII. Functional Ass.-,~s GCREC function is assessed by expressing the sequences encoding GCREC at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA
expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 ,ug of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 ,ug of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA
with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.
The influence of GCREC on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding GCREC and either CD64 or CD64-GFP.
CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mlZNA encoding GCREC and other genes of interest can be analyzed by northern analysis or microarray techniques.
XIV. Production of GCREC Specific Antibodies S GCREC substantially purified using polyacrylamide gel electrophoresis (PAGE;
see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.
Alternatively, the GCREC amino acid sequence is analyzed using LASERGENE
software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means lrnown to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.) Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A
peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-GCREC activity by, for example, binding the peptide or GCREC to a substrate, blocking with 1 % BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.
XV. Purification of Naturally Occurring GCREC Using Specific Antibodies Naturally occurring or recombinant GCREC is substantially purified by immunoaffinity chromatography using antibodies specific for GCREC. An immunoaffinity column is constructed by covalently coupling anti-GCREC antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.
Media containing GCREC are passed over the immunoaffmity column, and the column is washed under conditions that allow the preferential absorbance of GCREC (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GCREC binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such . as urea or thiocyanate ion), and GCREC is collected.
XVI. Identification of Molecules Which Interact with GCREC
GCREC, or biologically active fragments thereof, are labeled with'ZSI Bolton-Hunter reagent.
(See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GCREC, washed, and any wells with labeled GCREC complex are assayed. Data obtained using different concentrations of GCREC are used to calculate values for the number, affinity, and association of GCREC with the candidate molecules.
Alternatively, molecules interacting with GCREC are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).
GCREC may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K.
et al. (2000) U.S.
Patent No. 6,057,101).
XVII. Demonstration of GCREC Activity An assay for GCREC activity measures the expression of GCREC on the cell surface. cDNA
encoding GCREC is transfected into an appropriate mammalian cell line. Cell surface proteins are labeled with biotin as described (de la Fuente, M.A. et al. (1997) Blood 90:2398-2405).
Immunoprecipitations are performed using GCREC-specific antibodies, and immunoprecipitated samples are analyzed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of GCREC expressed on the cell surface.
In the alternative, an assay for GCREC activity is based on a prototypical assay for ligand/receptor-mediated modulation of cell proliferation. This assay measures the rate of DNA
synthesis in Swiss mouse 3T3 cells. A plasmid containing polynucleotides encoding GCREC is added to quiescent 3T3 cultured cells using transfection methods well known in the art. The transiently transfected cells are then incubated in the presence of [3H]thymidine, a radioactive DNA
precursor molecule. Varying amounts of GCREC ligand are then added to the cultured cells.
Incorporation of [3H]thymidine into acid-precipitable DNA is measured over an appropriate time interval using a radioisotope counter, and the amount incorporated is directly proportional to the amount of newly synthesized DNA. A linear dose-response curve over at least a hundred-fold GCREC ligand concentration range is indicative of receptor activity. One unit of activity per milliliter is defined as the concentration of GCREC producing a 50% response level, where 100%
represents maximal incorporation of [3H]thymidine into acid-precipitable DNA
(McKay, I. and I.
Leigh, eds. (1993) Growth Factors: A Practical Approach, Oxford University Press, New York NY, p.
73.) In a further alternative, the assay for GCREC activity is based upon the ability of GPCR
family proteins to modulate G protein-activated second messenger signal transduction pathways (e.g., cAMP; Gaudin, P. et al. (1998) J. Biol. Chem. 273:4990-4996). A plasmid encoding full length GCREC is txansfected into a mammalian cell line (e.g., Chinese hamster ovary (CHO) or human embryonic kidney (HEK-293) cell lines) using methods well-known in the art.
Transfected cells are grown in 12-well trays in culture medium for 48 hours, then the culture medium is discarded, and the attached cells are gently washed with PBS. The cells are then incubated in culture medium with or without ligand for 30 minutes, then the medium is removed and cells lysed by treatment with 1 M
perchloric acid. The CAMP levels in the lysate are measured by radioimmunoassay using methods well-known in the art. Changes in the levels of CAMP in the lysate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC
present in the transfected cells.
To measure changes in inositol phosphate levels, the cells are grown in 24-well plates containing 1x105 cellslwell and incubated with inositol-free media and [3H]myoinositol, 2 ~uCi/well, for 48 hr. The culture medium is removed, and the cells washed with buffer containing 10 mM LiCI
followed by addition of ligand. The reaction is stopped by addition of perchloric acid. Inositol phosphates are extracted and separated on Dowex AGl-X8 (Bio-Rad) anion exchange resin, and the total labeled inositol phosphates counted by liquid scintillation. Changes in the levels of labeled inositol phosphate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC present in the transfected cells.
XVIII. Identification of GCREC Ligands GCREC is expressed in a eukaryotic cell line such as CHO (Chinese Hamster Ovary) or HEK
(Human Embryonic Kidney) 293 which have a good history of GPCR expression and Which contain a wide range of G-proteins allowing for functional coupling of the expressed GCREC to downstream effectors. The transformed cells are assayed for activation of the expressed receptors in the presence of candidate ligands. Activity is measured by changes in intracellular second messengers, such as cyclic AMP or Ca2+. These may be measured directly using standard methods well known in the art, or by the use of reporter gene assays in which a luminescent protein (e.g.
firefly luciferase or green fluorescent protein) is under the transcriptional control of a promoter responsive to the stimulation of protein kinase C by the activated receptor (Milligan, G. et al. (1996) Trends Pharmacol. Sci. 17:235-237). Assay technologies are available for both of these second messenger systems to allow high throughput readout in multi-well plate format, such as the adenylyl cyclase activation FlashPlate Assay (NEN Life Sciences Products), or fluorescent Ca2+ indicators such as Fluo-4. AM (Molecular Probes) in combination with the FLIPR fluorimetric plate reading system (Molecular Devices). In cases where the physiologically relevant second messenger pathway is not known, GCREC may be coexpressed with the G-proteins Gaisne which have been demonstrated to couple to a wide range of G-proteins (Offermanns, S. and M.I. Simon (1995) J. Biol. Chem. 270:15175-15180), in order to funnel the signal transduction of the GCREC through a pathway involving phospholipase C and Ca2+
mobilization. Alternatively, GCREC may be expressed in engineered yeast systems which lack endogenous GPCRs, thus providing the advantage of a null background for GCREC
activation screening. These yeast systems substitute a human GPCR and Ga protein for the corresponding components of the endogenous yeast pheromone receptor pathway. Downstream signaling pathways are also modified so that the normal yeast response to the signal is converted to positive growth on selective media or to reporter gene expression (Broach, J.R. and J. Thorner (1996) Nature 3~4 (supp.):14-16). The receptors are screened against putative ligands including known GPCR ligands and other naturally occurring bioactive molecules. Biological extracts from tissues, biological fluids and cell supernatants are also screened.
Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.
A
H
N
~
-r1 1-~
O ~-I~-1rl~-I~-I~-Ic-I(17Wr-IpW-Iv-1c-Ic-1r-IP4~-Ic-I
U G~1Pafr1POP4Pan!U UW UW 0.1alW POU 0.1W
U
~ UU UU UU UInoU mU UUU U~ UU
~
H lDO NO r1L~Lf1tW-101N~DL~NM Or-1v-1d~
V
Od~01l0r1~Or1N Md~NODOd~Lf1r-1diOL~
00W ON 41t~00M MM N~ OOO d~l0t~L~
d~d~LIW-1Md~tf7l0OL~OLC7N01l0OM s-1v-I
'~ t~L~hd~t~l~L~N NL~OL 00l0L~oO 0000 O d~d~d~M d~d~cf'O Od~1.ndid~Ld~d't17d~d~
~ N
N
'~
~O
O
Z
rwl U
H
O~
W
O Or1NM d~Lnl0L~0001Oc-1NMd~111l0l~~
W NN NN NN NN NN MM MM.MMM MM
H
N
O H r-I c--1 r-I
'~ -Il -1l 1-1lCa~1-ICal l-I-Ilf~l-f ~
~
l . rr rr r. rU Ur Ur rc~ rU r.
- Afa~IC~AI~~I Ia faPaPafata f~A
r ~+~
U U.UUU UU UInoU InU UUU U~ UU
,''lflO NO r!~ InL~r101Nl0L~NM Oc-1c-Id~
N
H Od~01l0r1l0c-1N Md~NGOOd~L17rid~OL~
N00ON 01L~NM MM Nl0OOO d~lflt~l~
r1 did~Inc-1Md~Inl0OL~OInNO1l0OM v-I~-I
O L~h L~d~L~L~I~N NL~OC~00l0t~00O 00OO
W cH'd~d~M d~d~d~O Odi111d~d~L~d'd~Ind~di C~L~l~l~L~L~t~l0l0l'L11L~L~lflL~L~LC7L~L~
..
~
N
H
~
OI
~
W
O
~
LL
O v-IN Md~Inl0L~0001 v-IN Md~LC)l0L~N 01c-1v-Is--Iv-Ic-1u-Ir1r1v-Ir1 A
H
N
.1, tf1o In ,1Jl0O NO rlL~L(1L~c-I01Nl0L~NM Oc-Iv-1d~
U
~ Od101t0r1l0r1N Md~N00O~Lf1w-Id~OL~
00,NON 01L~ODM MM N~OOOO d~l0L~L~
H ~~ ~H M~ ~~pOl~OinNO1l0OM v-Ic-1 O
~ L~l~l~d~L~C~L~N Nl~Oh ~l0l~00O 00OD
~
d~d~~HM 'd~d~cttO OdiLnd'd'L~d~d~InCPd~
L~t~L~t~L~L~L~l0l0L~LnL'~L~l0L~<'LnL~L~
a~
(R N
~
td -ri 00 1 r1 O O
O
~ N U! L11 I l~LI N
h -.-I .1-~ r1 r1 fl.~ R,N ri N
U Cl~ ~
N f: O -.-IN r1 d~ N C7 N b7 ~L ,~' N
N U
.1.~ N ~I ~ U N >~ W I cd C7 ~ ~ U U
~ U U U
O P W O O U ~ O N ~ ,~ O -rl -.-I
~I N N N
~I r1 N I ~', ~, ri ~, ~ ,'~~ ~ U .~i r-I
O L ~I ~I~I
, rtfU7 C7 O ~ "~,'O d~ -rlO r-IU ~ , .!~ ~ r1 N
, U1 U' i-1 O ~I ~ U ~ u1 ~,' N aW
u7 r1 N >~'I O O n N
U' ftSN N O o1 .~.,N L r1U r1 r1 ,'~ M
N r1 ,.S",rI.G' -r-I -rl U ~, ,5 ,5 rCi N ,~,'01 (~(~ O N L~ N M
M ~ 01 N r1 ~C~ L!1 W I
O O -~'i-r-I S2~ ~'.,, M U ~.,lfl1~ U1 00 U o~ c-i U r-I O r1 t~
O ~I J~ .u v U N .1~(d O O ~ ~,' ~I P-S O1 I $1 M d' ,5 N (IS(IS ~ ~ r, w r-.~ L~ S-i r~ -ri c-I 01 ~,' O O O I7 M
I
(0 ~ J~ .U Ul U N F(', UlU1 F(,'~ O U7 r1 N ',7 l0 M r1 ~I~-I.i-101 S-I ..
w-I
'~lO ~ ~ U ~ P-~'I ~ '-' ~ ~ " I O ~ -r1 ~',v 01 U .1~I ~ l0 O M
~
O ,5 ~ra~ ~1 U U U ~ U U ~ C7 U ,!~
r1 ~I o~ td~ N .!~ d~
M o~
r1 O N W r1 c-I -r1.~, -rl-rlU v -rl a .!~ r-I-ri ~ di r1 r-,r, ~ ri t31 v t51 b1t'r~ ~ r1 b1 O
O 1~ .!J r1 I N N O
o1 rtfU7 m m rt N N U~ U m N U UW-1u1 ~ ~-I
N O b~ IO.!' o~ U --.-I
Ol ~ ~, ~., ~ ~i ~ f-i ~J~ ~i ~ ri ,5 .1~
r1 N ~1 ~-I ~i ..~-i0 d~ O 01 '-' b7 U r1 N O O S-I N ,4 v ~-I~-Irv r1 ~-I rIS
U ~ .!~ r1 -rl fir~-1''~(CS ~-1 o1 r-I u-I di O m ~ -r1-r1 O -ri O -ri O O -r1~ M O r-I
~ U .L.I cd ~ r1f.~N o~
N vo r1 -riU f~ ~ ~ f: f~ ~,'yri ~J.f'.f~ U l G' r1 f; ~-1O ''CS N f0 r1 .1~ N
rd r-I
o1 O f-IW td fd to (a \o (a cISU7 W.,''~
' ~,'N >-.,' .l~ U1 (d IJU7 r h,' t6 >37....
~ a U IJ U7S tA N 01 U7 N U7 ~ .l.- U7 f~
~ W (a O t51~ U7 U1 U7 7 ~ . . -~1O ~ U' c .
, ~ (~ U ( !~ ~ ~ ~ FC ~ ~
~- ~ ~I x ~ ~ O ~I R
~ N N o~ .l~
N I
x ~ ~' O io N . !~ O N N O Ix 1~ ..
W O ~ O O N J~ U N ~-I
I ~' L~ ~
J~
-i ., ~ - . ~ . ~ . . ~ ca .i~ ~
u1 ~ , 1~ S-I I, U IJ4J I ~-I u1 1~
O W -I ~-I "~ ~-I ~ ~
U
,x . ~~ ON O''d . 00 . O . . 0~ ~0 ON ~.l~N
N''d I t~0 NO I t~~t~ N a~
to ~a~~o x~ xa~~i~x.~ x~ x.>,xa~ rxv~ x-~I~.u~~,rx~h~.us~~
.O . rx (CS '-''-''-''-' ~ C~ '-' '-''~ '-'rrdd'-''-' '-' fa r1 ~I U7 r1 U ~ Sirr1 'J N ~ Ul ~ N O N v-I
l0 ,sa' Pa ~ N ~ ~ f~ ~ N N r, r, ,-,r, -, ~-, ~ ~
~.',-l (d .l-~N '~ Q)f-i.!~N ~,' .,~
c-t 1 M ?G . Ul S?t ..
~: r-Ir-Ir-Ir-I r1 r-i rI ri r-Ir-Ir-Ir-I r-I O
,.'7,.C,(d ~ U U U ''~ '~4-1O U N ?-1 (d r1 O ~ ,~-I N P~l 117 O d~
N 4-!4-14-I4-! 4-1 4-! 4-I4-I 4-I4-I4--I4-1 4-I W
O , ~.1O N N N O ~'.,~,'~-IO ~I (d ~-1 ~ N td ,.Q W
M 01 -r-1 L~
U '-'~ ~ ~ U ~ ~-I ~ '-'~ '-'~..~ ,J '-' ~
U .h C7 ~1 ~I LI .~. -ri-,~~ ~-I J.) 'a t17 v-I '~-a W W FC Gr-i N ~, I O d~
r rI N Lfll0 O CO d~ l0 c--1 00 O 01 -rI t0 10 00 c-I c-I u-I LC W -I c-1 c-I Lll N W W W W W W W W W W W
,.Q O O O O O O O O O O O
~I
O O O O O O O O O O O L~
O
U
W di d~ N wt N N v-1O O M O r1 r1 r1 A
~o c-Iw N d~ d1 d~ r1N o0 di c0 c-I
t11d~ N M 111 Ll7 t!1c-I COlD M 00 L~ ~O
C~, N l~ l0 O1 N 00 N M 01c~ d~ 00 O O
(a L~ lD N Ln In 01 In c0 N 01 l0 a0 LP1 d~
pa O O1 01 O In 01 In r1 ODlW -I d' N l0 ', I~ r1 01 00 O L~ O M ~ 01 d~ N Lf1 c-I
N N r1 N M c-I r1 v-Ic-I M ~D u-IL~ tIl d~
O
C7 l r31i31Ol I31 i;31X71Ol isX31Ol Ol b1 ~1 .~-W
N c~ c-I r1 ''O c-1ri w-Ic-I w-1 <i r1 A (~c-IA r1 c-I c~
-~1 ~l fa f~ (a ~1 A fa U U Pa U ~l ~1 fa ~ U U U U U U U in O U ~ U U U
~ l0 O N O r1 t~ L!1C~ c-I01 N l0 h N
N O d~ O1 ~O ~-1 l0 r1 N M d~ N OD O d' N
00 00 O N 01 L~ 00 M M M N ~O O O
d~ d~ Lflc-I M CH !.nl0 O L~ O 111 N 01 U L~ L~ t~ d~ C~ L~ t~ N N t~ O t~ 00 l0 r-I
~ dm r ~n M ~r ~r ~r o o dm i d~ d~
O
l.~
I-I L r L l r~ r C~ lO ~or i17L t l0 w I-I
N
..
,.
~Z
N
Ca Q O r1 N M 'd~
W
L4 r1 N M d~ In l0 h OD a1r1 r1 v-I c-1 c-i ri M M ~I
l~.N ~I U
~
O W , ~U O
lO
.1.~ N N 1~
~n O --. U U U
d~ -~
~d O N (CS
M CO
M
N o1 ~-I~1 4a ?-1 U7 01 r1 O
N
~-I ~y~t O .!, !I7 r1 -- ~-1~-I U
di ~-U~ O O r1 td M
U
r-I U U .~.,r1 o r1 w1 a3rtS O
rd cd o~
b1 4~4-1 O .1-~r-Ir-I U7 ~ U O O
'~ N
tr r- ~ U' u7u1 U
1 f~
~
.
',~,'.N U ~
-ri U7 N
1W-I U1IJ~ U7 td ~I ~-I r'-I
.x' ~f ~ ~ ~ .l.) O I O
O
P~ .-. u1m ,-,S-I
N ~ N
srs ~
''~
r-1 ~ Wd r-I!d U U
r-I
(IS
~ ~ ~ ~
~ C7 ~I ',~,'~
W o~ S-I
r.G
~ .,-1u 1 0 r1 ~o eoaW ~ o N ~
N ~ w w w w w a~
N O O O O O
O O o~O O r1 O
W r1 r1Ln N M
en A
H to N CO c-iCO
Ln CO01 d~ l~
L~ M M L~
(a O M M O c-I
(Y~ O 0000 O O
c-I 0101 N 01 N M M M v-ILO
O
U' b1 t51>31 b1 -~.~
N .-I
s-I~ c~ c~
~~I ~1 f~U f~ fa .1.~U U oo U U
i M O ~-W -1 cH
N u7 c-Id~ O
N
O d~to L L~
l0 O M c-1r1 U h aOO 00 c0 r1 O d~ 'd~t17 d~ d~
H l t~ttW
W
H
N
..
~1 O
1~
"Z, >~
U
Ca i H
r~~t OI
O Lf1 10L 00 01 W
W r1 c~r1 ri Ul rn H ~ ~ ~ H
ro U ~ 0 0 o z o a~ ~ ~ ~ 0 0 0 ~ ~ o n ~ CTaa W O P; p; P.' a W R:
U P4 fsa O
-ri W I I q W W W W ~ W
tn m +~ I CJlCIA 1 I I I ~ C!~
'TW
d ?, rxrxW w H H E-mx C-~r~r~ w c~H
O
.R
.-I W W ~ ~ U2 tryv7 W u7 W W ~ W U7 ,-~ H H ry' F(',~ FC H ~G' ~ a ~ a a ~ ~
ctS
.1-1 .1~
0.l P 0. P W
4 1 .~
d~ M S=i N
M . -rl ~-1 f~ H l N
L
1 S M a1 -1~ .1-I
~ ~
O l0 N N O fd v-i ~
d~
~
r-I~.,M O M ,'~' W i b7 r1 a C=.~-r1t~ f1,' c-I I -rlr1 U1 l0 ','>
I
IlkM LL O 01 ~ N Ul U7 l0 I
N
H
01O O ~y O H M t<j O ~y l0 ' ~-1x a '~ a1 N N
l P
O<
O ZjO r-I ~, ~1 r M
c-IO ~ M ~1 ' I d~O -1 a -.-1 ' -,-I
N ~ ..
M ..
E-~.f,'P~1~ o ~ ~ t~,s,''~ U
E-~N ~ C=a H
I ~II i .. .. o ~ a ~, ~ ~. 1 0 d1v F-IcI ~-I ~1 01 N ~-,1 ~ COO
tf)I n '~ ~1-1 -I0 ~-1 M
l0 ~
L
' O , O O 01 Ud Ln -I c 1 ,~~-1l1~I J~ .L-1O ~'.,Ln~I N r-101 -L~, N
N ~ N O
O O
N
I
M
O , C~ s~, f.2,o ~ cfia O >~ H o E-~o ~ ~ o ~ ~ O
o ' ~
J-~~ ~ N N N ~1 " ~-i .t-1~ P; O
M N ~ t~, N
N
U7~ U U1 U M U P-IU7 .-O ~ U1 ~ rI M ' ' W
~ M N W
M
' N N Cu Cl~ N ~ ~,N ~ W
Ln d~ N U7 ' Ul P, N .-iU S-IP~ ~I ~-I.. -,..I~ ,-riU P; -rl M 00 I ~ O d~
I I ~ 00 I
I
N ('dN N U Ln N ~-1ai Ul tIiN U di (dP;
U1 ~ t!1 00 N In M
U ~ ~I''d~4 '~ ~ O ~ td ;~~-IW r1 ~ O O
4-I d~~ t d~ m M O .-I
f~ d~ N
d~
tn s~ o N a~ c7 a~ a~ .u o c~,o In o ~. o H o, -~I I o r~ r1 ~' a a I r~ N I H
r~
~
N '~. w-I0-1 v-1 c-1S~.t'~ GaN a I GaW
.L) Q7d~ O CTa ~i M N t M ' ' ' ' O ,~-t~ N ~ .. ~ O ~, ~ O I W I
~~ N .~N H .. I U N N N ~( M N 'U N
' , ~ l0 .. X01 ~' , N
S ~ .. (O ' ( I NL~O I ~
N ~ ' O
' N
l0 , ~ (IN . N O N ~ ~ s~ , >~W ct' U ~ O mrl O N eo ~ ~I , ~If~ ~o N rl '-rl oo t~ ~ tw-I
d~ N
' ~ U rj U M U ~-1~ ~ ~ '~ r-I ~ L~
~ M ,'~ ~ ~ M~ Ff M . U7 M a >=i -Ia . ' ~,' ~,'O c-iL~ O f=i ~ W
N N f~'Fi L~ .. ' a O ~ ~ PG ~ L~
tIS ~ 1.n01 01 l ~ ~1 . ..I- O dl C7 ~ ..I LO - l L~
. . - l~
M l L~
N N -d~
U1 QJ. ~ , r r C N ',7N . r N , , N U~ N N , I ~ . . U1 O
~ v-iL~~ N O O ., M
U1 N Ul M
~. M
.1J .~.~i.1-~~ J-1 ..I-1.~.,.~.,-rl~,' (2~ .~.,,~' c-I
(," ~rW L r1 O ~ M ~,'N
',7 N ,5yN
O N
N -M ~-~I~n~~IO o~ oMOOm~ro0 o u~~-uqm ~~ ooOO <no~
I I ~ '~O ' ' I
' ~
~i ~i~-tf-1~ , ~-f~I l;.i(a ~i~-1O O .,I~
(~ -r1l0 I -1 O ~ ~ ' -r1O ~
l0 N ' LC7 ' d O
b7 (d.1~~ O t r1 ~ N df .7~QS.!->O W (fSW
~, ~ r1 M c-I O L ' ~ ~ P- S 'J1 I r-I In I ' ' n R
I -I C'; N (~ ~ n O L I ' W
~ ~ In W
t P
~
r -i i ,. n d , . -I .~ -I, 1 d , -1 r4 N
U~ H t~C7 fx C7 C7 W En W H .~ P; H W tn Ca 4-I~ ~ W W 4-I
H
W
C~
-O
r ai o0 0 ~-I
z z z ~ z o ~n N o0 o d~ d~
U d~
N
1J In l0 00 Ln 00 ,5y 00 M
.!-~
O M v-Ic-I w-I c-1 r1 N 01 -r1 wcn~nz z zz z z z O t!7 M Lf1 i.n M
c-I
L'~
O
r1 01 00 01 N c-1 l0 l0 In d~ l17 01 d~
l0 N
JJ 00 v-IN M N
di M M
O LO Lf~
O l0 l0 (~ c-I M U7 IJ~ Cl~
U7 UW 01 Il~
00 CJ~
N
H
-I a1 tn Ei ~-I H
r1 E-~ lfl t17 M
H l0 N O
~ 01 t0 d~
(a t1~ N ~ 00 ri M Lf1 H M
M 01 l0 l0 d~
L~
-r1 ~-I N N -I N
O M l0 M M
l4 CW LC7 M l0 w-I
M
,~ u~ t~ try u1 v1 u~ tn cn H u~ rwn E-~
~ ~ H
~., ~
N c-I L~ L~ M t!1 Ul O N CJs O
N In N N
W
c-1 1J c-1 M Lc1 N O
O \O N d~ Lf7 -4~ d~ r1 01 tf1 O
O
O c-i N N ~--I -i ~'.,N N M LW N
-r1 N di d~
N tD
L~
M
W U~ t!~>n u~ ~
W u~ H U~ cIW u~
tn u~ v1 u7 H U~
Ei N
O M
~
M N
-~ M d~
M O l0 ~, M l0 P
i O r1 r-Ic-I
O pp N O l0 c-1 N
Ln ~ M
U
O
~1 ~ ~ ~ ~ N
H
W
H
CN
~
Z H N M d~
>n 1n H
'TJ U '-Z ~ O
U l~
W l l ''d ~ In Hl cd ~ ; : w w ~
O
>
,~ u v H H H
r w w H H W
~
cd Cl~ O ~' FC
. ~
.I, ~ U
A 1 P4 P4 W PO a) I
di N
d~
O ~.I
~-I
r1 M J-1 W 01 I~ N
~
M
I U7 ~,' ~1 N O
~ ~' r ~1 -~-I .N ~--I
I ~-I
r~
H U1 N U1 (0 o M
r ',5 I
~2,.1~I >~ o o~
r r ~
N ''d~I r-i - ~', P-.' M
.~..,O
N
~ ~ Ul W
Ul ~',~ ~
W
I ~I U7 cIS U7 U1 N IO
r N ~-I4-I ~-I[1,' N lDO
d~ ~
O
M O ~I O O tl~ ri01 N M
~7 ,'~~-1.1-WiO J-~H N01 O
N
~~~ ~ H
r J-~~H WMMOIO O
u1 , UN mNVO U U~a~oo q H G' N N lO N W N N ~iW
N N M N
ra I -~IU ~I~xwN ~.1xxxaH ~I
N c-Ic>j~ U 1 1 I cdf~
U; H I r U ,'?"..,~ ~1 ~'~W '~ ~ N r .~.,O
4-I ~ ~ ~ r 00 N
~'., O 00 N C7 N W N N OH
r1 M N N N
~
N ~1 O r1 l11 r1 Hl ~t,' ~1W
.!-~ N M r fsa f~ I
',~
~, N ~,'w-Irv i p.~ .. W
O '~N ',~~ Cl~ ~ .. .. NN
~' f W O .. -1 i j ' ~ l0 l0 U
I '' 01 lO
I
~ -ri~,'C O ,~, O , ~'v O ~I I N O v-I W
M -rl c-1 r-1 .-1 ',~
U7 J~itfd~ U -1 U U M M (dfY, 'd dW N M M H
I
ry'01 I 1 I I Sa ~ ,'~ I
cH
fCf N 00 O Ci ~i ~i Z 00 00 w ~i O In M O1 ~' -j -j -1 O
H
r -, N N M z, ~ .
~n o m N m N W ---- NO
N -~ r r ~-I r H
O .I~ r1~ ~ .u p, .u H ~o r ~~
~ ~ ~r M M H o ~-I r1 cd cdUi Id O o o O ctt U7O
ri I r-IN N I r M 00 U7 (IS ~,'~1 ~I 't~ ~-IP'. N ~,'.
~ d~ -rlo o W to 01 p:
Ln 01 1 b) (a 1J ~ O ~ W N v-1 tlSW
~ .~., 00 O O O Ln d~ N
~ l0 " r1 r1f-1 I p.,' I I M In ~in-'T.' O ~-1' a r1 c-iN M d~
~
M v~ rpH r C7 w C7 C7 W w Hw q H 4-IPa ~ w w W x ~".,M
O Ln -r1 M
r-1 (~
(IS 00 r-1 -rl c--I
',?~
.!~ M
f=i ,~
O
N
U
N
O r-1 .-I
-.-1 G4 ",~, U~
O .-I 00 o~
r1 Lf') 00 a1 01 1J M v-I
N tO
(a U1 Cl~
H N
r-I O~ N
~ M
(d N d~
-ri N r1 O N r .I-~rn u1 ,.~ H tit ~', , N
N di N
tR tn M
N
.1~ ~-1 ~-I
O cH O
.7~
O N c-i ,i, r1 N
-r1 W u1 u1 v1 N
O
''C5 ~', "d -r-1 -ri N r1 -ri ' Fl, M N
p , N
H
W A W
.t-~U U
, r i.n o to r1 N
r m d m n U r r r-I
~ d~ d~
O
~-1 H r r W
H
O<
W
fa O
U1 ~ r H
'z, U O O
Z ~ ~
~
~ ~ ~ a x ~ U o o U r.~r~r~as w w ~n rx x o 0 a~
-~I w w w I I I W w w q A
~n m ~ I I I ~ rn u~ a I I I I
~s ~a ~, P;Ix P: P;P;w w Pa H E-~H H H f~
o ,~
r-I W W W W W x ~' ~i fl.~Ll7U7 Cl~ U7 H
~'-, cti H H H O ~C FC FC FC C~
.1~ ~ ~ ~
J.~
~~q ~ P
o ~-I 5~
'JyM N N O
c-1OI Q) N r1 d~
1 r-11 S-1 Ll7 l0 .1~
d~
d~ O1 ~ ' O tf1(C$
a H
~ N q N
x Fi G4 N W
N
O, t~, 1 ~, ~ x ~
d~ C7 .,_.i.. ~ -~ 117,-IL~ H ~, a ~-I
x ~ ~ a H
M N r1 O x O C~ M w di ~
a v ~ a~ ~M . a ~ H
I N o P4 -~i o, w w fL N
u~ o ~
r-,~n ~ I i~ o m m ~
~ I
N -- ~I as o ~1 A A Ix ~I
o ~n a ~r M Cl~ O 4-I O O W W O t31 lO l0 1 c-I
',~~.IW lO.1~~-I O .I~a a W ~ E-~!d In d~ O N M
N
a o C7~ f.~,N x s2~Pa w E-~ py ~I
~ co o, o, o, N I J-~ U N ~ W N n-~.,.~7,5Wf1 W (d M LO
Ln N U7 , 0 1 U ~ U O O U x U , O ~ H d~ C7 Ln OIF''.,N ',~O N UI N O U U O I W U7 d~ di o L cH I N
I
U7 ( r1 U r1M ~I ~ ~-I~I O U M P-',(IS
Ln In l0 ~ 01 d~
N ,-icd ~ r-IU d~ fW-mn~ W ~ ~ ~ oo I
r!? ~ M Lmn U ~',~ ~-II '-dU J~ '~ H H W ~-I f~ 'TJ
4-I W d' I ~,''N l0 a N
o ,~..o w as a~ w w a ~n mn . I M ,-1 I x I x N . q N I W -I C7 ~ ~-1E-~E-mo.. , .u ao o x M ..
a~ ..
o N ao ~ a -~i, I b~ W o o . w '~~ $ M M I n ' ~ ~o a~ 'D
~ ~ 5 ' ao ~
-I ao d' -I
~i W N (D U (C~ Ln -r-~ Q p v , r1 U d ~I w ~ d N rn , , , M M O m ~ O C O W v P; ~-i H C7 ',W-1 W a0 ~t,' '~-,t L
CI~ .!~cd ~',O U ri U .. ~ I U U
~ I I ~ M ~ .. C7 C7 I ai U
d~ -i m ~ I d~ rtS
~ ~ W tn I
~
~
~ f.~I O -~ ~ . , ~i N ' . ,~Z.,-.~1(($ N 10 d~ r1N .~'.n~ U~ N Ri N ' l4 H U
~-I QI~ ~.,-r1x M I W r1 L~ R=n d~ H -d~ l0 -r1O a ~I o cH d~ w I
a O ~'., N I o d~ m U
N ~ m M
' 01 M
I r~
o --~ ~ ~n ~ ct -~ , ~ n o o E-~~
~n ~ ~n . , I !~
~ ~r ~
i Q .h r-I~ ~ , -aJ u H .t H H n ~ .
~ tljU1 ~ O r1a d Ln .U Cy W N O ,<I
RS ~ c~ O x IN O Pa O O L~ M ..
-r1 I I N N I N
N l0 I
QS ~.,'~.,'~I ~II ~I ~-I N ~I W W ~ r1 ~, (If c-IN 00 O I ~, Ln C~ N O N
~ l!7 W 01 W N
o ~ b~ b1Wn .t 1~f~, U 00 , U U ~ ~ I , ~ -I~ ri IdC7~ o c<'tr ri W ao ~' .
I M I vo I W O LO U7 l d' M N -r1M M w-I
O P; d~
d' r . - ~ a w c~ =n N c7 x x x ~c , rn >nN ,a U w w m a H c7 ~C
A ~ ~ a, A ~n ,~r-I
c~c~ d~
.H o ao d~
,--I
zz ~
o m N d~
U r1 N N
M
o~
.!~ O
',?il0 .L.1M
O
O v-I
ri r1 -rl N
N
d~
W Z
L7 ~
u7 ~
S~
O d~
r1 01 Lf~
.h d~
In c-I
In L~
(a U7 iI1 N
N
H
N
r1 00 ,'?IO
l0 (a O
,S-I00 M
v-I
O
-ri M
O Ln l0 ~-I
d~
.1J U7 ~. U1 N
E-~
>~ Ea ~
~
N <' tt~
U1 ~
N ~
l~
.1~ Lf~ 00 O L~
l~ O1 v-I
O
O N tf7 ,.~,tf1 r1 In N
M
P, U7 ~
W cn tn u1 E-a H
In O
-r-Ic-1 ri N
N H
.-I U
.1~ Ln N N
N
U N
r1 O o (~
H ~O
W
H
O<
m x E-~ ~ ~ ~ x H
H H
r-I O O O f~ f~ ~l tISO O O
~ ~ O O ~ U a ~
W f.T~fsaa t.~ ~ O O fx fk f~ ~ f~7t O O
d W W O fY., W
m U
N
~I w w I I a a w w w w a~ I I q w u~ ~
~n 1.1 I I U7 Cl~ I I I I I I U1r-IUl r4 I I
rd ~
>, r~a: PGIxal w H H H H E-~fxw f~-~1w w H H
O
,.q r1 W W W W ,~,'~,' CIA U7 U7 U7 Cl)WW H4-I,~','~,'U)Ul ,t,' H H ry rC ~ ry'FC EnO H H r~Ft,' fd to .l~
.!-I
~ ~ ~~ ' ~' Pa t~ trl 5~.1W W W ~W Pa ~ W W
a lD M L~
~Di M to O~
d~
',?~00M 01 N N I 00 d~
~ ~ , I -r4 r! c-I dl I M fC, H
N ~ d~ri 01 N r-1>'~., 111 c-I N I
I
dl c-IU7 dl N a -r1 c-I II1N R.~'tIl O1 4-tDO N 117 N I N N N~-IN lD
N
G4.. p p l~ .!~~I ,~S-i~'.~d~ c-1 M
. M
>~ of o ~ ~.,0 0 0 -~I .U ~ H ,-I
ri ~ x .,-1. d~ p4 (~ ,--plN ~-1.Lf~N .td M O
y,C1~ I
L~ .I-~~',l0 W r1 w-I~ CL ~~ 4-I~r N O
O Ln M M
01 N -~O O ~ ~ ~ COO rIC31O ',?IO
r1 c-1 v-IN
c0 ~Itdo ~y ~,' ~ N U r1''r~.1-~r1 o r1 o FC, o r1 d~'o f~ U ;~a r-I N 4-I U1 ~ aO Ou~ a -r'I
a~ I r1 p.; x M
I N O p~l r1 b7 I ~1 S=',~I I,~,'~ W
O N U1 L~
01 Ul'~N .~, -r1 Ul O O ~Or-I U7 I ..
c-I O1 I l0 dl L~ '-~ ~I flj .!-1 ~I .J-1C~ '~ ~'~ ~I~-1~1 4-1 <'I
,~ O O O M L~ M r1 N O
N
a0 U1O 4-1 .f O ~ Ul N c-I OO O ~-i O
I c-! OQ , 00 r1 00 ~0 d1 ~
~
~
,5 ~IPa1J ~i td .h N N ri W~1 .U.l-1.1-1N J-1 c-I ',~ 01 c-1 U~ d~ M N Lc1 H l0 r1 LO
v-I
t~ O U', N ~-1 , U S-I, O ,, f~ i pn I GY, ~-1 o J Ix M
N r1 -io .h N , ~ N N ~ .t~NN N ~ N
~ .-i cry ~l I d~
d~ cI~ d~
E
N U1 ~ N U ~ .l-~ U ~-1W',O U1i UU U Ul U
r1 <-I w-i I t17P. t~ '',~
Do I
I
cnG' N .xN U7 ~, N ri U 5~N ~N N L N
f~ r-I tI7 o~ N In I
o0 ~7 o~ I
o U1 1 ri U -r1~I \O U Si '~ ''(j~O r1U ~1~I ~1 P-i'S-I
O I l0 ~ N Lf1 M ~O N
U' l0 Ol N
M
N c-I(0 ~ r-Ir1 I~' O I N N ~r IlfN G4 U l0 Ul ~ 01 l~ N 00 l0 s-i N l0 t!7 l~ N
L~
U~-1~ ~o ~11 ~~ Uao Uaaz mo .mo~M -~I~o~~INro~ ~u a~a~nzs~l~l .
~ o ,~a~ w ~ mn ~a o a~ o~ a~a~ a~ ~ a~
-~I ~n I 1 w ~ ~ . 1 ~C
u, ~I x ~C
N 't~N 1 r-I U' O r1 ,~ J..1.!-1~N r1r--1r-IL(1 r-I
.1J O C~ N .. I I I 'Jt O I
N r1 ..
..
O O r1 >_,'a a dl r1 , O U O ~ CL C~ W , '~ S ~ FC co 01 to t o NI ~~ dl H ..
111 N ao ~ 00 t~ S (a j M ~
H ~o di r L~ l M C l0 00 N L~
O
'' ~i -lN IIU ~ 41 M O -I 4-1-1 >~r OO ; r O
CJ ~I\ O1 ,.~ M .-II r1 N ~I O ~-I
>~ O ~ N M , r-n 'z,ri ~-I
I U' , L ~o w I L ~H
eo U1 ~ rti .S'.,U -r1 ~'., U ~.,''~-II rtiN UU U r1 U
''C~2 O ~ l ~ L 1 o1 x ',NP4 ~1~ I a M
' ~ o 0 -I I dl - O C7 FC o~ 1 M
d' I l ~ I
~ I
In O
t ~ , I NM-r~ t >:,Hr \ ~ ~,'~.,M~,N~'O~~rCO00 fa C N ~ rI1 ~ ~.,dlCHlOl r1 N ~.. -.I i N O H ~ ~,Lfl'd~1 dl L~ OD ~ ~p~ l N l ~ l MO ? 1 _' OD N
I -I - N
"
?-I C~H , - 0 O -I r -r > . ,, r r r U c- M w , ., M
-r1 S~ M ' ' ' U7 N Ul,S'rN -r1 O ~ ~ -.-1,.k~Ul ~N N (A N
W c-I 01 01 '' OO ., 01 N ~ N , N
, M ' ~ M
S ' ' ' ,1J ~ .~.~rS~h , Lf1 .i~~ r1 -rl.~.,~i I,,.1.J1~ ~ .1J
~i ~ a I O L~ M 00 '~H ~t ~(, ~(, 01 ~ .!-1 N ,5n Ln R ,S.a Q td tdU7 IdO O O N O O W r1 u7rtSOO O O O
r1 ~ I I I to M dl to Ln ~-1 I ~ I M
oo N ~ I t ,'' S-',~',<'I~I~-I ~I r1 ~I ~I U I ~',S-I~-I~I ~-I~ S-I
td O d~ O 01 N O N O O -ri M O 01 M
M N 01 N lO
v-1 >31 i:SlICi1J.1-~G~ U L~ f~ .!~O f=a(d.!-1 f.~i O , ~ 10 t W-I L c0 O o O o ~~ d~ L a~ aW
O t~ ~1 7 I I \o -I
I ~ ? -I I
~ d~
Lll -ri r1~1 00(a1 v 1.n I r~ , C 1~ IN N c O 01 01 00 M ~ ~1 q M
r1 w- d ~
M ~n ~nH ~ a C7 cn W C7 a ~ W H+-1C7C7 C7 w C7 ~-1 a fa U ~ H ~1 w w w ~ H w cn H
a ~ w cn w r~
M
',7~
l0 l~ 00 .-I 01 td O1 N
M
r1 C~td dl r1 L
d~
O
r-1 zzzzz ~.1 N d~ 41 N l N
L~
.!-1l0 M
~y 1W
M
r1 N
O dl w-I
r-I C~
r-I OD
c-I
r1 wc~~nzzzzzz z ~j dl M
11~
M
OO
~H
r1 c-I L~
L(1 LPl Ql L(1 O
dl dl OO
di Lf7 c-1 v-I
~
-rl N 111 M t11 d~ O
r1 l0 c-I
N
M
d~
M
N
N
N
.4W -I N
r1 00 r1 N
w-1 M
c-I dl H
~-I
v-I
c-I
r1 r1 v-I
I~
c-1 <>i W U~
E-1 u7 E-s H
u1 .-I
H
~
H
~
r1 l0 01 ,5y c-1 L~
v-I Ll7 M IIl w-I I
r-I
d~
M
a1 M
N
N
(I~ 00 01 ?-1 10 dl Ill O1 N r1 l0 N
L~
rl O
Lf1 L~
d~
, -ri r1 c-I
O N d~
M c-I
dl M
Lf1 dl l~
O
r1 r1 M
l0 ~ cn c~
u~ u~
u1 H
W H
a~ E-~
u~
cn of H
H
H
H
~
~ 00 N
~ ri N
~H O
M N
M
l0 L~
Lf7 L
O
O
r1 J-1 ~O N
O o~ v-I
.1..1N r1 r1 OD
~O N
M
L~
~
d~
In O
O r1 r1 .ti r1 M
-r1 M r1 ~N N
d~ d~
l0 L~
r1 N
d~
a0 W U~ cl~
W U1 v~
U~ u1 E-1 Ul H
cl~ H
v1 c!~
H
H
H
H
H
N
~ ~ ~
O ~
~ d~
'~
-r-I
-~-.I.-I
~1 u1 S?, dl M
(~' O
~
y N
TI
U
r-I
~
H
H ~
W
W o ~
O
Cl~ OW -I
H
z x H ~ x H H
~ ~ ~
ar~a~n~ o a ~ ~a ~ o a x ~ a~
I
U O Ix P17W fs-i Ul O !.Y, P~1W W fl.~ Ul N
-~I a w I I w w a w I 1 I w w ~n tn ~~ I I ~ ~ I Ana I I ~ ~ ~ I ~a ~s 5r H H W W fxW' G~H H H W W Pa !~ ~ wH
O
,~
r-1 U] U7 ,~I,'', W W H f~ U~U] ~i ~' ~' W W Hf~
,i,''~ ~ H H H O ~4'FC H H H HO
t6 (Ii .!-1 .1-1 a~ a a a a o x a a a a a orx ~a ~ ~ ~ ~
~
a w a~ r~ as ~ c>am w a~ a~ w ~w ~
A
c-I I O I r-I I O M r1 W eo ~I d~W W z r ~I M -rl Z d~ ' ~ M
H 01 ~ M ~ H to ~ H
1 N r1 H W M M 1 N
W .t~ ~ fsa ~-1 x -h o~
I
H U7 ((S 4-I N H ~ rti l0 4-I N
vo d~ cH
d~
P-n'O ~I Ci ~-1 LYl ~i N ~i ' O Cl~
s-I M
~i L~ 01 -r1~i ~ ~i ~ ~1 M -r1 ~'., R=n L~ LC1 P=W 1 M M
W M -rl (13-r1 yJ w W M r1 ~.,N -ri JJ
p.1 N M O
.~'rN U~ .~.,U7 (IS ,~I N UI ~, Ul (!S
O H c-I O L~
O I
~nw00 a~ O a ~1~ ~nw o ~r N O ~, s~~
I ' H o ~ CJO ~ o H o ~, ,-iZi O b~
o ~H I In Czyn N
eo o ~ a ~1 I ~ -~Ia~~ a a ~-I o a ~n M ~ o ~I r w N -I ~ o m ~ N a -~ H
o I
-m -I H m -~ N ~i tnm , H z ' , O ~'-,MI
M -'T-aN , ~ I L M O
f~ O W G4 .~. :
-I ~
~ H
U) O (~ ~ , M U7 U]O (tS R ~., ~.IOW
U~ W ~I ' U7I r1O I z H H M , u1 -- d~00 f~ z ' 4-I '~ W-Ifx o I W H
I H M o~ 4-I ~
d~
.-I
O H O ~-1 ~, a O O H H O ~1 .~, HO
N E-~ t ' N r1 01 'd~'~-~ M
L O
H W 1W O t~~I 1 .1~H W ~, .t~N cli ~1 I-1~
M F(,'-i a~ L~ H N ,'~ tt1I z '~-~ N M
w~ Haa n~N~~,'~S-INO 01~ wxHaa ~,ws~~~~I ~I O l~,..
W O~H N~ ~a .l~a.r,r1N4--IW O~H N ~.-IO .1.~ ~ coN4-I
I I
U f~' U U1 I C2y-IU U P4' U U1 .1J i MU
01 R'i I I ' ' ~I v-IlZi d~ d~ ' '~I
' o1 ~ ~ -I ' ~ ~
WN WO OloOo~H C,N ~(,N WdWO Nc HL G~ f~ N JN
U7 (Y I ~-I~., N U ~ QiI ,"L'',~I Ri Q7 r1 U ~-I
M ",L,'O l0 r1 ~I M C'4 1~ 00 C~ N Ln a~ I c7 N U ~aa~ ~I~I m7 x U U la a~ >.I~I
~n w w N w .
a ~ In U~I-IAoo~nz ~r.~w a~~~I o ~o A~r~nzM ~ wM~ a~ ~ ~1 001 ~' W P~ N L9 O J-1N W to !U C7 ~1 O .1~fU
-rl M O ' .1~d~O ' O 1W
H ' H 1 da a~ a w r-Io ~ a~ ~-Ia w x ~-I~r ~ a~ r1 .u x ' ,~ . ~, w a, ~I I~
w w o w -a t.~,N m W N p, W a w , N ~ ~ N~, In w ~ ~o o N o H oo H ~ v H N I ~o ~'.,',.7W ~ '~ N rtiU ~ ,.'7W O ~ X N t0 U~
d' O M H c-Io U d~~ ~ I 111 U
N t11 N O 17 O -rl L:~I N O O ,"~ O -r1 N ~'., ,~I41O
t~ 'h .-1I N M N .-I'~-~ ,5-~.-I z N
f~' a Ri f1-i N
U1 U O U r1 Id~ f~U U O H U r-I ~ cIS I p',U
'~ N H W ~o H ~ I ~I ~ W I eo - ~ ~ I~I
G4 I ~ I I ~ M ~ I i ~O I
W x N M U I I I N ~ ~ z U ~ M r I oN
N z W ~ M I r1 f~ w H W t~ ' .V ~ .-1 W H o~ oo ~ ~ ~o W ~ W' H M
o~
.~i~-1 H fx -r-I~1 ~ W ~1-~tH tx -~ ~I , N~ -~1-~1 O o~ o~n -~1 O d~ a~ M -~1 E-~ r1 H ~ri o~
~ H ~ O W ~
.u H H .u >~ ~ ~ .1-~.!-1H H W t~ f.~ >~ ~ Gv~ ~.r, >~ rl G4 M ~ .U ~-IH M FC .u H O ~
Q (0 O pa O O U7c0 O O O W O O O O U7Ic~ OO
-ri O O ' N ri O O H ' N I r1 O
H ' O I
rt fx W ~I ~ G H ~1~I fxW U Wo rd ~I ~ N~I ~I~I
o U d~ o . I ~I o ~ o rl I ~I
~ o o o~
~ ~ ~I W ~ O i ~ y ~ ~ W n I~ tHn N ~ ~'>JWI~
o ~ n i ~ ~ u ~ ~ l ~ d' ~ c'~'~ ~ I
l i ~ ~1 Po' ~
M - - I l . I - ~ .
u7 C7 f~ C7 ~ H ~ C7C7 C7Ix C7 P4 ~ H HN C7C7 f~ Ll C7 OI G4 f=~~ t'~~lC7 W W Ix r Pa r W H
W
-,-~I
ro ~
-~I ~ In 5., z >~ z o m N N
U
N
JJ O M
,'~y -LJ
O v-I M
r1 r1 w z z r'7 ~n ~' O O r1 O
-rl O O
M r1 N
.!~ N ~O
Lf1 LP1 M l0 W o u1 .-i H
H H
.-I U~
H
r1 O 01 ,5y M
l0 (() O ~
~ O N
r1 M N
O c-I N
M l11 .t~ u~ ~
~ H H
H H
~ H
f~, ~
N O O
N -I
.1J Ol M
O C-I O
.1-~O!) OW
~O -I
O u-I N
,ii u-I l0 -r-Ir1 L(1 l0 ~
p., u1 ~
p., H ~
u~ H H
H H
en N
O
I u~ o -~I
u~
FC M ~O
W' '~ q H
-~I U f~
.1-1Im U
~ N l0 N N c0 N
N ~O
~ O !f7 ~
U O t~
r1 5~ u1 d~
O
~1 H In L~
W
H
Oi W r1 N
Ca O
U1 c-I u-I
H
z x H ~ x H H
~ H H H
O f~ O ~ O ~-1 O U
O a O
U O P 0. W O R ~ W W t ~ 'a l S I~
N
G4 I I w c-1w I I I ~ ~ w ~u 1 I ~ ~ 1 I I ~n ~n ~ I I a ~s ~
~t H H IslW fY P4 H H Pa w W Ix fy G~ H
O
~?
.-I u~ c~ ~ ~ W W rn u1 ~ ~ ~ W W W Fu ,~ -G,'d, H H r.~r.~ H H H O
rti (a .t~
1' ~ ~
~
~' P0 P0 P4 P7 P4 W P4 a7 Pa ~
O 1 r ~o r ~ W n ?r W --rl ~
R
'u I ~ H W c-Ic-Ij a ~ dl lD L(1 ',' U
d~
.~ N -L-101 4-I P.i N M . ~'',~I-I N
N (d t=I N a Id P r I~ ~
IJ M
r O ~ -~II~ O
M x U ~ tr ~ ~ U ~~ ts.-Ir6 ~ ?I
W ~ W S.I
~
''/~'Pa r-1-r-I~.,r1 'Z,W r1 r r1 ~.,w1 r1 I N 01 M ~
W 'Z, r1 u1 O .fitw "~, r1 dl IA O 11 ~,'r1 o0 ~ o~ M 'J-1M dl N u7 tg H ~ '~ ~ U' H U N x 'z3N rl N
00 H In ~ H ~ ~ ~
m r H W rt ?I I ~.IH W o ~.W I ~I rt I
vo r ~ 1.no o H H ~t-W-I ~ U H E-~ 4-io .-I ~ U ~ 4-a U~ a a u1 a . N
o o tn I O eo -~IN ~ I o o lx -WO N N o 4-I
~ r.C eo ~ ~C ~~ w a ~ ~n ~ ~
o o I v I
a~ xzo ~~,~~ ~ ~ ~ xza n -I ~~ 1n -- ~
~ . -- r w W d~ f mo C7 r ~
w ~ w I mn ~ N I . ~ 4-1 ~ Ul .
M C7 d 4-1o H O t11a O
~-1 O H H di N
I H
H
P-i W C7 .4,~-Itd ~I W C7 11 N ~I rti~I W .V
U Cl~ I I tr1 C7 Cl~ i dl i U
tt1 H w s~ mr,~I o H w m-n~i a~ ~I o c~ , M w ca M a~
a ~~ wfx~Nr f.~r.u .u wo ww~ Nm ~ ,o, .u ~ N
I I ~I
U O U ~ r , U O U .!~~ >~ O U
M H d~ d~ ~~ a~ ~ H ~ M M ~~na~ x v or ~~nHvU ~n~C o~ ~~nHa~~n~M ~ ~
~a~r U7 U R'~ ~-I -riU U P: ~I >~'M -riU -riS-I
I FC .. dl 1 FC dl o1 -rl N ~ PO 01 Ix c0 N p W o~ ~ a: rt N r1 ~n r ~ a 1.n~ '~d~ m dl ~I 1 z W z d~ - -l ~
~ ~ ~ I a H
~ U
U W ~ ~ U ~ ~I a~rU mo ~ . o ,~ v 4-a dl U ~ r o www <n w~, I o ~I aM www mo wN . . I
N ~ r1 C7 ~ N ~ rl .-IC7 '~ O I r1 1~ f~ o d~ r o1 W o M N N ~I
H H r O ~ U1 7=L~ M ~,'.. Cl~ >0t!~',Cf~ r ~ a i L11P-~ O LO N W o N r1 N r U
a a ~ l d~ 3 In tn ~ rl r-C ~ N N W .-ir.~ ~ U .n ~' rt W O
O N ~ a I In o r ~ a d ~ H ~-1t b7 ~ 'Z, O 'x'~ ?-I~ 'z, O W "~ ,'~
N G4 M H H ~-I pClH r H
CJs r H U ri (0 I L H U U' -rl td I ~I U
'~ w O I W I N ~ ~ M U7 ' l L -I N - M
l a ~, W H ~,'r1 ~I CO w H ~,'f1 r -1 N r ~
N M w <H d N LC7W N M ~ N ri N
(CS H ~ I H o1 ~C q o1 ~ O ~ I O~
H 5-I~ H I ~ l t17 H H U1 111i ' ' 0o S
i .~j~.1 O r1 Ci ~ .~. W -r-1M ~ ~ . r r w H UI N M W-IO U1 ~ G N . ~i -I
-I P-i N 1 ~ Ul H N ~ -r1 M M l0 Q~
' =i 4 ' f~ O ~i 01 Ul ;~
W P dl C!1 U7 ' ~
W c O > r , ~ N -n ! , 1J ~ fi ~ r~
J R 1 1 , ' H ~ LJ d~ a ' N .L
' n 1 ~ ~ '~ W c!1 W d~ W I
Q .I Z, H -r .l , , , W - . . ., r O .
~, N W J- N m N , O ~ I N U2 fd ,'~O
rti O W O N ~ N O W . ~ N I N N
r1 N O ~ N O I I
W N
>~ u1 W ?a ?a ~ ~1 1.nW ~I W ~I ~ ~ H N
rtS ~ U .u o M I ~ U .h M o M I s~
~ ~ M dl a~ o U f~ U N .1~o U ~ ao U r~ .i~.1.~I
~ ~ ~ 0 o M ~ ~ O ~ o M ~ u1 :s a a I r A u rawr ~ a~x n M ~I o~ wao I a~rxs~~.u o~ wao i M ~ IM . a C7 o x fx ~, u~ H r x fx C7 U vi H r C7 ~n cri ~1 C7 C7 p.,H r f~ C7 f~ fx f~ U r r-C
fa w w ~
.u z z z ~
r ~-I r Im ~ rd o~ M
r vo ~o o ,,II$ r M
C~r1 N l0 Lf1 10 00 v-I
d~
c-I
z z zzzzzz z z s~
o m N ~ M
U ~ O
N O N
M d~
l0 .1-1WO tP7 '>t O l0 .!- In 01 l0 O
O
r e0 w zzzzzzz zzzz ~n s~
O ~ m rl N
r -W n r o1 rI
01 ,-I
d~
.1J M N
Ln l0 M Lll N
rti v~ U~
co cn H N
~o .-I H H
H N N
,5y LC1 O1 LP7 r (a I11 lO
~I 01 00 l0 O
dl r-I
M r ~ ~
~
N
.u,~~t c 1 c nHu 4 l~C
~ H
N to 00 N N c-1 01 l0 M Lf1 .1-~00 O
.!-~l0 c-I
Lf1 Lll O rl r1 ,S,'M M
r1 l0 l0 dl M
l0 G4 cn U~
W c4 u~
U~ u~ u~
H
N
O
~
'~
-~I
-rl L(7 M
-rI
U!
~ o1 M
~R
'i N
H r-1 -r-I~7 ~1 +~ U U
1 r N
O O dl O
O O
~ N Q1 ~
U
H
~ a' r ola H r ~O
W
H
a W M d' Ca O
~Hz ~l ~I
U O
zi Z z ~
w ~
I l I W
~ l ~n W I
~a n ?i P4~G~fx W w w E- H
O
,~
~ W W W H H H
rd U7 ry' r-C
.
U
+~
~ ~
~ U1 W P4 W P4 W
A
I
~y O I
r-I I N to L
to-ri o ~I o~ W
-i d~ d~
<i~ N ~ r1 CO
~, N
a 4-1 ~ ~ o ~
~ x o, ~ ~
.. 1n ~' '~i M
M d~ ~
o~-~I ~ W W En .-I
.-i O W
z x ~~
O 'Jyd~M~l N O
l ~
x q ~o,-4 P4 ~ f~ N
A rl En a ~1 ra v w m . w o 1 -- ~I U U W P4 oW . l~
o f~
co O ~I ~ U O
In eo W
N W
rI d~~.1 -a N ~1 w H o M o o a M
M Inf=aO f~ s~ u1 fx L4 t z H W t~
H t~
co E-i10 .!-1 N ~ Pa ~..hW l0 I W ,5 W l0 I lfl N
I d, ~ UM W tf7 (Y~OZUMMMCI~
I I
l0 001~ N N t~ o In W E-~
W o U H E-~
W I
Ul 01c-I-r1U ~-IP-n' N Ch Ri I
M ~0 M I I
N ~O
N N ~tdN '~-~U ~ W ~o ~o u1 W W Z to r.~ H d~
U ~' ~ ~I '~ W -ri z Cl d~
4-I H d~
H d~
W
~ O a~ c7 ;~ H W w -~I . ~ . W w as . a N Nzi~.-I.-I~ cdo E-~ a ..
.i.1 ~ ~ to O U Ol ~iIll~c-INWM .1..)ML~~O~ W ..
?~ 'i~(N d ' W H ..
S I ' ..N
' ~
~
H
~
,. I (M~ .-~. N W L
., -~I~~ ~1~M N ~ ~ w ~
N o -~1 1 w J l E-~~r z N
~ o io .o m.n'~, U1 .4.1N(a IU r1 ~I1 ,'~-~U M
~ N~ aI L!1 O O C.7 M M
' -I I l, H I
1 ' I I
a W I lO
d~
~ , r-I1 v1c W-I . vop z mo .I..~, N U~ ~to~ -ri N N , dm~
N ~ ',~~ W En H d~
rt -r1 ~ ~ d~
~I N N H M r1 ,5n H
O
r.~N IN U7 O U7 O 'r~94 W
'~I OI L '7-~
r.~ f~
1~ ~-Ir1~ ~ ,u i ~I O N ~
~ M o~ O .-1 w eo W
Q rd ~ rdm c~.-IO O ~d. fx O ao -~1 N r1 C-~ M o~
O O
<a ~ ~~ ~.II~I W 5.,o f~ rx M
O o as O N OO
.-I U Oi as b~bd .u~~, o ,.~0 ~ r~ ,-i ~ ~ In 0 1 G~ oo 0~ ~ ~ o ' -~I -a-~I~1 .uI ~ I N x I M
o ,-Ic-I M w d~
R a d~
'~ N
M ~nq cncnN ~~~x wa mr~~ Incnt,~t~wHww r >~
-, s~
o ~n N
U
N
h ~y J~
O
r1 -.-1 W
~
O
-r-IL
(d N
r-I Cl~
r1 M
',~y -r1 N
O ~-1 .~ W
E~
S~
~
~
u~ ~
N ~o 1~ -1 O r1 .4~
O N
,C r1 r1 W E-~
Cl~
In v O
zi ~,' 'Z3 -r-I
-r1 O
-rl (R
~' M
(~' 'O
-ri Ca .!~ U
M
O u'~
N
U L
r-I
O d' (~
H ~
W
H
p1 ..
W ~
~-1 O
Ul -I
H
z, ~
x H C
-~
U Z Z O O
~
U ~ W W p R
m -S
U ~ ~
1~ ~,' I r-!U1U2Ul Ul I I I
'~
N
~r ttffyfy -rlG4W ~ W C-~ Ei Ei O
~.l r-I U WW 4-IH ,~,',~,' ,'~i ,.C, rd td Cl~ O E-~H H H FC ~' FC
.l~
.!~
o w la o a a a a a a rd ~~
~
~A ~n w ~ w m m al a~ r~
N
r-1N
l0 c-I I N l~ 00 ' ~I
~I c-Il0O t11 I-I~I
N
M~, ~ [7M O 'd~ M O O
a Lfl O-r-IyJ L~p'., N r1 .l-Id-1 N I L~
NU7 (6 M W O O ~ i R,'O N
U b o ~
O 1 -rl' ~y !x O U U
N
''~jrl .hO r1 W '~' O N
o1,tee,', N - ~ !-1~-I
Ln,.G .~,P4~ N
N ' L(1 H~-1Ul ',~1($ -I rd I'W N
Iv ~I S-IS-I4-I ~ S-I O N
I N Ch O O O ~I .1-~O r1 r1 00c-i I
N~-I.h .1J.1.1N d 1.~
O ,~'W 01 C7O i i C~ ~".,U~ L~ ~
N I M L~
L~
01 -1~N N Na~>n tSINNO000 O O
M u1f.2~U U U Ul -rl U M U U
O w M M
M
FCS-'rN O O N r1 N N C7 ' C7 CJ
UI I -rlU ~I ~-1~1p.,' W -I I ~'.,~,' O ,5- I I L~ 00 I
O c-I(1jN M U L.I c-I -r1-rI
Ul 01 N c-I d~ O
CO
L(1 U ,'~;.~,~-I'~ '~'i~W O ''f.~ N N
4-1 r1 c-I' 01 N N N M
~', O01 N N N C7 1W N ",t.'A.~.!J
-rl W r-I -I '~.' -~,RS
N a P-i O ~N r-Ir-Irie0 ~ r-1 O O
1-1 N I ry' (~ I I
O O >~'~L ~ N N , ..
~ ' ~~ ~ ~ <-ix I .. ~o ' ~ S ~ I U .. di I ~ ' ao ~ to ; d~
I to M ~
, L ~'.,~t O O O , N O O , , N -rl S-1 x -r1 L~ O r-I I I
N O 01 r1 N
L~
U7 J-~(dd~ U U U r1 ~I U M CJ CJ
'~ ~' l0 c-I M M f~ ,'~
~ N Ci N
I I I
~ I I
'' x rd N I~f ~r ~ ' , a ~~Ino~,-i~, ~,..
, -~ - s~o~~ ?~ l ~ -1 O ~ --I- - ~o - -I ~
~ l 1 O -I I I
.. 0 ' ~ -I N
, r r - r - s 1 ' r w -w v W NUl N N N W O N O O
' ~ c-I N r1 c-I N N
' 01 M 1 1~ r1.~.,~, 13 .U.1..~~ .S~ .1-~ .1..J..WO
~., ~r ,~ ~,~Il c0 u1 01 d4 Hl O~
VS
o1 N N U1fd O O O O U O (~ U U
-r~ r-II I x x ~o o o~
a I tn O
V by b o~ ~ ~ ~ n N ~ ~ ~
o ~ o u ~ M o ~
~ o ~ o u I ~ o u 4 ~ ~ 1 ' o , -I -I
. , L l , l I (~ -I
l l I~
M -r-I-riS-I~4-II I I ., r n M r r O cnE v- o N N 0 N ow ow ~nA c~w i.~HN N N
,s o~~nc~wr~wm O~aw s~
~ r1 rt c~3~a ~I
.u m tom O
U
N
.!
~
~y J~
O o\
r-I
-rl W '~, U' U~
O N
-rl 01 yJ N
',?~d~
r1 c-I
O l0 ~, ~
~
N o~
U7 d~
N
.1-~00 O c-i .1~
O d ,s,'M
-ri N
N
N
M
N
-'~ U
N '~
N
~~ o a ~
H
w H
of W ~
~
C c l~ -I
H
Z
x H E-~
U Z Z O O
~ W W O
U Cl~W Ix f~
v r-1 W v I I I (~ W ~4 l~ ~', I Ulr-IUl Ul Ul I I I
'~
td 5r N w Ixr.~~1 w w w E-~ H H
O
,.R
r-I U W W H 4-I',~,-'~' ,~,'Ul C!~Cl~
,i;
(d (Ci U7 E-~O H H H r.~ ry ry' .1~ w o ~I a a a a a a v ~a ~ w r~ r~ r~ m m m N
r1 o~ H o~ ~o r-I I N L 00 ~
r1 v-I ,~,M N
M
c-IN I N a N
I ~-I~I M O Lf1 ~I ~I
N I
00 ~.,CI~~ 00 O d~ M O O
a LC) 01 r1 .1-1L~ p.,' N c-I .l.).1.) N I L~
U m t6 ME ~o oN o , , i 4-1~ N O O O N N
ry' to 'Z$.L7r1 O r-1 W ',~,' N N
N H ~
~ q ~I ~I
a ,ti.~. !>a.~, N
N ~ Lf7 I ~-I U7 (Y.,IfS ~I
L~ N
l4 ~1~I ~I 4-1 ~ ~I v v I N CJ
N O O O ~I .!~ O r1 r-I
to ~-I I
a ~i.!~.1-1h N cd .L~ ~ >~
O i a a i ~', S~ N ~
N I M d~
L~
l0 d~ J~N N N ~~1 O1N v0000 ..0O
x N m C~,U U U m -~I U M U U
o a M M
M
~ v v v v ,-I m vaxAa .
U1 I -r-I U ~Ft-I~-IW' ?-i S.J~'., o1 Gx, I I to 00 I I
N r1f~ N r1 U S-1 00 01 rI r1 U7 N L~ d~ O
l0 U '~,~, ~I'~'~ '~ W O '~S N N
4-I r1 N ~ 01 c-I N M
v-I
N N
s~~1 0 0,v v v~ c~r.-1 .u,-1vHr~~a .ua.~x N '~ v r1r1 r1 00 ~ r1 O O
.1J N I [a I 1 o v ~ , , v v ~, .. y~ ~
v ~ ~ ~ oo x I .. ~ ~
rtS ~ x U .. p, f~, I o I oo .. ~o ~n yo ~m n ,-1 N r1$~-, ~.IO O O -r1 v O O I I
N N O L~ O O r1 N
c-) Ul J-1 U U Ua l ~I UMMMM C7,'NC7H
~ ~ ~~ k ~
i (d N O N ~ ~',~ >-', ~y ~', '~y~
i ~ ~ ~ -1L ~ 01 ~ G LCI .. ..
-I l l O I~ -I ~
d~ O ~ 00 S -I
-I
-I
l .L.-I N . , , r r -I r -I -I
., ~ ~ c c c 01 c c r U7 N Ulv N v W O v O O
N --. r1 M r1 r1 N N
' ' N M
.l~ r1~, (.,.1..1l1 .J-1~ 11 .1-1 11 11 ~i ~(, ,5y C7 r1 L!1 CO to 01 l0 ~, a 01 N O
p ~ cdU7 ~ o o o o U O L U U
r1 I r1 I W ~ x ~o o o~
1 I 0o L
f~ ~',S.,' ~Ir-I~I ~I ''~ N ~-1 (I3(If c-1 r1 d~ 1 I I N O O d~
N
~1 >31flf .!~~ C~ CTaO 4-I Q~ M 4-I4-I
~ .~., O ~, O ~"IL~ O L~ O c-I
l~ 01 d~
C l M
-r1 r1~I IISI 1 I ,. r-I I N r-Irl M O u~N ~ c7c-I01 , 0 Ln Ga ~1 cn E-W 4-I C7 C7 N N M N o o f~ a x N o c7 w w w x ~ r~ i ~ cn w w x s~
~I
~
o ~a N
U
N
1~
',7y 1~
O l0 r1 r1 W Z
~.' O
r1 N
(d N
r-I U1 r-I o0 ,5y Ia N
r1 N
O
v ~
m v .u o, o 00 ~
o rlo .~
~i wwcnu~u~
v M
~4 P-~' y -i ~ A
+~ ~
v d' N
M
O O
~
W
H
H ~
W
p1 ..
En E-~H
''d ~ U 'Z, % '~-~ O
~ W h W O
U U7 ~ P fy, N i -r1 L4 N I I I I ~1 W
UI
~!-I I H UlUl U7 Ul I I
rtS
~, fx P4 ~I w W W W H H
O
,i1 ~ w w H H H H ' ' .l.)~ ~ O ~ F(, Ft, (a .
~~q w ~ P
M
~o is ~o N ~', L~ O
G4 r1 M M
I rd N H
M ~', O LC1di ~1 M I
N r1 ,.QL~p.,' N In r1 1J
~ N
~ r1 N N O O O
~ ~ ~
u, O -rla ~ di f~ ~I
o,N
r~ .ii.l-1W ~., N r~'I
r1 N Lfl n'-~.n I ~.IN n-''t,(~ LI r1 O1 Ln N
I
N '' ~1 ~I4-I ~ r1 ~I N
N I N [7 M
M ',~'~ O ~I .!~~.,O r-I
M .-I I
L
a S-1- 11N (d ~ .1.W , I 0oH o, N
O U1 i ~ ~',~-I~ ~
L17 N I M l~
H d~
N
J-11~,N ~ Cr N O O
N ~lM N O
O
O
, ~I U ~ -rl~-1U M U
N o (~ M
. M
M
.S~,N Ul N c-I UJ O N H
','~ N C7 "~a H
U! r1 U W -IQ'. . .1~~1 ~,' ~ I
I
I
u1 r0 N O ~oU ~I , ~ o~ ~I
. N o ~o W d~
o U .~,SI r ''OW O 47 ''CS N
4-I O N a1 M c-I N
P'., N
v-I
N
~ O a0 v U' l~ U N Gy .1~
r1 fxO r1 r1 ~r H
I f~
,~
O '~ N U7 r-1e0 , N r1 O
.4~ r1 0~ I eo ~1 E-~ 1 o ~ 1.1W O O ~I , ..
~' N Gu r1 o x 1 I .. p 6 ' ~ M U In .. io I M M " to ~ a~
~ o~
I -I
N ~o , ~'.,c ~ O , N S-~''. t N ~-IN N r1 L~ N O O 1 c-IH 01 01 r1 F(', .-I
O
U1 (O d~ I U r1 ~-Irl U M U~
rC$ 4 ' -I W'Lf1 v-1r1 N a ' H M
" ! I I
I
~., , U c ~i~ ,5y. ~., ',~.~
l (IS L~ O r1 , ~ - O ..
~ ~ ~ L~ l ~-Ic-I l OO N 00Li O 00 ~
il L~ 00 I
l l0 l N
-I
-I
-I
.L..1 ., l r . I r -r c r c v W O U7 ,~ O W O U N O
N ~- N O O M 1 N
c-I ~ 1 ~
J-1 .~.~i ~"I.1.~/?a .!JO 01 .!-Li ~r ~ c-ILC7 OO l0 O 01 G4 d J-L
p ~ U~ rt r0 O O U ~' O vo U
ri I r1 .. W of x H o o I t~
~
(IS ~' ~.I~ S~1'~ (O (O ~I (CS
C~ r1 N I 1 I I N O
d~ l~
N
N
t71 (~ J-1U1 ~LO 4-ir1 /.2~ 4-I
~ .~.,l0 .1.101lD 01 c-IM O
l d~ ' N 01 -I
l LClM L
I
N
r-1 ~I r1 I N Lc N r O N r 00u-I 1 N N -'~ r M cn E-W~ ~ U ~ o ~ a'7 o q u-I~n x E-~ ~ a w w cn w w s~
r., ~
ro H ~' '~
N
U
N
O
r-1 r1 W
Ul O o [~
r1 N
.!-1M
l0 td Ul M
H
r1 t' ?m H
~ H
r1 M
O t 1W' U1 O N
O
.1-101 O L~
-L~
O N
,.~il0 -~-I
W u~
u~
N
N
N
M
fz O
O
~ ~
H
H
W
of wao ~
H
W
x H
s~ U z o 0 ~ W O
U ~ ~
N
-ri W N I I [a W W
Ul 1J I Cl~r-IUl U~ I I I
''O
!a 5r ~.2;P4 f~-~Iw w H E-~H
O
,q W W H H
rtf HO ry' FCFC
.!~ ~ ~ ~ a a .h ~ ~w W ~ W 0.
q 1 d~
N
to H o1 M
r-I I N o0 r1 aD x N
o ~
r~ o In S-ii-1 -I i 00 ~,-'',~~ 00 d~ M O O
N
O1 -r1 J-1l~ N -1 J-1l~
N LW
Ot U7 (d M O o i i H N
~~ o ~ v a o ~I, . ~ o _ ~ q ~
0 0 a ~-I
ui ~ ~
~-1 U1 OI ~-I '~'~O
N
d~ ~1~-I~.1~ ~I N v N OO O .J~ O r1r1 M I
H ~-I.1J1J .l~10 .l~ a a M t ~
O ~ RAN-I ~MMMM ~
, ~'.,M
.1JNN N >:71 N O O O
OI N O O
O
U1 , UU U r1 U M U U
fsr M M
M
v a~a~ a~ ~n a~ a . a a a N -rlU ~-I?-I~I ~ ~I I ~',~
~ I I I~M
N rtSN ~-i~-I to Lc7 r1-ri U7 o~ ~D O d~
o0 U .~.,~1 ''~''~'~ O ''t~ N ~
4-I ~ N 00 c-1 M N
v-I
c-I
r1 -~ o ~o ~~ o .>, wn r=.,.s,.s, ~, ~ cn x a x ~ 'T5O r1r1 r-I, r-I O O
1~ N I U1 I 1 O ~', ~ , U
~,' N ,y.,~~ t11I ~ l0 , , ftf ~ U dWtWO d~~o 1 O It1 4) ~' ~I OO O N O O I I
01 N L~ O O N s-I
O
U7 UU U ~I U M C7C7 ',~~ M M E U
M
~ ~ ~
~
t~ ,.QN ~i~i ~i r5Y ~i L~ ,5y'>y d~ ~ ~ M Ll~ ....
L~
.r..iS-I W-I~ -,~-,-I-r-I~-I -ri ~-I?-I
.. d~ L~ ~ r-I ~-Ir-I
O r-I
r-I
r1 U7 N U! NN O O N O O
N ~ ~-IN a0 N N
M ~ ~
l .1~ ~ ~, .1~J-1.1.).1.7 .I-~ .t.l C; a H c-IL~ u1 0 01 a 01 N M
(d u7 ra OO O U O Wo U U
a 1 r-I I W OI ~ in o~O
I
~ ~ ~I ~1?a ~1 c~ ~I N N rd eo -~I o 1 I o o~ ~no o~ o~
C31 td .!-y.,iI a 4-I ~ M 4-I4-I
~ 01 O a0 L~ L~ r1O
OO d~ -Il -I O (~P~
L t( M M
I
M ri ~-If~ II I r 1 r r O w-I~~-Ic~v-100 n N owow u~A Hr~ cars.,c~xN ~wr~ww o~H
s~
-, ~ro cCico ~I
~
o ~n N
U
N
-tJ o ~y 1~
O d~
r1 -ri w~u~z s~
N N
l0 r1 U]
~-I
r-I H
5r ~ o ~I
-r1 M
O to J~ N
,.S~~
u1 N
J~ l0 a0 O L~
O c-IN
,C, d~
-r1 pa U1 Ea W U~
cJ~
N
N
~
c M
N c-1 '~ Ca -'~ U
~' d~
N
N
U
q ~
H
w a A
~ i z s~
r1 l0N N O\t'~ 01 lfl l~l(1 rl O N C~01 d~
U1 Nl~O r1Ol000N d~Ll7v-Id~l~Od~M M~ MO ON L~t1~LC7d~
O MO r-I l0NM l0l1)v-I0101COL11l0COO u-IL~NN Ot~O00Lf~Ln M 111o-IW -Iw-IN d~N l0c-1Olc-1w1~N N r1N LW-I L~v-INd1Nv-I
(11 S~
O
N
O
W t oo ~o o~ o~
M l0d~LO 00 Ll7L~M'd~00 01 N l0lDv-1 ~
M t~l0C'~ 01d~N ONt~N M L~ 11700d~dl M
111c-1L11c-I 00tnr1c-Iv-1l0r1Mv-I01Nv-Iv-Ic-1r1c-IM 0001v-IM ~-I00 I
(~O
O O ~O
O O '~O
d~ N I r1 N N ~-I I ~O d~--N
O O u-I O O O O l0 ,.'~~'I Mc-1O
R; H M W ~ ~ W o min Ho H
.u W ,~.O ~C, H O H rl ctim OH
H H o H' ~ o stn ~9C~
~ ~ ~ I ~
a ~ a ~ o ~n~ U
I
~ o N ~~ U
v o I7 w U N v-Iv-1 01c-I r1 v-1W -I O Mc-1L~y -Iv-I w-I
c-I~ I .x,~~ ~''~~ .v-I17r1,5r1',~c-1~ M17NLn ,~,~l~ ~-I'~
N xrl~l~ M LnC~NO I7Ln,T,L~x Nx d~ O1Q1Or1 t~N Hl0,'I,'O
U ~~ N LnLnl0O~NLC7O O0001tn.Nd~ l0M c--i00 00d~1l~~.Mlfl 010101 00OU.OL~M MN l0LnL~l0d~O l0c-IO1Ln O01NN Nt17 In r1N l~ a11O00b70 MO1Nc-1cH00000 b1M OIL~Nd~rid~O v-1v-I
Li7'd~O d~Or1 O L~dW-Ic-1d~CO00d~ 01~'diOLflN00LP1In t~N 'd~ O ,01Ls7 C31c-I~Od~ODM CON r1 O C~JL~ L~l0d~d~Ml0 ~ ' ~' O l0 Ltl CO -I-I~ON d~r1 ~
N OC L~ 11W-IM C7r1OLf7Ml~N OL~t~ CJtniM ca MLC7Nh Ul L~b1O7 InLW-I L~00Lf7t~ l0t~ G4 UI- L~L~
b1 N
N ~ L~ N
' r"~(j O 1,n d~ d~
l1 .
' .
O c-S L~ CO M 01 O
~.," O N v-1 N
N
1J ~tD c-I d~ ~ . O- Ln 01 O l0 r1 00 r1 00 N
d~
C~ U f~ I r1 O d~ M o1 di ~-I I c-I I o1 ~ lfl N O I I cr O c-I I I
1 r1 O I ct~ I
I r1 I
r) c-I O O r1 Lf1c-i C~ d~
(d l~ 00 01 01 ch N
l0 r1 N
N I O "N I I I l0 M
~I O I d~ l0 O O
~H
U1 w-I v-I l0 c-I .-Ic-i M r1 G4 v-I r1 v-I l0 r1 01 d! r1 l0 N
U
N
1~
t0 N 01 L~ ~-IO N 01 f=,'C~ O N d~ M M O t~
O O r1 t!7 00 O c-I N O
N
U~ r1 ~-I N u-I N c-I c-I N
a A
H
N
O r1 u-I v-I o-I o-Ir1 ~-i P4 r-1U U U U U U U t!1 U 1D O N O r-IL~ LI~ L~
N O d' ~1 lW -I lD r-i N
~
.L.)00 00 O N 01 L~ 00 M
,5yd~ d~ LO o-1 M d~ ~ l0 -U C~ t~ L~ d~ L t t~ N
r1 O d~ d~ d' M d~ d' d~ o H L C~ l~ L~ L L l~ to W
N
1~
O
NO
r~
U
A
t~' H
~
y r -I
Ot O P r1 N M d~ Lf7 l0 C~
W
p.tN N N N N N N N
Cl~
s~
+~
r1~ NO Md~C~01N r1M MlfllflNO v-1l0LC7d~00O u-IM d~L~ M O N
U1lONO L~N 00Lf~~OM 01N MN c-IlW-I01M M~-I~-I00LncNL~00O1 O Nl~O 01ON
O O l001OM L~N r-IN M00OO d~01d~l~L~01dicNM LhLnr1c<'CO M M01c-IL~d~M
M tl~MN dtCt~dtc-idrl0NM r1N Mc-iv-iM00v-I~-Ir1r-1~-W-I00c-Ir-IN rtl~N w-Id~N
W
~, O
N
O
(1101O1M Ml0L~ N 0ldi 0 0010 N 00 l0 l~ O1 l~O00M~NLf7O Ln d~d~Nd~t!700In 01L~N d~LIW-Id~ d~ L~r1.O1N v-I L~
r-IMN 00l0ON l0 L(7d~Mv-Il0d~l0 L~Nt~Ol~t~r1 c-I Lf7l0d~t~ O 00 t!7diMN Md~cf'l0Mr-Ir1M d~c-INv-IN r1M c--I0000l00100r1v-Iv-Ir-Id~N dW -Iu-Ir1 '~
N
I
N N ~ N
O O O O
O O.-. O ~ O
c-1--. MN d~ d~ I I~ I ~ ~ I N
O r-I NO O O 00OO c-iN O O t~ O
N W O HW P-~' f~,' N MN p,'O (Y., (Y,O z -i~ f~E-~ OH H H o oO o W W o H
S=', [-iCJ ''~',W (~ A o o d~O Cxr Gx,o N ~ r.~ H(~ H H o o~ diO H U o o o ~nO
W H H a I O
I IO I ~
~ M ~,~ w .~ U
~I M M'-' d~O '-'d~
V v v v fW-Iv-1 vr1 r1r1 w-Iu-1v-It~t1W -Ic-I~-1-Ir1r1r1Ol~ r1 tI7N
,'7(~r-1 ,~.lW-I N t'7~ N~ 'n..',~d 01l0.'~'''~'',~~Jt-JO00 l0W-Id~ f7O
O c-Ic-II'7rll0W'~' ~.Ov-1hc-1Ol0d~O(Vl0M u-10101dicHMM Csal0",.L',lD LIIWd1 U M c-IN ,"L,'01l0L~d~r101lW-I01Nv-Ir1M00MN l0r1L~O1d1Wv-Il4LC1v-IN InO00 00MO M~Oc-I00N00M~OODO r1N0001~10d~N L~N MO d~F(,'l4 l0d~C~01 r1l0N
N 01MO 01C~L~LnMO MO O-d~l0l0~37~Z.77~Lf1Md~tf1COd~M 01Cl~X71d~01M Z~ 'd~ML~
LnO00d~LI)00M OLf)l~O Ln01r1d~ v-Idid~.d~O1L~t~d~I O d~LC7 W-1O
01NM w-101NO O~01ON d1O r1CO N NW W-MMM O'(J 01ON Od~LC7 ~~~~ ~ ~
U r1Ol0dW-IOr1"01r1LPGO r)inLnO O ,-)O ~ON NN tf~~J-~N LP701J~ LOMr1 U1LWOL d~L d~00~1m tWo 0ou17Lr1L~'C7C7N t~t~t~L~LL LnUC7 L ttWo C7 LnL~LS) -rl -rl N
'-'N d~ 00 '~W ~ o L~
l0 N 10 00 ~ 00 ~ic-I M L~
.!~~ N L17 N ~
N lfl N r1 d~ N
U M t17 L!W -I 00 I c-I
N L~ L~ r1 N N
c-I I
riM r1 I c-1 l0 !tiM di d~ Ln c-I d~
N I I O I I
~It0 I t11 cH
~-I N
Ul~-t r-I of c-t <i F~05 r-I w-i rf d~ t N
U
~,'N l0 Ln O N
N M 01 In M M
N
W ~ r1 ~-I N N
-l A
H
N
1~c-I c-1 O PO r1 fYl ~-I r1 N U 0.l U P~l Pa r1o U in U U
U r1 o1 N to t~
N M d~ N 00 O
~
.1-1M M N l0 O
'~yO ~ O L11 N
U N L~ O L~ CO
r1 ~iO d~ In ~ di O
H ~o L Ln L L~
W
O
1~
O
NO
-I
z U
~H
.-I
a O ~ d1 O r-I N
W
p.~N N M M M
U) ~~irW -1 ~rmo vo o W
Ul 01l0d~00 r1t11r1u-I111r1NO~~N t!1d~
O rM MO d~d~r1r rr d~O v-ILf~O00 M ~N ~-IOl r1c-W-IM 01M 01r101r1v-IM
O
.,..I
.,1 O
W o1cH r-IN
l0O di O 00 l0 l0 r01u-I
r1r M N O l0 l0 Nr O
Ln r-1r100r-I r1c-Ir-1c-Iw-Ic-Ic-Ir1w-I00dir1 N N oN
N ~ O.-.OO
O N ON OO
I l II
O O M ,'~r1,~NN O
U~ I7 W c-I G4r1P-irO W
.1JW H o J,(~Of~OO W
o ~.~oU oo H
~ ~ ~~ ~~
cd a1 C7 00 r-1 o~ ocN
S-I O N L17 Nr1 v ftl r-I v-1 00 l0c-itIW-Id~O v-Ir1 r1 N~ c-1I'7 O d~.~,'01,'S',0111)I7,~00',1,' N ',.C,l0,."L',00 M N1.nd~rc-1M01Lf1M wdi U d~a-IrO t0l0d~01a101Nr Ml0~M
~, r-c-1N~ r N01c-I00M ~r01L!1O O10 N O00Nr ~1O~7l0~7l0~~1MN ~d~N
~$1 rM 01d~ 00 M M ... ~N ~
.
Lnr1Ns-! NHO O ,~-~ r1N ,I0r!
~
r1N l0'tf)~ Ml~Lf1~Ln,'~ LnO Mt1~
7~
u~ rr rm C7?sC7InC7InC7C7mr rm I I
U7 d~ M
- ~ 01 01 r ~-I
l~
'~ o ~ ~
N d~
s""rr-INM
.h N r . . to N ~-I
lfl ~-I
N
.~,.tU r1 00 lD N ODM
C~ ~
I
M
I
I
N I O c-I 10 O l~
O
I
c-I
O
r-IO u-i 00 c-I r101 (a d~ t11 00 l0 N
M
fl)O i I t I t f-II r d~
M
~-1 Ul 00 v-I r1 ~-I ~-I.-I
Cr.~c-1 01 01 r1 N
c-I
r1 N
U
N
.1.~
S'il0 If7 t!7 N 00N
O M d~ L~ d~ O Lf1 N
U7 N .-i 01 O1 ~-1r1 i--l H
O r1 c-1 r-I W a--1r1 N W P4 P~ U PaPO
-I U U U ~ U U
U N M O ~--I ~--1d~
U d~ N r1 di C7r ,.~5 .!~O O ~ l0 l~r _ 01 l0 O M r--Iw-1 'Jy U to r o0 O ~ op r-I
~ r d~ dm n a~d~
o H ~ r r m ~ r w N
+~
o NO
U
A
O M d~ Lf'I l0 (~pp W
W M M M M M M
Cl~
a .r., ro .N d~NM Mr1c-Ir1~ON c-ILC7 O OO NO O OO O OO
P4HH HH H Hf~z WW
Ul ~1~~ O54'aOW H HW
H HH zH H f~faPaf~
~ P4z HH H ~H z rCH
o a ~w ~ o~
N
H
a ~ ~~ ~~ w ~~ ~ ~~
H W f11pap7U U a1PaRaWW
U UU U~no UU U UU
J~ l0NO r1L~c-101lflL~Nd1 U O 0110w-1N M d~ODO d~L~
.J-10~ON O1M M Ml0O OL
N
'Jy'd~Lf7r1Ml0O L~t!1N 01ri U -I~C~~HL~N N L~L~00l0N
O
~i d~d~M d~O O d~d~d~L~d~
~I
H L~LL L~otoll t~toL
W '.
N
J.~
O
~O
~z U
~
Ca ~H
~
y r -I
OI
O O NM d~L~0001v-IN M~
W
W N NN NN N NM M MM
N ,-l o ~ ~
I >~ ~ r Id ~I f-0 b~-a ~ v r~
o o v ~I ~ ~ ~r z ~C r1 ra o -- ~
v 5,l ~1 ~
.u ~ 1n .u v o a, ~ ~s a o --1 ~ -~1 3 v ,~ s~, v ~
~; N G' ,-Q ~ ',~ DC U1 O U v ~-i U UI O N
TECHNICAL FIELD
This invention relates to nucleic acid and amino acid sequences of G-pxotein coupled receptors and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmunelinflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.
l0 BACKGROUND OF THE INVENTION
Signal transduction is the general process by which cells respond to extracellular signals.
Signal transduction across the plasma membrane begins with the binding of a signal molecule, e.g., a hormone, neurotransmitter, or growth factor, to a cell membrane receptor. The receptor, thus activated, triggers an intracellular biochemical cascade that ends with the activation of an intracellular target molecule, such as a transcription factor. This process of signal transduction regulates all types of cell functions including cell proliferation, differentiation, and gene transcription. The G-protein coupled receptors (GPCRs), encoded by one of the largest families of genes yet identified, play a central role in the transduction of extracellular signals across the plasma membrane. GPCRs have a proven history of being successful therapeutic targets.
GPCRs are integral membrane proteins characterized by the presence of seven hydrophobic transmembrane domains which together form a bundle of antiparallel alpha (a) helices. GPCRs range in size from under 400 to over 1000 amino acids (Strosberg, A.D. (I99I) Eur.
J. Biochem. 196:1-10;
Coughlin, S.R. (1994) Curr. Opin. Cell Biol. 6:191-197). The amino-terminus of a GPCR is extracellular, is of variable length, and is often glycosylated. The carboxy-terminus is cytoplasmic and generally phosphorylated. Extracellular loops alternate with intracellular loops and link the transmembrane domains. Cysteine disulfide bridges linking the second and third extracellular loops may interact with agonists and antagonists. The most conserved domains of GPCRs are the transmembrane domains and the first two cytoplasmic loops. The transmembxane domains account, in part, for structural and functional features of the receptor. In most cases, the bundle of a helices forms a ligand-binding pocket. The extracellular N-terminal segment, or one or more of the three extracellular loops, may also participate in ligand binding. Ligand binding activates the receptor by inducing a conformational change in intracellular portions of the receptor. In turn, the large, third intracellular Ioop of the activated receptor interacts with a heterotrimeric guanine nucleotide binding (G) protein complex which mediates further intracellular signaling activities, including the activation of second messengers such as cyclic AMP (cAMP), phospholipase C, and inositol triphosphate, and the interaction of the activated GPCR with ion channel proteins. (See, e.g., Watson, S. and S.
Arkinstall (1994) The G protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 2-6; Bolander, F.F. (1994) Molecular Endocrinolo~y, Academic Press, San Diego CA, pp. 162-176;
Baldwin, J.M. (1994) Curr. Opin. Cell Biol. 6:180-190.) GPCRs include receptors for sensory signal mediators (e.g., light and olfactory stimulatory molecules); adenosine, y-aminobutyric acid (GABA), hepatocyte growth factor, melanocortins, neuropeptide Y, opioid peptides, opsins, somatostatin, tachykinins, vasoactive intestinal polypeptide family, and vasopressin; biogenic amines (e.g., dopamine, epinephrine and norepinephrine, histamine, glutamate (metabotropic effect), acetylcholine (muscarinic effect), and serotonin); chemokines; lipid IO mediators of inflammation (e.g., prostaglandins and prostanoids, platelet activating factor, and leukotrienes); and peptide hormones (e.g., bombesin, bradykinin, calcitonin, CSa anaphylatoxin, endothelin, follicle-stimulating hormone (FSH), gonadotropic-releasing hormone (GnRH), neurokinin, and thyrotropin-releasing hormone (TRIT), and oxytocin). GPCRs which act as receptors for stimuli that have yet to be identified are known as orphan receptors.
The diversity of the GPCR family is further increased by alternative splicing.
Many GPCR
genes contain introns, and there are currently over 30 such receptors for which splice variants have been identified. The largest number of variations are at the protein C-terminus. N-terminal and cytoplasmic loop variants are also frequent, while variants in the extracellular loops or transmembrane domains are less common. Some receptors have more than one site at which variance can occur. The splicing variants appear to be functionally distinct, based upon observed differences in distribution, signaling, coupling, regulation, and ligand binding profiles (I~ilpatrick, G.J. et al.
(1999) Trends Pharmacol. Sci. 20:294-301).
GPCRs can be divided into three major subfamilies: the rhodopsin-like, secretin-like, and metabotropic glutamate receptor subfamilies. Members of these GPCR subfamilies share similar functions and the characteristic seven transmembrane structure, but have divergent amino acid sequences. The largest family consists of the rhodopsin-like GPCRs, which transmit diverse extracellular signals including hormones, neurotransmitters, and light.
Rhodopsin is a photosensitive GPCR found in animal retinas. In vertebrates, rhodopsin molecules are embedded in membranous stacks found in photoreceptor (rod) cells. Each rhodopsin molecule responds to a photon of light by triggering a decrease in cGMP levels which leads to the closure of plasma membrane sodium channels. In this manner, a visual signal is converted to a neural impulse.
Other rhodopsin-like GPCRs are directly involved in responding to neurotransmitters. These GPCRs include the receptors for adrenaline (adrenergic receptors), acetylcholine (muscarinic receptors), adenosine, galanin, and glutamate (N-methyl-D-aspartate/NMDA receptors). (Reviewed in Watson, S. and S. Arkinstall (1994) The G-Protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 7-9, 19-22, 32-35, 130-131, 214-216, 221-222; Habert-Ortoli, E. et al. (1994) Proc. Natl.
Acad. Sci. USA
91:9780-9783.) The galanin receptors mediate the activity of the neuroendocrine peptide galanin, which inhibits secretion of insulin, acetylcholine, serotonin and noradrenaline, and stimulates prolactin and growth hormone release. Galanin receptors are involved in feeding disorders, pain, depression, and Alzheimer's disease (Kask, K. et al. (1997) Life Sci. 60:1523-1533). Other nervous system rhodopsin-like GPCRs include a growing family of receptors for lysophosphatidic acid and other lysophospholipids, which appear to have roles in development and neuropathology (Chum J. et al.
(1999) CeII Biochem. Biophys. 30:213-242).
The largest subfamily of GPCRs, the olfactory receptors, axe also members of the rhodopsin-like GPCR family. These receptors function by transducing odorant signals.
Numerous distinct olfactory receptors are required to distinguish different odors. Each olfactory sensory neuron expxesses only one type of olfactory receptor, and distinct spatial zones of neurons expressing distinct receptors are found in nasal passages. For example, the RAlc receptor which was isolated from a rat brain library, has been shown to be limited in expression to very distinct regions of the brain and a defined zone of the olfactory epithelium (Raining, K. et al. (1998) Receptors Channels 6:141-151).
However, the expression of olfactory-like receptors is not confined to olfactory tissues. For example, three rat genes encoding olfactory-like receptors having typical GPCR
characteristics showed expression patterns not only in taste and olfactory tissue, but also in male reproductive tissue (Thomas, M.B. et al. (1996) Gene 178:1-5).
Members of the secretin-like GPCR subfamily have as their ligands peptide hormones such as secretin, calcitonin, glucagon, growth hormone-releasing hormone, parathyroid hormone, and vasoactive intestinal peptide. For example, the secretin receptor responds to secretin, a peptide hormone that stimulates the secretion of enzymes and ions in the pancreas and small intestine (Watson, su ra, pp. 278-283). Secretin receptors are about 450 amino acids in length and are found in the plasma membrane of gastrointestinal cells. Binding of secretin to its receptor stimulates the production of cAMP.
Examples of secretin-like GPCRs implicated in inflammation and the immune response include the EGF module-containing, mucin-like hormone receptor (Emrl) and CD97 receptor proteins. These GPCRs are members of the recently characterized EGF-TM7 receptors subfamily.
These seven transmembrane hormone receptors exist as heterodimers in vivo and contain between three and seven potential calcium-binding EGF-like motifs. CD97,is predominantly expressed in leukocytes and is markedly upregulated on activated B and T cells (McKnight, A.J. and S. Gordon (1998) J. Leukoc. Biol. 63:271-280).
The third GPCR subfamily is the metabotropic glutamate receptor family.
Glutamate is the major excitatory neurotransmitter in the central nervous system. The metabotropic glutamate receptors modulate the activity of intracellular effectors, and are involved in long-term potentiation (Watson, supra, p.130). The Ca2+-sensing receptor, which senses changes in the extracellular concentration of calcium ions, has a large extracellular domain including clusters of acidic amino acids which may be involved in calcium binding. The metabotropic glutamate receptor family also includes pheromone receptors, the GABAB receptors, and the taste receptors.
Other subfamilies of GPCRs include two groups of chemoreceptor genes found in the nematodes Caenorhabditis ele_gans and Caenorhabditis bri~~sae, which are distantly related to the mammalian olfactory receptor genes. The yeast pheromone receptors STE2 and STE3, involved in the response to mating factors on the cell membrane, have their own seven-transmembrane signature, as do the CAMP receptors from the slime mold Dictyostelium discoideum, which are thought to regulate the aggregation of individual cells and control the expression of numerous developmentally-regulated genes.
GPCR mutations, which may cause loss of function or constitutive activation, have been associated with numerous human diseases (Coughlin, supra). For instance, retinitis pigmentosa may arise from mutations in the rhodopsin gene. Furthermore, somatic activating mutations in the thyrotropin receptor have been reported to cause hyperfunctioning thyroid adenomas, suggesting that certain GPCRs susceptible to constitutive activation may behave as protooncogenes (Parma, J. et al.
(1993) Nature 365:649-651). GPCR receptors for the following ligands also contain mutations associated with human disease: lutenizing hormone (precocious puberty);
vasopressin VZ (X-linked nephrogenic diabetes); glucagon (diabetes and hypertension); calcium (hyperparathyroidism, hypocalcuria, hypercalceniia); parathyroid hormone (short limbed dwarfism);
(33 adrenoceptor (obesity, non-insulin-dependent diabetes mellitus); growth hormone releasing hormone (dwa~sm);
and adrenocorticotropin (glucocorticoid deficiency) (Wilson, S. et al. (1998) Br. J. Pharmocol.
125:1387-1392; Stadel, J.M. et al. (1997) Trends Pharmacol. Sci. 18:430-437).
GPCRs are also involved in depression, schizophrenia, sleeplessness, hypertension, anxiety, stress, renal failure, and several cardiovascular disorders (Horn, F. and G. Vriend (1998) J. Mol. Med.
76:464-468).
In addition, within the past 20 years several hundred new drugs have been recognized that are directed towards activating or inhibiting GPCRs. The therapeutic targets of these drugs span a wide range of diseases and disorders, including cardiovascular, gastrointestinal, and central nervous system disorders as well as cancer, osteoporosis and endometriosis (Wilson, s-unra;
Stadel, supra). For example, the dopamine agonist L-dopa is used to treat Parkinson's disease, while a dopamine antagonist is used to treat schizophrenia and the early stages of Huntington's disease. Agonists and antagonists of adrenoceptors have been used for the treatment of asthma, high blood pressure, other cardiovascular disorders, and anxiety; muscarinic agonists are used in the treatment of glaucoma and tachycardia; serotonin 5HT1D antagonists are used against migraine; and histamine Hl antagonists are used against allergic and anaphylactic reactions, hay fever, itching, and motion sickness (Horn, supra).
Recent research suggests potential future therapeutic uses for GPCRs in the treatment of metabolic disorders including diabetes, obesity, and osteoporosis. For example, mutant V2 vasopressin receptors causing nephrogenic diabetes could be functionally rescued in vitro by co-expression of a C-terminal V2 receptor peptide spanning the region containing the mutations. This result suggests a possible novel strategy for disease treatment (Schoneberg, T. et al. (1996) EMBO J.
15:1283-1291). Mutations in melanocortin-4. receptor (MC4R) are implicated in human weight regulation and obesity. As with the vasopressin V2 receptor mutants, these MC4R mutants are defective in trafficking to the plasma membrane (Ho, G. and R.G. MacKenzie (1999) J. Biol. Chem.
274:35816-35822), and thus might be treated with a similar strategy. The type 1 receptor for parathyroid hormone (PTH) is a GPCR that mediates the PTH-dependent regulation of calcium homeostasis in the bloodstream. Study of PTH/receptor interactions may enable the development of novel PTH receptor ligands for the treatment of osteoporosis (Mannstadt, M. et aI. (I999) Am. J.
Physiol. 277:F665-F675).
The chemokine receptor group of GPCRs have potential therapeutic utility in inflammation and infectious disease. (For review, see Locati, M. and P.M. Murphy (1999) Annu. Rev. Med.
50:425-440.) Chemokines are small polypeptides that act as intracellular signals in the regulation of leukocyte trafficking, hematopoiesis, and angiogenesis. Targeted disruption of various chemokine receptors in mice indicates that these receptors play roles in pathologic inflammation and in autoimmune disorders such as multiple sclerosis. Chemokine receptors are also exploited by infectious agents, including herpesviruses and the human immunodeficiency virus (HIV-1) to facilitate infection. A truncated version of chemokine receptor CCRS, which acts as a coreceptor for infection of T-cells by HIV-1, results in resistance to AIDS, suggesting that CCRS antagonists could be useful in preventing the development of AmS.
The discovery of new G-protein coupled receptors, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.
SUMMARY OF THE INVENTION
The invention features purified polypeptides, G-protein coupled receptors, referred to collectively as "GCREC" and individually as "GCREC-l," "GCREC-2," "GCREC-3,"
"GCREC-4,"
"GCREC-5," "GCREC-6," "GCREC-7," "GCREC-8," "GCREC-9," "GCREC-10," "GCREC-11,"
"GCREC-12," "GCREC-13," "GCREC-14," "GCREC-15," "GCREC-16," "GCREC-17," "GCREC-18," and "GCREC-19." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring annino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ
ID NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m N0:1-19.
In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ )D NO:1-19.
The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ
ll~ NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19.
In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-19. Tn another alternative, the polynucleotide is selected from the group consisting of SEQ m NO:20-38.
Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ )D NO:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: l-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.
The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ m N0:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ m N0:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m N0:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.
Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ m N0:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ll~ NO:1-19.
The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ 1D N0:20-38, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ m N0:20-38, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d).
In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.
Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ m N0:20-38, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ m N0:20-38, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA
equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.
The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ll7 N0:20-38, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ m N0:20-38, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d).
The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring, amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ m NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ m NO:1-19. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition.
The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ m N0:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ m NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:l-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: l-19. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional GCR.EC, comprising administering to a patient in need of such treatment the composition.
Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ 117 NO:1-19. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample.
In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional GCREC, comprising administering to a patient in need of such treatment the composition.
The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ m NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.
The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID
N0:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ m NO:1-19. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.
The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID N0:20-38, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.
The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ
ID N0:20-38, ii) a polynucleotide comprising a naturally occurnng polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID N0:20-38, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID
NO:20-38, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ >D N0:20-38, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv).
Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
BRIEF DESCRIPTION OF THE TABLES
Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.
Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.
Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.
Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.
Table 5 shows the representative cDNA library for polynucleotides of the invention.
Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.
Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.
DESCRIPTION OF THE INVENTION
Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
It must be noted that as used herein and in the appended claims, the singular forms "a," "an,"
and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs.
Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
DEFINITIONS
"GCREC" refers to the amino acid sequences of substantially purified GCREC
obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.
The term "agonist" refers to a molecule which intensifies or mimics the biological activity of GCREC. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by directly interacting with GCREC or by acting on components of the biological pathway in which GCREC
participates.
An "allelic variant" is an alternative form of the gene encoding GCREC.
Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.
Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
"Altered" nucleic acid sequences encoding GCREC include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as GCREC or a polypeptide with at least one functional characteristic of GCREC. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding GCREC, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GCREC. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GCREC. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of GCREC is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine.
Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.
The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.
"Amplification" xelates to the production of additional copies of a nucleic acid sequence.
Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.
The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of GCREC. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by directly interacting with GCREC or by acting on components of the biological pathway in which GCREC participates.
The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')z, and Fv fragments, which are capable of binding an epitopic determinant.
Antibodies that bind GCREC polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired.
Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.
The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.
The term "antisense" refers to any composition capable of base-pairing with the "sense"
(coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA;
RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the 3S designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.
The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "irnmunologically active" or "immunogenic"
refers to the capability of the natural, recombinant, or synthetic GCREC, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.
"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.
A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution.
Compositions comprising polynucleotide sequences encoding GCREC or fragments of GCREC may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCI), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).
"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL,-PCR
kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.
"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions.
The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.
Original Residue Conservative Substitution Ala Gly, Ser Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln, Glu Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile, Leu, Thr Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.
A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.
The term "derivative" refers to a chemically modified polynucleotide or polypeptide.
Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or innmunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.
A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.
"Differential expression" refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.
"Exon shuffling" refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.
A "fragment" is a unique portion of GCREC or the polynucleotide encoding GCREC
which is identical in sequence to but shorter in length than the parent sequence. A
fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A
fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule.
For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.
A fragment of SEQ >D N0:20-38 comprises a region of unique polynucleotide sequence that specifically identifies SEQ m N0:20-38, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ m N0:20-38 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ m N0:20-38 from related polynucleotide sequences. The precise length of a fragment of SEQ
m N0:20-38 and the region of SEQ m N0:20-38 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.
A fragment of SEQ m NO:1-19 is encoded by a fragment of SEQ ID N0:20-38. A
fragment of SEQ m N0:1-19 comprises a region of unique amino acid sequence that specifically identifies SEQ ID N0:1-19. For example, a fragment of SEQ ID NO:1-19 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ m NO:1-19.
The precise length of a fragment of SEQ m N0:1-19 and the region of SEQ m NO:1-19 to which the fragment ' corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.
A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A
"full length" polynucleotide sequence encodes a "full length" polypeptide sequence.
"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.
The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.
Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN
version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS
8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.
Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorF/bl2.html.
The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST
programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2Ø12 (April-21-2000) set at default parameters. Such default parameters may be, for example:
Matrix: BLOSUM62 Reward for match: 1 Penalty for mismatch: -2 Opera Gap: 5 and Extension Gap: 2 penalties Gap x drop-off.' SO
Expect: l0 Word Size: 11 Filter: on Percent identity ma.y be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.
Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.
The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions.
Such conservative substitutions, explained in more detail above, generally preserve the charge and-hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.
Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN
version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: I~tuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.
Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences"
tool Version 2Ø12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:
Matrix: BLOSUM62 Open Gap: 11 and Extension Gap: 1 pezzalties Gap x drop-off 50 Expect: 10 Word Size: 3 Filter: on Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.
"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in, size and which contain all of the elements required for chromosome replication, segregation and maintenance.
The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.
"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity.
Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing steps) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity.
Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1 % (w/v) SDS, and about 100 ~,g/ml sheared, denatured salmon sperm DNA.
Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T,~) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating Tm and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al.
(1989) Molecular Cloning: A Laboratory Manual, 2"d ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.
High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC
concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1 %.
Typically, blocking reagents are used to block non-specific hybridization.
Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 p,g/ml. Organic solvent, such as formamide at a concentration of about 35-50% vlv, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.
The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A
hybridization complex may be formed in solution (e.g., Cot or Rot analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).
The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amnno acid residues or nucleotides, respectively.
"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.
An "immunogenic fragment" is a polypeptide or oligopeptide fragment of GCREC
which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of GCREC which is useful in any of the antibody production methods disclosed herein or known in the art.
The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.
The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microanray.
The term "modulate" refers to a change in the activity of GCREC. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of GCREC.
The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.
"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.
"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition.
PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.
"Post-translational modification" of an GCREC may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of GCREC.
"Probe" refers to nucleic acid sequences encoding GCREC, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule.
Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.
"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).
Probes and primers as used in the present invention typically compxise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the, specification, including the tables, figures, and Sequence Listing, may be used.
Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloni~yA Laboratory Manual, 2°a ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biolo~y, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR
Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA.
PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).
Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR
primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases.
Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge LTI~) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.
A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence.
This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.
Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.
A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (LTTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.
"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes;
fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors;
magnetic particles; and other moieties known in the art.
An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.
The term "sample" is used in its broadest sense. A sample suspected of containing GCREC, nucleic acids encoding GCREC, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.
The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A
and the antibody will reduce the amount of labeled A that binds to the antibody.
The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60%a free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.
A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.
"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.
A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.
"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or vixal infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.
A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.
A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2Ø9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A
splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.
A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2Ø9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%
or greater sequence identity over a certain defined length of one of the polypeptides.
THE INVENTION
The invention is based on the discovery of new human G-protein coupled receptors (GCREC), the polynucleotides encoding GCREC, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections.
Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project 117). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide III) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ m NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.
Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog.
Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog.
Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ILK NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ~) for each polypeptide of the invention.
Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI]. Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.
Together, Tables 2 and 3 summarize the properties of each polypeptide of the invention, and these properties establish that the claimed polypeptides are G-protein coupled receptors. For example, SEQ ID NO:1 is 40% identical to Meleagris gallo~avo G protein-coupled P2Y nucleotide receptor (GenBank ID g2707256) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 4.0e-62, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ m NO: l also contains a rhodopsin family 7 transmembrane receptor domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and BLAST analyses provide further .
corroborative evidence that SEQ ll~ N0:1 is G-protein coupled receptor. SEQ ID
N0:2 was analyzed and annotated in a similar manner. These analyses indicate that SEQ ID N0:2 is a pheromone receptor (Dulac, C. and R. Axel (1995) Cell 83:195-206).
As a further example, SEQ ID N0:6 is 29% identical to human C-C chemokine receptor type 1 (GenBank ID g179985) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.6e-15, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID N0:6 also contains a 7 transmembrane receptor (rhodopsin family) domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and PROF1LESCAN analyses provide further corroborative evidence that SEQ ID NO:6 is a chemokine receptor.
As a further example, SEQ ID N0:9 is 95% identical to rat calcium-independent alpha-latrotoxin receptor (GenBank ID g3882981) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ )D NO:9 also contains a 7-transmembrane receptor (secretin family) domain and a latrophilin/CL-1-like GPS domain, as 2S determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLllVIPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID N0:9 is a latrophilin-related G-protein coupled receptor.
As a further example, SEQ ID N0:12 is 84% identical to Mus musculus G-protein coupled receptor GPR73 (GenBank ID g7248884) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 6.7e-166, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID
N0:12 also contains a 7 transmembrane receptor (rhodopsin family) domain as determined by searching for statistically significant matches in the hidden Markov model (I~VIM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMfS analysis reveals the presence of a rhodopsin-like GPCR supexfamily signature (See Table 3). Additional data from MOTIFS and PROFILESCAN
analyses provide further corroborative evidence that SEQ m N0:12 is a G-protein coupled receptor.
As a further example, SEQ ID N0:15 is 80% identical to rat serotonin receptor (GenBank ID
g310075) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 2.5e-152, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID N0:15 also contains a rhodopsin family receptor domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLI1VIPS, analyses provide further corroborative evidence that SEQ ID N0:15 is a G-protein coupled receptor.
As a further example, SEQ DJ N0:16 is 71% identical to mouse olfactory receptor E3 (GenBank ID g3983382) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.9e-88, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ m N0:16 also contains a rhodopsin family 7-transmembrane receptor domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOT1FS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID N0:16 is an olfactory G-protein coupled receptor.
As a further example, SEQ ID N0:17 is 83% identical to mouse olfactory G-protein coupled receptor G3 (GenBank ID g3983398) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is S.Oe-99, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ m N0:17 also contains a rhodopsin family 7-transmembrane receptor domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLM'S, MOT1FS, and PROF1LESCAN
analyses provide further corroborative evidence that SEQ ID NO:17 is an olfactory G-protein coupled receptor. SEQ
113 N0:2-5, SEQ ID N0:7-8, SEQ ID NO: IO-1 I, SEQ ID NO: I3-14, and SEQ TD
NO:I8-19 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ
ID NO: I-I9 are described in Table 7.
As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention.
Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID N0:20-38 or that distinguish between SEQ ID
N0:20-38 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA
sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5') and stop (3') positions of the cDNA and/or genomic sequences in column 5 relative to their respective full length sequences.
The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 7075196H1 is the identification number of an Incyte cDNA sequence, and BRAUTDR04 is the cDNA
library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., 71906055V1). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs (e.g., g900324) which contributed to the assembly of the full length polynucleotide sequences. In addition, the identification numbers in column 5 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, ITK) database (i.e., those sequences including the designation "ENST"). Alternatively, the identification numbers in column 5 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (i.
e., those sequences including the designation "NM" or "NT") or the NCBI RefSeq Protein Sequence Records (i.e., those sequences including the designation "NP"). Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, FL IiXXXI~X_NI 1Vz YYYYY_N3 1Vø represents a "stitched"
sequence in which ~XXXX is the identification number of the cluster of sequences to which the algorithm was applied, and YYYYY is the number of the prediction generated by the algorithm, and 2S N1,2,3...~ if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the identification numbers in column 5 may refer to assemblages of exons brought together by an "exon-stretching" algorithm. For example, FLXXX_gAAAAA_gBBBBB_1 IV is the identification number of a "stretched"
sequence, with XI~XXXX being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the "exon-stretching" algorithm was applied, gBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and N refernng to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the "exon-stretching" algorithm, a RefSeq identifier (denoted by "NM," "NP," or "NT") may be used in place of the GenBank identifier (i.e., gBBBBB).
Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V).
Prefix Type of analysis and/or examples of programs GNN, GFG,Exon prediction from genomic sequences using, for example, ENST GENSCAN (Stanford University, CA, USA) or FGENES
(Computer Genomics Group, The Sanger Centre, Cambridge, UK).
GBI Hand-edited analysis of genomic sequences.
FL Stitched or stretched genomic sequences (see Example V).
INCY Full length transcript and exon prediction from mapping of EST
sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.
In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.
Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.
The invention also encompasses GCREC variants. A preferred GCREC variant is one which has at least about 80°Io, or alternatively at least about 90%, or even at least about 95°Io amino acid sequence identity to the GCREC amino acid sequence, and which contains at least one functional or structural characteristic of GCREC.
The invention also encompasses polynucleotides which encode GCREC. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID N0:20-38, which encodes GCREC. The polynucleotide sequences of SEQ m N0:20-38, as presented in the Sequence Listing, embrace the equivalent RNA
sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.
The invention also encompasses a variant of a polynucleotide sequence encoding GCREC. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding GCREC. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID
N0:20-38 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:20-38. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of GCREC.
It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding GCREC, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurnng gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible colon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring GCREC, and all such variations are to be considered as being specifically disclosed.
Although nucleotide sequences which encode GCREC and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring GCREC
under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GCREC or its derivatives possessing a substantially different colon usage, e.g., inclusion of non-naturally occurring colons. Colons rnay be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular colons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GCREC and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.
The invention also encompasses production of DNA sequences which encode GCREC
and GCREC derivatives, or fragments thereof, entirely by synthetic chemistry.
After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GCREC or any fragment thereof.
Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ >l7 N0:20-38 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol.
152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."
Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the I~lenow fragment of DNA polymerise I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerise (Applied Biosystems), thermostable T7 polymerise (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerises and proofreading exonucleases such as those found in the ELONGASE
amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA
sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithW s which are well known in the art.
(See, e.g., Ausubel, F.M.
(1997) Short Protocols in Molecular Biolo~y, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biolo$y and Biotechnolo~y, Wiley VCH, New York NY, pp.
856-853.) The nucleic acid sequences encoding GCREC may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic.
2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (I988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA
fragments adjacent to known sequences in human and yeast artificial chromosome DNA.
(See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res.
19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFIIVDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids.the need to screen libraries and is useful in finding intronlexon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.
When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.
Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.
In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode GCREC may be cloned in recombinant DNA molecules that direct expression of GCREC, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express GCREC.
The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter GCREC-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA
shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.
The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat.
Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of GCREC, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial"
breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.
In. another embodiment, sequences encoding GCREC may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Sex. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser.
7:225-232.) Alternatively, GCREC itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques.
(See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Pro erties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems).
Additionally, the amino acid sequence of GCREC, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.
The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.) In order to express a biologically active GCREC, the nucleotide sequences encoding GCREC
or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding GCREC. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GCREC. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding GCREC and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used.
(See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.) Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GCREC and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et aI. (1989) Molecular Cloning; A
Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biolo~y, John Wiley & Sons, New York NY, ch. 9, 13, and 16.) A variety of expression vector/host systems may be utilized to contain and express sequences encoding GCREC. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra;
Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl.
Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technolo~y (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc.
Natl. Acad. Sci. USA
81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population.
(See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M.
et al. (1993) Proc.
Natl. Acad. Sci. USA 90(13):6340-6344; Butler, R.M. et al. (1985) Nature 317(6040):813-815;
McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, LM. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.
In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding GCREC. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding GCREC can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORTl plasmid (Life Technologies). Ligation of sequences encoding GCREC into the vector's multiple cloning site disrupts the lacZ gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M.
Schuster (1989) J. Biol.
Chem. 264:5503-5509.) When large quantities of GCREC are needed, e.g. for the production of antibodies, vectors which direct high level expression of GCREC may be used.
For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.
Yeast expression systems may be used for production of GCREC. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH
promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation.
(See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.) Plant systems may also be used for expression of GCREC. Transcription of sequences encoding GCREC may be driven by viral promoters, e.g., the 355 and 195 promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N.
(1987) EMBO J.
6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al.
(1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA
transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technoloay (1992) McGraw Hill, New York NY, pp. 191-196.) In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GCREC
may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses GCREC in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc.
Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.
Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J.
et al. (1997) Nat. Genet.
15:345-355.) For long term production of recombinant proteins in mammalian systems, stable expression of GCREC in cell lines is preferred. For example, sequences encoding GCREC can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector.
Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.
Any number of selection systems may be used to recover transformed cell lines.
These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in tk- and apr cells, respectively.
(See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, T. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dlafr confers resistance to methotrexate; neo confers resistance to the aminoglycosides neomycin and G-418; and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase;
respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., trpB and hisD, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc.
Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescentproteins (GFP; Clontech),13 glucuronidase and its substrate I3-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system.
(See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.) Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding GCREC is inserted within a marker gene sequence, transformed cells containing sequences encoding GCREC can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GCREC under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.
In general, host cells that contain the nucleic acid sequence encoding GCREC
and that express GCREC may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR
amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.
Immunological methods for detecting and measuring the expression of GCREC
using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked irrununosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GCREC is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS
Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. ( 1997) Current Protocols in Innnunolo~y, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) hnmunochemical Protocols, Humana Press, Totowa NJ.) A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GCREC
include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide.
Alternatively, the sequences encoding GCREC, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.
Host cells transformed with nucleotide sequences encoding GCREC may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GCREC may be designed to contain signal sequences which direct secretion of GCREC through a prokaryotic or eukaryotic cell membrane.
In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion.
Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity.
Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEI~293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.
In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GCR.EC may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric GCREC protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of GCREC
activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, c-myc, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the GCREC encoding sequence and the heterologous protein sequence, so that GCREC may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.
In a further embodiment of the invention, synthesis of radiolabeled GCREC may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These ystems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, 35S-methionine.
GCREC of the present invention or fragments thereof may be used to screen for compounds that specifically bind to GCREC. At least one and up to a plurality of test compounds may be screened for specific binding to GCREC. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.
In one embodiment, the compound thus identified is closely related to the natural ligand of GCREC, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunolo~y 1(2):
Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which GCREC
binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening fox these compounds involves producing appropriate cells which express GCREC, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing GCREC or cell membrane fractions which contain GCREC
are then contacted with a test compound and binding, stimulation, or inhibition of activity of either GCREC or the compound is analyzed.
An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable Iabel. For example, the assay may comprise the steps of combining at least one test compound with GCREC, either in solution or affixed to a solid support, and detecting the binding of GCREC to the compound.
Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compounds) may be free in solution or affixed to a solid support.
GCREC of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of GCREC. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for GCREC activity, wherein GCREC is combined. with at least one test compound, and the activity of GCREC in the presence of a test compound is compared with the activity of GCREC in the absence of the test compound. A change in the activity of GCREC in the presence of the test compound is indicative of a compound that modulates the activity of GCREC. Alternatively, a test compound is combined with an in vitro or cell-free system comprising GCREC under conditions suitable for GCREC activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of GCREC may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.
In another embodiment, polynucleotides encoding GCREC or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S.
Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo;
Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, I~.U.
et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.
Polynucleotides encoding GCREC may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al.
(1998) Science 282:1145-1147).
Polynucleotides encoding GCREC can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding GCREC is injected into animal ES cells, and the injected 15, sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease.
Alternatively, a mammal inbred to overexpress GCREC, e.g., by secreting GCREC
in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).
THERAPEUTICS
Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of GCREC and G-protein coupled receptors. In addition, the expression of GCREC
is closely associated with brain tissue, fetal brain tissue, colon polyps, diseased colon tissue, colon tumor tissue, diseased gallbladder tissue, heart tissue, diseased breast tissue, interleukin-5 stimulated eosinophils, tumor tissue, and reproductive tissues. Therefore, GCREC appears to play a role in cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections. In the treatment of disorders associated with increased GCREC
expression or activity, it is desirable to decrease the expression or activity of GCREC. In the treatment of disorders associated with decreased GCREC expression or activity, it is desirable to increase the expression or activity of GCREC.
Therefore, in one embodiment, GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, colon, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha 1-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmunelinflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and togavirus.
In another embodiment, a vector capable of expressing GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those described above.
In a further embodiment, a composition comprising a substantially purified GCREC in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC
including, but not limited to, those provided above.
In still another embodiment, an agonist which modulates the activity of GCREC
may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those listed above.
In a further embodiment, an antagonist of GCREC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCREC. Examples of such disorders include, but are not limited to, those cell proliferative, neurological, cardiovascular, IO gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections described above. In one aspect, an antibody which specifically binds GCREC may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express GCREC.
In an additional embodiment, a vector expressing the complement of the polynucleotide encoding GCREC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCREC including, but not limited to, those described above.
In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
An antagonist of GCREC may be produced using methods which are generally known in the are. In particular, purified GCREC may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GCREC.
Antibodies to GCREC may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.
For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with GCREC or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium~arvum are especially preferable.
It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to GCREC have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of GCREC amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.
Monoclonal antibodies to GCREC may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture.
These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D.
et al. (1985) J.
Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA
80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.) In addition, techniques developed for the production of "chimeric antibodies,"
such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Mornson, S.L. et al. (1984) Proc.
Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods laiown in the art, to produce GCREC-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.) Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl.
Acad. Sci. USA
86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.) Antibody fragments which contain specific binding sites for GCREC may also be generated.
For example, such fragments include, but are not limited to, F(ab')Z fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
(See, e.g., Huse, W.D.
et al. (1989) Science 246:1275-1281.) Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GCREC and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering GCREC epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).
Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for GCREC.
Affinity is expressed as an association constant, Ka, which is defined as the molar concentration of GCREC-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions.
The Ka determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple GCREC epitopes, represents the average affinity, or avidity, of the antibodies for GCREC. The Ka determined for a preparation of monoclonal antibodies, which are monospecific for a particular GCREC epitope, represents a true measure of affinity. High-affinity antibody preparations with Ka ranging from about 109 to 1012 Llmole are preferred for use in immunoassays in which the GCREC-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with Ka ranging from about 106 to 10' Llmole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of GCREC, preferably in active form, from the antibody (Catty, D. (1988) Antibodies.
Volume T: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A
Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).
The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibodylml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of GCREC-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, su~a, and Coligan et al. supra.) In another embodiment of the invention, the polynucleotides encoding GCREC, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding GCREC. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding GCREC. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.) In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (19.98) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) Blood 76:271; Ausubel, su ra; Uckert, W. and W. Walther (1994) Phaxmacol. Ther.
63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull.
51(1):217-225; Boado, R.J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morns, M.C. et al. (1997) Nucleic Acids Res.
25 ( 14):2730-2736.) In another embodiment of the invention, polynucleotides encoding GCREC may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cel175:207-216; Crystal, R.G. et al.
(1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX
deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, LM. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D.
(1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci.
USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falcipaxum and Trypanosoma cruzi). In the case where a genetic deficiency in GCREC expression or regulation causes disease, the expression of GCREC from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.
In a further embodiment of the invention, diseases or disorders caused by deficiencies in GCREC are treated by constructing mammalian expression vectors encoding GCREC
and introducing these vectors by mechanical means into GCREC-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev.
Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H.
Recipon (1998) Curr.
Opin. Biotechnol. 9:445-450).
Expression vectors that may be effective for the expression of GCREC include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA).
GCREC
may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or (3-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl.
Acad. Sci. USA 89:5547-5551; Gossen, M. et aI. (I995) Science 268:1766-1769;
Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-4.56), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND;
Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding GCREC from a normal individual.
Commercially available liposome transformation kits (e.g., the PERFECT LIPID
TRANSFECTION KIT, available from Invitxogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al.
(1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.
In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to GCREC expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding GCREC under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc.
Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al.
(1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol.
72:8463-8471; Zufferey, R.
et al. (1998) J. Virol. 72:9873-9880). U.5. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4+ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J.
Virol. 71:4707-4716;
Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).
In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding GCREC to cells which have one or more genetic abnormalities with respect to the expression of GCREC. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, LM. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.
In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding GCREC to target cells which have one or more genetic abnormalities with respect to the expression of GCREC. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing GCREC to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al.
(1999) Exp. Eye Res.
169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S.
Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.5. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol.
73:519-532 and Xu, H. et al.
(1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.
In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding GCREC to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol.
9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for GCREC into the alphavirus genome in place of the capsid-coding region results in the production of a large number of GCREC-coding RNAs and the synthesis of high levels of GCREC in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of GCREC into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction.
The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA
transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.
Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E.
and B.I. Carr, Molecular and Immunolo~ic Approaches, Futura Publishing, Mt.
Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.
Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage.
For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GCREC.
Specific ribozyme cleavage sites within any potential RNA target are initially identif ed by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable.
The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.
Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules.
These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis.
Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA
sequences encoding GCREC. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6.
Alternatively, these cDNA
constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.
RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.
An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding GCREC.
Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased GCREC expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding GCREC may be therapeutically useful, and in the treatment of disorders associated with decreased GCREC expression or activity, a compound which specifically promotes expression of the polynucleotide encoding GCREC may be therapeutically useful.
At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide;
and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding GCREC is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding GCREC are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding GCREC. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynueleotide can be carried out, for example, using a Schizosaccharom, ces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al.
(2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al.
(2000) Biochem. Biophys.
Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W.
et al. (2000) U.S.
Patent No. 6,022,691).
Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient.
Delivery by transfection, by liposorne injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat.
Biotechnol. 15:462-466.) Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.
An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and pxoteins.
Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of GCREC, antibodies to GCREC, and mimetics, agonists, antagonists, or inhibitors of GCREC.
The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.
Compositions for pulmonary administration may be prepared in liquid or dry powder form.
These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar xegion of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, . J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.
Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.
Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising GCREC or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, GCREC or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).
For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
A therapeutically effective dose refers to that amount of active ingredient, for example GCREC or fragments thereof, antibodies of GCREC, and agonists, antagonists or inhibitors of GCREC, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the EDSO (the dose therapeutically effective in 50% of the population) or LDso (the dose lethal to 50°7o of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LDSOlEDSO ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the EDSO
with little or no toxicity.
The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.
The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half life and clearance rate of the particular formulation.
Normal dosage amounts may vary from about O. l ,ug to 100,000 ,ug, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature arid generally available to practitioners in the art.
Those skilled in the axt will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.
DIAGNOSTICS
In another embodiment, antibodies which specifically bind GCREC may be used for the diagnosis of disorders characterized by expression of GCREC, or in assays to monitor patients being treated with GCREC or agonists, antagonists, or inhibitors of GCREC.
Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics.
Diagnostic assays for GCREC include methods which utilize the antibody and a label to detect GCREC in human body fluids or in extracts of cells or tissues. The antibodies ma.y be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.
A variety of protocols for measuring GCREC, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of GCREC expression.
Normal or standard values for GCREC expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, far example, human subjects, with antibodies to GCREC under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means.
Quantities of GCREC
expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.
In another embodiment of the invention, the polynucleotides encoding GCREC may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of GCREC
may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of GCREC, and to monitor regulation of GCREC levels during therapeutic intervention.
In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding GCREC or closely related molecules may be used to identify nucleic acid sequences which encode GCREC. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5'regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding GCREC, allelic variants, or related sequences.
Probes may also be used for the detection of related sequences, and may have at least 50%
sequence identity to any of the GCREC encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID
N0:20-38 or from genomic sequences including promoters, enhancers, and introns of the GCREC
gene.
Means for producing specific hybridization probes for DNAs encoding GCREC
include the cloning of polynucleotide sequences encoding GCREC or GCREC derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA
polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as 32P or 35S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.
Polynucleotide sequences encoding GCREC may be used for the diagnosis of disorders associated with expression of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, colon, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha 1-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmunelinflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and togavirus. The polynucleotide sequences encoding GCREC may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered GCREC' expression. Such qualitative or quantitative methods are well known in the art.
In a particular aspect, the nucleotide sequences encoding GCREC may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding GCREC may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding GCREC in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.
In order to provide a basis for the diagnosis of a disorder associated with expression of GCREC, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding GCREC, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder.
Deviation from standard values is used to establish the presence of a disorder.
Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject.
The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.
With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type rnay allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.
Additional diagnostic uses for oligonucleotides designed from the sequences encoding GCREC may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding GCREC, or a fragment of a polynucleotide complementary to the polynucleotide encoding GCREC, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.
In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC may be used to detect single nucleotide polymorphisms (SNPs).
SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like.
SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).
Methods which may also be used to quantify the expression of GCREC include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. hnmunol. Methods 159:235-244; Duplaa, C.
et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.
In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.
In another embodiment, GCREC, fragments of GCREC, or antibodies specific for GCREC
may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.
A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis,"
U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.
Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.
Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S.
and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families.
Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression~is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at http://www.niehs.nih.gov/oclnews/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.
In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.
Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type.
In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.
A proteomic profile may also be generated using antibodies specific for GCREC
to quantify the levels of GCREC expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem.
270:103-l I l; Mendoze, L.G. et al. (1999) Biotechniques 27:778-788).
Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.
Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.
In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.
In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A
difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.
Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al.
(1996) Proc. Natl. Acad. Sci.
USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application W095/251116;
Shalom D. et al.
(1995) PCT application W095/35505; Heller, R.A. et al. (1997) Proc. Natl.
Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed.
(1999) Oxford University Press, London, hereby expressly incorporated by reference.
In another embodiment of the invention, nucleic acid sequences encoding GCREC
may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence.
Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (PACs), bacterial artificial chromosomes (BACs), bacterial Pl constructions, or single chromosome cDNA libraries. (See, e.g., Harnngton, J.J.
et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134;
and Trask, B.J.
(1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl.
Acad. Sci. USA 83:7353-7357.) Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding GCREC on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.
In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps.
Often the placement of a gene on the chromosome of another mannmalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.
In another embodiment of the invention, GCREC, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between GC1ZEC and the agent being tested may be measured.
Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT
application W084/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with GCREC, or fragments thereof, and washed. Bound GCREC is then detected by methods well known in the art.
Purified GCREC
can also be coated directly onto plates for use in the aforementioned drug screening techniques.
Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.
In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GCREC specifically compete with a test compound for binding GCREC. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GCREC.
In additional embodiments, the nucleotide sequences which encode GCREC may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent.
The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 60/221,478, U.S. Ser. No. 60/223,268, U.S. Ser. No.
60/231,121, U.S. Ser.
No. 60/232,691, U.S. Ser. No. 60/235,146, U.S. Ser. No. 60/227,054, and U.S.
Ser. No. 60/232,243, are hereby expressly incorporated by reference.
EXAMPLES
I. Construction of cDNA Libraries Incyte cDNAs were derived from cDNA libraries described in the LlFESEQ GOLD
database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCI cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.
Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA
purity. In some eases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA
purification kit (Ambion, Austin TX).
In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA
libraries. Otherwise, cDNA was synthesized and cDNA libraries Were constructed with the UNIZAP
vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA
was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S 1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BIueMRF, or SOLR from Stratagene or DHSa, DH10B, or ElectroMAX
DHlOB from Life Technologies.
II. Isolation of cDNA Clones Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis.
Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Prornega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL
8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIA.GEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.
Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II
fluorescence scanner (Labsystems Oy, Helsinki, Finland).
III. Sequencing and Analysis Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows.
Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ.Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI
sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI
protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.
The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) Curr. Opin.
Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and I~VIMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences.
Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA
assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM.
Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).
Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.
Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, ,where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).
The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ
ID N0:20-38. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.
IV. Identification and Editing of Coding Sequences from Genomic DNA
Putative G-protein coupled receptors were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA
sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon.
The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode G-protein coupled receptors, the encoded polypeptides were analyzed by querying against PFAM models for G-protein coupled receptors.
Potential G-protein coupled receptors were also identified by homology to Incyte cDNA sequences that had been annotated as G-protein coupled receptors. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST
hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA
coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan predicted coding sequences.
V. Assembly of Genomic Sequence Data with cDNA Sequence Data "Stitched" Sequences Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA
sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences, to generate the longest possible sequence, as well as sequence variants.
Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.
"Stretched" Seguences Partial DNA sequences were extended to full length with an algorithm based on BLAST
analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST
analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example 1V. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog.
Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.
VI. Chromosomal Mapping of GCREC Encoding Polynucleotides The sequences which were used to assemble SEQ m N0:20-38 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ 1D N0:20-38 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Genethon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ LD NO:, to that map location.
Map locations are represented by ranges, or intervals, of human chromosomes.
The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM
distances are based on genetic markers mapped by Genethon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.
VII. Analysis of Polynucleotide Expression Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.) Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or L1FESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:
BLAST Score x Percent Identity 5 x minimum { length(Seq. 1), length(Seq. 2) }
The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP
(separated by gaps). If there is more than one HSP, then the pair with the highest BLAST
score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100%
identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50%
overlap at one end, or 79%
identity and 100% overlap.
Alternatively, polynucleotide sequences encoding GCREC are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA
sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue;
digestive system; embryonic structures; endocrine system; exocrine glands;
genitalia, female;
genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed;
or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding GCREC. cDNA sequences and cDNA
library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).
VIII. Extension of GCREC Encoding Polynucleotides Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.
Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.
High fidelity amplification was obtained by PCR using methods well known in the art. PCR
was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg2+, (NH4)ZS04, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec;
Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2:
94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min;
Step 5: Steps 2, 3, and 4 repeated 20 times;
Step 6: 68°C, 5 min; Step 7: storage at 4°C.
The concentration of DNA in each well was determined by dispensing 100 ~.l PICOGREEN
quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE
and 0.5 ~,l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II
(Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 ,u1 to 10 ~1 aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.
The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE
(Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LBl2x carb liquid media.
The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3:
60°C, 1 min; Step 4: 72°C, 2 min;
Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA
recoveries were reamplified using the same conditions as described above.
Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI
PRISM
BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5'regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.
IX. Labeling and Use of Individual Hybridization Probes Hybridization probes derived from SEQ ID N0:20-38 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 ,uCi of [y-3zP] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech).
An aliquot containing 10' counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases:
Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).
The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5%
sodium dodecyl sulfate.
Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.
X. Microarrays The linkage or synthesis of array elements upon a microaxray can be achieved utilizing photolithography, piezoelectric printing (ink jet printing, See, e.g., Baldeschweiler, supra.), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers.
Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, LTV, chemical, or mechanical bonding.
procedures. A typical array may be produced using available methods and machines well lalown to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalom D. et al. (1996) Genome Res. 6:639-645;
Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.) Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection.
After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element.
Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization.
The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.
Tissue or Cell Sample Preparation Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)~ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)+
RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/~,l oligo-(dT) primer (2lmer), 1X
first strand buffer, 0.03 units/~.1 RNase inhibitor, 500 ~,M dATP, 500 ~.M
dGTP, 500 ~,M dTTP, 40 ~,M dCTP, 40 ~,M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)''- RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)~ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37° C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH
Laboratories, Inc.
(CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mglml), 60 ml sodium acetate, and 300 ml of 100%
ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 p,1 5X SSC/0.2% SDS.
Microarra,~paration Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts.
PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert.
Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 ~.g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).
Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1 % SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4%
hydrofluoric acid (VWR
Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.
Array elements are applied to the coated glass substrate using a procedure described in US
Patent No. 5,807,522, incorporated herein by reference. 1 ~,l of the array element DNA, at an average concentration of 100 ng/~,1, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 n1 of array element sample per slide.
Microarrays are UV-crosslinked using a STRATALINI~ER UV-crosslinker (Stratagene).
Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water.
Non-specific binding sites are blocked by incubation of microarrays in 0.2%
casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°
C followed by washes in 0.2% SDS and distilled water as before.
Hybridization Hybridization reactions contain 9 ,u1 of sample mixture consisting of 0.2 ~,g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer.
The sample mixture is heated to 65° C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cmz coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 ,u1 of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45° C in a second wash buffer (0.1X
SSC), and dried.
Detection Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of CyS. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.
In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially.
Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT 81477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for CyS. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.
The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A
specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:.100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.
The output of the photomultiplier tube is digitized using a 12-bit RTI-835H
analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC
computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstallc (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.
A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).
XI. Complementary Polynucleotides Sequences complementary to the GCREC-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring GCREC.
Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of GCREC.
To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GCREC-encoding transcript.
XII. Expression of GCREC
Expression and purification of GCREC is achieved using bacterial or virus-based expression systems. For expression of GCREC in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA
transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3).
Antibiotic resistant bacteria express GCREC upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of GCREC in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Auto~raphica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding GCREC by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera fru~iperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases.
Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K.
et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al.
(1996) Hum. Gene Ther.
7:1937-1945.) In most expression systems, GCREC is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-~kilodalton enzyme from Schistosoma is onp icum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from GCREC at specifically engineered sites. FLAG, an F-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG
antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, su~a, ch. 10 and 16). Purified GCREC obtained by these methods can be used directly in the assays shown in Examples XVI,,XVII, and XVITI, where applicable.
XIII. Functional Ass.-,~s GCREC function is assessed by expressing the sequences encoding GCREC at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA
expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 ,ug of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 ,ug of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA
with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.
The influence of GCREC on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding GCREC and either CD64 or CD64-GFP.
CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mlZNA encoding GCREC and other genes of interest can be analyzed by northern analysis or microarray techniques.
XIV. Production of GCREC Specific Antibodies S GCREC substantially purified using polyacrylamide gel electrophoresis (PAGE;
see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.
Alternatively, the GCREC amino acid sequence is analyzed using LASERGENE
software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means lrnown to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.) Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A
peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-GCREC activity by, for example, binding the peptide or GCREC to a substrate, blocking with 1 % BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.
XV. Purification of Naturally Occurring GCREC Using Specific Antibodies Naturally occurring or recombinant GCREC is substantially purified by immunoaffinity chromatography using antibodies specific for GCREC. An immunoaffinity column is constructed by covalently coupling anti-GCREC antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.
Media containing GCREC are passed over the immunoaffmity column, and the column is washed under conditions that allow the preferential absorbance of GCREC (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GCREC binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such . as urea or thiocyanate ion), and GCREC is collected.
XVI. Identification of Molecules Which Interact with GCREC
GCREC, or biologically active fragments thereof, are labeled with'ZSI Bolton-Hunter reagent.
(See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GCREC, washed, and any wells with labeled GCREC complex are assayed. Data obtained using different concentrations of GCREC are used to calculate values for the number, affinity, and association of GCREC with the candidate molecules.
Alternatively, molecules interacting with GCREC are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).
GCREC may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K.
et al. (2000) U.S.
Patent No. 6,057,101).
XVII. Demonstration of GCREC Activity An assay for GCREC activity measures the expression of GCREC on the cell surface. cDNA
encoding GCREC is transfected into an appropriate mammalian cell line. Cell surface proteins are labeled with biotin as described (de la Fuente, M.A. et al. (1997) Blood 90:2398-2405).
Immunoprecipitations are performed using GCREC-specific antibodies, and immunoprecipitated samples are analyzed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of GCREC expressed on the cell surface.
In the alternative, an assay for GCREC activity is based on a prototypical assay for ligand/receptor-mediated modulation of cell proliferation. This assay measures the rate of DNA
synthesis in Swiss mouse 3T3 cells. A plasmid containing polynucleotides encoding GCREC is added to quiescent 3T3 cultured cells using transfection methods well known in the art. The transiently transfected cells are then incubated in the presence of [3H]thymidine, a radioactive DNA
precursor molecule. Varying amounts of GCREC ligand are then added to the cultured cells.
Incorporation of [3H]thymidine into acid-precipitable DNA is measured over an appropriate time interval using a radioisotope counter, and the amount incorporated is directly proportional to the amount of newly synthesized DNA. A linear dose-response curve over at least a hundred-fold GCREC ligand concentration range is indicative of receptor activity. One unit of activity per milliliter is defined as the concentration of GCREC producing a 50% response level, where 100%
represents maximal incorporation of [3H]thymidine into acid-precipitable DNA
(McKay, I. and I.
Leigh, eds. (1993) Growth Factors: A Practical Approach, Oxford University Press, New York NY, p.
73.) In a further alternative, the assay for GCREC activity is based upon the ability of GPCR
family proteins to modulate G protein-activated second messenger signal transduction pathways (e.g., cAMP; Gaudin, P. et al. (1998) J. Biol. Chem. 273:4990-4996). A plasmid encoding full length GCREC is txansfected into a mammalian cell line (e.g., Chinese hamster ovary (CHO) or human embryonic kidney (HEK-293) cell lines) using methods well-known in the art.
Transfected cells are grown in 12-well trays in culture medium for 48 hours, then the culture medium is discarded, and the attached cells are gently washed with PBS. The cells are then incubated in culture medium with or without ligand for 30 minutes, then the medium is removed and cells lysed by treatment with 1 M
perchloric acid. The CAMP levels in the lysate are measured by radioimmunoassay using methods well-known in the art. Changes in the levels of CAMP in the lysate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC
present in the transfected cells.
To measure changes in inositol phosphate levels, the cells are grown in 24-well plates containing 1x105 cellslwell and incubated with inositol-free media and [3H]myoinositol, 2 ~uCi/well, for 48 hr. The culture medium is removed, and the cells washed with buffer containing 10 mM LiCI
followed by addition of ligand. The reaction is stopped by addition of perchloric acid. Inositol phosphates are extracted and separated on Dowex AGl-X8 (Bio-Rad) anion exchange resin, and the total labeled inositol phosphates counted by liquid scintillation. Changes in the levels of labeled inositol phosphate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC present in the transfected cells.
XVIII. Identification of GCREC Ligands GCREC is expressed in a eukaryotic cell line such as CHO (Chinese Hamster Ovary) or HEK
(Human Embryonic Kidney) 293 which have a good history of GPCR expression and Which contain a wide range of G-proteins allowing for functional coupling of the expressed GCREC to downstream effectors. The transformed cells are assayed for activation of the expressed receptors in the presence of candidate ligands. Activity is measured by changes in intracellular second messengers, such as cyclic AMP or Ca2+. These may be measured directly using standard methods well known in the art, or by the use of reporter gene assays in which a luminescent protein (e.g.
firefly luciferase or green fluorescent protein) is under the transcriptional control of a promoter responsive to the stimulation of protein kinase C by the activated receptor (Milligan, G. et al. (1996) Trends Pharmacol. Sci. 17:235-237). Assay technologies are available for both of these second messenger systems to allow high throughput readout in multi-well plate format, such as the adenylyl cyclase activation FlashPlate Assay (NEN Life Sciences Products), or fluorescent Ca2+ indicators such as Fluo-4. AM (Molecular Probes) in combination with the FLIPR fluorimetric plate reading system (Molecular Devices). In cases where the physiologically relevant second messenger pathway is not known, GCREC may be coexpressed with the G-proteins Gaisne which have been demonstrated to couple to a wide range of G-proteins (Offermanns, S. and M.I. Simon (1995) J. Biol. Chem. 270:15175-15180), in order to funnel the signal transduction of the GCREC through a pathway involving phospholipase C and Ca2+
mobilization. Alternatively, GCREC may be expressed in engineered yeast systems which lack endogenous GPCRs, thus providing the advantage of a null background for GCREC
activation screening. These yeast systems substitute a human GPCR and Ga protein for the corresponding components of the endogenous yeast pheromone receptor pathway. Downstream signaling pathways are also modified so that the normal yeast response to the signal is converted to positive growth on selective media or to reporter gene expression (Broach, J.R. and J. Thorner (1996) Nature 3~4 (supp.):14-16). The receptors are screened against putative ligands including known GPCR ligands and other naturally occurring bioactive molecules. Biological extracts from tissues, biological fluids and cell supernatants are also screened.
Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.
A
H
N
~
-r1 1-~
O ~-I~-1rl~-I~-I~-Ic-I(17Wr-IpW-Iv-1c-Ic-1r-IP4~-Ic-I
U G~1Pafr1POP4Pan!U UW UW 0.1alW POU 0.1W
U
~ UU UU UU UInoU mU UUU U~ UU
~
H lDO NO r1L~Lf1tW-101N~DL~NM Or-1v-1d~
V
Od~01l0r1~Or1N Md~NODOd~Lf1r-1diOL~
00W ON 41t~00M MM N~ OOO d~l0t~L~
d~d~LIW-1Md~tf7l0OL~OLC7N01l0OM s-1v-I
'~ t~L~hd~t~l~L~N NL~OL 00l0L~oO 0000 O d~d~d~M d~d~cf'O Od~1.ndid~Ld~d't17d~d~
~ N
N
'~
~O
O
Z
rwl U
H
O~
W
O Or1NM d~Lnl0L~0001Oc-1NMd~111l0l~~
W NN NN NN NN NN MM MM.MMM MM
H
N
O H r-I c--1 r-I
'~ -Il -1l 1-1lCa~1-ICal l-I-Ilf~l-f ~
~
l . rr rr r. rU Ur Ur rc~ rU r.
- Afa~IC~AI~~I Ia faPaPafata f~A
r ~+~
U U.UUU UU UInoU InU UUU U~ UU
,''lflO NO r!~ InL~r101Nl0L~NM Oc-1c-Id~
N
H Od~01l0r1l0c-1N Md~NGOOd~L17rid~OL~
N00ON 01L~NM MM Nl0OOO d~lflt~l~
r1 did~Inc-1Md~Inl0OL~OInNO1l0OM v-I~-I
O L~h L~d~L~L~I~N NL~OC~00l0t~00O 00OO
W cH'd~d~M d~d~d~O Odi111d~d~L~d'd~Ind~di C~L~l~l~L~L~t~l0l0l'L11L~L~lflL~L~LC7L~L~
..
~
N
H
~
OI
~
W
O
~
LL
O v-IN Md~Inl0L~0001 v-IN Md~LC)l0L~N 01c-1v-Is--Iv-Ic-1u-Ir1r1v-Ir1 A
H
N
.1, tf1o In ,1Jl0O NO rlL~L(1L~c-I01Nl0L~NM Oc-Iv-1d~
U
~ Od101t0r1l0r1N Md~N00O~Lf1w-Id~OL~
00,NON 01L~ODM MM N~OOOO d~l0L~L~
H ~~ ~H M~ ~~pOl~OinNO1l0OM v-Ic-1 O
~ L~l~l~d~L~C~L~N Nl~Oh ~l0l~00O 00OD
~
d~d~~HM 'd~d~cttO OdiLnd'd'L~d~d~InCPd~
L~t~L~t~L~L~L~l0l0L~LnL'~L~l0L~<'LnL~L~
a~
(R N
~
td -ri 00 1 r1 O O
O
~ N U! L11 I l~LI N
h -.-I .1-~ r1 r1 fl.~ R,N ri N
U Cl~ ~
N f: O -.-IN r1 d~ N C7 N b7 ~L ,~' N
N U
.1.~ N ~I ~ U N >~ W I cd C7 ~ ~ U U
~ U U U
O P W O O U ~ O N ~ ,~ O -rl -.-I
~I N N N
~I r1 N I ~', ~, ri ~, ~ ,'~~ ~ U .~i r-I
O L ~I ~I~I
, rtfU7 C7 O ~ "~,'O d~ -rlO r-IU ~ , .!~ ~ r1 N
, U1 U' i-1 O ~I ~ U ~ u1 ~,' N aW
u7 r1 N >~'I O O n N
U' ftSN N O o1 .~.,N L r1U r1 r1 ,'~ M
N r1 ,.S",rI.G' -r-I -rl U ~, ,5 ,5 rCi N ,~,'01 (~(~ O N L~ N M
M ~ 01 N r1 ~C~ L!1 W I
O O -~'i-r-I S2~ ~'.,, M U ~.,lfl1~ U1 00 U o~ c-i U r-I O r1 t~
O ~I J~ .u v U N .1~(d O O ~ ~,' ~I P-S O1 I $1 M d' ,5 N (IS(IS ~ ~ r, w r-.~ L~ S-i r~ -ri c-I 01 ~,' O O O I7 M
I
(0 ~ J~ .U Ul U N F(', UlU1 F(,'~ O U7 r1 N ',7 l0 M r1 ~I~-I.i-101 S-I ..
w-I
'~lO ~ ~ U ~ P-~'I ~ '-' ~ ~ " I O ~ -r1 ~',v 01 U .1~I ~ l0 O M
~
O ,5 ~ra~ ~1 U U U ~ U U ~ C7 U ,!~
r1 ~I o~ td~ N .!~ d~
M o~
r1 O N W r1 c-I -r1.~, -rl-rlU v -rl a .!~ r-I-ri ~ di r1 r-,r, ~ ri t31 v t51 b1t'r~ ~ r1 b1 O
O 1~ .!J r1 I N N O
o1 rtfU7 m m rt N N U~ U m N U UW-1u1 ~ ~-I
N O b~ IO.!' o~ U --.-I
Ol ~ ~, ~., ~ ~i ~ f-i ~J~ ~i ~ ri ,5 .1~
r1 N ~1 ~-I ~i ..~-i0 d~ O 01 '-' b7 U r1 N O O S-I N ,4 v ~-I~-Irv r1 ~-I rIS
U ~ .!~ r1 -rl fir~-1''~(CS ~-1 o1 r-I u-I di O m ~ -r1-r1 O -ri O -ri O O -r1~ M O r-I
~ U .L.I cd ~ r1f.~N o~
N vo r1 -riU f~ ~ ~ f: f~ ~,'yri ~J.f'.f~ U l G' r1 f; ~-1O ''CS N f0 r1 .1~ N
rd r-I
o1 O f-IW td fd to (a \o (a cISU7 W.,''~
' ~,'N >-.,' .l~ U1 (d IJU7 r h,' t6 >37....
~ a U IJ U7S tA N 01 U7 N U7 ~ .l.- U7 f~
~ W (a O t51~ U7 U1 U7 7 ~ . . -~1O ~ U' c .
, ~ (~ U ( !~ ~ ~ ~ FC ~ ~
~- ~ ~I x ~ ~ O ~I R
~ N N o~ .l~
N I
x ~ ~' O io N . !~ O N N O Ix 1~ ..
W O ~ O O N J~ U N ~-I
I ~' L~ ~
J~
-i ., ~ - . ~ . ~ . . ~ ca .i~ ~
u1 ~ , 1~ S-I I, U IJ4J I ~-I u1 1~
O W -I ~-I "~ ~-I ~ ~
U
,x . ~~ ON O''d . 00 . O . . 0~ ~0 ON ~.l~N
N''d I t~0 NO I t~~t~ N a~
to ~a~~o x~ xa~~i~x.~ x~ x.>,xa~ rxv~ x-~I~.u~~,rx~h~.us~~
.O . rx (CS '-''-''-''-' ~ C~ '-' '-''~ '-'rrdd'-''-' '-' fa r1 ~I U7 r1 U ~ Sirr1 'J N ~ Ul ~ N O N v-I
l0 ,sa' Pa ~ N ~ ~ f~ ~ N N r, r, ,-,r, -, ~-, ~ ~
~.',-l (d .l-~N '~ Q)f-i.!~N ~,' .,~
c-t 1 M ?G . Ul S?t ..
~: r-Ir-Ir-Ir-I r1 r-i rI ri r-Ir-Ir-Ir-I r-I O
,.'7,.C,(d ~ U U U ''~ '~4-1O U N ?-1 (d r1 O ~ ,~-I N P~l 117 O d~
N 4-!4-14-I4-! 4-1 4-! 4-I4-I 4-I4-I4--I4-1 4-I W
O , ~.1O N N N O ~'.,~,'~-IO ~I (d ~-1 ~ N td ,.Q W
M 01 -r-1 L~
U '-'~ ~ ~ U ~ ~-I ~ '-'~ '-'~..~ ,J '-' ~
U .h C7 ~1 ~I LI .~. -ri-,~~ ~-I J.) 'a t17 v-I '~-a W W FC Gr-i N ~, I O d~
r rI N Lfll0 O CO d~ l0 c--1 00 O 01 -rI t0 10 00 c-I c-I u-I LC W -I c-1 c-I Lll N W W W W W W W W W W W
,.Q O O O O O O O O O O O
~I
O O O O O O O O O O O L~
O
U
W di d~ N wt N N v-1O O M O r1 r1 r1 A
~o c-Iw N d~ d1 d~ r1N o0 di c0 c-I
t11d~ N M 111 Ll7 t!1c-I COlD M 00 L~ ~O
C~, N l~ l0 O1 N 00 N M 01c~ d~ 00 O O
(a L~ lD N Ln In 01 In c0 N 01 l0 a0 LP1 d~
pa O O1 01 O In 01 In r1 ODlW -I d' N l0 ', I~ r1 01 00 O L~ O M ~ 01 d~ N Lf1 c-I
N N r1 N M c-I r1 v-Ic-I M ~D u-IL~ tIl d~
O
C7 l r31i31Ol I31 i;31X71Ol isX31Ol Ol b1 ~1 .~-W
N c~ c-I r1 ''O c-1ri w-Ic-I w-1 <i r1 A (~c-IA r1 c-I c~
-~1 ~l fa f~ (a ~1 A fa U U Pa U ~l ~1 fa ~ U U U U U U U in O U ~ U U U
~ l0 O N O r1 t~ L!1C~ c-I01 N l0 h N
N O d~ O1 ~O ~-1 l0 r1 N M d~ N OD O d' N
00 00 O N 01 L~ 00 M M M N ~O O O
d~ d~ Lflc-I M CH !.nl0 O L~ O 111 N 01 U L~ L~ t~ d~ C~ L~ t~ N N t~ O t~ 00 l0 r-I
~ dm r ~n M ~r ~r ~r o o dm i d~ d~
O
l.~
I-I L r L l r~ r C~ lO ~or i17L t l0 w I-I
N
..
,.
~Z
N
Ca Q O r1 N M 'd~
W
L4 r1 N M d~ In l0 h OD a1r1 r1 v-I c-1 c-i ri M M ~I
l~.N ~I U
~
O W , ~U O
lO
.1.~ N N 1~
~n O --. U U U
d~ -~
~d O N (CS
M CO
M
N o1 ~-I~1 4a ?-1 U7 01 r1 O
N
~-I ~y~t O .!, !I7 r1 -- ~-1~-I U
di ~-U~ O O r1 td M
U
r-I U U .~.,r1 o r1 w1 a3rtS O
rd cd o~
b1 4~4-1 O .1-~r-Ir-I U7 ~ U O O
'~ N
tr r- ~ U' u7u1 U
1 f~
~
.
',~,'.N U ~
-ri U7 N
1W-I U1IJ~ U7 td ~I ~-I r'-I
.x' ~f ~ ~ ~ .l.) O I O
O
P~ .-. u1m ,-,S-I
N ~ N
srs ~
''~
r-1 ~ Wd r-I!d U U
r-I
(IS
~ ~ ~ ~
~ C7 ~I ',~,'~
W o~ S-I
r.G
~ .,-1u 1 0 r1 ~o eoaW ~ o N ~
N ~ w w w w w a~
N O O O O O
O O o~O O r1 O
W r1 r1Ln N M
en A
H to N CO c-iCO
Ln CO01 d~ l~
L~ M M L~
(a O M M O c-I
(Y~ O 0000 O O
c-I 0101 N 01 N M M M v-ILO
O
U' b1 t51>31 b1 -~.~
N .-I
s-I~ c~ c~
~~I ~1 f~U f~ fa .1.~U U oo U U
i M O ~-W -1 cH
N u7 c-Id~ O
N
O d~to L L~
l0 O M c-1r1 U h aOO 00 c0 r1 O d~ 'd~t17 d~ d~
H l t~ttW
W
H
N
..
~1 O
1~
"Z, >~
U
Ca i H
r~~t OI
O Lf1 10L 00 01 W
W r1 c~r1 ri Ul rn H ~ ~ ~ H
ro U ~ 0 0 o z o a~ ~ ~ ~ 0 0 0 ~ ~ o n ~ CTaa W O P; p; P.' a W R:
U P4 fsa O
-ri W I I q W W W W ~ W
tn m +~ I CJlCIA 1 I I I ~ C!~
'TW
d ?, rxrxW w H H E-mx C-~r~r~ w c~H
O
.R
.-I W W ~ ~ U2 tryv7 W u7 W W ~ W U7 ,-~ H H ry' F(',~ FC H ~G' ~ a ~ a a ~ ~
ctS
.1-1 .1~
0.l P 0. P W
4 1 .~
d~ M S=i N
M . -rl ~-1 f~ H l N
L
1 S M a1 -1~ .1-I
~ ~
O l0 N N O fd v-i ~
d~
~
r-I~.,M O M ,'~' W i b7 r1 a C=.~-r1t~ f1,' c-I I -rlr1 U1 l0 ','>
I
IlkM LL O 01 ~ N Ul U7 l0 I
N
H
01O O ~y O H M t<j O ~y l0 ' ~-1x a '~ a1 N N
l P
O<
O ZjO r-I ~, ~1 r M
c-IO ~ M ~1 ' I d~O -1 a -.-1 ' -,-I
N ~ ..
M ..
E-~.f,'P~1~ o ~ ~ t~,s,''~ U
E-~N ~ C=a H
I ~II i .. .. o ~ a ~, ~ ~. 1 0 d1v F-IcI ~-I ~1 01 N ~-,1 ~ COO
tf)I n '~ ~1-1 -I0 ~-1 M
l0 ~
L
' O , O O 01 Ud Ln -I c 1 ,~~-1l1~I J~ .L-1O ~'.,Ln~I N r-101 -L~, N
N ~ N O
O O
N
I
M
O , C~ s~, f.2,o ~ cfia O >~ H o E-~o ~ ~ o ~ ~ O
o ' ~
J-~~ ~ N N N ~1 " ~-i .t-1~ P; O
M N ~ t~, N
N
U7~ U U1 U M U P-IU7 .-O ~ U1 ~ rI M ' ' W
~ M N W
M
' N N Cu Cl~ N ~ ~,N ~ W
Ln d~ N U7 ' Ul P, N .-iU S-IP~ ~I ~-I.. -,..I~ ,-riU P; -rl M 00 I ~ O d~
I I ~ 00 I
I
N ('dN N U Ln N ~-1ai Ul tIiN U di (dP;
U1 ~ t!1 00 N In M
U ~ ~I''d~4 '~ ~ O ~ td ;~~-IW r1 ~ O O
4-I d~~ t d~ m M O .-I
f~ d~ N
d~
tn s~ o N a~ c7 a~ a~ .u o c~,o In o ~. o H o, -~I I o r~ r1 ~' a a I r~ N I H
r~
~
N '~. w-I0-1 v-1 c-1S~.t'~ GaN a I GaW
.L) Q7d~ O CTa ~i M N t M ' ' ' ' O ,~-t~ N ~ .. ~ O ~, ~ O I W I
~~ N .~N H .. I U N N N ~( M N 'U N
' , ~ l0 .. X01 ~' , N
S ~ .. (O ' ( I NL~O I ~
N ~ ' O
' N
l0 , ~ (IN . N O N ~ ~ s~ , >~W ct' U ~ O mrl O N eo ~ ~I , ~If~ ~o N rl '-rl oo t~ ~ tw-I
d~ N
' ~ U rj U M U ~-1~ ~ ~ '~ r-I ~ L~
~ M ,'~ ~ ~ M~ Ff M . U7 M a >=i -Ia . ' ~,' ~,'O c-iL~ O f=i ~ W
N N f~'Fi L~ .. ' a O ~ ~ PG ~ L~
tIS ~ 1.n01 01 l ~ ~1 . ..I- O dl C7 ~ ..I LO - l L~
. . - l~
M l L~
N N -d~
U1 QJ. ~ , r r C N ',7N . r N , , N U~ N N , I ~ . . U1 O
~ v-iL~~ N O O ., M
U1 N Ul M
~. M
.1J .~.~i.1-~~ J-1 ..I-1.~.,.~.,-rl~,' (2~ .~.,,~' c-I
(," ~rW L r1 O ~ M ~,'N
',7 N ,5yN
O N
N -M ~-~I~n~~IO o~ oMOOm~ro0 o u~~-uqm ~~ ooOO <no~
I I ~ '~O ' ' I
' ~
~i ~i~-tf-1~ , ~-f~I l;.i(a ~i~-1O O .,I~
(~ -r1l0 I -1 O ~ ~ ' -r1O ~
l0 N ' LC7 ' d O
b7 (d.1~~ O t r1 ~ N df .7~QS.!->O W (fSW
~, ~ r1 M c-I O L ' ~ ~ P- S 'J1 I r-I In I ' ' n R
I -I C'; N (~ ~ n O L I ' W
~ ~ In W
t P
~
r -i i ,. n d , . -I .~ -I, 1 d , -1 r4 N
U~ H t~C7 fx C7 C7 W En W H .~ P; H W tn Ca 4-I~ ~ W W 4-I
H
W
C~
-O
r ai o0 0 ~-I
z z z ~ z o ~n N o0 o d~ d~
U d~
N
1J In l0 00 Ln 00 ,5y 00 M
.!-~
O M v-Ic-I w-I c-1 r1 N 01 -r1 wcn~nz z zz z z z O t!7 M Lf1 i.n M
c-I
L'~
O
r1 01 00 01 N c-1 l0 l0 In d~ l17 01 d~
l0 N
JJ 00 v-IN M N
di M M
O LO Lf~
O l0 l0 (~ c-I M U7 IJ~ Cl~
U7 UW 01 Il~
00 CJ~
N
H
-I a1 tn Ei ~-I H
r1 E-~ lfl t17 M
H l0 N O
~ 01 t0 d~
(a t1~ N ~ 00 ri M Lf1 H M
M 01 l0 l0 d~
L~
-r1 ~-I N N -I N
O M l0 M M
l4 CW LC7 M l0 w-I
M
,~ u~ t~ try u1 v1 u~ tn cn H u~ rwn E-~
~ ~ H
~., ~
N c-I L~ L~ M t!1 Ul O N CJs O
N In N N
W
c-1 1J c-1 M Lc1 N O
O \O N d~ Lf7 -4~ d~ r1 01 tf1 O
O
O c-i N N ~--I -i ~'.,N N M LW N
-r1 N di d~
N tD
L~
M
W U~ t!~>n u~ ~
W u~ H U~ cIW u~
tn u~ v1 u7 H U~
Ei N
O M
~
M N
-~ M d~
M O l0 ~, M l0 P
i O r1 r-Ic-I
O pp N O l0 c-1 N
Ln ~ M
U
O
~1 ~ ~ ~ ~ N
H
W
H
CN
~
Z H N M d~
>n 1n H
'TJ U '-Z ~ O
U l~
W l l ''d ~ In Hl cd ~ ; : w w ~
O
>
,~ u v H H H
r w w H H W
~
cd Cl~ O ~' FC
. ~
.I, ~ U
A 1 P4 P4 W PO a) I
di N
d~
O ~.I
~-I
r1 M J-1 W 01 I~ N
~
M
I U7 ~,' ~1 N O
~ ~' r ~1 -~-I .N ~--I
I ~-I
r~
H U1 N U1 (0 o M
r ',5 I
~2,.1~I >~ o o~
r r ~
N ''d~I r-i - ~', P-.' M
.~..,O
N
~ ~ Ul W
Ul ~',~ ~
W
I ~I U7 cIS U7 U1 N IO
r N ~-I4-I ~-I[1,' N lDO
d~ ~
O
M O ~I O O tl~ ri01 N M
~7 ,'~~-1.1-WiO J-~H N01 O
N
~~~ ~ H
r J-~~H WMMOIO O
u1 , UN mNVO U U~a~oo q H G' N N lO N W N N ~iW
N N M N
ra I -~IU ~I~xwN ~.1xxxaH ~I
N c-Ic>j~ U 1 1 I cdf~
U; H I r U ,'?"..,~ ~1 ~'~W '~ ~ N r .~.,O
4-I ~ ~ ~ r 00 N
~'., O 00 N C7 N W N N OH
r1 M N N N
~
N ~1 O r1 l11 r1 Hl ~t,' ~1W
.!-~ N M r fsa f~ I
',~
~, N ~,'w-Irv i p.~ .. W
O '~N ',~~ Cl~ ~ .. .. NN
~' f W O .. -1 i j ' ~ l0 l0 U
I '' 01 lO
I
~ -ri~,'C O ,~, O , ~'v O ~I I N O v-I W
M -rl c-1 r-1 .-1 ',~
U7 J~itfd~ U -1 U U M M (dfY, 'd dW N M M H
I
ry'01 I 1 I I Sa ~ ,'~ I
cH
fCf N 00 O Ci ~i ~i Z 00 00 w ~i O In M O1 ~' -j -j -1 O
H
r -, N N M z, ~ .
~n o m N m N W ---- NO
N -~ r r ~-I r H
O .I~ r1~ ~ .u p, .u H ~o r ~~
~ ~ ~r M M H o ~-I r1 cd cdUi Id O o o O ctt U7O
ri I r-IN N I r M 00 U7 (IS ~,'~1 ~I 't~ ~-IP'. N ~,'.
~ d~ -rlo o W to 01 p:
Ln 01 1 b) (a 1J ~ O ~ W N v-1 tlSW
~ .~., 00 O O O Ln d~ N
~ l0 " r1 r1f-1 I p.,' I I M In ~in-'T.' O ~-1' a r1 c-iN M d~
~
M v~ rpH r C7 w C7 C7 W w Hw q H 4-IPa ~ w w W x ~".,M
O Ln -r1 M
r-1 (~
(IS 00 r-1 -rl c--I
',?~
.!~ M
f=i ,~
O
N
U
N
O r-1 .-I
-.-1 G4 ",~, U~
O .-I 00 o~
r1 Lf') 00 a1 01 1J M v-I
N tO
(a U1 Cl~
H N
r-I O~ N
~ M
(d N d~
-ri N r1 O N r .I-~rn u1 ,.~ H tit ~', , N
N di N
tR tn M
N
.1~ ~-1 ~-I
O cH O
.7~
O N c-i ,i, r1 N
-r1 W u1 u1 v1 N
O
''C5 ~', "d -r-1 -ri N r1 -ri ' Fl, M N
p , N
H
W A W
.t-~U U
, r i.n o to r1 N
r m d m n U r r r-I
~ d~ d~
O
~-1 H r r W
H
O<
W
fa O
U1 ~ r H
'z, U O O
Z ~ ~
~
~ ~ ~ a x ~ U o o U r.~r~r~as w w ~n rx x o 0 a~
-~I w w w I I I W w w q A
~n m ~ I I I ~ rn u~ a I I I I
~s ~a ~, P;Ix P: P;P;w w Pa H E-~H H H f~
o ,~
r-I W W W W W x ~' ~i fl.~Ll7U7 Cl~ U7 H
~'-, cti H H H O ~C FC FC FC C~
.1~ ~ ~ ~
J.~
~~q ~ P
o ~-I 5~
'JyM N N O
c-1OI Q) N r1 d~
1 r-11 S-1 Ll7 l0 .1~
d~
d~ O1 ~ ' O tf1(C$
a H
~ N q N
x Fi G4 N W
N
O, t~, 1 ~, ~ x ~
d~ C7 .,_.i.. ~ -~ 117,-IL~ H ~, a ~-I
x ~ ~ a H
M N r1 O x O C~ M w di ~
a v ~ a~ ~M . a ~ H
I N o P4 -~i o, w w fL N
u~ o ~
r-,~n ~ I i~ o m m ~
~ I
N -- ~I as o ~1 A A Ix ~I
o ~n a ~r M Cl~ O 4-I O O W W O t31 lO l0 1 c-I
',~~.IW lO.1~~-I O .I~a a W ~ E-~!d In d~ O N M
N
a o C7~ f.~,N x s2~Pa w E-~ py ~I
~ co o, o, o, N I J-~ U N ~ W N n-~.,.~7,5Wf1 W (d M LO
Ln N U7 , 0 1 U ~ U O O U x U , O ~ H d~ C7 Ln OIF''.,N ',~O N UI N O U U O I W U7 d~ di o L cH I N
I
U7 ( r1 U r1M ~I ~ ~-I~I O U M P-',(IS
Ln In l0 ~ 01 d~
N ,-icd ~ r-IU d~ fW-mn~ W ~ ~ ~ oo I
r!? ~ M Lmn U ~',~ ~-II '-dU J~ '~ H H W ~-I f~ 'TJ
4-I W d' I ~,''N l0 a N
o ,~..o w as a~ w w a ~n mn . I M ,-1 I x I x N . q N I W -I C7 ~ ~-1E-~E-mo.. , .u ao o x M ..
a~ ..
o N ao ~ a -~i, I b~ W o o . w '~~ $ M M I n ' ~ ~o a~ 'D
~ ~ 5 ' ao ~
-I ao d' -I
~i W N (D U (C~ Ln -r-~ Q p v , r1 U d ~I w ~ d N rn , , , M M O m ~ O C O W v P; ~-i H C7 ',W-1 W a0 ~t,' '~-,t L
CI~ .!~cd ~',O U ri U .. ~ I U U
~ I I ~ M ~ .. C7 C7 I ai U
d~ -i m ~ I d~ rtS
~ ~ W tn I
~
~
~ f.~I O -~ ~ . , ~i N ' . ,~Z.,-.~1(($ N 10 d~ r1N .~'.n~ U~ N Ri N ' l4 H U
~-I QI~ ~.,-r1x M I W r1 L~ R=n d~ H -d~ l0 -r1O a ~I o cH d~ w I
a O ~'., N I o d~ m U
N ~ m M
' 01 M
I r~
o --~ ~ ~n ~ ct -~ , ~ n o o E-~~
~n ~ ~n . , I !~
~ ~r ~
i Q .h r-I~ ~ , -aJ u H .t H H n ~ .
~ tljU1 ~ O r1a d Ln .U Cy W N O ,<I
RS ~ c~ O x IN O Pa O O L~ M ..
-r1 I I N N I N
N l0 I
QS ~.,'~.,'~I ~II ~I ~-I N ~I W W ~ r1 ~, (If c-IN 00 O I ~, Ln C~ N O N
~ l!7 W 01 W N
o ~ b~ b1Wn .t 1~f~, U 00 , U U ~ ~ I , ~ -I~ ri IdC7~ o c<'tr ri W ao ~' .
I M I vo I W O LO U7 l d' M N -r1M M w-I
O P; d~
d' r . - ~ a w c~ =n N c7 x x x ~c , rn >nN ,a U w w m a H c7 ~C
A ~ ~ a, A ~n ,~r-I
c~c~ d~
.H o ao d~
,--I
zz ~
o m N d~
U r1 N N
M
o~
.!~ O
',?il0 .L.1M
O
O v-I
ri r1 -rl N
N
d~
W Z
L7 ~
u7 ~
S~
O d~
r1 01 Lf~
.h d~
In c-I
In L~
(a U7 iI1 N
N
H
N
r1 00 ,'?IO
l0 (a O
,S-I00 M
v-I
O
-ri M
O Ln l0 ~-I
d~
.1J U7 ~. U1 N
E-~
>~ Ea ~
~
N <' tt~
U1 ~
N ~
l~
.1~ Lf~ 00 O L~
l~ O1 v-I
O
O N tf7 ,.~,tf1 r1 In N
M
P, U7 ~
W cn tn u1 E-a H
In O
-r-Ic-1 ri N
N H
.-I U
.1~ Ln N N
N
U N
r1 O o (~
H ~O
W
H
O<
m x E-~ ~ ~ ~ x H
H H
r-I O O O f~ f~ ~l tISO O O
~ ~ O O ~ U a ~
W f.T~fsaa t.~ ~ O O fx fk f~ ~ f~7t O O
d W W O fY., W
m U
N
~I w w I I a a w w w w a~ I I q w u~ ~
~n 1.1 I I U7 Cl~ I I I I I I U1r-IUl r4 I I
rd ~
>, r~a: PGIxal w H H H H E-~fxw f~-~1w w H H
O
,.q r1 W W W W ,~,'~,' CIA U7 U7 U7 Cl)WW H4-I,~','~,'U)Ul ,t,' H H ry rC ~ ry'FC EnO H H r~Ft,' fd to .l~
.!-I
~ ~ ~~ ' ~' Pa t~ trl 5~.1W W W ~W Pa ~ W W
a lD M L~
~Di M to O~
d~
',?~00M 01 N N I 00 d~
~ ~ , I -r4 r! c-I dl I M fC, H
N ~ d~ri 01 N r-1>'~., 111 c-I N I
I
dl c-IU7 dl N a -r1 c-I II1N R.~'tIl O1 4-tDO N 117 N I N N N~-IN lD
N
G4.. p p l~ .!~~I ,~S-i~'.~d~ c-1 M
. M
>~ of o ~ ~.,0 0 0 -~I .U ~ H ,-I
ri ~ x .,-1. d~ p4 (~ ,--plN ~-1.Lf~N .td M O
y,C1~ I
L~ .I-~~',l0 W r1 w-I~ CL ~~ 4-I~r N O
O Ln M M
01 N -~O O ~ ~ ~ COO rIC31O ',?IO
r1 c-1 v-IN
c0 ~Itdo ~y ~,' ~ N U r1''r~.1-~r1 o r1 o FC, o r1 d~'o f~ U ;~a r-I N 4-I U1 ~ aO Ou~ a -r'I
a~ I r1 p.; x M
I N O p~l r1 b7 I ~1 S=',~I I,~,'~ W
O N U1 L~
01 Ul'~N .~, -r1 Ul O O ~Or-I U7 I ..
c-I O1 I l0 dl L~ '-~ ~I flj .!-1 ~I .J-1C~ '~ ~'~ ~I~-1~1 4-1 <'I
,~ O O O M L~ M r1 N O
N
a0 U1O 4-1 .f O ~ Ul N c-I OO O ~-i O
I c-! OQ , 00 r1 00 ~0 d1 ~
~
~
,5 ~IPa1J ~i td .h N N ri W~1 .U.l-1.1-1N J-1 c-I ',~ 01 c-1 U~ d~ M N Lc1 H l0 r1 LO
v-I
t~ O U', N ~-1 , U S-I, O ,, f~ i pn I GY, ~-1 o J Ix M
N r1 -io .h N , ~ N N ~ .t~NN N ~ N
~ .-i cry ~l I d~
d~ cI~ d~
E
N U1 ~ N U ~ .l-~ U ~-1W',O U1i UU U Ul U
r1 <-I w-i I t17P. t~ '',~
Do I
I
cnG' N .xN U7 ~, N ri U 5~N ~N N L N
f~ r-I tI7 o~ N In I
o0 ~7 o~ I
o U1 1 ri U -r1~I \O U Si '~ ''(j~O r1U ~1~I ~1 P-i'S-I
O I l0 ~ N Lf1 M ~O N
U' l0 Ol N
M
N c-I(0 ~ r-Ir1 I~' O I N N ~r IlfN G4 U l0 Ul ~ 01 l~ N 00 l0 s-i N l0 t!7 l~ N
L~
U~-1~ ~o ~11 ~~ Uao Uaaz mo .mo~M -~I~o~~INro~ ~u a~a~nzs~l~l .
~ o ,~a~ w ~ mn ~a o a~ o~ a~a~ a~ ~ a~
-~I ~n I 1 w ~ ~ . 1 ~C
u, ~I x ~C
N 't~N 1 r-I U' O r1 ,~ J..1.!-1~N r1r--1r-IL(1 r-I
.1J O C~ N .. I I I 'Jt O I
N r1 ..
..
O O r1 >_,'a a dl r1 , O U O ~ CL C~ W , '~ S ~ FC co 01 to t o NI ~~ dl H ..
111 N ao ~ 00 t~ S (a j M ~
H ~o di r L~ l M C l0 00 N L~
O
'' ~i -lN IIU ~ 41 M O -I 4-1-1 >~r OO ; r O
CJ ~I\ O1 ,.~ M .-II r1 N ~I O ~-I
>~ O ~ N M , r-n 'z,ri ~-I
I U' , L ~o w I L ~H
eo U1 ~ rti .S'.,U -r1 ~'., U ~.,''~-II rtiN UU U r1 U
''C~2 O ~ l ~ L 1 o1 x ',NP4 ~1~ I a M
' ~ o 0 -I I dl - O C7 FC o~ 1 M
d' I l ~ I
~ I
In O
t ~ , I NM-r~ t >:,Hr \ ~ ~,'~.,M~,N~'O~~rCO00 fa C N ~ rI1 ~ ~.,dlCHlOl r1 N ~.. -.I i N O H ~ ~,Lfl'd~1 dl L~ OD ~ ~p~ l N l ~ l MO ? 1 _' OD N
I -I - N
"
?-I C~H , - 0 O -I r -r > . ,, r r r U c- M w , ., M
-r1 S~ M ' ' ' U7 N Ul,S'rN -r1 O ~ ~ -.-1,.k~Ul ~N N (A N
W c-I 01 01 '' OO ., 01 N ~ N , N
, M ' ~ M
S ' ' ' ,1J ~ .~.~rS~h , Lf1 .i~~ r1 -rl.~.,~i I,,.1.J1~ ~ .1J
~i ~ a I O L~ M 00 '~H ~t ~(, ~(, 01 ~ .!-1 N ,5n Ln R ,S.a Q td tdU7 IdO O O N O O W r1 u7rtSOO O O O
r1 ~ I I I to M dl to Ln ~-1 I ~ I M
oo N ~ I t ,'' S-',~',<'I~I~-I ~I r1 ~I ~I U I ~',S-I~-I~I ~-I~ S-I
td O d~ O 01 N O N O O -ri M O 01 M
M N 01 N lO
v-1 >31 i:SlICi1J.1-~G~ U L~ f~ .!~O f=a(d.!-1 f.~i O , ~ 10 t W-I L c0 O o O o ~~ d~ L a~ aW
O t~ ~1 7 I I \o -I
I ~ ? -I I
~ d~
Lll -ri r1~1 00(a1 v 1.n I r~ , C 1~ IN N c O 01 01 00 M ~ ~1 q M
r1 w- d ~
M ~n ~nH ~ a C7 cn W C7 a ~ W H+-1C7C7 C7 w C7 ~-1 a fa U ~ H ~1 w w w ~ H w cn H
a ~ w cn w r~
M
',7~
l0 l~ 00 .-I 01 td O1 N
M
r1 C~td dl r1 L
d~
O
r-1 zzzzz ~.1 N d~ 41 N l N
L~
.!-1l0 M
~y 1W
M
r1 N
O dl w-I
r-I C~
r-I OD
c-I
r1 wc~~nzzzzzz z ~j dl M
11~
M
OO
~H
r1 c-I L~
L(1 LPl Ql L(1 O
dl dl OO
di Lf7 c-1 v-I
~
-rl N 111 M t11 d~ O
r1 l0 c-I
N
M
d~
M
N
N
N
.4W -I N
r1 00 r1 N
w-1 M
c-I dl H
~-I
v-I
c-I
r1 r1 v-I
I~
c-1 <>i W U~
E-1 u7 E-s H
u1 .-I
H
~
H
~
r1 l0 01 ,5y c-1 L~
v-I Ll7 M IIl w-I I
r-I
d~
M
a1 M
N
N
(I~ 00 01 ?-1 10 dl Ill O1 N r1 l0 N
L~
rl O
Lf1 L~
d~
, -ri r1 c-I
O N d~
M c-I
dl M
Lf1 dl l~
O
r1 r1 M
l0 ~ cn c~
u~ u~
u1 H
W H
a~ E-~
u~
cn of H
H
H
H
~
~ 00 N
~ ri N
~H O
M N
M
l0 L~
Lf7 L
O
O
r1 J-1 ~O N
O o~ v-I
.1..1N r1 r1 OD
~O N
M
L~
~
d~
In O
O r1 r1 .ti r1 M
-r1 M r1 ~N N
d~ d~
l0 L~
r1 N
d~
a0 W U~ cl~
W U1 v~
U~ u1 E-1 Ul H
cl~ H
v1 c!~
H
H
H
H
H
N
~ ~ ~
O ~
~ d~
'~
-r-I
-~-.I.-I
~1 u1 S?, dl M
(~' O
~
y N
TI
U
r-I
~
H
H ~
W
W o ~
O
Cl~ OW -I
H
z x H ~ x H H
~ ~ ~
ar~a~n~ o a ~ ~a ~ o a x ~ a~
I
U O Ix P17W fs-i Ul O !.Y, P~1W W fl.~ Ul N
-~I a w I I w w a w I 1 I w w ~n tn ~~ I I ~ ~ I Ana I I ~ ~ ~ I ~a ~s 5r H H W W fxW' G~H H H W W Pa !~ ~ wH
O
,~
r-1 U] U7 ,~I,'', W W H f~ U~U] ~i ~' ~' W W Hf~
,i,''~ ~ H H H O ~4'FC H H H HO
t6 (Ii .!-1 .1-1 a~ a a a a o x a a a a a orx ~a ~ ~ ~ ~
~
a w a~ r~ as ~ c>am w a~ a~ w ~w ~
A
c-I I O I r-I I O M r1 W eo ~I d~W W z r ~I M -rl Z d~ ' ~ M
H 01 ~ M ~ H to ~ H
1 N r1 H W M M 1 N
W .t~ ~ fsa ~-1 x -h o~
I
H U7 ((S 4-I N H ~ rti l0 4-I N
vo d~ cH
d~
P-n'O ~I Ci ~-1 LYl ~i N ~i ' O Cl~
s-I M
~i L~ 01 -r1~i ~ ~i ~ ~1 M -r1 ~'., R=n L~ LC1 P=W 1 M M
W M -rl (13-r1 yJ w W M r1 ~.,N -ri JJ
p.1 N M O
.~'rN U~ .~.,U7 (IS ,~I N UI ~, Ul (!S
O H c-I O L~
O I
~nw00 a~ O a ~1~ ~nw o ~r N O ~, s~~
I ' H o ~ CJO ~ o H o ~, ,-iZi O b~
o ~H I In Czyn N
eo o ~ a ~1 I ~ -~Ia~~ a a ~-I o a ~n M ~ o ~I r w N -I ~ o m ~ N a -~ H
o I
-m -I H m -~ N ~i tnm , H z ' , O ~'-,MI
M -'T-aN , ~ I L M O
f~ O W G4 .~. :
-I ~
~ H
U) O (~ ~ , M U7 U]O (tS R ~., ~.IOW
U~ W ~I ' U7I r1O I z H H M , u1 -- d~00 f~ z ' 4-I '~ W-Ifx o I W H
I H M o~ 4-I ~
d~
.-I
O H O ~-1 ~, a O O H H O ~1 .~, HO
N E-~ t ' N r1 01 'd~'~-~ M
L O
H W 1W O t~~I 1 .1~H W ~, .t~N cli ~1 I-1~
M F(,'-i a~ L~ H N ,'~ tt1I z '~-~ N M
w~ Haa n~N~~,'~S-INO 01~ wxHaa ~,ws~~~~I ~I O l~,..
W O~H N~ ~a .l~a.r,r1N4--IW O~H N ~.-IO .1.~ ~ coN4-I
I I
U f~' U U1 I C2y-IU U P4' U U1 .1J i MU
01 R'i I I ' ' ~I v-IlZi d~ d~ ' '~I
' o1 ~ ~ -I ' ~ ~
WN WO OloOo~H C,N ~(,N WdWO Nc HL G~ f~ N JN
U7 (Y I ~-I~., N U ~ QiI ,"L'',~I Ri Q7 r1 U ~-I
M ",L,'O l0 r1 ~I M C'4 1~ 00 C~ N Ln a~ I c7 N U ~aa~ ~I~I m7 x U U la a~ >.I~I
~n w w N w .
a ~ In U~I-IAoo~nz ~r.~w a~~~I o ~o A~r~nzM ~ wM~ a~ ~ ~1 001 ~' W P~ N L9 O J-1N W to !U C7 ~1 O .1~fU
-rl M O ' .1~d~O ' O 1W
H ' H 1 da a~ a w r-Io ~ a~ ~-Ia w x ~-I~r ~ a~ r1 .u x ' ,~ . ~, w a, ~I I~
w w o w -a t.~,N m W N p, W a w , N ~ ~ N~, In w ~ ~o o N o H oo H ~ v H N I ~o ~'.,',.7W ~ '~ N rtiU ~ ,.'7W O ~ X N t0 U~
d' O M H c-Io U d~~ ~ I 111 U
N t11 N O 17 O -rl L:~I N O O ,"~ O -r1 N ~'., ,~I41O
t~ 'h .-1I N M N .-I'~-~ ,5-~.-I z N
f~' a Ri f1-i N
U1 U O U r1 Id~ f~U U O H U r-I ~ cIS I p',U
'~ N H W ~o H ~ I ~I ~ W I eo - ~ ~ I~I
G4 I ~ I I ~ M ~ I i ~O I
W x N M U I I I N ~ ~ z U ~ M r I oN
N z W ~ M I r1 f~ w H W t~ ' .V ~ .-1 W H o~ oo ~ ~ ~o W ~ W' H M
o~
.~i~-1 H fx -r-I~1 ~ W ~1-~tH tx -~ ~I , N~ -~1-~1 O o~ o~n -~1 O d~ a~ M -~1 E-~ r1 H ~ri o~
~ H ~ O W ~
.u H H .u >~ ~ ~ .1-~.!-1H H W t~ f.~ >~ ~ Gv~ ~.r, >~ rl G4 M ~ .U ~-IH M FC .u H O ~
Q (0 O pa O O U7c0 O O O W O O O O U7Ic~ OO
-ri O O ' N ri O O H ' N I r1 O
H ' O I
rt fx W ~I ~ G H ~1~I fxW U Wo rd ~I ~ N~I ~I~I
o U d~ o . I ~I o ~ o rl I ~I
~ o o o~
~ ~ ~I W ~ O i ~ y ~ ~ W n I~ tHn N ~ ~'>JWI~
o ~ n i ~ ~ u ~ ~ l ~ d' ~ c'~'~ ~ I
l i ~ ~1 Po' ~
M - - I l . I - ~ .
u7 C7 f~ C7 ~ H ~ C7C7 C7Ix C7 P4 ~ H HN C7C7 f~ Ll C7 OI G4 f=~~ t'~~lC7 W W Ix r Pa r W H
W
-,-~I
ro ~
-~I ~ In 5., z >~ z o m N N
U
N
JJ O M
,'~y -LJ
O v-I M
r1 r1 w z z r'7 ~n ~' O O r1 O
-rl O O
M r1 N
.!~ N ~O
Lf1 LP1 M l0 W o u1 .-i H
H H
.-I U~
H
r1 O 01 ,5y M
l0 (() O ~
~ O N
r1 M N
O c-I N
M l11 .t~ u~ ~
~ H H
H H
~ H
f~, ~
N O O
N -I
.1J Ol M
O C-I O
.1-~O!) OW
~O -I
O u-I N
,ii u-I l0 -r-Ir1 L(1 l0 ~
p., u1 ~
p., H ~
u~ H H
H H
en N
O
I u~ o -~I
u~
FC M ~O
W' '~ q H
-~I U f~
.1-1Im U
~ N l0 N N c0 N
N ~O
~ O !f7 ~
U O t~
r1 5~ u1 d~
O
~1 H In L~
W
H
Oi W r1 N
Ca O
U1 c-I u-I
H
z x H ~ x H H
~ H H H
O f~ O ~ O ~-1 O U
O a O
U O P 0. W O R ~ W W t ~ 'a l S I~
N
G4 I I w c-1w I I I ~ ~ w ~u 1 I ~ ~ 1 I I ~n ~n ~ I I a ~s ~
~t H H IslW fY P4 H H Pa w W Ix fy G~ H
O
~?
.-I u~ c~ ~ ~ W W rn u1 ~ ~ ~ W W W Fu ,~ -G,'d, H H r.~r.~ H H H O
rti (a .t~
1' ~ ~
~
~' P0 P0 P4 P7 P4 W P4 a7 Pa ~
O 1 r ~o r ~ W n ?r W --rl ~
R
'u I ~ H W c-Ic-Ij a ~ dl lD L(1 ',' U
d~
.~ N -L-101 4-I P.i N M . ~'',~I-I N
N (d t=I N a Id P r I~ ~
IJ M
r O ~ -~II~ O
M x U ~ tr ~ ~ U ~~ ts.-Ir6 ~ ?I
W ~ W S.I
~
''/~'Pa r-1-r-I~.,r1 'Z,W r1 r r1 ~.,w1 r1 I N 01 M ~
W 'Z, r1 u1 O .fitw "~, r1 dl IA O 11 ~,'r1 o0 ~ o~ M 'J-1M dl N u7 tg H ~ '~ ~ U' H U N x 'z3N rl N
00 H In ~ H ~ ~ ~
m r H W rt ?I I ~.IH W o ~.W I ~I rt I
vo r ~ 1.no o H H ~t-W-I ~ U H E-~ 4-io .-I ~ U ~ 4-a U~ a a u1 a . N
o o tn I O eo -~IN ~ I o o lx -WO N N o 4-I
~ r.C eo ~ ~C ~~ w a ~ ~n ~ ~
o o I v I
a~ xzo ~~,~~ ~ ~ ~ xza n -I ~~ 1n -- ~
~ . -- r w W d~ f mo C7 r ~
w ~ w I mn ~ N I . ~ 4-1 ~ Ul .
M C7 d 4-1o H O t11a O
~-1 O H H di N
I H
H
P-i W C7 .4,~-Itd ~I W C7 11 N ~I rti~I W .V
U Cl~ I I tr1 C7 Cl~ i dl i U
tt1 H w s~ mr,~I o H w m-n~i a~ ~I o c~ , M w ca M a~
a ~~ wfx~Nr f.~r.u .u wo ww~ Nm ~ ,o, .u ~ N
I I ~I
U O U ~ r , U O U .!~~ >~ O U
M H d~ d~ ~~ a~ ~ H ~ M M ~~na~ x v or ~~nHvU ~n~C o~ ~~nHa~~n~M ~ ~
~a~r U7 U R'~ ~-I -riU U P: ~I >~'M -riU -riS-I
I FC .. dl 1 FC dl o1 -rl N ~ PO 01 Ix c0 N p W o~ ~ a: rt N r1 ~n r ~ a 1.n~ '~d~ m dl ~I 1 z W z d~ - -l ~
~ ~ ~ I a H
~ U
U W ~ ~ U ~ ~I a~rU mo ~ . o ,~ v 4-a dl U ~ r o www <n w~, I o ~I aM www mo wN . . I
N ~ r1 C7 ~ N ~ rl .-IC7 '~ O I r1 1~ f~ o d~ r o1 W o M N N ~I
H H r O ~ U1 7=L~ M ~,'.. Cl~ >0t!~',Cf~ r ~ a i L11P-~ O LO N W o N r1 N r U
a a ~ l d~ 3 In tn ~ rl r-C ~ N N W .-ir.~ ~ U .n ~' rt W O
O N ~ a I In o r ~ a d ~ H ~-1t b7 ~ 'Z, O 'x'~ ?-I~ 'z, O W "~ ,'~
N G4 M H H ~-I pClH r H
CJs r H U ri (0 I L H U U' -rl td I ~I U
'~ w O I W I N ~ ~ M U7 ' l L -I N - M
l a ~, W H ~,'r1 ~I CO w H ~,'f1 r -1 N r ~
N M w <H d N LC7W N M ~ N ri N
(CS H ~ I H o1 ~C q o1 ~ O ~ I O~
H 5-I~ H I ~ l t17 H H U1 111i ' ' 0o S
i .~j~.1 O r1 Ci ~ .~. W -r-1M ~ ~ . r r w H UI N M W-IO U1 ~ G N . ~i -I
-I P-i N 1 ~ Ul H N ~ -r1 M M l0 Q~
' =i 4 ' f~ O ~i 01 Ul ;~
W P dl C!1 U7 ' ~
W c O > r , ~ N -n ! , 1J ~ fi ~ r~
J R 1 1 , ' H ~ LJ d~ a ' N .L
' n 1 ~ ~ '~ W c!1 W d~ W I
Q .I Z, H -r .l , , , W - . . ., r O .
~, N W J- N m N , O ~ I N U2 fd ,'~O
rti O W O N ~ N O W . ~ N I N N
r1 N O ~ N O I I
W N
>~ u1 W ?a ?a ~ ~1 1.nW ~I W ~I ~ ~ H N
rtS ~ U .u o M I ~ U .h M o M I s~
~ ~ M dl a~ o U f~ U N .1~o U ~ ao U r~ .i~.1.~I
~ ~ ~ 0 o M ~ ~ O ~ o M ~ u1 :s a a I r A u rawr ~ a~x n M ~I o~ wao I a~rxs~~.u o~ wao i M ~ IM . a C7 o x fx ~, u~ H r x fx C7 U vi H r C7 ~n cri ~1 C7 C7 p.,H r f~ C7 f~ fx f~ U r r-C
fa w w ~
.u z z z ~
r ~-I r Im ~ rd o~ M
r vo ~o o ,,II$ r M
C~r1 N l0 Lf1 10 00 v-I
d~
c-I
z z zzzzzz z z s~
o m N ~ M
U ~ O
N O N
M d~
l0 .1-1WO tP7 '>t O l0 .!- In 01 l0 O
O
r e0 w zzzzzzz zzzz ~n s~
O ~ m rl N
r -W n r o1 rI
01 ,-I
d~
.1J M N
Ln l0 M Lll N
rti v~ U~
co cn H N
~o .-I H H
H N N
,5y LC1 O1 LP7 r (a I11 lO
~I 01 00 l0 O
dl r-I
M r ~ ~
~
N
.u,~~t c 1 c nHu 4 l~C
~ H
N to 00 N N c-1 01 l0 M Lf1 .1-~00 O
.!-~l0 c-I
Lf1 Lll O rl r1 ,S,'M M
r1 l0 l0 dl M
l0 G4 cn U~
W c4 u~
U~ u~ u~
H
N
O
~
'~
-~I
-rl L(7 M
-rI
U!
~ o1 M
~R
'i N
H r-1 -r-I~7 ~1 +~ U U
1 r N
O O dl O
O O
~ N Q1 ~
U
H
~ a' r ola H r ~O
W
H
a W M d' Ca O
~Hz ~l ~I
U O
zi Z z ~
w ~
I l I W
~ l ~n W I
~a n ?i P4~G~fx W w w E- H
O
,~
~ W W W H H H
rd U7 ry' r-C
.
U
+~
~ ~
~ U1 W P4 W P4 W
A
I
~y O I
r-I I N to L
to-ri o ~I o~ W
-i d~ d~
<i~ N ~ r1 CO
~, N
a 4-1 ~ ~ o ~
~ x o, ~ ~
.. 1n ~' '~i M
M d~ ~
o~-~I ~ W W En .-I
.-i O W
z x ~~
O 'Jyd~M~l N O
l ~
x q ~o,-4 P4 ~ f~ N
A rl En a ~1 ra v w m . w o 1 -- ~I U U W P4 oW . l~
o f~
co O ~I ~ U O
In eo W
N W
rI d~~.1 -a N ~1 w H o M o o a M
M Inf=aO f~ s~ u1 fx L4 t z H W t~
H t~
co E-i10 .!-1 N ~ Pa ~..hW l0 I W ,5 W l0 I lfl N
I d, ~ UM W tf7 (Y~OZUMMMCI~
I I
l0 001~ N N t~ o In W E-~
W o U H E-~
W I
Ul 01c-I-r1U ~-IP-n' N Ch Ri I
M ~0 M I I
N ~O
N N ~tdN '~-~U ~ W ~o ~o u1 W W Z to r.~ H d~
U ~' ~ ~I '~ W -ri z Cl d~
4-I H d~
H d~
W
~ O a~ c7 ;~ H W w -~I . ~ . W w as . a N Nzi~.-I.-I~ cdo E-~ a ..
.i.1 ~ ~ to O U Ol ~iIll~c-INWM .1..)ML~~O~ W ..
?~ 'i~(N d ' W H ..
S I ' ..N
' ~
~
H
~
,. I (M~ .-~. N W L
., -~I~~ ~1~M N ~ ~ w ~
N o -~1 1 w J l E-~~r z N
~ o io .o m.n'~, U1 .4.1N(a IU r1 ~I1 ,'~-~U M
~ N~ aI L!1 O O C.7 M M
' -I I l, H I
1 ' I I
a W I lO
d~
~ , r-I1 v1c W-I . vop z mo .I..~, N U~ ~to~ -ri N N , dm~
N ~ ',~~ W En H d~
rt -r1 ~ ~ d~
~I N N H M r1 ,5n H
O
r.~N IN U7 O U7 O 'r~94 W
'~I OI L '7-~
r.~ f~
1~ ~-Ir1~ ~ ,u i ~I O N ~
~ M o~ O .-1 w eo W
Q rd ~ rdm c~.-IO O ~d. fx O ao -~1 N r1 C-~ M o~
O O
<a ~ ~~ ~.II~I W 5.,o f~ rx M
O o as O N OO
.-I U Oi as b~bd .u~~, o ,.~0 ~ r~ ,-i ~ ~ In 0 1 G~ oo 0~ ~ ~ o ' -~I -a-~I~1 .uI ~ I N x I M
o ,-Ic-I M w d~
R a d~
'~ N
M ~nq cncnN ~~~x wa mr~~ Incnt,~t~wHww r >~
-, s~
o ~n N
U
N
h ~y J~
O
r1 -.-1 W
~
O
-r-IL
(d N
r-I Cl~
r1 M
',~y -r1 N
O ~-1 .~ W
E~
S~
~
~
u~ ~
N ~o 1~ -1 O r1 .4~
O N
,C r1 r1 W E-~
Cl~
In v O
zi ~,' 'Z3 -r-I
-r1 O
-rl (R
~' M
(~' 'O
-ri Ca .!~ U
M
O u'~
N
U L
r-I
O d' (~
H ~
W
H
p1 ..
W ~
~-1 O
Ul -I
H
z, ~
x H C
-~
U Z Z O O
~
U ~ W W p R
m -S
U ~ ~
1~ ~,' I r-!U1U2Ul Ul I I I
'~
N
~r ttffyfy -rlG4W ~ W C-~ Ei Ei O
~.l r-I U WW 4-IH ,~,',~,' ,'~i ,.C, rd td Cl~ O E-~H H H FC ~' FC
.l~
.!~
o w la o a a a a a a rd ~~
~
~A ~n w ~ w m m al a~ r~
N
r-1N
l0 c-I I N l~ 00 ' ~I
~I c-Il0O t11 I-I~I
N
M~, ~ [7M O 'd~ M O O
a Lfl O-r-IyJ L~p'., N r1 .l-Id-1 N I L~
NU7 (6 M W O O ~ i R,'O N
U b o ~
O 1 -rl' ~y !x O U U
N
''~jrl .hO r1 W '~' O N
o1,tee,', N - ~ !-1~-I
Ln,.G .~,P4~ N
N ' L(1 H~-1Ul ',~1($ -I rd I'W N
Iv ~I S-IS-I4-I ~ S-I O N
I N Ch O O O ~I .1-~O r1 r1 00c-i I
N~-I.h .1J.1.1N d 1.~
O ,~'W 01 C7O i i C~ ~".,U~ L~ ~
N I M L~
L~
01 -1~N N Na~>n tSINNO000 O O
M u1f.2~U U U Ul -rl U M U U
O w M M
M
FCS-'rN O O N r1 N N C7 ' C7 CJ
UI I -rlU ~I ~-1~1p.,' W -I I ~'.,~,' O ,5- I I L~ 00 I
O c-I(1jN M U L.I c-I -r1-rI
Ul 01 N c-I d~ O
CO
L(1 U ,'~;.~,~-I'~ '~'i~W O ''f.~ N N
4-1 r1 c-I' 01 N N N M
~', O01 N N N C7 1W N ",t.'A.~.!J
-rl W r-I -I '~.' -~,RS
N a P-i O ~N r-Ir-Irie0 ~ r-1 O O
1-1 N I ry' (~ I I
O O >~'~L ~ N N , ..
~ ' ~~ ~ ~ <-ix I .. ~o ' ~ S ~ I U .. di I ~ ' ao ~ to ; d~
I to M ~
, L ~'.,~t O O O , N O O , , N -rl S-1 x -r1 L~ O r-I I I
N O 01 r1 N
L~
U7 J-~(dd~ U U U r1 ~I U M CJ CJ
'~ ~' l0 c-I M M f~ ,'~
~ N Ci N
I I I
~ I I
'' x rd N I~f ~r ~ ' , a ~~Ino~,-i~, ~,..
, -~ - s~o~~ ?~ l ~ -1 O ~ --I- - ~o - -I ~
~ l 1 O -I I I
.. 0 ' ~ -I N
, r r - r - s 1 ' r w -w v W NUl N N N W O N O O
' ~ c-I N r1 c-I N N
' 01 M 1 1~ r1.~.,~, 13 .U.1..~~ .S~ .1-~ .1..J..WO
~., ~r ,~ ~,~Il c0 u1 01 d4 Hl O~
VS
o1 N N U1fd O O O O U O (~ U U
-r~ r-II I x x ~o o o~
a I tn O
V by b o~ ~ ~ ~ n N ~ ~ ~
o ~ o u ~ M o ~
~ o ~ o u I ~ o u 4 ~ ~ 1 ' o , -I -I
. , L l , l I (~ -I
l l I~
M -r-I-riS-I~4-II I I ., r n M r r O cnE v- o N N 0 N ow ow ~nA c~w i.~HN N N
,s o~~nc~wr~wm O~aw s~
~ r1 rt c~3~a ~I
.u m tom O
U
N
.!
~
~y J~
O o\
r-I
-rl W '~, U' U~
O N
-rl 01 yJ N
',?~d~
r1 c-I
O l0 ~, ~
~
N o~
U7 d~
N
.1-~00 O c-i .1~
O d ,s,'M
-ri N
N
N
M
N
-'~ U
N '~
N
~~ o a ~
H
w H
of W ~
~
C c l~ -I
H
Z
x H E-~
U Z Z O O
~ W W O
U Cl~W Ix f~
v r-1 W v I I I (~ W ~4 l~ ~', I Ulr-IUl Ul Ul I I I
'~
td 5r N w Ixr.~~1 w w w E-~ H H
O
,.R
r-I U W W H 4-I',~,-'~' ,~,'Ul C!~Cl~
,i;
(d (Ci U7 E-~O H H H r.~ ry ry' .1~ w o ~I a a a a a a v ~a ~ w r~ r~ r~ m m m N
r1 o~ H o~ ~o r-I I N L 00 ~
r1 v-I ,~,M N
M
c-IN I N a N
I ~-I~I M O Lf1 ~I ~I
N I
00 ~.,CI~~ 00 O d~ M O O
a LC) 01 r1 .1-1L~ p.,' N c-I .l.).1.) N I L~
U m t6 ME ~o oN o , , i 4-1~ N O O O N N
ry' to 'Z$.L7r1 O r-1 W ',~,' N N
N H ~
~ q ~I ~I
a ,ti.~. !>a.~, N
N ~ Lf7 I ~-I U7 (Y.,IfS ~I
L~ N
l4 ~1~I ~I 4-1 ~ ~I v v I N CJ
N O O O ~I .!~ O r1 r-I
to ~-I I
a ~i.!~.1-1h N cd .L~ ~ >~
O i a a i ~', S~ N ~
N I M d~
L~
l0 d~ J~N N N ~~1 O1N v0000 ..0O
x N m C~,U U U m -~I U M U U
o a M M
M
~ v v v v ,-I m vaxAa .
U1 I -r-I U ~Ft-I~-IW' ?-i S.J~'., o1 Gx, I I to 00 I I
N r1f~ N r1 U S-1 00 01 rI r1 U7 N L~ d~ O
l0 U '~,~, ~I'~'~ '~ W O '~S N N
4-I r1 N ~ 01 c-I N M
v-I
N N
s~~1 0 0,v v v~ c~r.-1 .u,-1vHr~~a .ua.~x N '~ v r1r1 r1 00 ~ r1 O O
.1J N I [a I 1 o v ~ , , v v ~, .. y~ ~
v ~ ~ ~ oo x I .. ~ ~
rtS ~ x U .. p, f~, I o I oo .. ~o ~n yo ~m n ,-1 N r1$~-, ~.IO O O -r1 v O O I I
N N O L~ O O r1 N
c-) Ul J-1 U U Ua l ~I UMMMM C7,'NC7H
~ ~ ~~ k ~
i (d N O N ~ ~',~ >-', ~y ~', '~y~
i ~ ~ ~ -1L ~ 01 ~ G LCI .. ..
-I l l O I~ -I ~
d~ O ~ 00 S -I
-I
-I
l .L.-I N . , , r r -I r -I -I
., ~ ~ c c c 01 c c r U7 N Ulv N v W O v O O
N --. r1 M r1 r1 N N
' ' N M
.l~ r1~, (.,.1..1l1 .J-1~ 11 .1-1 11 11 ~i ~(, ,5y C7 r1 L!1 CO to 01 l0 ~, a 01 N O
p ~ cdU7 ~ o o o o U O L U U
r1 I r1 I W ~ x ~o o o~
1 I 0o L
f~ ~',S.,' ~Ir-I~I ~I ''~ N ~-1 (I3(If c-1 r1 d~ 1 I I N O O d~
N
~1 >31flf .!~~ C~ CTaO 4-I Q~ M 4-I4-I
~ .~., O ~, O ~"IL~ O L~ O c-I
l~ 01 d~
C l M
-r1 r1~I IISI 1 I ,. r-I I N r-Irl M O u~N ~ c7c-I01 , 0 Ln Ga ~1 cn E-W 4-I C7 C7 N N M N o o f~ a x N o c7 w w w x ~ r~ i ~ cn w w x s~
~I
~
o ~a N
U
N
1~
',7y 1~
O l0 r1 r1 W Z
~.' O
r1 N
(d N
r-I U1 r-I o0 ,5y Ia N
r1 N
O
v ~
m v .u o, o 00 ~
o rlo .~
~i wwcnu~u~
v M
~4 P-~' y -i ~ A
+~ ~
v d' N
M
O O
~
W
H
H ~
W
p1 ..
En E-~H
''d ~ U 'Z, % '~-~ O
~ W h W O
U U7 ~ P fy, N i -r1 L4 N I I I I ~1 W
UI
~!-I I H UlUl U7 Ul I I
rtS
~, fx P4 ~I w W W W H H
O
,i1 ~ w w H H H H ' ' .l.)~ ~ O ~ F(, Ft, (a .
~~q w ~ P
M
~o is ~o N ~', L~ O
G4 r1 M M
I rd N H
M ~', O LC1di ~1 M I
N r1 ,.QL~p.,' N In r1 1J
~ N
~ r1 N N O O O
~ ~ ~
u, O -rla ~ di f~ ~I
o,N
r~ .ii.l-1W ~., N r~'I
r1 N Lfl n'-~.n I ~.IN n-''t,(~ LI r1 O1 Ln N
I
N '' ~1 ~I4-I ~ r1 ~I N
N I N [7 M
M ',~'~ O ~I .!~~.,O r-I
M .-I I
L
a S-1- 11N (d ~ .1.W , I 0oH o, N
O U1 i ~ ~',~-I~ ~
L17 N I M l~
H d~
N
J-11~,N ~ Cr N O O
N ~lM N O
O
O
, ~I U ~ -rl~-1U M U
N o (~ M
. M
M
.S~,N Ul N c-I UJ O N H
','~ N C7 "~a H
U! r1 U W -IQ'. . .1~~1 ~,' ~ I
I
I
u1 r0 N O ~oU ~I , ~ o~ ~I
. N o ~o W d~
o U .~,SI r ''OW O 47 ''CS N
4-I O N a1 M c-I N
P'., N
v-I
N
~ O a0 v U' l~ U N Gy .1~
r1 fxO r1 r1 ~r H
I f~
,~
O '~ N U7 r-1e0 , N r1 O
.4~ r1 0~ I eo ~1 E-~ 1 o ~ 1.1W O O ~I , ..
~' N Gu r1 o x 1 I .. p 6 ' ~ M U In .. io I M M " to ~ a~
~ o~
I -I
N ~o , ~'.,c ~ O , N S-~''. t N ~-IN N r1 L~ N O O 1 c-IH 01 01 r1 F(', .-I
O
U1 (O d~ I U r1 ~-Irl U M U~
rC$ 4 ' -I W'Lf1 v-1r1 N a ' H M
" ! I I
I
~., , U c ~i~ ,5y. ~., ',~.~
l (IS L~ O r1 , ~ - O ..
~ ~ ~ L~ l ~-Ic-I l OO N 00Li O 00 ~
il L~ 00 I
l l0 l N
-I
-I
-I
.L..1 ., l r . I r -r c r c v W O U7 ,~ O W O U N O
N ~- N O O M 1 N
c-I ~ 1 ~
J-1 .~.~i ~"I.1.~/?a .!JO 01 .!-Li ~r ~ c-ILC7 OO l0 O 01 G4 d J-L
p ~ U~ rt r0 O O U ~' O vo U
ri I r1 .. W of x H o o I t~
~
(IS ~' ~.I~ S~1'~ (O (O ~I (CS
C~ r1 N I 1 I I N O
d~ l~
N
N
t71 (~ J-1U1 ~LO 4-ir1 /.2~ 4-I
~ .~.,l0 .1.101lD 01 c-IM O
l d~ ' N 01 -I
l LClM L
I
N
r-1 ~I r1 I N Lc N r O N r 00u-I 1 N N -'~ r M cn E-W~ ~ U ~ o ~ a'7 o q u-I~n x E-~ ~ a w w cn w w s~
r., ~
ro H ~' '~
N
U
N
O
r-1 r1 W
Ul O o [~
r1 N
.!-1M
l0 td Ul M
H
r1 t' ?m H
~ H
r1 M
O t 1W' U1 O N
O
.1-101 O L~
-L~
O N
,.~il0 -~-I
W u~
u~
N
N
N
M
fz O
O
~ ~
H
H
W
of wao ~
H
W
x H
s~ U z o 0 ~ W O
U ~ ~
N
-ri W N I I [a W W
Ul 1J I Cl~r-IUl U~ I I I
''O
!a 5r ~.2;P4 f~-~Iw w H E-~H
O
,q W W H H
rtf HO ry' FCFC
.!~ ~ ~ ~ a a .h ~ ~w W ~ W 0.
q 1 d~
N
to H o1 M
r-I I N o0 r1 aD x N
o ~
r~ o In S-ii-1 -I i 00 ~,-'',~~ 00 d~ M O O
N
O1 -r1 J-1l~ N -1 J-1l~
N LW
Ot U7 (d M O o i i H N
~~ o ~ v a o ~I, . ~ o _ ~ q ~
0 0 a ~-I
ui ~ ~
~-1 U1 OI ~-I '~'~O
N
d~ ~1~-I~.1~ ~I N v N OO O .J~ O r1r1 M I
H ~-I.1J1J .l~10 .l~ a a M t ~
O ~ RAN-I ~MMMM ~
, ~'.,M
.1JNN N >:71 N O O O
OI N O O
O
U1 , UU U r1 U M U U
fsr M M
M
v a~a~ a~ ~n a~ a . a a a N -rlU ~-I?-I~I ~ ~I I ~',~
~ I I I~M
N rtSN ~-i~-I to Lc7 r1-ri U7 o~ ~D O d~
o0 U .~.,~1 ''~''~'~ O ''t~ N ~
4-I ~ N 00 c-1 M N
v-I
c-I
r1 -~ o ~o ~~ o .>, wn r=.,.s,.s, ~, ~ cn x a x ~ 'T5O r1r1 r-I, r-I O O
1~ N I U1 I 1 O ~', ~ , U
~,' N ,y.,~~ t11I ~ l0 , , ftf ~ U dWtWO d~~o 1 O It1 4) ~' ~I OO O N O O I I
01 N L~ O O N s-I
O
U7 UU U ~I U M C7C7 ',~~ M M E U
M
~ ~ ~
~
t~ ,.QN ~i~i ~i r5Y ~i L~ ,5y'>y d~ ~ ~ M Ll~ ....
L~
.r..iS-I W-I~ -,~-,-I-r-I~-I -ri ~-I?-I
.. d~ L~ ~ r-I ~-Ir-I
O r-I
r-I
r1 U7 N U! NN O O N O O
N ~ ~-IN a0 N N
M ~ ~
l .1~ ~ ~, .1~J-1.1.).1.7 .I-~ .t.l C; a H c-IL~ u1 0 01 a 01 N M
(d u7 ra OO O U O Wo U U
a 1 r-I I W OI ~ in o~O
I
~ ~ ~I ~1?a ~1 c~ ~I N N rd eo -~I o 1 I o o~ ~no o~ o~
C31 td .!-y.,iI a 4-I ~ M 4-I4-I
~ 01 O a0 L~ L~ r1O
OO d~ -Il -I O (~P~
L t( M M
I
M ri ~-If~ II I r 1 r r O w-I~~-Ic~v-100 n N owow u~A Hr~ cars.,c~xN ~wr~ww o~H
s~
-, ~ro cCico ~I
~
o ~n N
U
N
-tJ o ~y 1~
O d~
r1 -ri w~u~z s~
N N
l0 r1 U]
~-I
r-I H
5r ~ o ~I
-r1 M
O to J~ N
,.S~~
u1 N
J~ l0 a0 O L~
O c-IN
,C, d~
-r1 pa U1 Ea W U~
cJ~
N
N
~
c M
N c-1 '~ Ca -'~ U
~' d~
N
N
U
q ~
H
w a A
~ i z s~
r1 l0N N O\t'~ 01 lfl l~l(1 rl O N C~01 d~
U1 Nl~O r1Ol000N d~Ll7v-Id~l~Od~M M~ MO ON L~t1~LC7d~
O MO r-I l0NM l0l1)v-I0101COL11l0COO u-IL~NN Ot~O00Lf~Ln M 111o-IW -Iw-IN d~N l0c-1Olc-1w1~N N r1N LW-I L~v-INd1Nv-I
(11 S~
O
N
O
W t oo ~o o~ o~
M l0d~LO 00 Ll7L~M'd~00 01 N l0lDv-1 ~
M t~l0C'~ 01d~N ONt~N M L~ 11700d~dl M
111c-1L11c-I 00tnr1c-Iv-1l0r1Mv-I01Nv-Iv-Ic-1r1c-IM 0001v-IM ~-I00 I
(~O
O O ~O
O O '~O
d~ N I r1 N N ~-I I ~O d~--N
O O u-I O O O O l0 ,.'~~'I Mc-1O
R; H M W ~ ~ W o min Ho H
.u W ,~.O ~C, H O H rl ctim OH
H H o H' ~ o stn ~9C~
~ ~ ~ I ~
a ~ a ~ o ~n~ U
I
~ o N ~~ U
v o I7 w U N v-Iv-1 01c-I r1 v-1W -I O Mc-1L~y -Iv-I w-I
c-I~ I .x,~~ ~''~~ .v-I17r1,5r1',~c-1~ M17NLn ,~,~l~ ~-I'~
N xrl~l~ M LnC~NO I7Ln,T,L~x Nx d~ O1Q1Or1 t~N Hl0,'I,'O
U ~~ N LnLnl0O~NLC7O O0001tn.Nd~ l0M c--i00 00d~1l~~.Mlfl 010101 00OU.OL~M MN l0LnL~l0d~O l0c-IO1Ln O01NN Nt17 In r1N l~ a11O00b70 MO1Nc-1cH00000 b1M OIL~Nd~rid~O v-1v-I
Li7'd~O d~Or1 O L~dW-Ic-1d~CO00d~ 01~'diOLflN00LP1In t~N 'd~ O ,01Ls7 C31c-I~Od~ODM CON r1 O C~JL~ L~l0d~d~Ml0 ~ ' ~' O l0 Ltl CO -I-I~ON d~r1 ~
N OC L~ 11W-IM C7r1OLf7Ml~N OL~t~ CJtniM ca MLC7Nh Ul L~b1O7 InLW-I L~00Lf7t~ l0t~ G4 UI- L~L~
b1 N
N ~ L~ N
' r"~(j O 1,n d~ d~
l1 .
' .
O c-S L~ CO M 01 O
~.," O N v-1 N
N
1J ~tD c-I d~ ~ . O- Ln 01 O l0 r1 00 r1 00 N
d~
C~ U f~ I r1 O d~ M o1 di ~-I I c-I I o1 ~ lfl N O I I cr O c-I I I
1 r1 O I ct~ I
I r1 I
r) c-I O O r1 Lf1c-i C~ d~
(d l~ 00 01 01 ch N
l0 r1 N
N I O "N I I I l0 M
~I O I d~ l0 O O
~H
U1 w-I v-I l0 c-I .-Ic-i M r1 G4 v-I r1 v-I l0 r1 01 d! r1 l0 N
U
N
1~
t0 N 01 L~ ~-IO N 01 f=,'C~ O N d~ M M O t~
O O r1 t!7 00 O c-I N O
N
U~ r1 ~-I N u-I N c-I c-I N
a A
H
N
O r1 u-I v-I o-I o-Ir1 ~-i P4 r-1U U U U U U U t!1 U 1D O N O r-IL~ LI~ L~
N O d' ~1 lW -I lD r-i N
~
.L.)00 00 O N 01 L~ 00 M
,5yd~ d~ LO o-1 M d~ ~ l0 -U C~ t~ L~ d~ L t t~ N
r1 O d~ d~ d' M d~ d' d~ o H L C~ l~ L~ L L l~ to W
N
1~
O
NO
r~
U
A
t~' H
~
y r -I
Ot O P r1 N M d~ Lf7 l0 C~
W
p.tN N N N N N N N
Cl~
s~
+~
r1~ NO Md~C~01N r1M MlfllflNO v-1l0LC7d~00O u-IM d~L~ M O N
U1lONO L~N 00Lf~~OM 01N MN c-IlW-I01M M~-I~-I00LncNL~00O1 O Nl~O 01ON
O O l001OM L~N r-IN M00OO d~01d~l~L~01dicNM LhLnr1c<'CO M M01c-IL~d~M
M tl~MN dtCt~dtc-idrl0NM r1N Mc-iv-iM00v-I~-Ir1r-1~-W-I00c-Ir-IN rtl~N w-Id~N
W
~, O
N
O
(1101O1M Ml0L~ N 0ldi 0 0010 N 00 l0 l~ O1 l~O00M~NLf7O Ln d~d~Nd~t!700In 01L~N d~LIW-Id~ d~ L~r1.O1N v-I L~
r-IMN 00l0ON l0 L(7d~Mv-Il0d~l0 L~Nt~Ol~t~r1 c-I Lf7l0d~t~ O 00 t!7diMN Md~cf'l0Mr-Ir1M d~c-INv-IN r1M c--I0000l00100r1v-Iv-Ir-Id~N dW -Iu-Ir1 '~
N
I
N N ~ N
O O O O
O O.-. O ~ O
c-1--. MN d~ d~ I I~ I ~ ~ I N
O r-I NO O O 00OO c-iN O O t~ O
N W O HW P-~' f~,' N MN p,'O (Y., (Y,O z -i~ f~E-~ OH H H o oO o W W o H
S=', [-iCJ ''~',W (~ A o o d~O Cxr Gx,o N ~ r.~ H(~ H H o o~ diO H U o o o ~nO
W H H a I O
I IO I ~
~ M ~,~ w .~ U
~I M M'-' d~O '-'d~
V v v v fW-Iv-1 vr1 r1r1 w-Iu-1v-It~t1W -Ic-I~-1-Ir1r1r1Ol~ r1 tI7N
,'7(~r-1 ,~.lW-I N t'7~ N~ 'n..',~d 01l0.'~'''~'',~~Jt-JO00 l0W-Id~ f7O
O c-Ic-II'7rll0W'~' ~.Ov-1hc-1Ol0d~O(Vl0M u-10101dicHMM Csal0",.L',lD LIIWd1 U M c-IN ,"L,'01l0L~d~r101lW-I01Nv-Ir1M00MN l0r1L~O1d1Wv-Il4LC1v-IN InO00 00MO M~Oc-I00N00M~OODO r1N0001~10d~N L~N MO d~F(,'l4 l0d~C~01 r1l0N
N 01MO 01C~L~LnMO MO O-d~l0l0~37~Z.77~Lf1Md~tf1COd~M 01Cl~X71d~01M Z~ 'd~ML~
LnO00d~LI)00M OLf)l~O Ln01r1d~ v-Idid~.d~O1L~t~d~I O d~LC7 W-1O
01NM w-101NO O~01ON d1O r1CO N NW W-MMM O'(J 01ON Od~LC7 ~~~~ ~ ~
U r1Ol0dW-IOr1"01r1LPGO r)inLnO O ,-)O ~ON NN tf~~J-~N LP701J~ LOMr1 U1LWOL d~L d~00~1m tWo 0ou17Lr1L~'C7C7N t~t~t~L~LL LnUC7 L ttWo C7 LnL~LS) -rl -rl N
'-'N d~ 00 '~W ~ o L~
l0 N 10 00 ~ 00 ~ic-I M L~
.!~~ N L17 N ~
N lfl N r1 d~ N
U M t17 L!W -I 00 I c-I
N L~ L~ r1 N N
c-I I
riM r1 I c-1 l0 !tiM di d~ Ln c-I d~
N I I O I I
~It0 I t11 cH
~-I N
Ul~-t r-I of c-t <i F~05 r-I w-i rf d~ t N
U
~,'N l0 Ln O N
N M 01 In M M
N
W ~ r1 ~-I N N
-l A
H
N
1~c-I c-1 O PO r1 fYl ~-I r1 N U 0.l U P~l Pa r1o U in U U
U r1 o1 N to t~
N M d~ N 00 O
~
.1-1M M N l0 O
'~yO ~ O L11 N
U N L~ O L~ CO
r1 ~iO d~ In ~ di O
H ~o L Ln L L~
W
O
1~
O
NO
-I
z U
~H
.-I
a O ~ d1 O r-I N
W
p.~N N M M M
U) ~~irW -1 ~rmo vo o W
Ul 01l0d~00 r1t11r1u-I111r1NO~~N t!1d~
O rM MO d~d~r1r rr d~O v-ILf~O00 M ~N ~-IOl r1c-W-IM 01M 01r101r1v-IM
O
.,..I
.,1 O
W o1cH r-IN
l0O di O 00 l0 l0 r01u-I
r1r M N O l0 l0 Nr O
Ln r-1r100r-I r1c-Ir-1c-Iw-Ic-Ic-Ir1w-I00dir1 N N oN
N ~ O.-.OO
O N ON OO
I l II
O O M ,'~r1,~NN O
U~ I7 W c-I G4r1P-irO W
.1JW H o J,(~Of~OO W
o ~.~oU oo H
~ ~ ~~ ~~
cd a1 C7 00 r-1 o~ ocN
S-I O N L17 Nr1 v ftl r-I v-1 00 l0c-itIW-Id~O v-Ir1 r1 N~ c-1I'7 O d~.~,'01,'S',0111)I7,~00',1,' N ',.C,l0,."L',00 M N1.nd~rc-1M01Lf1M wdi U d~a-IrO t0l0d~01a101Nr Ml0~M
~, r-c-1N~ r N01c-I00M ~r01L!1O O10 N O00Nr ~1O~7l0~7l0~~1MN ~d~N
~$1 rM 01d~ 00 M M ... ~N ~
.
Lnr1Ns-! NHO O ,~-~ r1N ,I0r!
~
r1N l0'tf)~ Ml~Lf1~Ln,'~ LnO Mt1~
7~
u~ rr rm C7?sC7InC7InC7C7mr rm I I
U7 d~ M
- ~ 01 01 r ~-I
l~
'~ o ~ ~
N d~
s""rr-INM
.h N r . . to N ~-I
lfl ~-I
N
.~,.tU r1 00 lD N ODM
C~ ~
I
M
I
I
N I O c-I 10 O l~
O
I
c-I
O
r-IO u-i 00 c-I r101 (a d~ t11 00 l0 N
M
fl)O i I t I t f-II r d~
M
~-1 Ul 00 v-I r1 ~-I ~-I.-I
Cr.~c-1 01 01 r1 N
c-I
r1 N
U
N
.1.~
S'il0 If7 t!7 N 00N
O M d~ L~ d~ O Lf1 N
U7 N .-i 01 O1 ~-1r1 i--l H
O r1 c-1 r-I W a--1r1 N W P4 P~ U PaPO
-I U U U ~ U U
U N M O ~--I ~--1d~
U d~ N r1 di C7r ,.~5 .!~O O ~ l0 l~r _ 01 l0 O M r--Iw-1 'Jy U to r o0 O ~ op r-I
~ r d~ dm n a~d~
o H ~ r r m ~ r w N
+~
o NO
U
A
O M d~ Lf'I l0 (~pp W
W M M M M M M
Cl~
a .r., ro .N d~NM Mr1c-Ir1~ON c-ILC7 O OO NO O OO O OO
P4HH HH H Hf~z WW
Ul ~1~~ O54'aOW H HW
H HH zH H f~faPaf~
~ P4z HH H ~H z rCH
o a ~w ~ o~
N
H
a ~ ~~ ~~ w ~~ ~ ~~
H W f11pap7U U a1PaRaWW
U UU U~no UU U UU
J~ l0NO r1L~c-101lflL~Nd1 U O 0110w-1N M d~ODO d~L~
.J-10~ON O1M M Ml0O OL
N
'Jy'd~Lf7r1Ml0O L~t!1N 01ri U -I~C~~HL~N N L~L~00l0N
O
~i d~d~M d~O O d~d~d~L~d~
~I
H L~LL L~otoll t~toL
W '.
N
J.~
O
~O
~z U
~
Ca ~H
~
y r -I
OI
O O NM d~L~0001v-IN M~
W
W N NN NN N NM M MM
N ,-l o ~ ~
I >~ ~ r Id ~I f-0 b~-a ~ v r~
o o v ~I ~ ~ ~r z ~C r1 ra o -- ~
v 5,l ~1 ~
.u ~ 1n .u v o a, ~ ~s a o --1 ~ -~1 3 v ,~ s~, v ~
~; N G' ,-Q ~ ',~ DC U1 O U v ~-i U UI O N
4-I ~ O 1~ $ td -a ~1 ~a v .u o rd 3 ~ <n ~1 ~ ~ o ~ ~ ~ ~1 s~
v M r~ ~ 4 ~
1 1 '' ~ j ~
td N ~I ~i ~, N !!S - U7 ~.j r1 N O .!- ~ C
S N U ?t N O H O
''d ) ~ ri Ul O R~ O (If ~ f I ~i d N ' I
~ 4 ' I~ ''C3 ~ i l i i ~
N U7 O v ~L '-' U7 -I ~ l . ~ O -,L7 .1J -I . H ~,' r U O ~ -r1 I . r r-t N r ~, - -I
( 4-! r-I -rl 'Zj u7 T O UI .-I u1 -rl r-1 ~I ~ v U U1 rlf N O r1 'J
-rl U7 f-I U S-I O ~-I td N r-I O .U -- rd r-I ~y-~1 td .!~ t6 ~ .U .!..l O .h ni -.-I U rtf ZS U N
~ U7 4-I N 1~ N r-i N '~ ,5 O u1 O v O 'T3 r1 ~
.!~ ~ td ~ cd u7 u1 ~-I v -rl ~I 1-t r-I
l 1 '~ N O C
W '~ -I ' -I
l ~ ' N N
W O ~
O
B
l O -r1 r r .! , Ul .! ~1 r ~, .
~-I h 'C3 (d U7 ~ O .l- .~, f (IS ~-I U (d .1~ -I
U7 ,.t~ 1-1 ~ U (f ~,' .I~ .~i ~ r v ~ G
~,' O r1 r-1 .1J
v U O ~,' r1 U tl~
cCf 4-I to N 'Z3 rd U1 .1.-1 v rtS O W-i ttS ~ (d 'TS
r1 ,sue' fd (d ~ ~' .t~ ~ N ~ O 5r :-', ~j ~r ~-I
s~ ~; P N ~; N -.-1 td U ~-I r-I O O ~ W Id u1 '' v -.-I Id N .1..1 W cd ''d U ~ '~ .-I
' ' ~-I v I IJ
' ~ '~ 4 ~
1 s S
N
~
l ~ ., p r-I .h W U7 - .
O -rl y., . -rl N N (d U1 N .~ O .!- td ?-I ~,' U ~-I U .
~ Id ~ cd -rl -I i ~ ~'~ ., 1 -~-i O U7 ~-I N N l -1 -r ~, -~I ~ .
>j ? I ., J N 4 4a ~,' O b~ u7 ~
1 l '~ N O
N ~ ~
l t l 1 '~
O I O 'd u1 ~ rd ''d '~
.!- S.1 c - w c ~ .1. .. r U1 .1-1-f'-...Q U r ~ -.
4-I ~ U7 U1 U1 I ~
~I -r-1 ~ -I S'.. v N ri 4-I W
td ~-I r -I ~ N ~ ItS ,~
O ~ ~.,'' 4i U7 U~ O ~
t~ i4-1 .!~ r-1 1 3 -r-I ?-I N'D u ' l 1 O v U ~
~ N ~ 6 N
~
d d v r-I N C r r -O ~., U , t r 1 f($ r-I . ~ c -rl .
N ~,' . Id -I t w1 U7 , U fd 'ZS cd fd Id ''~
~., O -r-1 r1 ~-I r1 r-I td r-I
v ''~ W 4-I ,t,' r1 131 ',7 1n o ~ -,~ 0 ~ s~ +~ la a r1 ~ ~ v U ~ o o -~1 ~I m ,~ I . -~ s~ r1 .u .u 1 ~
-~1 ~1 --I ~-I U1 -(-I ~-I ~ -.-I -r-I, w-1 N u7 ~ rtS ~'' .s;
~'.,U - ,s; ..C,' .U r-i '~ ~ U -rl rtf 3 .13 N r-I r-I
.h 4-I tJI U 4-I U U '~S .1.~ ~ u1 -rl N O 1~ O
-rl .!-1 .I~ r1 ~-I O ~I D ~,' .!-~ O a-I
b~ .~, (<i a r~ .>, ~1 U ~1 v ~ v o ~n ~ s cn .-1 3 -~I ~~n , r1 ~ o ~ v ~ ~a v ca ~ a ?. ~ -~
3 ~, zscd~a~v~3~~lv,.~ra ~IU r1 ~n o .uo~avrl ~3 ~~-3~a~rl~~a ~ N r-I U N U ~,' .~i N rtS -t'. ~ '~ O ri ~
Id r1 r-1 rtS ~ 'i~ ~I O O ~ O .l-1 ~". ~
J~
.1J ~1 O .l~ J-1 U7 O O .i-1~-I --i ~C O ri U N U7 r-I .~, ~ 1~ .~., r1 .~ ~-I N .1~
+~ v ,5r bW-1cd O ,~ N Id ~ -~I U ~S ,~ u1 ~-I O U1 r1 .-I N
~ , rd rtf N N 4-I ~ ~ ,~ ~ -.-1 .1..~
o u ~ u zi u~ ~ - u r u o 1 ~ ~ ~u 1 o rt ~ ~
l v > ~
~ v u 3 ~
s ~1 ~, . s .
-~I 0 ~ . ~ .
,.~ o ~ . r ~ o s ~a -~1 s ,~ .
v 1 W U7 0 r1 ~ v >~ v o ~1 >~ ~ ~ ~a .u N .u ~a v ~ l ~, v U U7 v - ~
U 4 1 ~
l U dF ~ Q U7 U1 S S -I ~1'~ (0 O N O
' -W U1 J.- r . ,.
~ r1 ~,'' ~; 7 U ~ r -r1 ,5..,"~ -, r( . ., .7 ,5 -1 U7 1.1 S ,5y r-I ~'., N N r-I
-r-1 ~ r-I .1J ~ 4-.I , ~1 -rl U7 O -rl f~ ~I (d N
ffS Ll1 r1 ~ N Ei ~ O X U 't! Id U r-I -.-I +~ 5r O
oo ~ cd oo r1 4.1 O ~ '~ ~ ~-I
~I U
rd -FC -rl ~, r.~ ,.C ~-I N ~ -.-i .L.1 1~ I U
~1 td .l~ v ~ H -~1 ''d -rl '~ U1 O 4--I N w .U ~ v O
N ~ (<i .~., r1 U N .l-1 U1 '~ .~., ~I r-I to r1 .U ' ?S 4' r-I -r-I N .~., ~ (l) ',~ C,' rd ~ ~i 1=,' ~ I N l ''~ O O t ~ N ~ d 7 O ' b O S -i v d ~ ~ O
d O 3 C
.4 p I O rli h t 5 U7 ., 5r -I r -~ r l ~ ,~ .h I U r ''d Z
U .!~ u7 r1 ~I )~ O O >~ ~I
N N I Gv F
N N 1~ u7 s~ 1 1~ ~
~ ~1 v O '~
U1 bl-~IU 'Ci ~ 1-~ O U ~i U~ t~ U1 -ri td rti 5~ Q., .1J ~ 1-I ~ ~ ~,' ~.1 rd -rl O td .1.y clS ~-I
~1 >~ ~ v >~ ~ ~ :a ?~ ~ ~ r1 ~a ~ .u rr rt ~ o ~a 3 v U m o ~ -~r o r~
.u -~I o ,.~ -~1 v ~I r1 0 ~a ~n r~ u-1 v o .u 3 ~a -1 v ~I ~n ~ ~1-~1v v o .u ~I -~I ~1 S~
v r~
m m ~1 0 -~1 cn 5 v .u o ~1 ~1 ~, o ~, ~, s~ v .~
~I s~ ~I -~1 r1 w ~ m ~n ~a ~ ~a o ' ~ 4 .u 4 C
O I 1 1 I N ' N l U1 1 (d b1 U (d I N U7 f '~ - ~
1~ l I, S 1 -I v -I ~1 ~
~
~
~, ~ - . - .
o -1 r . r ,.
~ 0 ~ ~ a v , 3 ~ rt rd r 1 v -- . r - l s~ ~ v -~I .
v , ~ v ~a .
., -t o la ~ o ~ ~ ~a u -~1 ~I ~
''O ~ r - .
U ,-~ '~ r1 '~ >-'., .-I ''LWIj ~I ~I O .IWO (p v $ U1 ~,' ~. N ~-1 fR W 4-I N ,IZ
'~ ',~ r-I U7 m v v la o v ~a ~ -~I t~ v r1 ~-I ,~ as r1 u~ ,~
r1 ~ ~ o -~1 -~I o ~I ~ ~ 3 ~ ~
v ~, u~
m .u .u .u .u ~ ~ v ~ cn +~ -~1 ~1 ~ o o ~a ~ .u m ~-I ~, ~ .u ~I ~ L1 ~ -~1 ~ o v ?~ ca td U td G' U O O -rl ,C'',f0 ..Q '~ r-I -r1 U N O
~ r1 U (!S v fd v O U~ r-I
r1 U
g ~ r1 o v ~ ~ ~ ~ U .u r1 U v m r1 4-1 0 >~ w .u ~ .u ~1 ~I s~ .u ~ ~I v .-. o :3, ~
v ~I o ~1 >~ ~I v 3 v v o o ~a ~ v ~ ta~I o .-1-~I
o u~ v N ~ -~1 -~1 o zi ~o U
~I
~
",~,.1~ U1 4-I .1~ ~ ~1 N ~ U1 .1~ U ~ f~ ~-1 U ~ O
4-I U oo '~ .~ ~-rl tti '-' r-I td > r , ' ~I u1 -rl r1 u1 N ~, s: -~1 -~I ~ u7 O U7 ~ o N a p > s U1 d ~I 5r ~ G
N ' ?~ ~ O ~-I ~ f:
'' ' ' ' "
~
' fa ~ (!j to J.J r1 .1J .l-1C, ?-1 U7 N ~ ~-I (a N ., (a ~ -r-I I -r-I fit U7 >_ ~-I (CS ' C, ~'I , (d J-,5 Jy ~-I v ~, " ' ' "
' .4 O U ,~ tn O ~ tIS U7 U7 -r1 -1-.t r1 1~ ~., r1 $ ~(, (6 U ~-I .. O O U ,~
N -r1 $ .l.W-I .~, N (d U f ~, r1 -a-I
' ,~ U ~ O ~1 U ~ .~., -r1 S-1 U7 .1~ cd N S-I N
N J-~ ~ 4-1 N -.-1 O rd -I-1 U
Cl) d ' ~1 U) .I~ O -4~ ~ O v i I 1 ~ -I
~ ~ -1 U f ~ ~ ' ~
v U . ~ U O U ~
O
O ~
"
r O G r , r l t - 7 -1 f ~, u7 ~ -I I -I
~': J, O ~ -I- q O >
b1 -ri l 4-1 O b1 O cd f v ''d .
m O v u7 ~; U ~-I ~ '~ N En ~ t 1 v r as . r , 3 tn ~I , as -~1 -v ~ us ca ro ~I s.1 ~I U ~ ~ v ~ v v ~ r-I
>~ ~n 5 .-1 r-I U
v ~ 3 , 3 ~ >~ ~ v ~a ~ v r1 v ~ v ~ .u U ~a rt ~ ~ ~ ~ m -~1 . ~a ~-I ~ rn >~ -~I v ~ o ?. ~
N U7 ri '~ S-I ~ -r-1 .!-1-ri tR O i71 .i~ .h rt1 r-i -r-I .i-W d r-i r1 -rl O 'Zi U1 rti ~ u1 U f-i ~ ~-I ~ rd ~ ~, us 3 0 ~., o -~1 a-I u~ ra it >~, ~ v ~ r1 M
~n ~ .u ~ ~, v ~a ~ ra ~1 v -r1 ?-I ~ N ~ ~-I '~ U7 rd ~ ~ 3 U7 >;.,'' ~ ~I
(d d~ '~ ~r N N O U ~ U O O U .S, ''i~ '~
.1~ ~-I ~
~I td rl t~ ~ cd r-I ~ H N -rl W d cd ?i O trri U N U .~ ~ ~ ~ N --1 , N N O S~
cd N 0 p, ~I zi ~a ~1 , U ra ra rd ~I ~, 0 3 ~ ~I -- o ~ ~-1 ~ v r1 ~ ~ ~1 0 r1 ~ .~ rd U -~I ~a ra .u 3 ~1 cti .~ v ~ O ,~ m ~ N N r1 N td S-1 rt ~ O 4-1 U
U1 N td U r1 O O O ~ N Ls U ri .1J N -.-1 ~ t0 b1 1J ~.,'~ O ~C ~ .1-~ N ~
v N 1.1 f-1~ 1~ r-i ~-1 L.p.l ~I v v (~
u1 .4.a 4-1 ~ .u ,-C,' U
O r1 U 4-I r-I N U ~-,' U ciS ~-I U 'Z, U U ''~
b1 ~-I ,5r Ul -~1 w-I O O v N r1 N U C51 ~'., N O 4i (0 U
~",''d rd ~ U .1~ r1 ri ,5..,'' ",.f' .~ ~1 N N v 'R ~-I
~., -rl ?-I 4-1 U ~-I r1 N !~ O U
r1 '~
O ~,' "L3 S-I ~,' 'Ii U ''~ ~' ~I U7 r1 ''~ U U r1 'a O ~, O (0 $ .R (d O ''CS -rl (d -r1 U N ~ ~,' ~ b7 ''~ U f=,' N
-r1(d N 1.1 (a v ',.J r1 N .1J r-1 ~"., O O ~1 .1.~
~-t O ,c-I r1 ~., -rl (d ,h f; t~ v U
U) fd ,5t N r1 ~ U1 cIS
.1..1?-I ~,, U7 .-1 ~ ~.,'' O ~ U1 U Uf v U ~ v f~ f;
4-I ~: .L.) v 4-I O O w1 -ri rt ''C5 '~,'~-I ''(j O bl,~a' '~
L N rI -~', U7 r-I 1 ~'. O ~i ~ ~ U7 ,.C,' N .~, td U7 N O ~,' 1"' N ~-1 N C37 N (~ N
O ~i ~ ~-1 -r1'~ ~I O f0 fa ~-I N ~I 'L~ O (d N 1=i ~-1 .1-1 r1 '~ -r1 '~ .1-~ .l-WI r1 -r1 ~ v ~-I ~ -ri to U1 N ~-I (a ''~ r-I (~ 4-1 C,' I N ~ U U O ~ !J N r-I ~ U U N O O fd v ~,' ',7 N U7 ~ r1 O U r1 U S=,' U1 O U7 .1~
$ N f"-. ~
-~-1 U m rt ~ b~ ~ ~a v -~ ~ v o .u ,~ v ~ c~
p u~ 3 ,~ ~I o ~ ~ -~1 r1 s~ ~ -~I v U1rd .~, PIl (d .~, '~ 'Jt .~.,U1 '~ r1 O O O .1.~ ~ -r1 O U r1 U r1 ~,' .U (I$ fir' .l-1 R -r1 .~, N
M ..ti 'n' -r1 fCS O S.,' N
N -rl O (~ U r1 O ~ I ttS U c~ r1 tCS U '~ <'I <'I
.~.,~ ~,' '-O U (0 '~ U1 v r1 r1 N
a .~t rd 3 0 -~1 ~ ra u, ~ m 3 0 a~ ~u ca m ~ t~ ~a v ~a v ~d w o ~1 m ~ ~ rd ~ r1 ~ -~1 ~ ~ '~ .!-1 ~ U tn v '~ 1 v ~I '~ O ,-r1 v ~
.1.~U N -~I 'Zi O Ui N s~ N -rl ~
O v S~
?,~ m ?~ ~ M ~a .N -r-I ~I ~, ~I o v 3 ~ .u .>, -~1 rd -~1 ~ rt is v ,~ -~ .u ~ .u -r-1 ~-I ~
v -r-1 v ~1In ~I ~I o ~I ~I ~1 ~s ~s ~I ~a ~ u~ ~ v ~ ~a ~ ~
v ~a -~1 o v >~ s~ ra as ra ~ ~ 0 5 .u .u ~I .u r1 td~ (d (d I N N U ~-I .I~ 1r3 td ,5 ~,' U r1 (~
? .U W O '~ O (a ~ ~I N v U U td -r1 r1 F-I
U7 ~ S-1 U1 U1 v ~I ) ~ v U1 1 !~ to - l ~ l O
~ O -I N N CI1 N ~
W l ~ i ~-~I '~ l ~- -I b1 J
~ O -IJ --1 O b1 d -I ., -I r , ..
,.Q-ri . . r -I , r U7 - ,~ (d r r r fd -ri Id (R . ,~ I ., O ~-1 ~ ., '~ r U1 . tti -.-I tn O .~., ?~I
r r1 '~ ,5 ~''~ ~:
w-I ~-I O ''d rI ,.Q tn i; N t31 O
U 'L3 ~-I
r1.~; .~i .-I N ~ O ~I Via'' ri u1 .S=i -r-1 !-I N ~
-r-I?~1 ~-I -r-I ~ U N .G Sr' ~,' O .S', .S', ~,' N N ~-i ~ ,fir ~ w-1 ~ ~ ~ ,!~
a E-m E-~ a ?r bW E-W ~-1 ~ ~n a M C~ ~ ~u ~I ~ ~, ~I
~ w -~ .u u~ ~1 U ~I -~I -~1 ~C -~I N-1 ~
b~ .~ m ~ ,.~ ~ o N '-1 '-I
c~
~ A Z O ~ U U
N ~ ~ ~ H H
J W W W
Lfl l0 c-I d~ M N
O O O O N O
W
~1W W ~ !a O
~ w f~ H H
U
I ~.I
a~ .>, ,--I zt a~ o ~ ~ i u ~ ~ ~
~
a~ ~ c>3 c t 5 zt a a~ n .I ~ .
.!~ cd ~r fly cd .-I r1 rtS
O ~'' O U ,r~ -r1 N .I-~ ~ H cd U N U .L~ ~I
-- .1.~ ct3 .u ~ .1.~
S-I
~I ~ O cd O r-I N -ri SI >~ -i~ O
tI~ N U .1~ (d (d ~., N ~-I LnU1 , L7)'~ (C$ ~
" U U -.-I N U1 ~r ~
r-1 ~) '~ O ~,'' ~ Ir1 O '~ ~.,' r1 O
r1 U 4-I r1 r1 c~ -rl J-1 ~'., N ~-I (d f1-i H7''d U ct~ cIf -1-~ .~., ~ 4J U1 O U7 r1 O r1 ~-I
5..,'' 'd 4-I CS TJ Htn U7 r1 N 4-i ~', U cd O -r1 -r1 ~1 ~I O
N ~ l O ~
~ l U1 U
~
N O -r1 N .!--1rG'., O r1 U r r S-I ?-I ~,' . r-I (CS
r1 ~-I U . r1 G4 (CI 'LS N O ~-I Ul ~,' (0 ~"., d$ S-I fa'' .~, U v O N
U N f~ r1 .!~~-I N N ~-I .-I l.~
P N ,.~ ~, 4-1 N O 'Lf U
f.~ U S-I ~; .!-I
>~ ~ .~ cd -.-i4-I , -.-I N ~-i O ''d ~ cd ~ .i~ N U
'd 1.1 cd td 5~
~
~I -~I ~ a o 3~ ~ s~ ~I o ~ .u ~I
~I so, ~-I ~ U a~ a~ .u ~ ~I cd ' ) ~
cd '' d U1 O
~ d ~
.R di ~ , 'Tjr1 .L- c N f~ U .R C c ,5y .!-1 +~ I J
O Ip ~ .s c6 ~ ~ ~ 4-.I ~
~-I -~-I O U) N -r1 ~-I ~., ~1 -r-I U7 N r-I .N
(d rlrl~,''NO N.l~~rl(dO '~UNf~~C3f=,' N
O O ~r N rt -t~cd ~ N ~ ~I O N w-I
N ~-I ri U7 c0 ~ cd O r1 O ~ 'T3 .t-~ ~ N N ~ O cdr1 -.-1 r1 ~1 .!->
U -ri td -.-t ~ ~ -.-1 U U
N ~ N s=, U1 ~ O ~,' U1 r1O ~-1 O .~., 4-I c6 ,~,' U7 -1, U N O '~ S-I r-I U
-r1 (~ t17 r1 ~ .t~ Ul ~tR ~ ~'., O U cd cd .1-~ O ~ 'L'S ~,' r1 ~,' O
~' U7 .~ ~I
~
.ti U1 U .-) ~.,-r1 '~ U '~ 'Wrl -ri f=i ~", .J-1 ',~ cti ,-Q ?-I
N O ,~-i t57 O U1 N .I-~ r1~ U1 N O N '~ '~
~,' .U ~.,'' O N
x-1 cd ,5y -.-I N U .Nd, N rd (CS ',~ ~,' ~-1 '~ (CS ~I -I-~ ~i ~-I .!-~
r1 'O ~-1 N ~i Oa r-I J.-~ .I-~ U7r-I -~'', ~ O -.-I
U7 -rl t=,' W 5y U1 N cIS .I~
~ N O ,t-, N ~
.-I O O ''Cidi rti cd ' O ~ U ~
-s", ~ c~ ~~ .-I .~ .!~ c0 U7 ~ ~r ~ O ~' N
' ~ ~ U1 O
~ ~ 1 -'' h N -I ~ ~ . ~
O ~ l. .S
(a ~ -, - -1J ~ b) ~ U7 .-I 5 l L ~-1 S~ cIS
I O I ~1 1 WIS 1=' -I
' ICS
. r ~ N r. , - , ' ri, y f~ r . O ir., ~1 , ~ 4-I r1 U1 f~'' N ~ r-I O O U ~y4-I
U U -r1 N ' ~ ~ x'-.r-1 .!-1 yf Q~ r1 ~ ;3 U1 ',~' -.-I O
S-I ~ r-I
~'., ~,' ~ .l-I O U7 S~,U7 ~,' -r1 ~ O O
dS ctS -r-I U1 S-1 c~ r1 -r-1 r-1 N N
tT
U1 ttS U .t-~ O~ cIi -4~ .~,'.O S''., ~-rl -rl '~ U1 O ,.C; .U r1 ' ~-I cd U1 .1~
~ ~
~ ~ O ?i ~ ~; ~-.-I tR .!-> .!
,-4 ~ N N -~ -r1 ,.~ ~ ~ U
r~ N U S tn l.1. ~ ai U
O O b N ttf N f-I
~ rd ar ~
-N
l O ~ S~ f -r1 > >~ a r, ~ W cti >~' -I U7 U1r ''d cd H r1 ~; -rl -~
O O N cd U r1 -ri ~ ~ U O ~ U1 .4.~ O -.-i N ~'ZSO.1..~ U N N -rl 4-1 Cr 'Z'S U1 ~I O r1 H .1..1 -ri cIi cd U ~-I ;~ NU ~ r-I .-1 c>3 , ri c~ U7 ~ ~,'' I ~,'' >~' ''d Zi U
U ~ r1 O ~ cd O O N ~y ~y-rl ~,' N ~ ~,' O -r-I -rl r1 ~ '~ ~ -L~ ~Sa U ~ ,~ .1~ S~ ~ U
N N ,t,'' -rl b) S-I .-I
'd J.-I C-a ~
rd O ~ U1 O U O.t~ U U S-I O Ul ~,' ~ N ~.,'' di ~ ~-I r-I
~ ~-1 N W-I N ?-I ~-1N '~ N N -r1 ?-i cd .!.- N J.-~ N ~ ~C N N N cd r1 cd J-~
' 4-I r-1 4--I l1-1~''., r-1 U ~t-W -1 '~ ~i r-I .~i Ut G>a -rt .-t U N ~-I N .1J U
l ~ ~
i ~
O O
''i3 ~
~ di cd O Itf rd~ r ., ZS N ~ '~ -r '-d O
~y ~I U I .-I ,s..,-' U7 Z3 ~ I ~-I
f~ ~-I U I -~', -r1 -r1 ,~,' ,Q c>$
-.-I W G' cti ,5.~
s~ a~ tn a~ a~~I o 3 cd ~n a~ ~-I
-- .u ~, c~ ~u c~
c>3 ,E,~ c~ .u s~ -N .I~in cd ~I ~ .u ~ w is ca ~ r1 ~ ?~ ' U
.
~ ~a ca cart a~ .~ ~w ~s ~ ~
a~ w ~s tn o r1 s~ a~ o ~I ~s ca ~s ~, ' ' ' ' ' ' b7-r-Ir-I -rl r-I r1,T~ U ~ -rl r-I ~, S-I ,~ O r1 OU trf ca ri U1 U7 ~; r1 ~, !IS Jr r-I O UI O .!~ 3 ' O (I$
N r1 O I t~ ~., U 5=; cd .L~ i4 .~., .~', ~, ~, ' -r1 Ul (d U7 NLc~ ' U7 -rl .R U7 ~,' S-I CS ~.," N tip N U1 U tA N ~-1 O r1 N O
' ~
' ' " "
..~, -r-I -~-I -r-Itn N N ,Q .Q ~-1 b7 -r-I U cd ctS 1~ td U1 N
.S O r1 O ,~, O
., '~ ~-I
(d ~ ,5 f.2~ cd -L.) U1 ~.~' .-i U7 .-I U O (d ~i ~ .I~ .1~
t~ ,5..,'' O
-rl O ~ ~ ~C ~U F(,' ~
' ~ 0 ~ ~
U ~ '' ' ~
j R ~ U
Cj U -r (d ~--rl -I
" l ~-, U r ~ ~ s~
O S, -I S-I N cIS c~S
~ i - ~
-I .
N -II
-t -I ~ -''C5 'd -R ~' U
N .~ r . r '~ O ~
., ~ I ~ -rl + -I ~ ~ r O ''C3 b1 .
ca 2i l O 'd ~ ~
~ 1 H U ~-I
~
>~ . - t37r ~ ~ N
-r-I ~ . ~I f~ .!-I
-I t5~ r-I ca .-I
. to .!-~
tn r-I O
~ N
~I 5;.," ~', G:'CS 4-I -rl ~; N ri S-I O .t.1 -r-I ~: U '~y Cl .!~ G' N cti ~-1 ~; O
U1 W I (d .-1 r1N N ~': .~. a-I ri O f~ ?-I N O ?-I ~ S-1 N N O H
ca U7 ?-I U7 U1~ 'Ci ~-rl U1 ctS
.~ U r1 ~ ri ~y O CS f.~a .N ,~ r-I ~I N cIS -rl H
3 ~ ca ~ ~ ~-~I a~ .u ~I ~ ~
~ ~I ca U .u ~ ~ r1 ' ~ ' ' ca O '~ U1 J O td ~ f: N
'~ U1 '' '~Jy N U r1 U ~
' U ' 41 tv ' i-1 ' ~
N
' .1J O r-i ~ O NU U1 ~, 4-I N O ~ O r-I ~ N cd 'i3 f~' ~ ,5r ~ r-I -I td 1..1 S-1 G ~-I J
N I ri ~ O O r1 ~-I
~,' ~' O
J.-~
O .h N J.-) .1~.~. N ,L,' 1-1 r1 N aS -r1 f0 N .1-~ r1 ~ ~,' N c6 N N ri ~-I ~d ~1 .l.-~
r1 U l0 U .~.,UO ~-I .!~ ,.C,''U (A r-1 ~"., ,G 1.1 ,ii Ul N .I-1 O N
U N N N ~
' ' r;.h , ~ .!~ ~ .1~ ~t3 UI U7 .~ ~ ca U
O.!~ cd U~ f-I ?-I.i; -I
~ S-I (d ~' ~ ctf E-~ r1 ~I U ~,' (d O ~S (S ~' O W .~,' O
(a ~ -r1 ~r ~ h h -~I~ J.WI .1.~ -Vcd ~ r1 ,.~ .1.I ~
~ N ?-I ctf O O cd -.-I
U Cj U .O
of .1)-r-I U7 4-~ u1 U1S-I U7 .-. U7 cti O N ~-I -L.~ cd ri 'C3 ~
cIS
N ~.,' -~, GiUI .~'~ U7 ~' U ~
.1-) O ,~,' U1 ~' ~ ~ .l U
,~, N ~ '~ l b7 N
~ ~ l ~ N N
' 5 d ' ' -r1,si O .!-~ O cd Or .O -r X-I~ .1-I ~i UctS O G U 'd O
U7 U ~,' U U ?-I ( .1-1 E-~ B -rl ~ z -rl X11 !11 'C~ ~!~ N J-~ O ~'., (d O ri O .~'., U ,.C; cI3 Urt o w 3 ~ ~ cn .I~ o ~ r1 .u a~ ~ .u N s~ w -~I .u o s~
ca U1r1 fly r-1 U1 U7rtS S-I U J.-)U1 O U1 S-I t~ ~-I ctf cIS .~., 'LS ~-I N
U ' N
rtS
ON ~6 O ai cd-rt O N m W td I r1 f~.R u7 U O N ~ ~ N .~2 cti ~ U1 aU 3 U ?,-~I3 w ~.~ ~ +~ ~ zi 3 ~I ~
o U ;~ -~I ~n ~
.~'.,~ U1 ''d 'T3 tR O U7 t(S U
N ~-1 -r1 ~ '-' ~ 'LS
' ~ i U1 N
> U N
t' O ~~ r-i ~' cd ~y O U7 .h ~ ., CS ~~..,, .- ~r N O ~ U2 rtf .1-N ~ O 7 ~ ~
~ H
~
~
~,'' -1 .~ ~O ~ r-I N ~ cd ~ N
cd O U1 -I -r ~-1 ~
UI ~ l ~
~ ~ N
ctS
~I.!-~ S-1 O ~-1 ~-IUl r1 r1 ~,' S-I M
O c~ O ~1 ~., Ul l~ -r1 N
N O .J.) -r-i r1 r1 N
S-i ,~n'S ~ r-I ,.5~ W-r1 r1 O (IS ~ d1 -I~
n-I J.J clj N ~-I J.-) ~C, U
U7 U1 ~I U1 .l~ 'Z'S .~ J.-I
.!-.-Ir-I .-I -~-1w1 r1~ ctS S: ,~ .-I cIi O O N O ~I -.-I O .1-I
.-i .-I ~-1 clS 5~ -~ >~ ~-I
O SC
~l4-I rl Ul rl ~lH b7 U .u +~ ~l ctS
U U ~ ~r ,~,' 1~ W W cd '~ '~ U ~', cd tt~ -r-1 N cd H
U U U~ U
H H ~ H
N HU
f.~ ~ S~W
M r1 r-1~-I N
O O OO O
,'J O DCH ',7 ' H~ x 7~ ~ f o ~ a w W ~ .,~ ~ ~ I o o ,n ~ ..~ on ~ c. ~ o v--i ~ W N O ~ ~.r M of I Pr ~ 'G ~ ~ i > t-n "Zs ~ ~ ~ ~ cd ~ O ~i N ~O ~ V7 O i~ V ,..NNr N ~p ~ U ~ ri > ~ N ~ ""' ~ o o ~ o II
,D ~ ~ ~ ~ N O ~ ~ ~ i~ ~ ~n 1-i V .U .~., W ~ w N bA O .'~~., I I ~, r i ,w; ~ o 04 ~ ~ ~ ~ ~ '~ 04 0 , '~ ~. d ',.' p., y 4-i ,.D ,.., ~ U ~ ~~ O ~. t-~
~w ~
W o ~i > W ~ o~, ~ ~ ~i w ~ g ~ ~ ~o U i.-;;
U
O ~ 00 ~ ~ U ~ ~ ' ' r, ~ t~ O~ op D
. ~ m ov z C7 ,-, o °' o °' ~ a r_. ~ ' '-' ~ N a~ ,-.
U U U ~ ~ °' °° "~ ~ °' '~ ~ ~ N ' a M b a~'.~
a ~ o " N ~ ~ :x ~ °' t~ G4 W ~ o o .~ ~ ~ x ,-.
U U U ~ ~ ~ ~ ~ ~s ~ o x W ~ ~r o i N ~. a, °~,''' °~,~''' d ~ ~ u'! °° ~'' 'h ~ "~
°° :x '° M $' ~ ° >
0 o U o ~ ~ M '~ vi ~ ~ N ~ ~ .~,°c o . ' ~~
w w ~ w ~ ~~ ~:~W~~ x b a, ~, p, >, m ' U ~ c~ os ~ c~ o is 0 0 ° o Gz!o:° ~v~~.E-,~ ~" U i~
o en ~' ~ ° ' ~ ~ '~ U
ix1 f~ ~ 0.1 ~ d' d 3 ~ o°', '~ ~ ~ i .°x ~ ~ ~ ' ~' ~ Q"
~o.~ od %~d x~ ~~~ ..c~~
--i cs: d d r~. d d c~ Z w Z ~ ~ d x d vi c~ U "~ c~ ... to Z
H
~ o ~ ~ ~ w U v, N _cC 4~ ~ ~ ~ b~A
'O .f", U .Ut'., '~ U .O ~ O N rUn ,b y ~ O ~ > .b ,~ b-0 ' ,~f.",~ SG cC C/1 ° N ~ cn w ~' p O p~ ~ '+~ ~ U c~ ~r ~ ~ ~ ~b ~ ~ cG
fr' ~d bA ~ ~ L~ U b ~ ~ G O ~' V m ~ '~ ai U
p ,.d ;b ~ ccs ~ t~ U ~ c~ ~,, ~ >,"
p" c0 .~ U ~ O °~'" U ~ V d m ~ ~ ,FCC, O ~' N vi cC (~ . ~ ~ ~ .f. (~ w ~ ~ ~ ~ ~ c'nG U
s.. ~ o .v °~ U ~ E-' Y
U ,~ ~ ~, '~ Y ~ w ~' i~ p o ~r w° a ~ o ~' ~ w .C a "G ~ c~
O ~ pp ~ U Pa ~ U O ~ ~ v~
m 4~ 0 U ~tU~- .~ ~,~UJ~~ ~'~'O~
O 'O N 'yn ~ C N cct ~ N ~ t-, U ~n O~ OU N ~~nUaf ~a3~4r ~O ~ .~.' U'bcUn N N cG . Y N ..O .~prr N v~ ~ > a~.yn . m O .f, .~ O G .~" a~ d ~R C .gyp'' ~"~ U N O ~ m p ~ ~,' ~ ~ O
cd c~ N tn 3 ~~ ~~' .y"'~, ~ .~ N 4a 7 o w ~ ~ ~ ~s "° " a p ,~
o 'Y ~ Y ~ 'Y o .~ ;o a ~ .n o ~ ~ .~ p;
p., w °
on '~ A ~~ ~'n ~° a .~ o ~ '~ ~ ~ ~ o ~ O ~ a o°n >~ ,~
s~ ~ w ~ o. Pa ~r ~ ~ P-. ~ ~r ~ c~ ~ a' p s. o -d o A d ~ d ~ d d ~ a ~ d '~ ~ ,°' ~ d ~ A w° '~ ~ :c a.
w .n w H
e~c ~ ~ E~ d W
w ~ ~ ~ ~ w U -o ~ ~°
o °' :~ °' ~D
O ~ '~ O ~j~' y ~.., y.., .~ ~ C7 ~ ~u H a" ~ 0 0 0 .c o ..~. U ~ ~p .-i i~r ~ ' G O ~ O N
w z ~~.~ ~~ ~ _ N .~T ~.j N ~"
Vj O by ~ ~ H ~ N ~
p ~ ~ ~ ~ .O O
~ O~ ~ ~ ~ Or, ~ p ~/ N
O ~ ~ ~ ~ O C~ W
~-o~ ~~ o~,~~f.~t~~ ~ .~~ ion o0 c H ~ ~ ~ ~ ~ ~~ ~ ~ ~ U _~ ~ o i ~ N ~ ~ ~ '~ ;~ o ~ o ~a; ~ ~ b ~ ~° ~ .x a~ ~ C7 v ~ ~ c~ o r; ~ ,.,_, a o v~ ~ ~ ov ~' a~ ~ P4 0 0 ~. .b V ~ .-. ~ ~'s°' w °~ b oo ~ cn . C7 P, ~., '. ~ o oho oho '~ CV ~ .~, ~ '~ p ~ ~. i~, cd p f-4 , ~ ~"'" U .~ dD Pn oW'~ ~~oo '~'' ~ o°°, ~~~ ouoi ~~~' ° ~p.'U
M ~ M .~ " y c~ cC '~ N ~ ~ ~ ~ ~O ,~ S''~ ~ ~ U ~ ~ N ~O n'~ N b ~ ~_. ~ U
N N FG ~ ..~-~ ~ .d d' oo ~ eC c'~ 'Gi M ~o P-~ M W '~~~ _~ y,°~'~
_~ ~ ~:
'-' W p cC N CL, N O ~ nj ~ N ~ N ~ _~ ~ O P-i N
N
~ > > ' ~' d o~"o a~ ~' ~c ~ ~ 3 ~ x U ~ ~ v~ ~' a~ ~ ~ y L7 .x due' .~ ~ '~ ~ E' ~ ~ ~ ai ~p o ~ ~ o ~ .~ .C ° ~
°O..° v ~
cn cn ~ G7 ~ 00 ~ F"'y--i y ~, ~y'i bA :--n p U i 4., ~ ;n ~,; ~ .~ ~ ~ :~ r,., ~ b a ~ i ~ ~ ~ r p ~ ~ a ; '~ ~' v ~ ~~°°z w~~ ~~~ ~~ ~ z°U wNa~
N ~ 'n o a~ ~ ~ '~ on ~ ° v U ~ ~, E"~ ,~, L~ N .b ~ p ccf p, 'O ~ GJ U .1"Ur U far T7 a"
W
y> ~I O Q. ~ ~ cct U .-~. O
O" ~ ~ b ~~ ,_., ~ R,a ~ . N ~ b 'gyp N
~F." ~ L~'. w U in b p ~ ~ C
'W n ~ V ~ O ~ b0 ~ ~ O
V ~ ,~ ~U ~ .Y ~ O m > ~
U ~ ~.. by b "~ y U '~ ?pG w ~3 .,t', ..'''', ~ U ~ ~~ b U ~,~ O
~, ~ U ~ O O ~ '~" ~ by '~ c~ ~" ~ -~. O P-i W v~ c~C ~ pr ~ .O ~ b-0 O O ~ ~ N ~
O ,~.~ ,.~ ~ s' ~ '~ ~ P. N .C O 'b n b cC~ Y~ ~~~~ ~> ~y 3U~ cdt~-ny V y a~ o~ y ~ ~ ~ ,~ ~ ~. ~ ~ o v~ .~ ~ b on 3 ~' '~ a~ can o ~ r~. a~ ou . a~ ~ ~ ~ a~
ayi ~ eu .r o 4. ~s ~
as ~ ~ ~ ~~ o ~ ~ '~: -~ ~ ,a ~ o ~ Pi :.-~ .~ ~N U :'' ,.C c~ ~ ~ ~ .D O ,~ U
'~ bOp cn b N C"» ~ ~ ~ G p, .fl by ~ ~ ~ '~ WJ ~ N
iG~C t'~d~ .C~~~ y~"y O~ ~w ~~'p O .i~.
.~r b ~ ~ P-i O ~ ~ b4 ~ 3 ~ s~. ~ ~ t3, ~ ~ p. cC
~ U o ~ ~ ~ ~ ~ d ~ -o d -d ca ~ ..c U
'C ø~ U ~ 4r m U
CL w P'~-. ~ U ~ ~ H
<110> INCYTE GENOMICS, INC.
THORNTON, Michael PATTERSON, Chandra LAL, Preeti BURFORD, Neil YUE, Henry GANDHI, Ameena R.
ELLIOTT, Vicki S.
RAMKUMAR, Jayalaxini BAUGHN, Mariah R.
KALLICK, Deborah A.
WALIA, Narinder K.
HAFALIA,April J.A.
YAO, Monic,~ue G.
LU, Yan TRIBOULEY, Catherine M.
POLICKY, Jennifer L.
KEARNEY, Liam GRAUL, Richard WARREN, Bridget LEE, Ernestine A.
DING, Li <120> G-PROTEIN COUPLED RECEPTORS
<130> PI-0176 PCT
<140> To Be Assigned <141> Herewith <150> 60/221,478; 60/223,268; 60/227,054; 60/231,121; 60/232,243;
60/232,691; 60/235,146 151> 2000-07-27; 2000-08-03; 2000-08-21; 2000-09-08; 2000-09-23;
2000-09-15; 2000-09-22 <160> 38 <170> PERL Program <210> 1 <211> 339 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474806CD1 <400> 1 Met Leu Ser Ile Leu Leu Pro Ser Arg Gly Ser Arg Ser Gly Ser Arg Arg Gly Ala Leu Leu Leu Glu Gly A1a Ser Arg Asp Met Glu Lys Va1 Asp Met Asn Thr Ser Gln Glu Gln Gly Leu Cys Gln Phe Ser Glu Lys Tyr Lys Gln Val Tyr Leu Ser Leu Ala Tyr Ser Ile Ile Phe Ile Leu Gly Leu Pro Leu Asn Gly Thr Val Leu Trp His Ser Trp Gly Gln Thr Lys Arg Trp Ser Cys Ala Thr Thr Tyr Leu Val Asn Leu Met Val Ala Asp Leu Leu Tyr Va1 Leu Leu Pro Phe Leu Ile Ile Thr Tyr Ser Leu Asp Asp Arg Trp Pro Phe Gly Glu Leu Leu Cys Lys Leu Val His Phe Leu Phe Tyr Ile Asn Leu Tyr Gly Ser Ile Leu Leu Leu Thr Cys Ile Ser Val His Gln Phe Leu Gly Val Trp His Pro Leu Cys Ser Leu Pro Tyr Arg Thr Arg Arg His Ala Trp Leu Gly Thr Ser Thr Thr Trp Ala Leu Va1 Val Leu Gln Leu Leu Pro Thr Leu A1a Phe Ser His Thr Asp Tyr Ile Asn Gly Gln Met Ile Trp Tyr Asp Met Thr Ser Gln Glu Asn Phe Asp Arg Leu Phe Ala Tyr Gly Ile Val Leu Thr Leu Ser Gly Phe Leu Ser Pro Ser Leu Val Ile Leu Val Cys Tyr Ser Leu Met Val Arg Ser Leu Ile Lys Pro Glu G1u Asn Leu Met Arg Thr Gly Asn Thr Ala Arg Ala Arg Ser Ile Arg Thr Ile Leu Leu Val Cys Gly Leu Phe Thr Leu Cys Phe Val Pro Phe His Ile Thr Arg Ser Phe Tyr Leu Thr Ile Cys Phe Leu Leu Ser Gln Asp Cys Gln Leu Leu Met Ala Pro Ser Val Ala Tyr Lys Ile Trp Arg Pro Leu Val Ser Val Ser Ser Cys Leu Asn Pro Val Leu Tyr Phe Leu Ser Arg Gly Ala Lys Ile Glu Ser Gly Ser Ser Arg Asn <210> 2 <211> 335 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474840CD1 <400> 2 Met Thr Pro G1y Gly Arg Ala Cys Ser Glu Met Arg Ser Cys His Cys Ala Pro Ala Trp Ala Thr Glu Arg Asp Ser Val Ser Lys Lys Lys Lys Asn Lys Lys Lys Asn Leu Phe Ser Gln Ala Thr Ile Gly Leu Leu Ala Asn Thr Phe Phe Leu Phe Phe Asn Ile Phe Ile Phe Leu Gln Asp Gln Lys Ser Lys Pro His Asp Leu Ile Ser Cys Asn Ser Ala Phe Ile His Val Val Met Phe Leu Thr Val Val Asp Ala Trp Pro Pro Asp Met Pro Glu Ser Leu His Leu Gly Asn Glu Phe Lys Phe Lys Ser Leu Ser Tyr Ile Asn Arg Val Arg Met Gly Leu Cys Ile Cys Asn Ile Cys Leu Leu Ser Ile His Gln Ala Asn Thr I1e Ser Pro Asn Asn Phe Cys Leu Ala Arg Leu Lys Gln Lys Phe Thr Asn Asn Ile Ile Met Ser Ser Phe Phe Ser Phe Phe Phe Trp Ser Ile Asn Leu Ser Phe Ser Tyr Asn Ile Va1 Phe Phe Thr Val Ala Ser Ser Asn Val Thr Gln Asn Ser Leu Pro Lys Gly Ser Asn Thr Val His Phe Leu Pro Met Lys Ser Phe Met Arg Lys Val Phe Phe Thr Leu Thr Leu Ser Arg Asp Val Phe Ile Ile Gly Ile Thr Leu His Ser Ile Ala His Met Val Ile Leu Val Ser Arg His Glu Thr Gln Ser Gln His Leu His Ser Ile Ser Ile Ser Pro Gln Ala Phe Pro Glu Lys Arg Ala Ala Gln Thr Ile Pro Leu Leu Val Ser Tyr Cys Leu Val Met Cys Trp Val Asp Leu Ile Ile Ser Ser Ser Ser Thr Leu Leu Trp Thr Cys Asn Pro Val Phe Leu Ser Met Gln Asn Leu Val Gly Asp Val Tyr Ala Thr Val Val Leu Leu Glu Gln Ile Ser Ser Asp Lys Asn Ile Val Asp Ile Leu Gln Asn Met Gln Ser Ala Ile Lys Leu <210> 3 <211> 428 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7475092CD1 <400> 3 Met Gln Arg Lys G1u Lys Ala Lys Cys Pro Gln Glu A1a Pro Ala Gly Arg Glu Pro Ser Thr Pro Gly Gly Gly Ser Gly G1y Gly Gly Ala Val Ala Ala A1a Ser Gly Ala Ala Val Pro Gly Ser Val Gln Leu Ala Leu Ser Val Leu His Ala Leu Leu Tyr Ala Ala Leu Phe Ala Phe Ala Tyr Leu Gln Leu Trp Arg Leu Leu Leu Tyr Arg Glu Arg Arg Leu Ser Tyr G1n Ser Leu Cys Leu Phe Leu Cys Leu Leu Trp Ala Ala Leu Arg Thr Thr Leu Phe Ser Ala Ala Phe Ser Leu Ser Gly Ser Leu Pro Leu Leu Arg Pro Pro Ala His Leu His Phe Phe Pro His Trp Leu Leu Tyr Cys Phe Pro Ser Cys Leu Gln Phe Ser Thr Leu Cys Leu Leu Asn Leu Tyr Leu Ala Glu Val Ile Cys Lys Val Arg Cys Ala Thr Glu Leu Asp Arg His Lys Ile Leu Leu His Leu Gly Phe Ile Met Ala Ser Leu Leu Phe Leu Val Val Asn Leu Thr Cys A1a Met Leu Val His Gly Asp Val Pro Glu Asn Gln Leu Lys Trp Thr Val Phe Val Arg Ala Leu Zle Asn Asp Ser Leu Phe Ile Leu Cys Ala Ile Ser Leu Val Cys Tyr Ile Cys Lys Ile 215 .220 225 Thr Lys Met Ser Ser Ala Asn Val Tyr Leu Glu Ser Lys Gly Met Ser Leu Cys Gln Thr Val Val Val Gly Ser Val Val Ile Leu Leu Tyr Ser Ser Arg Ala Cys Tyr Asn Leu Val Val Val Thr Ile Ser Gln Asp Thr Leu Glu Ser Pro Phe Asn Tyr G1y Trp Asp Asn Leu Ser Asp Lys Ala His Val Glu Asp Ile Ser Gly Glu Glu Tyr Ile Val Phe Gly Met Val Leu Phe Leu Trp Glu His Val Pro Ala Trp Ser Val Val Leu Phe Phe Arg Ala Gln Arg Leu Asn Gln Asn Leu Ala Pro Ala Gly Met I1e Asn Ser His Ser Tyr Ser Ser Arg Ala Tyr Phe Phe Asp Asn Pro Arg Arg Tyr Asp Ser Asp Asp Asp Leu Pro Arg Leu Gly Ser Ser Arg Glu Gly Ser Leu Pro Asn Ser G1n Ser Leu Gly Trp Tyr Gly Thr Met Thr Gly Cys G1y Ser Ser Ser Tyr Thr Val Thr Pro His Leu Asn Gly Pro Met Thr Asp Thr Ala Pro Leu Leu Phe Thr Cys Ser Asn Leu Asp Leu Asn Asn His His Ser Leu Tyr Val Thr Pro Gln Asn <210> 4 <211> 330 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7341260CD1 <400> 4 Met Thr Pro Asn Ser Thr G1y Glu Val Pro Ser Pro Ile Pro Lys Gly Ala Leu Gly Leu Ser Leu Ala Leu Ala Ser Leu Ile Ile Thr Ala Asn Leu Leu Leu Ala Leu Gly Ile Ala Trp Asp Arg Arg Leu Arg Ser Pro Pro Ala Gly Cys Phe Phe Leu Ser Leu Leu Leu Ala Gly Leu Leu Thr Gly Leu Ala Leu Pro Thr Leu Pro Gly Leu Trp Asn Gln Ser Arg Arg Gly Tyr Trp Ser Cys Leu Leu Val Tyr Leu Ala Pro Asn Phe Ser Phe Leu Ser Leu Leu Ala Asn Leu Leu Leu Va1 His Gly Glu Arg Tyr Met Ala Val Leu Arg Pro Leu Gln Pro Pro Gly Ser Ile Arg Leu Ala Leu Leu Leu Thr Trp Ala Gly Pro Leu Leu Phe A1a Ser Leu Pro Ala Leu Gly Trp Asn His Trp Thr Pro Gly Ala Asn Cys Ser Ser Gln Ala Ile Phe Pro Ala Pro Tyr Leu Tyr Leu Glu Val Tyr Gly Leu Leu Leu Pro Ala Val Gly Ala Ala Ala Phe Leu Ser Val Arg Val Leu Ala Thr Ala His Arg Gln Leu Gln Asp Ile Cys Arg Leu Glu Arg Ala Val Cys Arg Asp Glu Pro Ser Ala Leu Ala Arg Ala Leu Thr Trp Arg Gln Ala Arg Ala Gln Ala Gly Ala Met Leu Leu Phe Gly Leu Cys Trp Gly Pro Tyr Val Ala Thr Leu Leu Leu Ser Val Leu Ala Tyr Glu Gln Arg Pro Pro Leu Gly Pro Gly Thr Leu Leu Ser Leu Leu Ser Leu Gly Ser Ala Ser Ala Ala Ala Val Pro Va1 Ala Met Gly Leu Gly Asp Gln Arg Tyr Thr Ala Pro Trp Arg Ala Ala Ala Gln Arg Cys Leu Gln Gly Leu Trp Gly Arg Ala Ser Arg Asp Ser Pro Gly Pro Ser Ile Ala Tyr His Pro Ser Ser Gln Ser Ser Val Asp Leu Asp Leu Asn <210> 5 <211> 676 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7473911CD1 <400> 5 Met Asn Lys Asn Asn Lys Pro Ser Ser Phe Ile A1a Ile Arg Asn Ala Ala Phe Ser Glu Val Gly Ile Gly Ile Ser A1a Asn Ala Met Leu Leu Leu Phe His Ile Leu Thr Cys Leu Leu Lys His Arg Thr Lys Pro Ala Asp Leu Ile Val Cys His Val Ala Leu Ile His Ile Ile Leu Leu Leu Pro Thr Glu Phe Ile Ala Thr Asp Ile Phe Gly Ser Gln Asp Ser Glu Asp Asp Ile Lys His Lys Ser Val Ile Tyr Arg Arg Asn Arg Gln Ser Gln His Phe His Ser Thr Asn Leu Ser Pro Lys Ala Pro Pro Glu Lys Met Ala Thr Gln Thr Ile Leu Leu Leu Val Ser Cys Phe Val Ile Val Tyr Val Leu Asp Cys Val Val Ala Ser Cys Ser Gly Leu Val Trp Asn Ser Asp Pro Val Arg His Arg Val Gln Met Leu Val Asp Asn Gly Tyr Ala Thr Ile Ser Pro Ser Val Leu Pro Arg Leu Thr Ala Pro Asn Glu Trp Arg Ala Ser Val Tyr Leu Asn Asp Ser Leu Asn Lys Cys Ser Asn Gly Arg Leu Leu Cys Val Asp Arg Gly Leu Asp Glu Gly Pro Arg Ser Val Pro Lys Cys Ser Glu Ser Glu Thr Asp Glu Asp Tyr Ile Va1 Leu Arg Ala Pro Leu Arg Glu Asp Glu Pro Lys Asp Gly Gly Ser Val Gly Asn Ala Ala Leu Val Ser Pro Glu Ala Ser Ala Glu Glu Glu Glu Glu Arg Glu Glu Gly Gly Glu A1a Cys Gly Leu Glu Arg Thr Gly Ala Gly G1y Glu Gln Val Asp Leu Gly Glu Leu Pro Asp His Glu Glu Lys Ser Asn Gln Lys Val Ala Ala Ala Thr Leu Glu Asp Arg Thr Gln Asp Glu Pro Ala Glu Glu Ser Cys Gln Ile Val Leu Phe Gln Asn Asn Cys Met Asp Asn Phe Val Thr Ser Leu Thr Gly Ser 320 ~ 325 330 Pro Tyr Glu Phe Phe Pro Thr Lys Ser Thr Ser Phe Cys Arg Glu Ser Cys Ser Pro Phe Ser Glu Ser Val Lys Ser Leu Glu Ser Glu Gln Ala Pro Lys Leu Gly Leu Cys Ala Glu Glu Asp Pro Val Val Gly Ala Leu Cys Gly Gln His Gly Pro Leu Gln Asp Gly Val Ala Glu Gly Pro Thr Ala Pro Asp Val Val Val Leu Pro Lys Glu Glu Glu Lys Glu Glu Val Ile Val Asp Asp Met Leu Ala Asn Pro Tyr Val Met Gly Asp Glu Gly Glu Glu Glu Glu Glu Glu Phe Va1 Asp Asp Thr Leu Ala Asn Pro Tyr Val Met Gly Val Gly Leu Pro Gly Arg Gly Gly Glu Glu Glu Glu Glu Glu Glu Va1 Val Asp Asp Thr Leu Ala Ser Leu Tyr Lys Met Gly Glu Glu His Arg His Lys Gly Leu Ala Pro Leu Trp Glu Gly Gly Gln Lys Pro Ser Gln Lys Leu Pro Pro Lys Lys Pro Asp Leu Arg Gln Val Pro Gln Pro Leu Ala Ser Glu Val Pro Gln Arg Arg Gln Glu Arg Ala Val Val Thr Glu Gly Arg Pro Leu Glu Ala Ser Arg Ala Leu Pro Ala Lys Pro Arg Ala Phe Thr Leu Tyr Pro Arg Ser Phe Ser Val Glu Gly Gln Glu I1e Pro Val Ser Ile Ser Val Tyr Trp Glu Pro Glu Gly Ser Gly Leu Asp Asp His Arg Ile Lys Arg Lys Glu Glu His Leu Ser Val Val Ser Gly Ser Phe Ser Gln Arg Asn His Leu Pro Ser Ser Gly Thr Ser Thr Pro Ser Ser Met Val Asp Ile Pro Pro Pro Phe Asp Leu Ala Cys Ile Thr Lys Lys Pro Ile Thr Lys Ser Ser Pro Ser Leu Leu Ile Asp Ser Asp Ser Pro Asp Lys Tyr Lys Lys Lys Lys Ser Ser Phe Lys Arg Phe Leu Ala Leu Met Phe Asn Lys Met Glu 650 655 ~ 660 Arg Pro Gly Thr Met Ala His Ala Cys His Pro Ser Thr Leu Gly Ser <210> 6 <211> 372 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474767CD1 <400> 6 Met Glu His Thr His Ala His Leu Ala Ala Asn Ser Ser Leu Ser Trp Trp Ser Pro Gly Ser Ala Cys Gly Leu Gly Phe Val Pro Val Val Tyr Tyr Ser Leu Leu Leu Cys Leu Gly Leu Pro Ala Asn Ile Leu Thr Val Ile Ile Leu Ser Gln Leu Val Ala Arg Arg Gln Lys Ser Ser Tyr Asn Tyr Leu Leu Ala Leu Ala Ala Ala Asp Ile Leu Val Leu Phe Phe Ile Val Phe Va1 Asp Phe Leu Leu Glu Asp Phe Ile Leu Asn Met Gln Met Pro Gln Val Pro Asp Lys Ile Ile Glu Val Leu Glu Phe Ser Ser I1e His Thr Ser Ile Trp Ile Thr Val Pro Leu Thr Ile Asp Arg Tyr Ile Ala Val Cys His Pro Leu Lys Tyr His Thr Val Ser Tyr Pro Ala Arg Thr Arg Lys Val Ile Val Ser Val Tyr Ile Thr Cys Phe Leu Thr Ser Ile Pro Tyr Tyr Trp Trp Pro Asn Ile Trp Thr Glu Asp Tyr Ile Ser Thr Ser Val His His Val Leu Ile Trp Ile His Cys Phe Thr Val Tyr Leu Val Pro Cys Ser Ile Phe Phe Ile Leu Asn Ser Ile Ile Val Tyr Lys Leu Arg Arg Lys Ser Asn Phe Arg Leu Arg Gly Tyr Ser Thr Gly Lys Thr Thr Ala Ile Leu Phe Thr Ile Thr Ser Ile Phe Ala Thr Leu Trp Ala Pro Arg Ile Ile Met Ile Leu Tyr His Leu Tyr Gly Ala Pro Ile Gln Asn Arg Trp Leu Val His Ile Met Ser Asp Ile Ala Asn Met Leu Ala Leu Leu Asn Thr Ala Ile Asn Phe Phe Leu Tyr Cys Phe Ile Ser Lys Arg Phe Arg Thr Met Ala Ala Ala Thr Leu Lys Ala Phe Phe Lys Cys Gln Lys Gln Pro Val Gln Phe Tyr Thr Asn His Asn Phe Ser Ile Thr Ser Ser Pro Trp Ile Ser Pro Ala Asn Ser His Cys Ile Lys Met Leu Val Tyr Gln Tyr Asp Lys Asn Gly Lys Pro I1e Lys Ser Arg Asn Asp Ser Lys Ser Ser Tyr Gln Phe Glu Asp Ala Ile Gly Ala Cys Val Ile Ile Leu <210> 7 <211> 271 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7475815CD1 <400> 7 Met Asn Lys Asn Asn Lys Pro Ser Ser Phe Ile Ala Ile Arg Asn Ala Ala Phe Ser Glu Val G1y Ile Gly Ile Ser Ala Asn A1a Met Leu Leu Leu Phe His Ile Leu Thr Cys Leu Leu Lys His Arg Thr Lys Pro Ala Asp Leu Ile Val Cys His Val Ala Leu Ile His Ile Ile Leu Leu Leu Pro Thr Glu Phe Ile Ala Thr Asp Ile Phe Gly Ser Gln Asp Ser Glu Asp Asp Tle Lys His Lys Ser Val Ile Tyr Arg Tyr Arg Leu Met Arg Gly Leu Ser Ile Ser Thr Thr Cys Leu Leu Ser Ile Leu Pro Ala Ile Thr Cys Ser Pro Arg Ser Ser Cys Leu Ala Val Phe Lys Asp Ser His Ile Thr Asn His Val Ala Phe Ser Ser Val Phe His Ile Ser Ile Ser Asp Ser Phe Leu Val Ser Thr Leu Pro Ile Lys Asn Leu Ala Ser Asn Ser Leu Thr Phe Val Thr Gln Ser Cys Ser Ala Gly Tle Gly Ser Arg Pro Pro Ser Ser Gly Tyr Met Val Ile Leu Leu Ser Arg Arg Asn Arg Gln Ser Gln His Phe His Ser Thr Asn Leu Ser Pro Lys Ala Pro Pro Glu Lys Met Ala Thr Gln Thr Ile Leu Leu Leu Val Ser Cys Phe Val Ile Val Tyr Val Leu Asp Cys Va1 Val Ala Ser Cys Ser Gly Leu Val Trp Asn Ser Asp Pro Va1 Arg His Arg Val Gln Met Leu Val Asp Asn Gly Tyr Ala Thr Ile Ser Pro Ser Val Leu Va1 Ser Thr Glu Lys <210> 8 <211> 611 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 60263275CD1 <400> 8 Met Gln Gly Pro Leu Leu Leu Pro Gly Leu Cys Phe Leu Leu Ser Leu Phe Gly Ala Val Thr Gln Lys Thr Lys Asn Ile Asn Glu Cys Thr Pro Pro Tyr Ser Val Tyr Cys Gly Phe Asn Ala Val Cys Tyr Asn Val Glu Gly Ser Phe Tyr Cys Gln Cys Val Pro Gly Tyr Arg Leu His Ser Gly Asn Glu Gln Phe Ser Asn Ser Asn Glu Asn Thr Cys Gln Asp Thr Thr Ser Ser Lys Thr Thr Gln Gly Arg Lys Glu Leu Gln Lys Ile Val Asp Lys Phe Glu Ser Leu Leu Thr Asn Gln Thr Leu Trp Arg Thr Glu Gly Arg Gln Glu Ile Ser Ser Thr Ala 1l0 115 120 Thr Thr Ile Leu Arg Asp Val Glu Ser Lys Val Leu Glu Thr Ala 125 130 l35 Leu Lys Asp Pro Glu Gln Lys Val Leu Lys Ile Gln Asn Asp Ser Val Ala Ile Glu Thr Gln Ala Ile Thr Asp Asn Cys Ser Glu Glu Arg Lys Thr Phe Asn Leu Asn Val Gln Met Asn Ser Met Asp Ile Arg Cys Ser Asp Ile Ile Gln Gly Asp Thr Gln Gly Pro Ser Ala Ile Ala Phe Ile Ser Tyr Ser Ser Leu Gly Asn Ile Ile Asn Ala Thr Phe Phe Glu Glu Met Asp Lys Lys Asp Gln Val Tyr Leu Asn Ser Gln Val Val Ser Ala Ala Ile G1y Pro Lys Arg Asn Val Ser Leu Ser Lys Ser Val Thr Leu Thr Phe Gln His Val Lys Met Thr Pro Ser Thr Lys Lys Val Phe Cys Val Tyr Trp Lys Ser Thr Gly Gln Gly Ser Gln Trp Ser Arg Asp Gly Cys Phe Leu Ile His Val Asn Lys Ser His Thr Met Cys Asn Cys Ser His Leu Ser Ser Phe Ala Val Leu Met Ala Leu Thr Ser Gln Glu Glu Asp Pro Val Leu Thr Val Ile Thr Tyr Val Gly Leu Ser Val Ser Leu Leu Cys Leu Leu Leu Ala Ala Leu Thr Phe Leu Leu Cys Lys Ala Ile Gln Asn Thr Ser Thr Ser Leu His Leu Gln Leu Ser Leu Cys Leu Phe Leu Ala His Leu Leu Phe Leu Val Gly Ile Asp Arg Thr G1u Pro Lys Val Leu Cys Ser Ile Ile Ala Gly Ala Leu His Tyr Leu Tyr Leu Ala A1a Phe Thr Trp Met Leu Leu Glu Gly Val His Leu Phe Leu Thr Ala Arg Asn Leu Thr Va1 Val Asn Tyr Ser Ser Ile Asn Arg Leu Met Lys Trp Ile Met Phe Pro Val Gly Tyr Gly Val Pro Ala Val Thr Val Ala I1e Ser Ala Ala Ser Trp Pro His Leu Tyr Gly Thr A1a Asp Arg Cys Trp Leu His Leu Asp Gln Gly Phe Met Trp Ser Phe Leu Gly Pro Val Cys Ala Ile Phe Ser Ala Asn Leu Val Leu Phe Ile Leu Val Phe Trp Ile Leu Lys Arg Lys Leu Ser Ser Leu Asn Ser G1u Val Ser Thr Ile Gln Asn Thr Arg Met Leu A1a Phe Lys Ala Thr Ala Gln Leu Phe Ile Leu Gly Cys Thr Trp Cys Leu Gly Leu Leu Gln Val Gly Pro Ala A1a G1n Val Met Ala Tyr Leu Phe Thr Ile Ile Asn Ser Leu Gln Gly Phe Phe Ile Phe Leu Val Tyr Cys Leu Leu Ser Gln Gln Val Gln Lys Gln Tyr Gln Lys Trp Phe Arg Glu Ile Val Lys Ser Lys Ser Glu Ser Glu Thr Tyr Thr Leu Ser Ser Lys Met Gly Pro Asp Ser Lys Pro Ser Glu G1y Asp Val Phe Pro Gly Gln Val Lys Arg Lys Tyr <210> 9 <211> 1469 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 60203310CD1 <400> 9 Met Trp Pro Ser Gln Leu Leu Ile Phe Met Met Leu Leu Ala Pro Ile Ile His Ala Phe Ser Arg Ala Pro I1e Pro Met Ala Val Val Arg Arg Glu Leu Ser Cys Glu Ser Tyr Pro Ile G1u Leu Arg Cys Pro Gly Thr Asp Val Tle Met Ile Glu Ser Ala Asn Tyr Gly Arg Thr Asp Asp Lys Ile Cys Asp Ser Asp Pro Ala Gln Met Glu Asn Ile Arg Cys Tyr Leu Pro Asp Ala Tyr Lys Ile Met Ser Gln Arg Cys Asn Asn Arg Thr Gln Cys Ala Val Val Ala Gly Pro Asp Val Phe Pro Asp Pro Cys Pro G1y Thr Tyr Lys Tyr Leu Glu Val Gln Tyr G1u Cys Val Pro Tyr Lys Val Glu Gln Lys Val Phe Leu Cys Pro G1y Leu Leu Lys Gly Val Tyr Gln Ser Glu His Leu Phe Glu Ser Asp His Gln Ser Gly Ala Trp Cys Lys Asp Pro Leu Gln Ala Ser Asp Lys Ile Tyr Tyr Met Pro Trp Thr Pro Tyr Arg Thr Asp Thr Leu Thr Glu Tyr Ser Ser Lys Asp Asp Phe Ile Ala Gly Arg Pro Thr Thr Thr Tyr Lys Leu Pro His Arg Val Asp Gly Thr Gly Phe Val Val Tyr Asp Gly Ala Leu Phe Phe Asn Lys Glu Arg Thr Arg Asn Ile Val Lys Phe Asp Leu Arg Thr Arg Ile Lys Ser Gly Glu Ala Ile Ile Ala Asn Ala Asn Tyr His Asp Thr Ser Pro Tyr Arg Trp G1y G1y Lys Ser Asp Ile Asp Leu Ala Va1 Asp Glu Asn Gly Leu Trp Val Ile Tyr Ala Thr Glu Gln Asn Asn Gly Lys Ile Thr A1a Asp Arg Cys Trp Leu His Leu Asp Gln Gly Phe Val Ile Ser G1n Leu Asn Pro Tyr Thr Leu Arg Ile Glu Gly Thr Trp Asp Thr Ala Tyr Asp Lys Arg Ser Ala Ser Asn Ala Phe Met Ile Cys Gly Ile Leu Tyr Val Val Lys Ser Val Tyr Glu Asp Asp Asp Asn Glu Ala Thr Gly Asn Lys Ile Asp Tyr Ile Tyr Asn Thr Asp Gln Ser Lys Asp Ser Leu Val Asp Val Pro Phe Pro Asn Ser Tyr Gln Tyr Ile Ala Ala Val Asp Tyr Asn Pro Arg Asp Asn Leu Leu Tyr Val Trp Asn Asn Tyr His Va1 Val Lys Tyr Ser Leu Asp Phe Gly Pro Leu Asp Ser Arg Ser Gly Gln A1a His His Gly Gln Val Ser Tyr Ile Ser Pro Pro Ile $is Leu Asp Ser Glu Leu Glu Arg Pro Ser Val Lys Asp Ile Ser Thr Thr Gly Pro Leu Gly Met Gly Ser Thr Thr Thr Ser Thr Thr Leu Arg Thr Thr Thr Leu Ser Pro Gly Arg Ser Thr Thr Pro Ser Val Ser Gly Arg Arg Asn Arg Ser Thr Ser Thr Pro Ser Pro Ala Va1 Glu Val Leu Asp Asp Met Thr Thr His Leu Pro Ser Ala Ser Ser Gln Ile Pro Ala Leu Glu Glu Ser Cys Glu Ala Val Glu Ala Arg Glu I1e Met Trp Phe Lys Thr Arg Gln Gly Gln Ile Ala Lys Gln Pro Cys Pro Ala Gly Thr I1e Gly Val Ser Thr Tyr Leu Cys Leu Ala Pro Asp Gly Ile Trp Asp Pro Gln Gly Pro Asp Leu Ser Asn Cys Ser Ser Pro Trp Val Asn His Ile Thr Gln Lys Leu Lys Ser Gly Glu Thr Ala Ala Asn Ile Ala Arg Glu Leu Ala Glu Gln Thr Arg Asn His Leu Asn Ala 575 . 580 585 Gly Asp Ile Thr Tyr Ser Val Arg Ala Met Asp Gln Leu Val G1y Leu Leu Asp Val Gln Leu Arg Asn Leu Thr Pro Gly Gly Lys Asp Ser Ala Ala Arg Ser Leu Asn Lys Leu Gln Lys Arg Glu Arg Ser Cys Arg Ala Tyr Val Gln Ala Met Val Glu Thr Val Asn Asn Leu Leu Gln Pro Gln Ala Leu Asn Ala Trp Arg Asp Leu Thr Thr Ser Asp Gln Leu Arg Ala A1a Thr Met Leu Leu Ha.s Thr Val Glu Glu Ser A1a Phe Val Leu Ala Asp Asn Leu Leu Lys Thr Asp Ile Val Arg Glu Asn Thr Asp Asn Ile Lys Leu Glu Va1 Ala Arg Leu Ser Thr Glu Gly Asn Leu Glu Asp Leu Lys Phe Pro Glu Asn Met Gly His G1y Ser Thr Ile Gln Leu Ser Ala Asn Thr Leu Lys Gln Asn Gly Arg Asn Gly Glu Ile Arg Val Ala Phe Val Leu Tyr Asn Asn Leu Gly Pro Tyr Leu Ser Thr Glu Asn Ala Ser Met Lys Leu Gly Thr Glu Ala Leu Ser Thr Asn His Ser Val Ile Val Asn Ser Pro Val Ile Thr Ala Ala Ile Asn Lys Glu Phe Ser Asn Lys Val Tyr Leu Ala Asp Pro Val Val Phe Thr Val Lys His Ile Lys Gln Ser Glu Glu Asn Phe Asn Pro Asn Cys Ser Phe Trp Ser Tyr Ser Lys Arg Thr Met Thr G1y Tyr Trp Ser Thr Gln Gly Cys Arg Leu Leu Thr Thr Asn Lys Thr His Thr Thr Cys Ser Cys Asn His Leu Thr Asn Phe Ala Val Leu Met Ala His Val Glu Val Lys His Ser Asp Ala Val His Asp Leu Leu Leu Asp Val Ile Thr Trp Val Gly Ile Leu Leu Ser Leu Val Cys Leu Leu I1e Cys Ile Phe Thr Phe Cys Phe Phe Arg Gly Leu Gln Ser Asp Arg Asn Thr Ile His Lys Asn Leu Cys Ile Ser Leu Phe Val Ala Glu Leu Leu Phe Leu Ile Gly Ile Asn Arg Thr Asp Gln Pro Ile Ala Cys Ala Val Phe Ala Ala Leu Leu His Phe Phe Phe Leu Ala Ala Phe Thr Trp Met Phe Leu Glu Gly Val Gln Leu Tyr Ile Met Leu Val Glu Val Phe Glu Ser Glu His Ser Arg Arg Lys Tyr Phe Tyr Leu Val Gly Tyr Gly Met Pro Ala Leu Ile Val Ala Val Ser Ala Ala Val Asp Tyr Arg Ser Tyr Gly Thr Asp Lys Val Cys Trp Leu Arg Leu Asp Thr Tyr Phe Ile Trp Ser Phe Ile Gly Pro Ala Thr Leu Ile Ile Met Leu Asn Val Ile Phe Leu Gly Ile Ala Leu Tyr Lys Met Val His His Thr A1a Ile Leu Lys Pro Glu Ser Gly Cys Leu Asp Asn Ile Asn Tyr Glu Asp Asn Arg Pro Phe Ile Lys Ser Trp Val Ile Gly Ala Ile Ala Leu Leu Cys Leu Leu Gly Leu Thr Trp Ala Phe Gly Leu Met Tyr Ile Asn Glu Ser Thr Val Ile Met Ala Tyr Leu Phe Thr Ile Phe Asn Ser Leu Gln Gly Met Phe Ile Phe Ile Phe His Cys Val Leu Gln Lys Lys Val Arg Lys Glu Tyr Gly Lys Cys Leu Arg Thr His Cys Cys Ser Gly Lys Ser Thr Glu Ser Ser Ile Gly Ser Gly Lys Thr Ser G1y Ser Arg Thr Pro Gly Arg Tyr Ser Thr Gly Ser G1n Ser Arg Ile Arg Arg Met Trp Asn Asp Thr Val Arg Lys Gln Ser Glu Ser Ser Phe Ile Thr Gly Asp Ile Asn Ser Ser Ala Ser Leu Asn Arg Glu Gly Leu Leu Asn Asn Ala Arg Asp Thr Ser Val Met Asp Thr Leu Pro Leu Asn Gly Asn His Gly Asn Ser Tyr Ser Ile Ala Ser Gly Glu Tyr Leu Ser Asn Cys Val Gln Ile Ile Asp Arg Gly Tyr Asn His Asn Glu Thr Ala Leu Glu Lys Lys Ile Leu Lys Glu Leu Thr Ser Asn Tyr Ile Pro Ser Tyr Leu Asn Asn His 1265 1270 .1275 Glu Arg Ser Ser Glu Gln Asn Arg Asn Leu Met Asn Lys Leu Val Asn Asn Leu Gly Ser Gly Arg Glu Asp Asp Ala Ile Va1 Leu Asp Asp Ala Thr Ser Phe Asn His Glu Glu Ser Leu Gly Leu Glu Leu Ile His Glu Glu Ser Asp Ala Pro Leu Leu Pro Pro Arg Val Tyr Ser Thr Glu Asn His Gln Pro His His Tyr Thr Arg Arg Arg Ile Pro Gln Asp His Ser Glu Ser Phe Phi Pro Leu Leu Thr Asn Glu His Thr Glu Asp Leu Gln Ser Pro His Arg Asp Ser Leu Tyr Thr Ser Met Pro Thr Leu Ala Gly Val Ala Ala Thr Glu Ser Val Thr Thr Ser Thr Gln Thr Glu Pro Pro Pro Ala Lys Cys G1y Asp Ala Glu Asp Val Tyr Tyr Lys Ser Met Pro Asn Leu Gly Ser Arg Asn His Val His Gln Leu His Thr Tyr Tyr Gln Leu Gly Arg Gly Ser Ser Asp Gly Phe Ile Val Pro Pro Asn Lys Asp Gly Thr Pro Pro Glu Gly Ser Ser Lys Gly Pro Ala His Leu Val Thr Ser Leu <210> 10 <211> 469 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No~: 7477349CD1 <400> 10 Met Asp Pro Ser Val Val Ser Asn Glu Tyr Tyr Asp Val Ala His Gly Ala Lys Asp Pro Val Val Pro Thr Ser Leu Gln Asp Ile Thr Ala Val Leu Gly Thr Glu Ala Tyr Thr Glu Glu Asp Lys Ser Met Val Ser His Ala G1n Lys Ser Gln His Ser Cys Leu Ser His Ser Arg Trp Leu Arg Ser Pro Gln Va1 Thr Gly Gly Ser Trp Asp Leu Arg Ile Arg Pro Ser Lys Asp Ser Ser Ser Phe Arg Gln Ala Gln Cys Leu Arg Lys Asp Pro Gly Ala Asn Asn His Leu Glu Ser Gln Gly Val Arg Gly Thr Ala Gly Asp Ala Asp Arg Glu Leu Arg Gly Pro Ser Glu Lys Ala Thr Ala Gly Gln Pro Arg Val Thr Leu Leu Pro Thr Pro Asn Val Ser Gly Leu Ser Gln Glu Phe Glu Ser His Trp Pro Glu Ile Ala Glu Arg Ser Pro Cys Val A1a Gly Val I1e Pro Val Ile Tyr Tyr Ser Val Leu Leu Gly Leu Gly Leu Pro Val Ser Leu Leu Thr Ala Val Ala Leu A1a Arg Leu Ala Thr Arg Thr Arg Arg Pro Ser Tyr Tyr Tyr Leu Leu Ala Leu Thr Ala Ser Asp Ile Ile Ile Gln Val Val Ile Val Phe Ala Gly Phe Leu Leu G1n Gly Ala Val Leu Ala Arg Gln Val Pro Gln Ala Val Val Arg Thr Ala Asn Ile Leu Glu Phe Ala Ala Asn His Ala Ser Va1 Trp Ile Ala Ile Leu Leu Thr Val Asp Arg Tyr Thr Ala Leu Cys His Pro Leu His His Arg Ala Ala Ser Ser Pro Gly Arg Thr Arg Arg Ala Ile Ala Ala Va1 Leu Ser A1a Ala Leu Leu Thr Gly Ile Pro Phe Tyr Trp Trp Leu Asp Met Trp Arg Asp Thr Asp Ser Pro Arg Thr Leu Asp Glu Va1 Leu Lys Trp Ala His Cys Leu Thr Val Tyr Phe Ile Pro Cys Gly Val Phe Leu Val Thr Asn Ser Ala Ile Ile His Arg Leu Arg Arg Arg Gly Arg Ser Gly Leu Gln Pro Arg Val Gly Lys Ser Thr Ala Ile Leu Leu Gly Ile Thr Thr Leu Phe Thr Leu Leu Trp A1a Pro Arg Val Phe Val Met Leu Tyr His Met Tyr Val Ala Pro Val His Arg Asp Trp Arg Val His Leu Ala Leu Asp Val Ala Asn Met Val Ala Met Leu His Thr Ala Ala Asn Phe Gly Leu Tyr Cys Phe Val Ser Lys Thr Phe Arg Ala Thr Val Arg Gln Val Ile His Asp Ala Tyr Leu Pro Cys Thr Leu Ala Ser Gln Pro Glu Gly Met Ala Ala Lys Pro Val Met Glu Pro Pro Gly Leu Pro Thr Gly Ala Glu Val <210> 11 <211> 335 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 55002225CD1 <400> 11 Met Asn Pro Phe His Ala Ser Cys Trp Asn Thr Ser Ala Glu Leu Leu Asn Lys Ser Trp Asn Lys Glu Phe Ala Tyr Gln Thr A1a Ser Val Val Asp Thr Val Ile Leu Pro Ser Met Ile Gly Ile Ile Cys Ser Thr Gly Leu Val Gly Asn Ile Leu Ile Val Phe Thr Ile I1e Arg Ser Arg Lys Lys Thr Val Pro Asp Ile Tyr Ile Cys Asn Leu Ala Val Ala Asp Leu Val His Ile Val Gly Met Pro Phe Leu Ile His Gln Trp Ala Arg Gly Gly Glu Trp Val Phe Gly Gly Pro Leu Cys Thr Ile Ile Thr Ser Leu Asp Thr Cys Asn Gln Phe Ala Cys Ser Ala Ile Met Thr Val Met Ser Val Asp Arg Tyr Phe Ala Leu Val Gln Pro Phe Arg Leu Thr Arg Trp Arg Thr Arg Tyr Lys Thr Ile Arg Ile Asn Leu Gly Leu Trp Ala Ala Ser Phe Ile Leu Ala Leu Pro Val Trp Val Tyr Ser Lys Val Ile Lys Phe Lys Asp Gly Val Glu Ser Cys Ala Phe Asp Leu Thr Ser Pro Asp Asp Val Leu Trp Tyr Thr Leu Tyr Leu Thr Ile Thr Thr Phe Phe Phe Pro Leu Pro Leu Ile Leu Val Cys Tyr Ile Leu Ile Leu Cys Tyr Thr Trp Glu Met Tyr Gln Gln Asn Lys Asp Ala Arg Cys Cys Asn Pro Ser Val Pro Lys Gln Arg Val Met Lys Leu Thr Lys Met Val Leu Val Leu Val Va1 Val Phe Ile Leu Ser Ala Ala Pro Tyr His Val Ile Gln Leu Val Asn Leu Gln Met Glu Gln Pro Thr Leu Ala Phe Tyr Val Gly Tyr Tyr Leu Ser Ile Cys Leu Ser Tyr Ala Ser Ser Ser Ile Asn Pro Phe Leu Tyr Ile Leu Leu Ser Gly Thr Pro G1n I1e 305 3l0 315 Gln Arg Arg Ala Thr Glu Lys Glu Ile Asn Asn Met Gly Asn Thr Leu Lys Ser His Phe <210> 12 <211> 630 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7475686CD1 <400> 12 Met Arg Leu Gly Pro Va1 Pro Ala Arg Ala Arg Ala Leu Leu Ser Trp Val Arg Gly Leu Glu Ser Arg Gly Gly Glu Trp Thr Lys Cys Ile Val Gln Leu Gly His Leu Leu Ala Thr Gln His Pro Ala Ala Pro Thr Cys Gly Val Val Ser Ser Ala Leu Val Met His Ser Thr Asp Val Cys Leu Ala Pro Thr Met His Gln Ala Leu Asp Trp Ala Ala Gly Ile Trp Phe Thr Gly Arg Leu Gly Leu Arg Glu His Lys Ser Leu Ala Gln Gly Asp Ser Val Cys Pro Cys Glu Ser Glu Leu Gly Asp Phe Gln Val Tyr Gly Leu Val Ser Thr Glu G1y Val Va1 Ser Cys Phe Gly Glu Lys Thr Pro Gln His Pro Gly Pro Pro Ala Ser Leu Ser Leu Ala Asn Arg Cys His Asn Val Val Thr Ala Va1 Gly Ala Trp Pro Ala His Gly Ser I1e Leu Gly Asn Val Pro Glu Ala Pro Val Gly Ala Asp Val Leu Gly Ala Gly Gly Cys Asp Trp Ala Asp Lys Glu Ala Leu Ala Pro Gly Gln Arg Ala Lys Val His Ile Leu Leu Glu Ser Ser Gly Gln Ser Asp Pro Ser Tyr Ala Va1 Leu Pro Asp Ser Trp Ala Ala Thr G1u G1y Phe Pro Thr Tyr Arg Ser Gln Val Ser Ser Pro Arg Ile Pro Gly Ser Ser Ile Trp Leu Gly Ser Gly Ser Gly Trp Pro Ile Leu Gly Glu Leu Arg Glu Cys Asp Gln Met Phe Ser Cys Met Leu Pro Thr Gly Cys Ala Ser Phe Gln Asp Pro Gly Arg Tyr Gly Asp Tyr Asp Leu Pro Met Asp Glu Asp Glu Asp Met Thr Lys Thr Arg Thr Phe Phe Ala Ala Lys Ile Val Ile Gly Ile Ala Leu Ala Gly Ile Met Leu Val Cys Gly Ile Gly Asn Phe Val Phe Ile Ala Ala Leu Thr Arg Tyr Lys Lys Leu Arg Asn Leu Thr Asn Leu Leu Ile Ala Asn Leu Ala Ile Ser Asp Phe Leu Val Ala Ile Ile Cys Cys Pro Phe Glu Met Asp Tyr Tyr Val Val Arg Gln Leu Ser Trp Glu His Gly His Val Leu Cys Ala Ser Val Asn Tyr Leu Arg Thr Val Ser Leu Tyr Val Ser Thr Asn Ala Leu Leu Ala Ile Ala I1e Asp Arg Tyr Leu Ala Ile Val His Pro Leu Lys Pro Arg Met Asn Tyr Gln Thr Ala Ser Phe Leu Ile Ala Leu Val Trp Met Val Ser Ile Leu Ile A1a Ile Pro Ser Ala Tyr Phe Ala Thr Glu Thr Va1 Leu Phe Ile Val Lys Ser Gln Glu Lys I1e Phe Cys Gly Gln I1e Trp Pro Val Asp Gln G1n Leu Tyr Tyr Lys Ser Tyr Phe Leu Phe Ile Phe Gly Val Glu Phe Val Gly Pro Val Val Thr Met Thr Leu Cys Tyr Ala Arg Ile Ser Arg Glu Leu Trp Phe Lys Ala Val Pro Gly Phe Gln Thr Glu Gln I1e Arg Lys Arg Leu Arg Cys Arg Arg Lys Thr Val Leu Val Leu Met Cys Ile Leu Thr Ala Tyr Val Leu Cys Trp Ala Pro Phe Tyr Gly Phe Thr Ile Val Arg Asp Phe Phe Pro Thr Val Phe Val Lys Glu Lys His Tyr Leu Thr Ala Phe Tyr Val Val Glu Cys I1e Ala Met Ser Asn Ser Met Ile Asn Thr Val Cys Phe Val Thr Val Lys Asn Asn Thr Met Lys Tyr Phe Lys Lys Met Met Leu Leu His Trp Arg Pro Ser Gln Arg Gly Ser Lys Ser Ser Ala Asp Leu Asp Leu Arg Thr Asn Gly Val Pro Thr Thr Glu Glu Val Asp Cys Ile Arg Leu Lys <210> 13 <211> 695 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7482007CD1 <400> 13 Met Lys Met Lys Ser Gln A1a Thr Met Ile Cys Cys Leu Val Phe Phe Leu Ser Thr Glu Cys Ser His Tyr Arg Ser Lys Ile His Leu Lys Ala Gly Asp Lys Leu G1n Ser Pro Glu Gly Lys Pro Lys Thr Gly Arg Ile Gln Glu Lys Cys Glu Gly Pro Cys Ile Ser Ser Ser Asn Cys Ser Gln Pro Cys Ala Lys Asp Phe His Gly Glu Ile Gly Phe Thr Cys Asn .Gln Lys Lys Trp Gln Lys Ser Ala Glu Thr Cys Thr Ser Leu Ser Val Glu Lys Leu Phe Lys Asp Ser Thr Gly Ala Ser Arg Leu Ser Val Ala A1a Pro Ser Ile Pro Leu His Ile Leu Asp Phe Arg Ala Pro Glu Thr Ile G1u Ser Val A1a Gln Gly Ile Arg Lys Asn Cys Pro Phe Asp Tyr Ala Cys Ile Thr Asp Met Val Lys Ser Ser Glu Thr Thr Ser Gly Asn Ile Ala Phe Ile Val Glu Leu Leu Lys Asn Ile Ser Thr Asp Leu Ser Asp Asn Va1 Thr Arg Glu Lys Met Lys Ser Tyr Ser Glu Val Ala Asn His Ile Leu Asp Thr Ala Ala Ile Ser Asn Trp Ala Phe Ile Pro Asn Lys Asn Ala Ser Ser Asp Leu Leu Gln Ser Val Asn Leu Phe Ala Arg Gln Leu His Ile His Asn Asn Ser G1u Asn Ile Val Asn Glu Leu Phe Ile Gln Thr Lys G1y Phe His I1e Asn His Asn Thr Ser Glu Lys Ser Leu Asn Phe Ser Met Ser Met Asn Asn Thr Thr Glu Asp Ile Leu Gly Met Val Gln Ile Pro Arg Gln Glu Leu Arg Lys Leu Trp Pro Asn Ala Ser Gln Ala Ile Ser Ile Ala Phe Pro Thr Leu Gly Ala Ile Leu Arg Glu Ala His Leu Gln Asn Val Ser Leu Pro Arg Gln Val Asn Gly Leu Val Leu Ser Val Val Leu Pro Glu Arg Leu Gln Glu Ile Ile Leu Thr Phe Glu Lys Ile Asn Lys Thr Arg Asn Ala Arg Ala Gln Cys Val Gly Trp His Ser Lys Lys Arg Arg Trp Asp Glu Lys Ala Cys Gln Met Met Leu Asp Ile Arg Asn Glu Val Lys Cys Arg Cys Asn Tyr Thr Ser Val Val Met Ser Phe Ser Ile Leu Met Ser Ser Lys Ser Met Thr Asp Lys Val Leu Asp Tyr Ile Thr Cys Ile Gly Leu Ser Val Ser Ile Leu Ser Leu Val Leu Cys Leu Ile Ile Glu Ala Thr Val Trp Ser Arg Val Val Val Thr G1u Ile Ser Tyr Met Arg His Val Cys Ile Val Asn Ile Ala Val Ser Leu Leu Thr Ala Asn Val Trp Phe Ile Ile Gly Ser His Phe Asn Ile Lys Ala Gln Asp Tyr Asn Met Cys Val Ala Val Thr Phe Phe Ser His Phe Phe Tyr Leu Ser Leu Phe Phe Trp Ile Leu Phe Lys Ala Leu Leu Ile I1e Tyr Gly Ile Leu Val Ile Phe Arg Arg Met Met Lys Ser Arg Met Met Val Ile Gly Phe Ala Ile Gly Tyr Gly Cys Pro Leu Ile Ile Ala Val Thr Thr Val Ala Ile Thr Gly Pro Val Lys Gly Tyr Met Arg Pro Glu Ala Cys Trp Leu Asn Trp Asp Asn Thr Lys Ala Leu Leu A1a Phe Ala Ile Pro Ala Phe Val Ile Val Ala Val Asn Leu Ile Val Val Leu Val Val Ala Val Asn Thr Gln Arg Pro Ser I1e Gly Ser Ser Lys Ser Gln Asp Val Val Ile Ile Met Arg Ile Ser Lys Asn Val Ala Ile Leu Thr Pro Leu Leu Gly Leu Thr Trp G1y Phe Gly Ile Ala Thr Leu Ile Glu Gly Thr Ser Leu Thr Phe His Ile Ile Phe Ala Leu Leu Asn Ala Phe Gln Gly Phe Phe Ile Leu Leu Phe Gly Thr Ile Met Asp His Lys Ile Arg Asp Ala Leu Arg Met Arg Met Ser Ser Leu Lys Gly Lys Ser Arg Ala Ala Glu Asn Ala Ser Leu Gly Pro Thr Asn Gly Ser Lys Leu Met Asn Arg Gln Gly <210> 14 <211> 633 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 6769042CD1 <400> 14 Met Tyr Phe Thr Ala Ala Ile Gly Lys His Ala Leu Leu Ser Ser Thr Leu Pro Ser Leu Phe Met Thr Ser Thr Ala Ser Pro Val Met Pro Thr Asp Ala Tyr His Pro Ile Ile Thr Asn Leu Thr Glu Glu Arg Lys Thr Phe Gln Ser Pro Gly Val Ile Leu Ser Tyr Leu Gln Asn Val Ser Leu Ser Leu Pro Ser Lys Ser Leu Ser Glu Gln Thr Ala Leu Asn Leu Thr Lys Thr Phe Leu Lys Ala Val Gly Glu Ile Leu Leu Leu Pro Gly Trp Ile Ala Leu Ser Glu Asp Ser Ala Val Val Leu Ser Leu Ile Asp Thr Ile Asp Thr Val Met Gly His Val Ser Ser Asn Leu His Gly Ser Thr Pro Gln Val Thr Val G1u Gly Ser Ser Ala Met A1a Glu Phe Ser Val Ala Lys Ile Leu Pro Lys Thr Val Asn Ser Ser His Tyr Arg Phe Pro Ala His Gly Gln Ser Phe Ile Gln Ile Pro His Glu Ala Phe His Arg His Ala Trp Ser 170 175 7.80 Thr Val Val Gly Leu Leu Tyr His Ser Met His Tyr Tyr Leu Asn Asn Ile Trp Pro Ala His Thr Lys Ile Ala Glu Ala Met His His Gln Asp Cys Leu Leu Phe Ala Thr Ser His Leu Ile Ser Leu Glu Val Ser Pro Pro Pro Thr Leu Ser Gln Asn Leu Ser Gly Ser Pro Leu Ile Thr Val His Leu Lys His Arg Leu Thr Arg Lys Gln His Ser Glu Ala Thr Asn Ser Ser Asn Arg Val Phe Val Tyr Cys Ala Phe Leu Asp Phe Ser Ser Gly Glu Gly Val Trp Ser Asn His Gly Cys Ala Leu Thr Arg Gly Asn Leu Thr Tyr Ser Val Cys Arg Cys Thr His Leu Thr Asn Phe Ala Ile Leu Met Gln Val Val Pro Leu Glu Leu Ala Arg G1y His G1n Val Ala Leu Ser Ser Ile Ser Tyr Val Gly Cys Ser Leu Ser Val Leu Cys Leu Val Ala Thr Leu Val Thr Phe Ala Val Leu Ser Ser Val Ser Thr Ile Arg Asn Gln Arg Tyr His Ile His Ala Asn Leu Ser Phe Ala Val Leu Val Ala Gln Va1 Leu Leu Leu Ile Ser Phe Arg Leu Glu Pro Gly Thr Thr Pro Cys Gln Val Met Ala Val Leu Leu His Tyr Phe Phe Leu Ser Ala Phe Ala Trp Met Leu Val Glu Gly Leu His Leu Tyr Ser Met Val Ile Lys Val Phe Gly Ser Glu Asp Ser Lys His Arg Tyr Tyr Tyr Gly Met Gly Trp Gly Phe Pro Leu Leu Ile Cys Ile Ile Ser Leu Ser Phe Ala Met Asp Ser Tyr Gly Thr Ser Asn Asn Cys Trp Leu Ser Leu Ala Ser Gly Ala Ile Trp Ala Phe Val Ala Pro Ala Leu Phe Val Ile Val Val Asn Ile Gly Ile Leu Ile Ala Val Thr Arg Val Ile Ser Gln Ile Ser A1a Asp Asn Tyr Lys Ile His G1y Asp Pro Ser Ala Phe Lys Leu Thr Ala Lys Ala Val Ala Val Leu Leu Pro Ile Leu Gly Thr Ser Trp Val Phe Gly Val Leu Ala Val Asn Gly Cys Ala Val Val Phe Gln Tyr Met Phe Ala Thr Leu Asn Ser Leu Gln Gly Leu Phe Ile Phe Leu Phe His Cys Leu Leu Asn Ser Glu Val Arg Ala Ala Phe Lys His Lys Ile Lys Val Trp Ser Leu Thr Ser Ser Ser Ala Arg Thr Ser Asn Ala Lys Pro Phe His Ser Asp Leu Met Asn Gly Thr Arg Pro Gly Met Ala Ser Thr Lys Leu Ser Pro Trp Asp Lys Ser Ser His Ser Ala His Arg Val Asp Leu Ser Ala Val <210> 15 <211> 370 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7476053CD1 <400> 15 Met Glu Ala Ala Ser Leu Ser Val Ala Thr Ala Gly Val Ala Leu 1 5 l0 15 Ala Leu Gly Pro Glu Thr Ser Ser Gly Thr Pro Ser Pro Arg Gly Ile Leu Gly Ser Thr Pro Ser Gly Ala Val Leu Pro Gly Arg Gly Pro Pro Phe Ser Val Phe Thr Val Leu Val Val Thr Leu Leu Val Leu Leu Ile Ala Ala Thr Phe Leu Trp Asn Leu Leu Val Pro Val Thr Ile Pro Arg Val Arg Ala Phe His Arg Val Pro His Asn Leu Val Ala Ser Thr Ala Val Ser Asp Glu Leu Val Ala Ala Leu Ala Met Pro Pro Ser Leu Ala Ser G1u Leu Ser Thr Gly Arg Arg Arg Leu Leu Gly Arg Ser Leu Cys His Val Trp Ile Ser Phe Asp Ala Leu Cys Cys Pro Ala Gly Leu Gly Asn Val Ala Ala Ile Ala Leu Gly Arg Asp Gly A1a Ile Thr Arg His Leu Gln His Thr Leu Arg Thr Arg Ser Arg Ala Ser Leu Leu Met Ile Ala Leu Ala Arg Val Pro Ser Ala Leu Ile Ala Leu Ala Pro Leu Leu Phe Gly Arg Gly Glu Va1 Cys Asp Ala Arg Leu Gln Arg Cys Gln Val Ser Arg Glu Pro Ser Tyr Ala Ala Phe Ser Thr Arg Gly Ala Phe His Leu Pro 20!37 Leu Gly Val Val Pro Phe Val Tyr Arg Lys Ile Tyr Glu Ala Ala Lys Phe Arg Phe Gly Arg Arg Arg Arg Ala Val Leu Pro Leu Pro Ala Thr Met G1n Val Lys Glu Ala Pro Asp Glu Ala Glu Val Val Phe Thr Ala His Cys Lys Ala Thr Val Ser Phe Gln Val Ser G1y Asp Ser Trp Arg Glu Gln Lys Glu Arg Arg Ala Ala Met Met Val Gly Ile Leu Ile Gly Val Phe Val Leu Cys Trp Ile Pro Phe Phe Leu Thr Glu Leu Ile Ser Pro Leu Cys Ala Cys Ser Leu Pro Pro Ile Trp Lys Ser Ile Phe Leu Trp Leu Gly Tyr Ser Asn Ser Phe Phe Asn Pro Leu Ile Tyr Thr Ala Phe Asn Lys Asn Tyr Asn Asn Ala Phe Lys Ser Leu Phe Thr Lys Gln Arg <210> 16 <211> 324 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7480410CD1 <400> 26 Met Gly Met Glu Gly Leu Leu Gln Asn Ser Thr Asn Phe Val Leu Thr Gly Leu Ile Thr His Pro Ala Phe Pro Gly Leu Leu Phe Ala Ile Val Phe Ser Ile Phe Val Val Ala Ile Thr Ala Asn Leu Val Met Ile Leu Leu Ile His Met Asp Ser Arg Leu His Thr Pro Met Tyr Phe Leu Leu Ser Gln Leu Ser Ile Met Asp Thr Ile Tyr Ile Cys Ile Thr Val Pro Lys Met Leu Gln Asp Leu Leu Ser Lys Asp Lys Thr Ile Ser Phe Leu Gly Cys A1a Va1 Gln Ile Phe Leu Tyr Leu Thr Leu Tle Gly Gly Glu Phe Phe Leu Leu G1y Leu Met Ala Tyr Asp Arg Tyr Val Ala Val Cys Asn Pro Leu Arg Tyr Pro Leu Leu Met Asn Arg Arg Val Cys Leu Phe Met Val Val Gly Ser Trp Val Gly Gly Ser Leu Asp Gly Phe Met Leu Thr Pro Val Thr Met Ser Phe Pro Phe Cys Arg Ser Arg Glu Ile Asn His Phe Phe Cys Glu Ile Pro Ala Val Leu Lys Leu Ser Cys Thr Asp Thr Ser Leu Tyr Glu Thr Leu Met Tyr Ala Cys Cys Val Leu Met Leu Leu Ile Pro Leu Ser Val Ile Ser Val Ser Tyr Thr His Ile Leu Leu Thr Val His Arg Met Asn Ser Ala Glu Gly Arg Arg Lys Ala Phe Ala Thr Cys Ser Ser His Ile Met Val Val Ser Val Phe Tyr Gly Ala Ala Phe Tyr Thr Asn Val Leu Pro His Ser Tyr His Thr Pro Glu Lys Asp Lys Val Val Ser Ala Phe Tyr Thr Ile Leu Thr Pro Met Leu Asn Pro Leu Ile Tyr Ser Leu Arg Asn Lys Asp Val Ala Ala Ala Leu Arg Lys Val Leu Gly Arg Cys Gly Ser Ser G1n Ser Ile Arg Val Ala Thr Val Ile Arg Lys Gly <210> 17 <211> 315 <212> PRT
<213> Homo Sapiens <220>
<22l> misc_feature <223> Incyte ID No: 55036418CD1 <400> 17 Met Glu Thr Trp Val Asn Gln Ser Tyr Thr Asp Gly Phe Phe Leu Leu Gly I1e Phe Ser His Ser Thr Ala Asp Leu Val Leu Phe Ser Val Va1 Met Ala Val Phe Thr Val Ala Leu Cys Gly Asn Val Leu Leu Ile Phe Leu Ile Tyr Met Asp Pro His Leu His Thr Pro Met Tyr Phe Phe Leu Ser Gln Leu Ser Leu Met Asp Leu Met Leu Val Cys Thr Asn Val Pro Lys Met Ala Ala Asn Phe Leu Ser Gly Arg Lys Ser Ile Ser Phe Val Gly Cys Gly Ile Gln Ile Gly Leu Phe Val Cys Leu Val Gly Ser Glu G1y Leu Leu Leu Gly Leu Met Ala Tyr Asp Arg Tyr Val Ala Ile Ser His Pro Leu His Tyr Pro Ile Leu Met Asn Gln Arg Val Cys Leu Gln Ile Thr Gly Ser Ser Trp 140 l45 150 Ala Phe Gly Ile Ile Asp Gly Leu Ile Gln Met Val Val Val Met Asn Phe Pro Tyr Cys Gly Leu Arg Lys Val Asn His Phe Phe Cys Glu Met Leu Ser Leu Leu Lys Leu Ala Cys Val Asp Thr Ser Leu Phe Glu Lys Val Ile Phe Ala Cys Cys Val Phe Met Leu Leu Phe Pro Phe Ser Ile Ile Val Ala Ser Tyr A1a His Ile Leu Gly Thr Val Leu Gln Met His Ser Ala Gln Ala Trp Lys Lys Ala Leu Ala Thr Cys Ser Ser His Leu Thr Ala Val Thr Leu Phe Tyr Gly Ala Ala Met Phe I1e Tyr Leu Arg Pro Arg His Tyr Arg Ala Pro Ser His Asp Lys Val Ala Ser Ile Phe Tyr Thr Val Leu Thr Pro Met Leu Asn Pro Leu Ile Tyr Ser Leu Arg Asn Arg Glu Val Met Gly Ala Leu Arg Lys Gly Leu Asp Arg Cys Arg Ile Gly Ser Gln His <210> 18 <211> 324 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7481701CD1 <400> 18 Met Glu Ser Pro Asn Gln Thr Thr Ile Gln Glu Phe Ile Phe Ser Ala Phe Pro Tyr Ser Trp Val Lys Ser Val Val Cys Phe Val Pro Leu Leu Phe Ile Tyr Ala Phe Ile Val Val Gly Asn Leu Val Ile Ile Thr Val Val Gln Leu Asn Thr His Leu His Thr Pro Met Tyr Thr Phe Ile Ser Ala Leu Ser Phe Leu Glu Ile Trp Tyr Thr Thr Ala Thr Ile Pro Lys Met Leu Ser Ser Leu Leu Ser Glu Arg Ser I1e Ser Phe Asn Gly Cys Leu Leu Gln Met Tyr Phe Phe His Ser Thr G1y Ile Cys Glu Val Cys Leu Leu Thr Val Met Ala Phe Asp His Tyr Leu Ala Ile Cys Ser Pro Leu His Tyr Pro Ser Ile Met Thr Pro Lys Leu Cys Thr Gln Leu Thr Leu Ser Cys Cys Val Cys Gly Phe Ile Thr Pro Val Pro Glu Ile Ala Trp Ile Ser Thr Leu Pro Phe Cys Gly Ser Asn His Leu Glu His Ile Phe Cys Asp Phe Leu Pro Val Leu Arg Leu Ala Cys Thr Asp Thr Arg Ala Ile Val Met Ile Gln Val Val Asp Val Ile His Ala Val Glu Ile Ile Thr Ala Val Met Leu Ile Phe Met Ser Tyr Asp Gly Ile Val Ala Val Ile Leu Arg Ile His Ser Ala Gly G1y Arg Arg Thr Ala Phe Ser Thr Cys Val Ser His Phe Ile Val Phe Ser Leu Phe Phe Gly Ser Val Thr Leu Met Tyr Leu Arg Phe Ser Ala Thr Tyr Ser Leu Phe Trp Asp Ile Ala Ile Ala Leu Ala Phe Ala Val Leu Ser Pro Phe Phe Asn Pro Ile Ile Tyr Ser Leu Arg Asn Lys Glu Ile Lys Glu Ala Ile Lys Lys His Ile Gly Gln Ala Lys Ile Phe Phe Ser Val Arg Pro Gly Thr Ser Ser Lys Ile Phe <210> 19 <211> 312 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7481774CD1 <400> 19 Met Glu Pro Trp Gln His Pro Thr His Phe Ile Leu Leu Gly Phe Ser Asp Arg Pro His Leu Glu Arg IIe Leu Phe Val Val Ile Leu Ile Ala Tyr Leu Leu Thr Leu Val Gly Asn Thr Thr Ile Ile Leu Val Ser Arg Leu Asp Pro His Leu His Thr Pro Met Tyr Phe Phe Leu Ala His Leu Ser Phe Leu Asp Leu Ser Phe Thr Thr Ser Ser Ile Pro Gln Leu Leu Tyr Asn Leu Asn Gly Cys Asp Lys Thr Ile Ser Tyr Met Gly Cys Ala I1e Gln Leu Phe Leu Phe Leu Gly Leu Gly Gly Val Glu Cys Leu Leu Leu Ala Val Met Ala Tyr Asp Arg Cys Val Ala Ile Cys Lys Pro Leu His Tyr Met Val Ile Met Asn Pro Arg Leu Cys Arg Gly Leu Va1 Ser Val Thr Trp Gly Cys Gly Val Ala Asn Ser Leu Ala Met Ser Pro Val Thr Leu Arg Leu Pro Arg Cys Gly His His Glu Val Asp His Phe Leu Cys Glu Met Pro Ala Leu Ile Arg Met Ala Cys Ile Ser Thr Val Ala Ile Asp Gly Thr Val Phe Val Leu Ala Val Gly Val Val Leu Ser Pro Leu Val Phe Ile Leu Leu Ser Tyr Ser Tyr Ile Val Arg Ala Val Leu Gln Ile Arg Ser Ala Ser Gly Arg Gln Lys A1a Phe Gly Thr Cys Gly Ser His Leu Thr Va1 Val Ser Leu Phe Tyr Gly Asn Ile Ile Tyr Met Tyr Met Gln Pro Gly Ala Ser Ser Ser Gln Asp Gln Gly Lys Phe Leu Thr Leu Phe Tyr Asn Ile Val Thr Pro Leu Leu Asn Pro Leu Ile Tyr Thr Leu Arg Asn Arg Glu Val Lys Gly Ala Leu Gly Arg Leu Leu Leu Gly Lys Arg Glu Leu Gly Lys Glu <210> 20 <211> 1076 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474806CB1 <400> 20 caaagttgaa tgccgggttg gggcagaggc tgatgccgtg ctgaggtcat gatgttatgc 60 tgtccatttt gcttccttcc aggggaagca gaagcgggag ccgtcgtgga gctctgctcc 120 tggagggagc ctcccgggac atggagaagg tggacatgaa tacatcacag gaacaaggtc 180 tctgccagtt ctcagagaag tacaagcaag tctacctctc cctggcctac agtatcatct 240 ttatcctagg gctgccacta aatggcactg tcttgtggca ctcctggggc caaaccaagc 300 gctggagctg tgccaccacc tatctggtga acctgatggt ggccgacctg ctttatgtgc 360 tattgccctt cctcatcatc acctactcac tagatgacag gtggcccttc ggggagctgc 420 tctgcaagct ggtgcacttc ctgttctata tcaaccttta cggcagcatc ctgctgctga 480 cctgcatctc tgtgcaccag ttcctaggtg tgtggcaccc actgtgttcg ctgccctacc 540 ggacccgcag gcatgcctgg ctgggcacca gcaccacctg ggccctggtg gtcctccagc 600 tgctgcccac actggccttc tcccacacgg actacatcaa tggccagatg atctggtatg 660 acatgaccag ccaagagaat tttgatcggc tttttgccta cggcatagtt ctgacattgt 720 ctggctttct ttccccctcc ttggtcattt tggtgtgcta ttcactgatg gtcaggagcc 780 tgatcaagcc agaggagaac ctcatgagga caggcaacac agcccgagcc aggtccatcc 840 ggaccatcct actggtgtgt ggcctcttca ccctctgttt tgtgcccttc catatcactc 300 gCtCCttCta CCtCaCCatC tgCtttCtgC tttCtCagga ctgccagctc ttgatggcac 960 ccagtgtggc ctacaagata tggaggcctc tggtgagtgt gagcagctgc ctcaacccag 1020 tcctgtactt tctttcaagg ggggcaaaaa tagagtcagg ctcctccaga aactga 1076 <210> 21 <211> 1102 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474840CB1 <400> 21 ggaggctgag gcaggagaat ggcatgaccc caggaggcag agcttgcagt gagatgagat 60 catgccactg tgctccagcc tgggcaacag agcgagactc tgtctcaaaa aaaaaaaaaa 120 acaaaaaaaa aaaccttttt tcccaagcta ccattggact tttagccaac acctttttcc 180 ttttcttcaa catcttcata ttccttcagg atcagaaatc gaagccccat gacctcatca 240 gctgtaattc ggccttcatt catgtagtga tgttcctcac tgtggtggat gcttggcctc 300 cagatatgcc tgaatcactg cacttaggga atgagttcaa atttaagtcc ttgtcctaca 360 taaacagagt gaggatgggc ctatgtatct gtaacatctg tctcctgagt atacaccagg 420 ccaacaccat cagccccaac aacttctgtt tggcaaggct taaacagaaa ttcacaaata 480 acattatcat gtcatctttt ttttcttttt ttttttggtc catcaatttg tctttcagtt 540 ataacatagt attctttact gtggcttctt ctaatgtgac ccagaacagt ctacctaagg 600 gcagcaatac tgttcacttt ctccccatga agtccttcat gagaaaagta ttttttactc 660 tgacattatc cagggatgtc ttcattatag gaattacact gcattcaatt gcacacatgg 720 tgatccttgt gtccaggcat gagacgcaat ctcagcacct tcacagcatc agcatctctc 780 cacaagcctt cccagagaaa agggctgctc agaccatccc gctgttagtg agctactgtc 840 tggtcatgtg ctgggtggac ctcatcatct catcttcttc aaccctgctg tggacgtgta 900 acccagtctt cctgagtatg cagaaccttg tgggcgatgt ctatgccact gttgttctac 960 tggaacaaat cagctctgat aaaaatatag ttgacattct ccaaaatatg caaagtgcta 1020 taaagcttta acaagttggc gatggaaaac atttctaaaa aatagtcttc tcctatagtt 1080 caattgttca agtagccctg ga 1102 <210> 22 <211> 2529 <212> DNA ' <213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7475092CB1 <400> 22 ggctccggtg tttcccgccg ttcatgcagc gaaaagagaa agcaaaatgc cctcaggagg 60 ctccagccgg ccgcgagccc tccacgcccg gcgggggcag cggaggcgga ggcgccgtcg 120 ctgcagcctc aggcgccgcg gtgccgggct ccgtgcagtt ggcgctgagc gtcctgcacg 180 ccctgctcta cgccgcgctg ttcgcctttg cctacctgca gctgtggcgg ctgctcctgt 240 accgcgagcg gcggctgagt taccagagcc tctgcctctt cctctgtctc ctgtgggcag 300 cgctcaggac caccctcttc tccgccgcct tctcgctcag cggctccctg cccttgctcc 360 ggccgcccgc tcacctgcac ttcttccccc actggctgct ctactgcttc ccctcctgtc 420 tccagttctc cacgctctgt ctcctcaacc tctacctggc ggaggttata tgtaaagtca 480 gatgtgccac tgaacttgac agacacaaaa ttctactgca tttgggcttt ataatggcaa 540 gcctgctctt tttagtggtg aacttgactt gcgcaatgct agttcatgga gatgtcccag 600 aaaatcagtt gaagtggact gtgtttgttc gagcattaat taatgatagc ctgtttattc 660 tttgtgccat ctctttagtg tgttacatat gcaaaattac aaaaatgtca tcagctaatg 720 tctacctcga atcaaagggt atgtctctgt gccagactgt cgtcgtgggc tctgtagtca 780 ttcttctgta ctcttccaga gcttgttata atttggtggt ggtcaccata tctcaggata 840 cattagaaag tccatttaat tatggctggg ataatctttc agataaggct catgtagaag 900 acataagtgg agaagagtat atagtatttg gaatggtcct ctttctgtgg gaacatgtgc 960 cagcatggtc ggtggtactg tttttccggg cacagagatt aaaccagaat ttggcacctg 1020 ctggcatgat aaatagtcac agttatagtt ccagagctta ctttttcgac aatccaagac 1080 gatatgatag tgatgatgac ctgccaagac tgggaagttc aagagaagga agtttaccaa 1140 attcgcaaag tttgggctgg tatggcacca tgactgggtg tggcagcagc agttacacag 1200 tcactcccca cctgaatgga cctatgacag atactgctcc tttgctcttt acttgtagta 1260 atttagattt gaacaatcat catagcttat atgtgacacc acaaaactga cagcatcacc 1320 aagtcatgat tcttgagttg tttttcataa atgtgtatat tcaatgtgtt taaattccat 1380 ctacataaac attccattat ctgttgcaac tgaaaacaaa atctggaagt gtggctgtgt 1440 ttggtaaata acacagctat tatttttgac ctcttcatag taaaatgaag taaaatggaa 1500 agtttggagt aggagaaaag agagattaga tcttaaggca cttgatggcc tccaaaaatc 1560 ctgactttgg aacatcaaat gcatatgtgc acttttatct ttgttctgag tcactgcagt 1620 ccccaaagtc atatgccaat gttcacactg aaatactgta ttgtacacca aactggaagg 1680 caattttcct atgaaaatca aagccggtat attcattggt atgctctata cagatatctt 1740 aataaaaatt ttatagtgtg aacagtgcac agagttaagg cataaaaatg tatcattctt 1800 tataaaaatc tactgaaaat gtgtaatcat tgaagacagt tcttttaagc atgattttaa 2860 aatagcaact gaaattcaat cattttaaac aaatgatggt agtaatccat tagttatggc 1920 cagcagtgtt ctttggagag ccacaataat ttcaagagga aaatatacca gtgaaaattg 1980 tgtggctatt ttgagtagaa ttggtcagtt gattattttg tgtaattgag atatatgtag 2040 tagtttaagc atgattcttg aagaaagcaa tagtgacttt tgcataggga gattttggta 2100 gaaacttctt gggactaaac aagtttagag atgcatttaa gaattattca caaaatgtgt 2160 aattctaaat taaaacataa atatattttc aaaagcattt gatttctctg aagcatgata 2220 tagctggtct tacctagtga atcaggattg tcctcaggta aatgaaatca tgatacatta 2280 ttgcagtgaa ctcaagtgca atactttgta agacatataa ttcctatgat tttcacattt 2340 ttatatctta tatatgggaa aagccaaatt aaattgaatt cagattaatt ccagcattag 2400 actaaatgag caaacttaag taaatgtaca aactaggtaa gtataaaacc acaggttaac 2460 aatattggag tacttttaga attacattaa aactgtctta aatgtcctat cccaaatcta 2520 aaaaaaaaa 2529 <210> 23 <211> 1847 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7341260CB1 <400> 23 gggggaggca ggcctcccag ttgctgcagt ttggaatatg tcaggtccca ccctcccaga 60 ggcggggcca gggctgagtc ctgccagcct catttctcta tccctctgag aacccagacg 120 ggcagagcct gggtaggaga gcctggcccc gctgtcccca ctgggtggag acaccatgca 180 cttggtccac ttgtgctctt cagccaggac accagacatg gtccaaaccg ctgcagggct 240 ggctgcagca actccctgac actcaggaag gcccaggctg ggcaggcaat acctgctccc 300 aacagccatg catgccggct gccgctccag gactcccctg tccccaggac caagatgacg 360 cccaacagca ctggcgaggt gcccagcccc attcccaagg gggctttggg gctctccctg 420 gccctggcaa gcctcatcat caccgcgaac ctgctcctag ccctgggcat cgcctgggac 480 cgccgcctgc gcagcccacc tgctggctgc ttcttcctga gcctactgct ggctgggctg 540 ctcacgggtc tggcattgcc cacattgcca gggctgtgga accagagtcg ccggggttac 600 tggtcctgcc tCCtCgtCta CttggCtCCC aaCttCtCCt tCCtCtCCCt gCttgCCaaC 660 ctcttgctgg tgcacgggga gcgctacatg gcagtcctga ggccactcca gccccctggg 720 agcattcggc tggccctgct cctcacctgg gctggtcccc tgCtCtttgC CagtCtgCCC 780 gctctggggt ggaaccactg gacccctggt gccaactgca gctcccaggc tatcttccca 840 gccccctacc tgtacctcga agtctatggg ctcctgctgc ccgccgtggg tgctgctgcc 900 ttcctctctg tccgcgtgct ggccactgcc caccgccagc tgcaggacat ctgccggctg 960 gagcgggcag tgtgccgcga tgagccctcc gccctggccc gggcccttac ctggaggcag 1020 gcaagggcac aggctggagc catgctgctc ttcgggctgt gctgggggcc ctacgtggcc 1080 acactgctcc tctcagtcct ggcctatgag cagcgcccgc cactggggcc tgggacactg 1140 ttgtccctcc tctccctagg aagtgccagt gcagcggcag tgcccgtagc catggggctg 1200 ggcgatcagc gctacacagc cccctggagg gcagccgccc aaaggtgcct gcaggggctg 1260 tggggaagag cctcccggga cagtcccggc cccagcattg cctaccaccc aagcagccaa 1320 agcagtgtcg acctggactt gaactaaagg aagggcctct gctgactcct accagagcat 1380 ccgtccagct cagccatcca gcctgtctct actgggcccc acttctctgg atcagagacc 1440 ctgcctctgt ttgaccccgc actgactgaa taaagctcct ctggccgtta aaaaaaaaaa 1500 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaac aaacaaacag 1560 aaaaaaaaaa aaaagaacac acaaagaaca cagaacaaac caagcagcac accacacaca 1620 aaaacaatgc acacacagaa caagacacaa tcagagacag agagcacaca gcacggaccc 1680 cagccacgcc cccagcactg accaccacga cccgacacag aaacgaacac tgaagactca 1740 acgcacaaaa cgacaaccag accacaagcc aaccgcctca cgccccagca acgaacacac 1800 atacaaaacc aaaccgagac aacccacata cagccaaaca aaccaca 1847 <210> 24 <211> 2031 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7473911CB1 <400> 24 atgaataaaa acaacaaacc ttccagtttc atagccataa gaaatgctgc tttctctgaa 60 gtcggcattg ggatctctgc caatgccatg ctccttctct tccacatcct cacgtgcctt 120 ctcaagcaca ggaccaagcc cgctgacctg atcgtttgtc atgtggctct aatccatatc 180 atattgctgc tacccacaga gttcatagct acagatattt ttgggtctca ggattcagag 240 gatgacatca aacataagtc agttatctac aggcgtaaca ggcagtccca gcattttcac 300 agcaccaacc tttctccaaa agcaccccca gaaaaaatgg ccacgcagac cattcttctg 360 ctcgtgagtt gctttgtgat tgtgtatgtt ttggactgtg ttgtcgcctc ctgctcagga 420 ctggtgtgga acagtgatcc agtccgtcat cgagtccaga tgctggtgga caatggctat 480 gccaccatca gtccttcagt gctacccagg ctgactgccc caaacgagtg gagagccagt 540 gtgtacctga atgacagctt gaacaaatgc agcaacggac ggctgctctg tgtagacagg 600 gggcttgatg aggggccccg gtccgtccca aagtgctctg agtcagagac cgacgaggat 660 tacatcgtcc tcagggctcc gctgagggag gacgaaccca aggacggggg cagtgtgggg 720 aatgcagccc tggtgtctcc cgaggcctct gcagaagagg aagaggagcg tgaggaggga 780 ggcgaggcat gtggcctgga gaggacagga gctggtgggg agcaggttga ccttggtgaa 840 ctacctgacc atgaggagaa aagcaaccag aaagtggcag ctgccaccct ggaggaccgc 900 acacaggatg agcctgctga ggagagctgc cagatcgtcc ttttccagaa caactgcatg 960 gacaactttg tgacttccct cacaggaagc ccctacgagt tcttcccaac caagagcacc 1020 tctttttgca gggagagctg ttctcctttt tctgagtcag tgaaaagctt agaatcagag 1080 caggcaccaa agttggggct gtgtgcggag gaggaccccg tggttggggc tttgtgtggc 1140 cagcatggac ccttgcaaga tggagtggcg gagggtccca cagcccctga tgtggtggtc 1200 ctgccgaagg aggaggagaa ggaggaggtc attgtggatg acatgctggc caacccctat 1260 gtgatgggag atgaggggga ggaggaggag gaggagttcg tggatgacac actggccaac 1320 ccctatgtga tgggagtggg cctgccagga agaggagggg aggaggagga ggaggaggag 1380 gtcgtggatg acacgctggc cagcctctat aagatgggag aagaacatcg acacaagggc 1440 ctggccccac tctgggaagg tggccagaaa ccgtcccaga aactgccccc aaagaaacca 1500 gatctgaggc aggttcctca gcccctggca tcggaggtgc cgcagaggag gcaggaaaga 1560 gctgttgtca ctgaagggag gcccctggaa gccagcaggg ccttgccagc aaagcccagg 1620 gccttcactt tataccctcg gtcgttctcc gtggaaggcc aagagattcc tgtttccatc 1680 tctgtgtact gggagccaga agggtcgggg ttagatgacc acaggataaa gaggaaagag 1740 gaacatctct ctgtcgtgtc tgggagtttc tcccagagaa accaccttcc atccagcggc 1800 acctccacgc cttcttccat ggtcgacatc ccacctcctt tcgacctggc ctgcatcacc 1860 aagaagccca tcacaaagag ctctccctct ctcctgatcg acagcgactc cccggacaag 1920 tacaagaaga agaagtcatc ctttaagcgg ttcctggcgc tgatgtttaa caagatggag 1980 aggccaggca cgatggctca tgcctgtcat cccagcactt tgggaagctg a 2031 <210> 25 <211> 1130 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474767CB1 <400> 25 ggggcgcgct catggagcac acgcacgccc acctcgcagc caacagctcg ctgtcttggt 60 ggtcccccgg ctcggcctgc ggcttgggtt tcgtgcccgt ggtctactac agcctcttgc 120 tgtgcctcgg tttaccagca aatatcttga cagtgatcat cctctcccag ctggtggcaa 180 gaagacagaa gtcctcctac aactatctct tggcactcgc tgctgccgac atcttggtcc 240 tctttttcat agtgtttgtg gacttcctgt tggaagattt catcttgaac atgcagatgc 300 ctcaggtccc cgacaagatc atagaagtgc tggaattctc atccatccac acctccatat 360 ggattactgt accgttaacc attgacaggt atatcgctgt ctgccacccg ctcaagtacc 420 acacggtctc atacccagcc cgcacccgga aagtcattgt aagtgtttac atcacctgct 480 tcctgaccag catcccctat tactggtggc ccaacatctg gactgaagac tacatcagca 540 cctctgtgca tcacgtcctc atctggatcc actgcttcac cgtctacctg gtgccctgct 600 ccatcttctt catcttgaac tcaatcattg tgtacaagct caggaggaag agcaattttc 660 gtctccgtgg ctactccacg gggaagacca ccgccatctt gttcaccatt acctccatct 720 ttgccacact ttgggccccc cgcatcatca tgattcttta ccacctctat ggggcgccca 780 tccagaaccg ctggctggta cacatcatgt ccgacattgc caacatgcta gcccttctga 840 acacagccat caacttcttc ctctactgct tcatcagcaa gcggttccgc accatggcag 900 ccgccacgct caaggctttc ttcaagtgcc agaagcaacc tgtacagttc tacaccaatc 960 ataacttttc cataacaagt agcccctgga tctcgccggc aaactcacac tgcatcaaga 1020 tgctggtgta ccagtatgac aaaaatggaa aacctataaa aagtcgtaat gacagcaaaa 1080 gctcctacca gtttgaagat gccattggag cttgtgtcat catcctgtga 1130 <210> 26 <211> 1202 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7475815CB1 <400> 26 caggttctgc aatacaattg gaaacaactc attgctcctg cctatgaaga agtagaacta 60 tggtaaaaat aagaaaatgc cttcccaata atagggagtt gtactatgga agtaatatgg 120 aggcccagca atgggaatca tagtccagcc atgatggcat agtcatggga gaagagagag 180 ggtggggatg gcttccagga gggtgtgaag agggggtcca gtactgaagg gggaaaagat 240 gcatcagaat taattaatgt attttgatga tggcaatagt gttggttgag attggtgaag 300 gtagtaatat ttgtgatatt tttgttgctt ttctccctag acattaacta tgtgcttatt 360 ttccccataa gatgaataaa aacaacaaac cttccagttt catagccata agaaatgctg 420 ctttctctga agtcggcatt gggatctctg ccaatgccat gctccttctc ttccacatcc 480 tcacgtgcct tctcaagcac aggaccaagc ccgctgacct gatcgtttgt catgtggctc 540 taatccatat catattgctg ctacccacag agttcatagc tacagatatt tttgggtctc 600 aggattcaga ggatgacatc aaacataagt cagttatcta caggtacagg ttgatgagag 660 gCCtCtCCat ttCCaCCa.CC tgCCtgCtga gtatcctccc ggccatcacc tgcagcccca 720 gaagctcctg tttggcagtg ttcaaagatt ctcacatcac caaccacgtt gctttctctt 780 ccgtcttcca catatccatt agtgacagct tcttagtctc cactcttccc atcaaaaatc 840 tggcctcaaa tagccttaca tttgtcactc aatcctgctc tgctgggatc ggctcacggc 900 ccccctccag tggatacatg gtgattctct tgtccaggcg taacaggcag tcccagcatt 960 ttcacagcac caacctttct ccaaaagcac ccccagaaaa aatggccacg cagaccattc 1020 ttctgctcgt gagttgcttt gtgattgtgt atgttttgga ctgtgttgtc gcctcctgct 1080 caggactggt gtggaacagt gatccagtcc gtcatcgagt ccagatgctg gtggacaatg 1140 gctatgccac catcagtcct tcagtgctag tcagtactga aaaatgaatg atcaaagtct 1200 ga 1202 <210> 27 <211> 2079 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 60263275CB1 <400> 27 tacggcacag tagagagctt ccagggctgg ctggcgtggg atacccgtac cacagaaatg 60 cagggaccat tgcttcttcc aggcctctgc tttctgctga gcctctttgg agctgtgact 120 cagaaaacca aaaacattaa tgaatgtaca ccaccctata gtgtatattg tggatttaac 180 gctgtgtgtt acaatgtcga aggaagtttc tactgtcaat gtgtcccagg atatagactg 240 cattctggga atgaacaatt cagtaattcc aatgagaaca cctgtcagga caccacctcc 300 tcaaagacaa cccagggcag gaaagagctg caaaagattg tggacaaatt tgagtcactt 360 ctcaccaatc agactttatg gagaacagaa gggagacaag aaatctcatc cacagctacc 420 actattctcc gggatgtgga atcgaaagtt ctagaaactg ccttgaaaga tccagaacaa 480 aaagtcctga aaatccaaaa cgatagtgta gctattgaaa ctcaagcgat tacagacaat 540 tgctctgaag aaagaaagac attcaacttg aacgtccaaa tgaactcaat ggacatccgt 600 tgcagtgaca tcatccaggg agacacacaa ggtcccagtg ccattgcctt tatctcatat 660 tcttctcttg gaaacatcat aaatgcaact ttttttgaag agatggataa gaaagatcaa 720 gtgtatctga actctcaggt tgtgagtgct gctattggac ccaaaaggaa cgtgtctctc 780 tccaagtctg tgacgctgac tttccagcac gtgaagatga cccccagtac caaaaaggtc 840 ttctgtgtct actggaagag cacagggcag ggcagccagt ggtccaggga tggctgcttc 900 ctgatacacg tgaacaagag tcacaccatg tgtaattgca gtcacctgtc cagcttcgct 960 gtcctgatgg ccctgaccag ccaggaggag gatcccgtgc tgactgtcat cacctacgtg 1020 gggctgagcg tctctctgct gtgcctcctc ctggcggccc tcacttttct cctgtgtaaa 1080 gccatccaga acaccagcac ctcactgcat ctgcagctct cgctctgcct cttcctggcc 1140 cacctcctct tcctcgtggg gattgatcga actgaaccca aggtgctgtg ctccatcatc 1200 gccggtgctt tgcactatct ctacctggcc gccttcacct ggatgctgct ggagggtgtg 1260 cacctcttcc tcactgcacg gaacctgaca gtggtcaact actcaagcat caatagactc 1320 atgaagtgga tcatgttccc agtcggctat ggcgttcccg ctgtgactgt ggccatttct 1380 gcagcctcct ggcctcacct ttatggaact gctgatcgat gctggctcca cctggaccag 1440 ggattcatgt ggagtttcct tggcccagtc tgtgccattt tctctgcgaa tttagtattg 1500 tttatcttgg tcttttggat tttgaaaaga aaactttcct ccctcaatag tgaagtgtca 1560 accatccaga acacaaggat gctggctttc aaagcaacag ctcagctctt catcctgggc 1620 tgcacatggt gtctgggctt gctacaggtg ggtccagctg cccaggtcat ggcctacctc 1680 ttcaccatca tcaacagcct ccaaggcttc ttcatcttct tggtctactg cctcctcagc 1740 cagcaggtcc agaaacaata tcaaaagtgg tttagagaga tcgtaaaatc aaaatctgag 1800 tctgagacat acacactttc cagcaagatg ggtcctgact caaaacccag tgagggggat 1860 gtttttccag gacaagtgaa gagaaaatat taaaactaga atattcaact ccatatggaa 1920 aatcatatcc atggatctct ttggcattat gaagaatgaa gctaaggaaa agggaattca 1980 ttaaacatat catccttgga gaggaagtaa tcaaccttta cttcccaaac tgtttgttct 2040 ccacaatagg tctcaacaaa tgtgtggtaa attgcatta 2079 <210> 28 <211> 5324 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 60203310CB1 <400> 28 ggcggcagca gcagcagcaa gaggaggaga agcagcccca gctatgactg ccgcatgtta 60 atagctgccg ctgggtccct cggctgctgc tggagacaga gcctgactcc gaagttgtgc 120 aactgtggac tgggagagac atttgaaccc tcttttcttt tcgctcccct tttgccccct 180 tggggtgtgt gaagcgagga acgtaaagga aggcgaacat ttggctctct ttttccttcc 240 cctttctccg tggctgtgta gcggaagaaa gggaagagag actttttgtt gttgtttcct 300 tgactggggt ctccaccctc ctgctgcttt ctctgcgctt cgattctcgt tatttgccgc 360 gtgtJggttgg gggtgtctgc acaggggccg gccggtcttt tgccccgggc tcaatggctg 420 gattgtggaa actgcacccg ccttcaggtt gttgagcaac tgatgggacg atctcaggga 480 ccggcgttta cgaaaggttt cagatttggg atattggtgt ttctgttttg gagaaattat 540 tctttttctt tttaatttga agaaaaatca tcagtcttgg aatacagaag agaaactaga 600 aatatacgta ttttgtttca catttgaaca gtcattcttg aggaatactc catacctgag 660 tagacagcca tgtggccatc gcagctacta attttcatga tgctcttagc tccaataatt 720 catgetttca gccgtgcccc aattccaatg gctgtggtcc gcagagagct atcctgtgag 780 agctatccta tagagcttcg ctgtccagga acagacgtca tcatgataga aagtgccaac 840 tatggcagga ctgatgacaa aatttgtgac tctgaccctg ctcagatgga gaatatccga 900 tgttatctgc cagatgccta taagattatg tctcaaagat gcaataacag aacccagtgt 960 gcagtggtgg caggtcctga tgtttttcca gacccgtgtc caggaaccta taaatacctt 1020 gaagtgcagt atgaatgtgt cccttacaaa gtggaacaaa aagtttttct ttgtcctgga 1080 ctactaaaag gagtatacca gagtgaacat ttgtttgagt ccgaccacca atctggggcg 1140 tggtgcaaag accctctgca ggcatctgac aagatttatt atatgccctg gactccctac 1200 agaactgata ccctgactga gtattcatcc aaggatgact tcattgctgg aagaccaact 1260 acaacctaca agctccctca tagggtggat ggcacaggat ttgtagtgta tgatggagct 1320 ttgttcttca acaaagagcg caccaggaac atagtaaagt ttgatttgcg gactaggata 1380 aagagtggag aggctatcat agcaaatgcc aattaccatg atacctcccc ttaccgatgg 1440 ggaggcaaat ctgacataga cctggcagta gatgagaatg ggctatgggt aatctatgca 150'0 acagaacaaa acaatggtaa aattgtcatt agtcaattga acccttacac cctacggatc 1560 gaaggaacat gggatactgc atatgataaa aggtcagctt ccaatgcctt tatgatttgt 1620 ggaattctgt atgtggtcaa atctgtatat gaggatgatg acaatgaggc tactggaaat 1680 aagattgact acatttacaa cactgaccaa agcaaggata gtttggtgga tgtacccttt 1740 cctaattcat accagtacat tgcagctgtg gattacaacc ccagggacaa cctactttat 1800 gtatggaata actatcacgt cgtgaaatat tctttggatt ttggacctct ggatagtaga 1860 tcagggcagg cacatcatgg acaagtttca tacatttctc cgccaattca ccttgactct 1920 gagctagaaa gaccctctgt taaagatatc tctaccacag gacctcttgg catgggaagc 1980 actaccacca gtaccaccct tcggaccaca actttgagcc caggaaggag taccaccccg 2040 tcagtgtcag gaagaagaaa ccggagtact agtaccccat ctccagctgt cgaggtactt 2100 gatgacatga ccacacacct tccatcagca tcgtcccaaa tcccagctct cgaagagagc 2160 tgtgaggctg tggaagcccg agaaatcatg tggtttaaga ctcgtcaagg acagatagca 2220 aagcagccat gccctgcagg aactataggt gtatcaactt atctatgcct tgctcctgat 2280 ggaatttggg atccccaagg tccagatctc agcaactgtt cttctccttg ggtcaatcat 2340 ataacacaga agttgaaatc tggtgaaaca gctgccaaca ttgctagaga gctggctgaa 2400 cagacaagaa atcacttgaa tgctggggac atcacctact ctgtccgggc catggaccag 2460 ctggtaggcc tcctagatgt acagcttcgg aacttgaccc caggtggaaa agatagtgct 2520 gcccggagtt tgaacaagct tcagaaaaga gagcgctctt gcagagccta tgtccaggca 2580.
atggtcgaga cagttaacaa cctccttcag ccacaagctt tgaatgcatg gagagacctg 2640 actacgagtg atcagctgcg tgcggccacc atgttgcttc atactgtgga ggaaagtgct 2700 tttgtgctgg ctgataacct tttgaagact gacattgtca gggagaacac agacaatatt 2760 aaattggaag ttgcaagact gagcacagaa ggaaacttag aagacctaaa atttccagaa 2820 aacatgggcc atggaagcac tatccagctg tctgcaaata ccttaaagca aaatggccga 2880 aatggagaga tcagagtggc ctttgtcctg tataacaact tgggtcctta tttatccacg 2940 gagaatgcca gtatgaagtt gggaacggaa gctttgtcca caaatcattc tgttattgtc 3000 aattcccctg ttattacggc agcaataaac aaagagttca gtaacaaggt ttatttggct 3060 gatcctgtgg tatttactgt taaacatatc aagcagtcag aggaaaattt caaccctaac 3120 tgttcatttt ggagctactc caagcgtaca atgacaggtt attggtcaac acaaggctgt 3180 cggctcctga caacaaataa gacacatact acatgctctt gtaaccacct aacaaatttt 3240 gcagtactga tggcacatgt ggaagttaag cacagtgatg cggtccatga cctccttctg 3300 gatgtgatca cgtgggttgg aattttgctg tcccttgttt gtctcctgat ttgcatcttc 3360 acattttgct ttttccgcgg gctccagagt gaccgtaaca ccatccacaa gaacctctgc 3420 atcagtctct ttgtagcaga gctgctcttc ctgattggga tcaaccgaac tgaccaaccg 3480 attgcctgtg ctgttttcgc tgccctgtta catttcttct tcttggctgc cttcacctgg 3540 atgttccttg agggggtgca gctttatatc atgctggtgg aggtttttga gagtgaacat 3600 tcacgtagga aatactttta tctggtcggc tatgggatgc ctgcactcat tgtggctgtg 3660 tcagctgcag tagactacag gagttatgga acagataaag tatgttggct ccgacttgac 3720 acctacttca tttggagttt tataggacca gcaactttga taattatgct taatgtaatc 3780 ttccttggga ttgctttata taaaatggtt catcatactg ctatactgaa acctgaatca 3840 ggctgtcttg ataacatcaa ctatgaggat aacagaccct tcatcaagtc atgggttata 3900 ggtgcaatag ctcttctctg cctattagga ttgacctggg cctttggact catgtatatt 3960 aatgaaagca cagtcatcat ggcctatctc ttcaccattt tcaattctct acagggaatg 4020 tttatattta ttttccattg tgtcctacag aagaaggtac gaaaagagta tgggaaatgc 4080 ctgcgaacac attgctgtag tggcaaaagt acagagagtt ccattggttc agggaaaaca 4140 tctggttctc gaactcctgg acgctactcc acaggctcac agagccgaat ccgtagaatg 4200 tggaatgaca cggttcgaaa gcagtcagag tcttccttta ttactggaga cataaacagt 4260 tcagcgtcac tcaacagaga ggggcttctg aacaatgcca gggatacaag tgtcatggat 4320 actctaccac tgaatggtaa ccatggcaat agttacagca ttgccagcgg cgaatacctg 4380 agcaactgtg tgcaaatcat agaccgtggc tataaccata acgagaccgc cctagagaaa 4440 aagattctga aggaactcac ttccaactat atcccttctt acctgaacaa ccatgagcgc 4500 tccagtgaac agaacaggaa tctgatgaac aagctggtga ataaccttgg cagtggaagg 4560 gaagatgatg ccattgtcct ggatgatgcc acctcgttta accacgagga gagtttgggc 4620 ctggaactca ttcatgagga atctgatgct cctttgctgc ccccaagagt atactccacc 4680 gagaaccacc agccacacca ttataccaga aggcggatcc cccaagacca cagtgagagc,4740 tttttccctt tgctaaccaa cgagcacaca gaagatctcc agtcacccca tagagactct 4800 ctctatacca gcatgccgac actggctggt gtggccgcca cagagagtgt taccaccagc 4860 acccagaccg aacccccacc ggccaaatgt ggtgatgccg aagatgttta ctacaaaagc 4920 atgccaaacc taggctccag aaaccacgtc catcagctgc atacttacta ccagctaggt 4980 cgcggcagca gtgatggatt tatagttcct ccaaacaaag atgggacccc tcccgaggga 5040 agttcaaaag gaccggctca tttggtcact agtctataga agatgacaca gaaattggaa 5100 ccaacaaaac tgctaacacc ttgttgactg ttctgagttg atataagcag tggtaataat 5160 gtgtgtactc ctaaatcttt atgctgtcct ctaaagacaa acacaaactc tcagactttt 5220 ttttttcaac tgggatttaa ggtcagccca ggggagaaag ataactgcta aaattcccct 5280 gtaccccatc ctttcttgtc ctttccccct tcagatggag actt 5324 <210> 29 <211> 1962 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7477349CB1 <400> 29 atggatccca gcgttgttag caatgagtat tatgatgttg cccatggagc aaaagatcca 60 gtggtcccca cttccctgca ggacatcact gctgtcctgg gtacagaagc atatactgag 120 gaagacaaat caatggtgtc ccatgcacag aaaagccagc attcttgtct cagccattcc 180 aggtggctga ggtctccaca ggtcacaggg ggaagctggg acctccgaat aaggccatcc 240 aaggactcca gCagtttccg~ccaggctcag tgtctgcgta aggatcctgg ggcaaacaac 300 cacttggaga gccaaggggt gagaggtaca gctggcgatg ctgacaggga gctgcgggga 360 ccctcagaaa aagccacagc tggccagcca cgagtgaccc tgctgcccac gcccaacgtc 420 agcgggctga gccaggagtt tgaaagccac tggccagaga tcgcagagag gtccccgtgt 480 gtggctggcg tcatccctgt catctactac agtgtcctgc tgggcttggg gctgcctgtc 540 agcctcctga ccgcagtggc cctggcgcgc cttgccacca ggaccaggag gccctcctac 600 tactaccttc tggcgctcac agcctcggat atcatcatcc aggtggtcat cgtgttcgcg 660 ggcttcctcc tgcagggagc agtgctggcc cgccaggtgc cccaggctgt ggtgcgcacg 720 gccaacatcc tggagtttgc tgccaaccac gcctcagtct ggatcgccat cctgctcacg 78O
gttgaccgct acactgccct gtgccacccc ctgcaccatc gggccgcctc gtccccaggc 840 cggacccgcc gggccattgc tgctgtcctg agtgctgccc tgttgaccgg catccccttc 900 tactggtggc tggacatgtg gagagacacc gactcaccca gaacactgga cgaggtcctc 960 aagtgggctc actgtctcac tgtctatttc atcccttgtg gcgtgttcct ggtcaccaac 1020 tcggccatca tccaccggct acggaggagg ggccggagtg ggctgcagcc ccgggtgggc 1080 aagagcacag ccatcctcct gggcatcacc acactgttca ccctcctgtg ggcgccccgg 1140 gtcttcgtca tgctctacca catgtacgtg gcccctgtcc accgggactg gagggtccac 1200 ctggccttgg atgtggccaa catggtggcc atgctccaca cggcagccaa cttcggcctc 1260 tactgctttg tcagcaagac tttccgggcc actgtccgac aggtcatcca cgatgcctac 1320 ctgccctgca ctttggcatc acagccagag ggcatggcgg cgaagcctgt gatggagcct 1380 ccgggactcc ccacaggggc agaagtgtag aggagggggc ccagctaggg agctcagggt 1440 ggctcatggc cacatgtact ggggcctttg aggttgtacc caaaacacgt ttatcaacag 1500 cttgctttcc ttgggtgggg gtggaggctc ctcctttggg tgtggctccc aggtagagag 1560 gaggacaact tagccagctc ttatgtttgc ttcaccagca atccctattt cctgggaaga 1620 tgaaagggca ctgccaggca caggctaata gcatcagtgc tgtgggcatt cctttgcggg 180 gggcattttg cctggctcat cgtgaatgcc agattaatgt tggttgaatg gatagaaaaa 1740 cggcctctca ttttcgtaac tgaggcagga gaatcgcttg aacccaggag acggaggttg 1800 cagcgagctg agatcgcgcc atagaaacac catggaactc caacctgggc aacaagagtg 1860 aaacttcgac tcaaaaaaaa aagagaaaaa acacattagg taacagtttc tttttagcat 1920 ttgtgtaacc tttaataaaa taaagtgata atcaaaaaaa as 1962 <210> 30 <211> 1558 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 55002225CB1 <400> 30 attttattcg cgaaggcacc ccacgctcct agaaaagagc acgacgcacc cgatgctcgg 60 attggatgaa gtggcaaagc tttaatccct ggaaagtcca cgaacaatga atccatttca 120 tgcatcttgt tggaacacct ctgccgaact tttaaacaaa tcctggaata aagagtttgc 180 ttatcaaact gccagtgtgg tagatacagt catcctccct tccatgattg ggattatctg 240 ttcaacaggg ctggttggca acatcctcat tgtattcact ataataagat ccaggaaaaa 300 aacagtccct gacatctata tctgcaacct ggctgtggct gatttggtcc acatagttgg 360 aatgcctttt cttattcacc aatgggcccg agggggagag tgggtgtttg gggggcctct 420 ctgcaccatc atcacatccc tggatacttg taaccaattt gcctgtagtg ccatcatgac 480 tgtaatgagt gtggacaggt actttgccct cgtccaacca tttcgactga cacgttggag 540 aacaaggtac aagaccatcc ggatcaattt gggcctttgg gcagcttcct ttatcctggc 600 attgcctgtc tgggtctact cgaaggtcat caaatttaaa gacggtgttg agagttgtgc 660 ttttgatttg acatcccctg acgatgtact ctggtataca ctttatttga cgataacaac 720 tttttttttc cctctaccct tgattttggt gtgctatatt ttaattttat gctatacttg 780 ggagatgtat caacagaata aggatgccag atgctgcaat cccagtgtac caaaacagag 840 agtgatgaag ttgacaaaga tggtgctggt gctggtggta gtctttatcc tgagtgctgc 900 cccttatcat gtgatacaac tggtgaactt acagatggaa cagcccacac tggccttcta 960 tgtgggttat tacctctcca tctgtctcag ctatgccagc agcagcatta acccttttct 1020 ctacatcctg ctgagtggaa cgcctcaaat ccaaagaaga gcgactgaga aggaaatcaa 1080 caatatggga aacactctga aatcacactt ttaggaaagt acatggatca ccatgagtct 1140 agacatgatt gtctatctta ctggtattat tagaaagggc aggtgtaccg atatgtttat 1200 gcccattctt cttgtgtact tgtgactctt agcagcatgg aagagaagtg taaccatgca 1260 aatacaatga gcttaatatg ctaactttag caagatgtaa aatgttgatc tatattgtgg 1320 gtagggaatg ggatagtctg agatacccag gcttcatgat ggtgtatatt atttcagcat 1380 attataaact agtcactaat gaaaatggcc atccatgacc attgactcaa aactcaccaa 1440 ggaacctgac cttgccctcc acactgcggc ctcactgtaa cagtttcctc aaggttccta 1500 ggagggtatc accttagagt gaagtctaaa atttggctat tttttatcta ttaaaaat 1558 <210> 31 <211> 2304 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7475686CB1 <400> 31 atgcggctgg gacctgtccc agcccgggcg cgcgccctct tgtcttgggt tagggggctg 60 gaaagccgag gaggggagtg gaccaaatgc attgttcagc tgggtcatct ccttgctacc 120 cagcatcccg cggcgcccac atgtggagtc gtttccagcg ccctggtcat gcactcaaca 180 gatgtctgtc tagcccccac tatgcaccag gcactggact gggcagcagg aatttggttt 240 acaggaagat taggactcag agagcataaa tcactggccc agggtgactc agtctgtcca 300 tgtgaaagtg aacttggtga tttccaagtc tatggcttgg tcagtacaga aggagtggtg 360 tcctgctttg gagagaagac cccgcagcat cctggccctc ctgcttcatt gtccctggcc 420 aacaggtgcc acaacgttgt gacagctgta ggagcctggc cagctcatgg gagcatcctt 480 ggaaatgttc cagaagcccc tgtgggagct gatgtgttgg gggctggagg atgtgactgg 540 gcagacaaag aggccctggc ccctgggcaa agggcaaagg tgcacattct tcttgagagt 600 tctggacagt ctgatccatc ctatgctgtc cttcctgaca gctgggcagc cacggagggt 660 ttcccaactt acagatctca ggtctcctct ccccgcatcc cgggtagttc catctggtta 720 ggcagtgggt ctggttggcc tatacttggg gaactcaggg aatgtgacca gatgttctcc 780 tgcatgttgc ccactggttg tgcctccttc caggatccag gacgttatgg tgattatgac 840 ctccctatgg atgaggatga ggacatgacc aagacccgga ccttcttcgc agccaagatc 900 gtcattggca ttgcactggc aggcatcatg ctggtctgcg gcatcggtaa ctttgtcttt 960 atcgctgccc tcacccgcta taagaagttg cgcaacctca ccaatctgct cattgccaac 1020 ctggccatct ccgacttcct ggtggccatc atctgctgcc ccttcgagat ggactactac 1080 gtggtacggc agctctcctg ggagcatggc cacgtgctct gtgcctccgt caactacctg 1140 cgcaccgtct ccctctacgt ctccaccaat gccttgctgg ccattgccat tgacaggtat 1200 ctcgccatcg ttcacccctt gaaaccacgg atgaattatc aaacggcctc cttcctgatc 1260 gccttggtct ggatggtgtc cattctcatt gccatcccat cggcttactt tgcaacagaa 1320 acggtcctct ttattgtcaa gagccaggag aagatcttct gtggccagat ctggcctgtg 1380 gatcagcagc tctactacaa gtcctacttc ctcttcatct ttggtgtcga gttcgtgggc 1440 cctgtggtca ccatgaccct gtgctatgcc aggatctccc gggagctctg gttcaaggca 1500 gtccctgggt tccagacgga gcagattcgc aagcggctgc gctgccgcag gaagacggtc 1560 ctggtgctca tgtgcattct cacggcctat gtgctgtgct gggcaccctt,ctacggtttc 1620 accatcgttc gtgacttctt ccccactgtg ttcgtgaagg aaaagcacta cctcactgcc 1680 ttctacgtgg tcgagtgcat cgccatgagc aacagcatga tcaacaccgt gtgcttcgtg 1740 acggtcaaga acaacaccat gaagtacttc aagaagatga tgctgctgca ctggcgtccc 1800 tcccagcggg ggagcaagtc cagtgctgac cttgacctca gaaccaacgg ggtgcccacc 1860 acagaagagg tggactgtat caggctgaag tgacccactg gtgtcacaca attgaaaacc 1920 ccagtccagt actcagagca tcacccacca tcaaccaagt tcataggctg catgggaaat 1980 gacatctgtg ttcatgcctc ccccgtgccc tcaagaagcc gaatgctgca aagtcgtaac 2040 atacaatgag actagacatg aaccaaatca gctgacattt actgatatcc gctcgacacc 2100 tactgtgtcc acaatcccaa caaggagatt agacacaagg agcagcaact gacatggact 2160 gaacatgtac tgtgtgcaag ccaaaccaat gagattaaca gggacagcag gagctgaatt 2220 atcttactat gtatcaaacc tgttgttcac aaattaaact acagtccaac ttgggtcaca 2280 tcgttttatt tcccattcat tttt 2304 <210> 32 <211> 2322 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature ' <223> Incyte ID No: 7482007CB1 <400> 32 cccatttcaa aaatggagaa gacagatcac tgccactgac caggaccgtg ggaggtgcca 60 cgtgatggtg aggcatcatg ctagggagct gagctctgac cttcctgctg ggtgattctc 120 cacctctggg ctgctagatc tacttcctgg atgccgtgaa gatcctcatg tatgaaaatg 180 aagtcccagg caaccatgat ttgctgctta gtgttctttc tgtccacaga atgttcccac 240 tatagatcca agattcacct aaaagctgga gataaacttc aaagccctga agggaaaccc 300 aagactggaa ggatccaaga gaaatgcgaa ggaccttgta tttcttcttc caactgcagc 360 cagccctgtg ctaaggactt tcatggagaa ataggattta catgtaatca aaaaaagtgg 420 caaaaatcag ctgaaacatg tacaagcctt tctgtggaaa aactctttaa ggactcaact 480 ggtgcatctc gcctttctgt agcagcacca tctatacctc tgcatattct agactttcga 540 gctccagaga ccattgagag tgtagctcaa ggaatccgta agaactgccc ctttgattat 600 gcctgcatca ctgacatggt gaaatcatca gaaacaacat ctggaaatat tgcatttata 660 gtggagttat taaaaaatat ttctacagac ttgtctgata atgttactcg agagaaaatg 720 aagagctata gtgaagtggc Caaccacatc ctcgacacag cagccatttc aaactgggct 780 ttcattccca acaaaaatgc cagctcggat ttgttgcagt cagtgaattt gtttgccaga 840 caactccaca tccacaataa ttctgagaac attgtgaatg aactcttcat tcagacaaaa 900 gggtttcaca tcaaccataa tacctcagag aaaagcctca atttctccat gagcatgaac 960 aataccacag aagatatctt aggaatggta cagattccca ggcaagagct aaggaagctg 1020 tggccaaatg catcccaagc cattagcata gctttcccaa ccttgggggc tatcctgaga 1080 gaagcccact tgcaaaatgt gagtcttccc agacaggtaa atggtctggt gctatcagtg 1140 gttttaccag aaaggttgca agaaatcata ctcaccttcg aaaagatcaa taaaacccgc 1200 aatgccagag cccagtgtgt tggctggcac tccaagaaaa ggagatggga tgagaaagcg 1260 tgccaaatga tgttggatat caggaacgaa gtgaaatgcc gctgtaacta caccagtgtg 1320 gtgatgtctt tttccattct catgtcctcc aaatcgatga ccgacaaagt tctggactac 1380 atcacctgca ttgggctcag cgtctcaatc ctaagcttgg ttctttgcct gatcattgaa 1440 gccacagtgt ggtcccgggt ggttgtgacg gagatatcat acatgcgtca cgtgtgcatc 1500 gtgaatatag cagtgtccct tctgactgcc aatgtgtggt ttatcatagg ctctcacttt 1560 aacattaagg cccaggacta caacatgtgt gttgcagtga catttttcag ccactttttc 1620 tacctctctc tgtttttctg gattctcttc aaagcattgc tcatcattta tggaatattg 1680 gtcattttcc gtaggatgat gaagtcccga atgatggtca ttggctttgc cattggctat 1740 gggtgcccat tgatcattgc tgtcactaca gttgctatca cagggccagt gaaaggctac 1800 atgagacctg aggcctgttg gcttaactgg gacaatacca aagccctttt agcatttgcc 1860 atcccggcgt tcgtcattgt ggctgtaaat ctgattgtgg ttttggttgt tgctgtcaac 1920 actcagaggc cctctattgg cagttccaag tctcaggatg tggtcataat tatgaggatc 1980 agcaaaaatg ttgccatcct cactccactg ctgggactga cctggggttt tggaatagcc 2040 actctcatag aaggcacttc cttgacgttc catataattt ttgccttgct caatgctttc 2100 cagggttttt tcatcctgct gtttggaacc attatggatc acaagataag agatgctttg 2160 aggatgagga tgtcttcact gaaggggaaa tcgagggcag ctgagaatgc atcactaggc 2220 ccaaccaatg gatctaaatt aatgaatcgt caaggatgaa atgctgcccc atttctcatg 2280 gatgtcctga gaccaagagg ggagatccag gagaaagagg cc 2322 <210> 33 <211> 2366 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 6769042CB1 <400> 33 atttaggtga cactatagaa gagcccagtg tgctggaaag gagatcgcca tgtacttcac 60 tgctgccatt ggaaagcatg ctttattgtc ttcaacgctg ccaagcctct tcatgacatc 120 cacagcaagc cccgtgatgc ccacagatgc ctaccatccc atcataacca acctgacaga 180 agagagaaaa accttccaaa gtcccggagt gatactgagt tacctccaaa atgtatccct 240 cagcttaccc agtaagtccc tctcggagca gacagccttg aatctcacca agaccttctt 300 aaaagccgtg ggagagatcc ttctactgcc tggttggatt gctctgtcag aggacagcgc 360 cgtggtactg agtctcatcg acactattga caccgtcatg iggccatgtat cctccaacct 420 gcacggcagc acgccccagg tcaccgtgga gggctcctct gccatggcag agttttccgt 480 ggccaaaatc ctgcccaaga ccgtgaattc ctcccattac cgcttcccgg cccacgggca 540 gagcttcatc cagatccccc acgaggcctt ccacaggcac gcctggagca ccgtcgtggg 600 tctgctgtac cacagcatgc actactacct gaacaacatc tggcccgccc acaccaagat 660 cgcggaggcc atgcatcacc aggactgcct gctgttcgcc accagccacc tgatttccct 720 ggaggtgtcc ccaccaccca ccctgtctca gaacctgtcg ggctctccac tcattacggt 780 ccacctcaag cacagattga cacgtaagca gcacagtgag gccaccaaca gcagcaaccg 840 agtcttcgtg tactgcgcct tcctggactt cagctccgga gaaggggtct ggtcgaacca 900 cggctgtgcg ctcacgagag gaaacctcac ctactccgtc tgccgctgca ctcacctcac 960 caactttgcc atcctcatgc aggtggtccc gctggagctt gcacgcggac accaggtggc 1020 gctgtcgtct atcagctatg tgggctgctc cctctccgtg ctctgcctgg tggccacgct 1080 ggtcaccttc gccgtgctgt cctccgtgag caccatccgg aaccagcgct accacatcca 1140 cgccaacctg tccttcgccg tgctggtggc ccaggtcctg ctgctcatta gtttccgcct 1200 cgagccaggc acgaccccct gccaagtgat ggccgtgctc ctacactact tcttcctgag 1260 tgccttcgca tggatgctgg tggaggggct gcacctctac agcatggtga tcaaggtctt 1320 tgggtcggag gacagcaagc accgttacta ctatgggatg ggatggggtt ttcctcttct 1380 gatctgcatc atttcactgt catttgccat ggacagttac ggaacaagca acaattgctg 1440 gctgtcgttg gcgagtggcg ccatctgggc ctttgtagcc cctgccctgt ttgtcatcgt 1500 ggtcaacatt ggcatcctca tcgctgtgac cagagtcatc tcacagatca gcgccgacaa 1560 ctacaagatc catggagacc ccagtgcctt caagttgacg gccaaggcag tggccgtgct 1620 gctgcccatc ctgggtacct cgtgggtctt tggcgtgctt gctgtcaacg gttgtgctgt 1680 ggttttccag tacatgtttg ccacgctcaa ctccctgcag ggactgttca tattcctctt 1740 tcattgtctc ctgaattcag aggtgagagc cgccttcaag cacaaaatca aggtctggtc 1800 gctcacgagc agctccgccc gcacctccaa cgcgaagccc ttccactcgg acctcatgaa 1860 tgggacccgg ccaggcatgg cctccaccaa gctcagccct tgggacaaga gcagccactc 1920 tgcccaccgc gtcgacctgt cagccgtgtg agccgggagg ctgccaacca ggccaggctg 1980 cgctcagaac acaccccccc aaacagaatg aaatgcccca cctttgccca tggaccctct 2040 ccttgctgct gtctggacat gggtgttgtg gccccgagac agctgtcctc ccctgtgact 2100 ctggctgtcg gagcacactg CtCagCCCag cagcctgatg cccaggccag cgtgggccct 2160 cctgccttgc atccacccgt gggctgagtg acttcctcgg gggattccca ggacacagtg 2220 gcctgacttg tgatggtgcc cttgagcctc ccttcatcac tcagcatcag accagcgagg 2280 cagggcatcg gggccggtcc cgcagcccgg agggatgtca gctctgtgct ggggggttgg 2340 ggcccgccCC aagtgtcagg ccccgc 2366 <210> 34 <211> 1458 <212> DNA
<213> Homo Sapiens <220>
34!37 <221> misc_feature <223> Incyte ID No: 7476053CB1 <400> 34 atggaggccg ctagcctttc agtggccacc gccggcgttg cccttgccct gggacccgag 60 accagcagcg ggaccccaag cccgagaggg atactcggtt cgaccccgag cggcgccgtc 120 ctgccgggcc gagggccgcc cttctctgtc ttcacggtcc tggtggtgac gctgctagtg 180 ctgctgatcg ctgccacttt cctgtggaac ctgctggttc cggtcaccat cccgcgggtc 240 CgtgCCttCC aCCgCgtgCC gcataacttg gtggcctcga cggccgtctc ggacgaacta 300 gtggcagcgc tggcgatgcc accgagcctg gcgagtgagc tgtcgaccgg gcgacgtcgg 360 ctgctgggcc ggagcctgtg ccacgtgtgg atctccttcg acgccctgtg CtgCCCCgCC 420 ggcctcggga acgtggcggc catcgccctg ggccgcgacg gggccatcac acggcacctg 480 cagcacacgc tgcgcacccg cagccgcgcc tcgttgctca tgatcgcgct cgcccgggtg 540 ccgtcggcgc tcatcgccct cgcgccgctg ctctttggcc ggggcgaggt gtgcgacgct 600 CggCtCCagC gctgccaggt gagccgggaa ccctcctatg CCgCCttCtC CdCCCgCggC 660 gccttccacc tgccgcttgg cgtggtgccg tttgtctacc ggaagatcta cgaggcggcc 720 aagtttcgtt tcggccgccg ccggagagct gtgctgccgt tgccggccac catgcaggtg 780 aaggaagcac ctgatgaggc tgaagtggtg ttcacggcac attgcaaagc aacggtgtcc 840 ttccaggtga gcggggactc ctggcgggag cagaaggaga ggcgagcagc catgatggtg 900 ggaattctga ttggcgtgtt tgtgctgtgc tggatcccct tcttcctgac ggaactcatc 960 agcccactct gtgcctgcag cctgcccccc atctggaaaa gcatatttct gtggcttggc 1020 tactccaatt ctttcttcaa ccccctgatt tacacagctt ttaacaagaa ctacaacaat 1080 gccttcaaga gcctctttac taagcagaga tgaacacagg ggttagagag acatgggtag 1140 attttaagga ggaaggaact tggacttttt cgtcagtgat ctgagattct tccctccaca 1200 gctgagtgct aatgctgtat tgagagttat accattgggc ctggactgta gaagcagcag 1260 agccaaggtt ctcaagaaag acagcaaagg tctggcagat gttgtaacta tgccttcttc 1320 ccatgtgcat ggcagacatt gccaattggt catggcttgg ctccccactg agcaggaact 1380 tggtctcaga atcctttcca ggacagcacc ctaggcagct actgttgatt atttaaaatt 1440 gatgcaagac ttgaaaaa 1458 <210> 35 <211> 975 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte zD No: 7480410CB1 <400> 35 atgggcatgg agggtcttct ccagaactcc actaacttcg tcctcacagg cctcatcacc 60 CatCCtgCCt tCCCCgggCt tCtCtttgCa atagtCttCt ccatctttgt ggtggctata 120 acagccaact tggtcatgat tctgctcatc Cacatggact cccgcctcca cactcccatg 180 tacttcttgc tcagccagct ctccatcatg gataccatct acatctgtat cactgtcccc 240 aagatgctcc aggacctcct gtccaaggac aagaccattt ccttcctggg ctgtgcagtt 300 cagatcttcc tctacctgac cctgattgga ggggaattct tcctgctggg tctcatggcc 360 tatgaccgct atgtggctgt gtgcaaccct ctacggtacc ctctcctcat gaaccgcagg 420 gtttgcttat tcatggtggt cggctcctgg gttggtggtt ccttggatgg gttcatgctg 480 actcctgtca ctatgagttt ccccttctgt agatcccgag agatcaatca ctttttctgt 540 gagatcccag ccgtgctgaa gttgtcttgc acagacacgt cactctatga gaccctgatg 600 tatgcctgct gcgtgctgat gctgcttatc cctctatctg tcatctctgt ctcctacacg 660 cacatcctcc tgactgtcca caggatgaac tctgctgagg gccggcgcaa agcctttgct 720 acgtgttcct cccacattat ggtggtgagc gttttctacg gggcagcctt ctacaccaac 780 gtgctgcccc actcctacca cactccagag aaagataaag tggtgtctgc cttctacacc 840 atcctcaccc ccatgctcaa cccactcatc tacagcttga ggaataaaga tgtggctgca 900 gctctgagga aagtactagg gagatgtggt tcctcccaga gcatcagggt ggcgactgtg 960 atcaggaagg gctag 975 <210> 36 <211> 948 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 55036418CB1 <400> 36 atggagacgt gggtgaacca gtcctacaca gatggcttct tcctcttagg catcttctcc 60 cacagtactg ctgaccttgt cctcttctcc gtggttatgg cggtcttcac agtggccctc 120 tgtgggaatg tcctcctcat cttcctcatc tacatggacc ctcaccttca cacccccatg 180 tacttcttcc tcagccagct ctccctcatg gacctcatgt tggtctgtac caatgtgcca 240 aagatggcag ccaacttcct gtctggcagg aagtccatct cctttgtggg ctgtggcata 300 caaattggcc tctttgtctg tcttgtggga tctgaggggc tcttgctggg actcatggct 360 tatgaccgct atgtggccat tagccaccca cttcactatc ccatcctcat gaatcagagg 420 gtctgtctcc agattactgg gagctcctgg gcctttggga taatcgatgg cttgatccag 480 atggtggtag taatgaattt cccctactgt ggcttgagga aggtgaacca tttcttctgt 540 gagatgctat ccttgttgaa gctggcctgt gtagacacat ccctgtttga gaaggtgata 600 tttgcttgct gtgtcttcat gcttctcttc ccattctcca tcatcgtggc ctcctatgct 660 cacattctag ggactgtgct gcaaatgcac tctgctcagg cctggaaaaa ggccctggcc 720 acctgctcct cccacctgac agctgtcacc ctcttctatg gggcagccat gttcatctac 780 ctgaggccta ggcactaccg ggcccccagc catgacaagg tggcctctat cttctacacg 840 gtccttactc ccatgctcaa ccccctcatt tacagcttga ggaacaggga ggtgatgggg 900 gcactgagga aggggctgga ccgctgcagg atcggcagcc agcactga 948 <210> 37 <211> 1086 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature .
<223> Incyte ID No: 7481701CB1 <400> 37 ggctctattc agacgctggc ttcttgtaag tgtattcctt tatccaatag tagatgcctc 60 ctagaaggct tgagtgcact ggaaattgaa actctcactt tcaacttgga gatggagagc 120 cccaatcaaa ccaccattca ggagtttatc ttctccgctt tcccttattc ctgggttaag 180 tctgttgtct gctttgttcc actgctcttc atctatgctt tcattgttgt tggaaacctg 240 gtcatcatca cagtggtcca gttgaatact cacctccaca ctcccatgta tacttttatc 300 agtgctcttt cttttctgga gatttggtat accacagcca caatcccaaa gatgctgtct 360 agcctgctta gtgagaggag catttccttc aatggttgtc tcctgcagat gtatttcttc 420 cattccaccg gcatctgtga ggtgtgtctc ttgacagtta tggcctttga ccactacctg 480 gccatatgca gccctcttca ttatccctct atcatgaccc ccaagctatg tacccaactg 540 actttaagtt gctgtgtttg tggctttatc acacccgttc ctgagattgc ctggatctct 600 acactgccat tttgtggttc gaatcacctt gaacatatct tctgtgactt cctcccagtg 660 ctgcgtctgg cctgcacaga cacacgagcc atcgtcatga ttcaggtagt ggatgtcatt 720 catgcagtgg agattattac agctgtgatg Ctcatcttca tgtcctacga tggtattgtg 780 gctgtaattc tacgtattca ttcagctgga ggccgccgca cagcattttc cacgtgtgtc 840 tctcacttca ttgtcttttc gctcttcttt ggcagtgtga ctctcatgta cctacgcttc 900 tctgccacct actctttgtt ctgggatata gccattgctc tggcctttgc agttttgtct 960 cccttcttca accccattat ctatagcctg aggaataaag aaataaaaga agctataaaa 1020 aagcacatag gtcaagctaa gatatttttt tccgtaagac cagggacctc aagtaagata 1080 ttttag 1086 <210> 38 <211> 1529 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7481774CB1 <400> 38 aagggagacc acagtgagag ggagccctga gcagaagtaa ggctgtcaca aggctggaag 60 cagagaacat ccccatggaa ctgaagacag catgctgcat ccctgggagg agggagctct 120 taaggaagtt ccaaggattg atatttctgt tcagctgcag tagagatgga tggaaccatg 180 gcagcaccca acccatttca tcctactggg attctctgac cgaccccatc tggagaggat 240 cctctttgtg gtcatcctga tcgcgtacct cctgaccctc gtaggcaaca ccaccatcat 300 cctggtgtcc cggctggacc cccacctcca cacccccatg tacttcttcc tcgcccacct 360 ttccttcctg gacctcagtt tcaccaccag CtCCatCCCC CagCtgCtCt acaaccttaa 420 tggatgtgac aagaccatca gctacatggg ctgtgccatc cagctcttcc tgttcctggg 480 tctgggtggt gtggagtgcc tgcttctggc tgtcatggcc tatgaccggt gtgtggctat 540 ctgcaagccc ctgcactaca tggtgatcat gaaccccagg ctctgccggg gcttggtgtc 600 agtgacctgg ggctgtgggg tggccaactc cttggccatg tctcctgtga ccctgcgctt 660 accccgctgt gggcaccacg aggtggacca cttcctgtgt gagatgcccg ccctgatccg 720 gatggcctgc atcagcactg tggccatcga cggcaccgtc tttgtcctgg cggtgggtgt 780 tgtgctgtcc cccttggtgt ttatcctgct ctcttacagc tacattgtga gggctgtgtt 840 acaaattcgg tcagcatcag gaaggcagaa ggccttcggc acctgcggct cccatctcac 900 tgtggtctcc cttttctatg gaaacatcat ctacatgtac atgcagccag gagccagttc 960 ttcccaggac cagggcaagt tcctcacgct cttctacaac attgtcaccc ccctcctcaa 1020 tcctctcatc tacaccctca gaaacagaga ggtgaagggg gcactgggaa ggttgcttct 1080 ggggaagaga gagctaggaa aggagtaaag gcatctccac ctgacttcac ctccatccag 1140 ggccactggc agcatctgga acggctgaat tccagctgat attagcccac gactcccaac 1200 ttgccttttt ctggactttt gtgaggctgt ttcagttctg acattatgtg tttttgttgt 1260 tgctcttaaa attgagacgg ggtctcactc tgtcacctag ggtggagtgc agtggtgcca 2320 ccatagctcc ttcgactatt gggcttaagc gatcctcccc cacctcagcc ttccaagtaa 1380 ctgggactac aggtgtgcat cactggcagt gggaattgtg gcttttctgt cttctatgga 1440 gacggggtct tgctgtgttg accaggctgg tcccaaactc ctggcctcat gtgatcctcc 1500 tgccatggcc tcctaaagtt ctgggatta
v M r~ ~ 4 ~
1 1 '' ~ j ~
td N ~I ~i ~, N !!S - U7 ~.j r1 N O .!- ~ C
S N U ?t N O H O
''d ) ~ ri Ul O R~ O (If ~ f I ~i d N ' I
~ 4 ' I~ ''C3 ~ i l i i ~
N U7 O v ~L '-' U7 -I ~ l . ~ O -,L7 .1J -I . H ~,' r U O ~ -r1 I . r r-t N r ~, - -I
( 4-! r-I -rl 'Zj u7 T O UI .-I u1 -rl r-1 ~I ~ v U U1 rlf N O r1 'J
-rl U7 f-I U S-I O ~-I td N r-I O .U -- rd r-I ~y-~1 td .!~ t6 ~ .U .!..l O .h ni -.-I U rtf ZS U N
~ U7 4-I N 1~ N r-i N '~ ,5 O u1 O v O 'T3 r1 ~
.!~ ~ td ~ cd u7 u1 ~-I v -rl ~I 1-t r-I
l 1 '~ N O C
W '~ -I ' -I
l ~ ' N N
W O ~
O
B
l O -r1 r r .! , Ul .! ~1 r ~, .
~-I h 'C3 (d U7 ~ O .l- .~, f (IS ~-I U (d .1~ -I
U7 ,.t~ 1-1 ~ U (f ~,' .I~ .~i ~ r v ~ G
~,' O r1 r-1 .1J
v U O ~,' r1 U tl~
cCf 4-I to N 'Z3 rd U1 .1.-1 v rtS O W-i ttS ~ (d 'TS
r1 ,sue' fd (d ~ ~' .t~ ~ N ~ O 5r :-', ~j ~r ~-I
s~ ~; P N ~; N -.-1 td U ~-I r-I O O ~ W Id u1 '' v -.-I Id N .1..1 W cd ''d U ~ '~ .-I
' ' ~-I v I IJ
' ~ '~ 4 ~
1 s S
N
~
l ~ ., p r-I .h W U7 - .
O -rl y., . -rl N N (d U1 N .~ O .!- td ?-I ~,' U ~-I U .
~ Id ~ cd -rl -I i ~ ~'~ ., 1 -~-i O U7 ~-I N N l -1 -r ~, -~I ~ .
>j ? I ., J N 4 4a ~,' O b~ u7 ~
1 l '~ N O
N ~ ~
l t l 1 '~
O I O 'd u1 ~ rd ''d '~
.!- S.1 c - w c ~ .1. .. r U1 .1-1-f'-...Q U r ~ -.
4-I ~ U7 U1 U1 I ~
~I -r-1 ~ -I S'.. v N ri 4-I W
td ~-I r -I ~ N ~ ItS ,~
O ~ ~.,'' 4i U7 U~ O ~
t~ i4-1 .!~ r-1 1 3 -r-I ?-I N'D u ' l 1 O v U ~
~ N ~ 6 N
~
d d v r-I N C r r -O ~., U , t r 1 f($ r-I . ~ c -rl .
N ~,' . Id -I t w1 U7 , U fd 'ZS cd fd Id ''~
~., O -r-1 r1 ~-I r1 r-I td r-I
v ''~ W 4-I ,t,' r1 131 ',7 1n o ~ -,~ 0 ~ s~ +~ la a r1 ~ ~ v U ~ o o -~1 ~I m ,~ I . -~ s~ r1 .u .u 1 ~
-~1 ~1 --I ~-I U1 -(-I ~-I ~ -.-I -r-I, w-1 N u7 ~ rtS ~'' .s;
~'.,U - ,s; ..C,' .U r-i '~ ~ U -rl rtf 3 .13 N r-I r-I
.h 4-I tJI U 4-I U U '~S .1.~ ~ u1 -rl N O 1~ O
-rl .!-1 .I~ r1 ~-I O ~I D ~,' .!-~ O a-I
b~ .~, (<i a r~ .>, ~1 U ~1 v ~ v o ~n ~ s cn .-1 3 -~I ~~n , r1 ~ o ~ v ~ ~a v ca ~ a ?. ~ -~
3 ~, zscd~a~v~3~~lv,.~ra ~IU r1 ~n o .uo~avrl ~3 ~~-3~a~rl~~a ~ N r-I U N U ~,' .~i N rtS -t'. ~ '~ O ri ~
Id r1 r-1 rtS ~ 'i~ ~I O O ~ O .l-1 ~". ~
J~
.1J ~1 O .l~ J-1 U7 O O .i-1~-I --i ~C O ri U N U7 r-I .~, ~ 1~ .~., r1 .~ ~-I N .1~
+~ v ,5r bW-1cd O ,~ N Id ~ -~I U ~S ,~ u1 ~-I O U1 r1 .-I N
~ , rd rtf N N 4-I ~ ~ ,~ ~ -.-1 .1..~
o u ~ u zi u~ ~ - u r u o 1 ~ ~ ~u 1 o rt ~ ~
l v > ~
~ v u 3 ~
s ~1 ~, . s .
-~I 0 ~ . ~ .
,.~ o ~ . r ~ o s ~a -~1 s ,~ .
v 1 W U7 0 r1 ~ v >~ v o ~1 >~ ~ ~ ~a .u N .u ~a v ~ l ~, v U U7 v - ~
U 4 1 ~
l U dF ~ Q U7 U1 S S -I ~1'~ (0 O N O
' -W U1 J.- r . ,.
~ r1 ~,'' ~; 7 U ~ r -r1 ,5..,"~ -, r( . ., .7 ,5 -1 U7 1.1 S ,5y r-I ~'., N N r-I
-r-1 ~ r-I .1J ~ 4-.I , ~1 -rl U7 O -rl f~ ~I (d N
ffS Ll1 r1 ~ N Ei ~ O X U 't! Id U r-I -.-I +~ 5r O
oo ~ cd oo r1 4.1 O ~ '~ ~ ~-I
~I U
rd -FC -rl ~, r.~ ,.C ~-I N ~ -.-i .L.1 1~ I U
~1 td .l~ v ~ H -~1 ''d -rl '~ U1 O 4--I N w .U ~ v O
N ~ (<i .~., r1 U N .l-1 U1 '~ .~., ~I r-I to r1 .U ' ?S 4' r-I -r-I N .~., ~ (l) ',~ C,' rd ~ ~i 1=,' ~ I N l ''~ O O t ~ N ~ d 7 O ' b O S -i v d ~ ~ O
d O 3 C
.4 p I O rli h t 5 U7 ., 5r -I r -~ r l ~ ,~ .h I U r ''d Z
U .!~ u7 r1 ~I )~ O O >~ ~I
N N I Gv F
N N 1~ u7 s~ 1 1~ ~
~ ~1 v O '~
U1 bl-~IU 'Ci ~ 1-~ O U ~i U~ t~ U1 -ri td rti 5~ Q., .1J ~ 1-I ~ ~ ~,' ~.1 rd -rl O td .1.y clS ~-I
~1 >~ ~ v >~ ~ ~ :a ?~ ~ ~ r1 ~a ~ .u rr rt ~ o ~a 3 v U m o ~ -~r o r~
.u -~I o ,.~ -~1 v ~I r1 0 ~a ~n r~ u-1 v o .u 3 ~a -1 v ~I ~n ~ ~1-~1v v o .u ~I -~I ~1 S~
v r~
m m ~1 0 -~1 cn 5 v .u o ~1 ~1 ~, o ~, ~, s~ v .~
~I s~ ~I -~1 r1 w ~ m ~n ~a ~ ~a o ' ~ 4 .u 4 C
O I 1 1 I N ' N l U1 1 (d b1 U (d I N U7 f '~ - ~
1~ l I, S 1 -I v -I ~1 ~
~
~
~, ~ - . - .
o -1 r . r ,.
~ 0 ~ ~ a v , 3 ~ rt rd r 1 v -- . r - l s~ ~ v -~I .
v , ~ v ~a .
., -t o la ~ o ~ ~ ~a u -~1 ~I ~
''O ~ r - .
U ,-~ '~ r1 '~ >-'., .-I ''LWIj ~I ~I O .IWO (p v $ U1 ~,' ~. N ~-1 fR W 4-I N ,IZ
'~ ',~ r-I U7 m v v la o v ~a ~ -~I t~ v r1 ~-I ,~ as r1 u~ ,~
r1 ~ ~ o -~1 -~I o ~I ~ ~ 3 ~ ~
v ~, u~
m .u .u .u .u ~ ~ v ~ cn +~ -~1 ~1 ~ o o ~a ~ .u m ~-I ~, ~ .u ~I ~ L1 ~ -~1 ~ o v ?~ ca td U td G' U O O -rl ,C'',f0 ..Q '~ r-I -r1 U N O
~ r1 U (!S v fd v O U~ r-I
r1 U
g ~ r1 o v ~ ~ ~ ~ U .u r1 U v m r1 4-1 0 >~ w .u ~ .u ~1 ~I s~ .u ~ ~I v .-. o :3, ~
v ~I o ~1 >~ ~I v 3 v v o o ~a ~ v ~ ta~I o .-1-~I
o u~ v N ~ -~1 -~1 o zi ~o U
~I
~
",~,.1~ U1 4-I .1~ ~ ~1 N ~ U1 .1~ U ~ f~ ~-1 U ~ O
4-I U oo '~ .~ ~-rl tti '-' r-I td > r , ' ~I u1 -rl r1 u1 N ~, s: -~1 -~I ~ u7 O U7 ~ o N a p > s U1 d ~I 5r ~ G
N ' ?~ ~ O ~-I ~ f:
'' ' ' ' "
~
' fa ~ (!j to J.J r1 .1J .l-1C, ?-1 U7 N ~ ~-I (a N ., (a ~ -r-I I -r-I fit U7 >_ ~-I (CS ' C, ~'I , (d J-,5 Jy ~-I v ~, " ' ' "
' .4 O U ,~ tn O ~ tIS U7 U7 -r1 -1-.t r1 1~ ~., r1 $ ~(, (6 U ~-I .. O O U ,~
N -r1 $ .l.W-I .~, N (d U f ~, r1 -a-I
' ,~ U ~ O ~1 U ~ .~., -r1 S-1 U7 .1~ cd N S-I N
N J-~ ~ 4-1 N -.-1 O rd -I-1 U
Cl) d ' ~1 U) .I~ O -4~ ~ O v i I 1 ~ -I
~ ~ -1 U f ~ ~ ' ~
v U . ~ U O U ~
O
O ~
"
r O G r , r l t - 7 -1 f ~, u7 ~ -I I -I
~': J, O ~ -I- q O >
b1 -ri l 4-1 O b1 O cd f v ''d .
m O v u7 ~; U ~-I ~ '~ N En ~ t 1 v r as . r , 3 tn ~I , as -~1 -v ~ us ca ro ~I s.1 ~I U ~ ~ v ~ v v ~ r-I
>~ ~n 5 .-1 r-I U
v ~ 3 , 3 ~ >~ ~ v ~a ~ v r1 v ~ v ~ .u U ~a rt ~ ~ ~ ~ m -~1 . ~a ~-I ~ rn >~ -~I v ~ o ?. ~
N U7 ri '~ S-I ~ -r-1 .!-1-ri tR O i71 .i~ .h rt1 r-i -r-I .i-W d r-i r1 -rl O 'Zi U1 rti ~ u1 U f-i ~ ~-I ~ rd ~ ~, us 3 0 ~., o -~1 a-I u~ ra it >~, ~ v ~ r1 M
~n ~ .u ~ ~, v ~a ~ ra ~1 v -r1 ?-I ~ N ~ ~-I '~ U7 rd ~ ~ 3 U7 >;.,'' ~ ~I
(d d~ '~ ~r N N O U ~ U O O U .S, ''i~ '~
.1~ ~-I ~
~I td rl t~ ~ cd r-I ~ H N -rl W d cd ?i O trri U N U .~ ~ ~ ~ N --1 , N N O S~
cd N 0 p, ~I zi ~a ~1 , U ra ra rd ~I ~, 0 3 ~ ~I -- o ~ ~-1 ~ v r1 ~ ~ ~1 0 r1 ~ .~ rd U -~I ~a ra .u 3 ~1 cti .~ v ~ O ,~ m ~ N N r1 N td S-1 rt ~ O 4-1 U
U1 N td U r1 O O O ~ N Ls U ri .1J N -.-1 ~ t0 b1 1J ~.,'~ O ~C ~ .1-~ N ~
v N 1.1 f-1~ 1~ r-i ~-1 L.p.l ~I v v (~
u1 .4.a 4-1 ~ .u ,-C,' U
O r1 U 4-I r-I N U ~-,' U ciS ~-I U 'Z, U U ''~
b1 ~-I ,5r Ul -~1 w-I O O v N r1 N U C51 ~'., N O 4i (0 U
~",''d rd ~ U .1~ r1 ri ,5..,'' ",.f' .~ ~1 N N v 'R ~-I
~., -rl ?-I 4-1 U ~-I r1 N !~ O U
r1 '~
O ~,' "L3 S-I ~,' 'Ii U ''~ ~' ~I U7 r1 ''~ U U r1 'a O ~, O (0 $ .R (d O ''CS -rl (d -r1 U N ~ ~,' ~ b7 ''~ U f=,' N
-r1(d N 1.1 (a v ',.J r1 N .1J r-1 ~"., O O ~1 .1.~
~-t O ,c-I r1 ~., -rl (d ,h f; t~ v U
U) fd ,5t N r1 ~ U1 cIS
.1..1?-I ~,, U7 .-1 ~ ~.,'' O ~ U1 U Uf v U ~ v f~ f;
4-I ~: .L.) v 4-I O O w1 -ri rt ''C5 '~,'~-I ''(j O bl,~a' '~
L N rI -~', U7 r-I 1 ~'. O ~i ~ ~ U7 ,.C,' N .~, td U7 N O ~,' 1"' N ~-1 N C37 N (~ N
O ~i ~ ~-1 -r1'~ ~I O f0 fa ~-I N ~I 'L~ O (d N 1=i ~-1 .1-1 r1 '~ -r1 '~ .1-~ .l-WI r1 -r1 ~ v ~-I ~ -ri to U1 N ~-I (a ''~ r-I (~ 4-1 C,' I N ~ U U O ~ !J N r-I ~ U U N O O fd v ~,' ',7 N U7 ~ r1 O U r1 U S=,' U1 O U7 .1~
$ N f"-. ~
-~-1 U m rt ~ b~ ~ ~a v -~ ~ v o .u ,~ v ~ c~
p u~ 3 ,~ ~I o ~ ~ -~1 r1 s~ ~ -~I v U1rd .~, PIl (d .~, '~ 'Jt .~.,U1 '~ r1 O O O .1.~ ~ -r1 O U r1 U r1 ~,' .U (I$ fir' .l-1 R -r1 .~, N
M ..ti 'n' -r1 fCS O S.,' N
N -rl O (~ U r1 O ~ I ttS U c~ r1 tCS U '~ <'I <'I
.~.,~ ~,' '-O U (0 '~ U1 v r1 r1 N
a .~t rd 3 0 -~1 ~ ra u, ~ m 3 0 a~ ~u ca m ~ t~ ~a v ~a v ~d w o ~1 m ~ ~ rd ~ r1 ~ -~1 ~ ~ '~ .!-1 ~ U tn v '~ 1 v ~I '~ O ,-r1 v ~
.1.~U N -~I 'Zi O Ui N s~ N -rl ~
O v S~
?,~ m ?~ ~ M ~a .N -r-I ~I ~, ~I o v 3 ~ .u .>, -~1 rd -~1 ~ rt is v ,~ -~ .u ~ .u -r-1 ~-I ~
v -r-1 v ~1In ~I ~I o ~I ~I ~1 ~s ~s ~I ~a ~ u~ ~ v ~ ~a ~ ~
v ~a -~1 o v >~ s~ ra as ra ~ ~ 0 5 .u .u ~I .u r1 td~ (d (d I N N U ~-I .I~ 1r3 td ,5 ~,' U r1 (~
? .U W O '~ O (a ~ ~I N v U U td -r1 r1 F-I
U7 ~ S-1 U1 U1 v ~I ) ~ v U1 1 !~ to - l ~ l O
~ O -I N N CI1 N ~
W l ~ i ~-~I '~ l ~- -I b1 J
~ O -IJ --1 O b1 d -I ., -I r , ..
,.Q-ri . . r -I , r U7 - ,~ (d r r r fd -ri Id (R . ,~ I ., O ~-1 ~ ., '~ r U1 . tti -.-I tn O .~., ?~I
r r1 '~ ,5 ~''~ ~:
w-I ~-I O ''d rI ,.Q tn i; N t31 O
U 'L3 ~-I
r1.~; .~i .-I N ~ O ~I Via'' ri u1 .S=i -r-1 !-I N ~
-r-I?~1 ~-I -r-I ~ U N .G Sr' ~,' O .S', .S', ~,' N N ~-i ~ ,fir ~ w-1 ~ ~ ~ ,!~
a E-m E-~ a ?r bW E-W ~-1 ~ ~n a M C~ ~ ~u ~I ~ ~, ~I
~ w -~ .u u~ ~1 U ~I -~I -~1 ~C -~I N-1 ~
b~ .~ m ~ ,.~ ~ o N '-1 '-I
c~
~ A Z O ~ U U
N ~ ~ ~ H H
J W W W
Lfl l0 c-I d~ M N
O O O O N O
W
~1W W ~ !a O
~ w f~ H H
U
I ~.I
a~ .>, ,--I zt a~ o ~ ~ i u ~ ~ ~
~
a~ ~ c>3 c t 5 zt a a~ n .I ~ .
.!~ cd ~r fly cd .-I r1 rtS
O ~'' O U ,r~ -r1 N .I-~ ~ H cd U N U .L~ ~I
-- .1.~ ct3 .u ~ .1.~
S-I
~I ~ O cd O r-I N -ri SI >~ -i~ O
tI~ N U .1~ (d (d ~., N ~-I LnU1 , L7)'~ (C$ ~
" U U -.-I N U1 ~r ~
r-1 ~) '~ O ~,'' ~ Ir1 O '~ ~.,' r1 O
r1 U 4-I r1 r1 c~ -rl J-1 ~'., N ~-I (d f1-i H7''d U ct~ cIf -1-~ .~., ~ 4J U1 O U7 r1 O r1 ~-I
5..,'' 'd 4-I CS TJ Htn U7 r1 N 4-i ~', U cd O -r1 -r1 ~1 ~I O
N ~ l O ~
~ l U1 U
~
N O -r1 N .!--1rG'., O r1 U r r S-I ?-I ~,' . r-I (CS
r1 ~-I U . r1 G4 (CI 'LS N O ~-I Ul ~,' (0 ~"., d$ S-I fa'' .~, U v O N
U N f~ r1 .!~~-I N N ~-I .-I l.~
P N ,.~ ~, 4-1 N O 'Lf U
f.~ U S-I ~; .!-I
>~ ~ .~ cd -.-i4-I , -.-I N ~-i O ''d ~ cd ~ .i~ N U
'd 1.1 cd td 5~
~
~I -~I ~ a o 3~ ~ s~ ~I o ~ .u ~I
~I so, ~-I ~ U a~ a~ .u ~ ~I cd ' ) ~
cd '' d U1 O
~ d ~
.R di ~ , 'Tjr1 .L- c N f~ U .R C c ,5y .!-1 +~ I J
O Ip ~ .s c6 ~ ~ ~ 4-.I ~
~-I -~-I O U) N -r1 ~-I ~., ~1 -r-I U7 N r-I .N
(d rlrl~,''NO N.l~~rl(dO '~UNf~~C3f=,' N
O O ~r N rt -t~cd ~ N ~ ~I O N w-I
N ~-I ri U7 c0 ~ cd O r1 O ~ 'T3 .t-~ ~ N N ~ O cdr1 -.-1 r1 ~1 .!->
U -ri td -.-t ~ ~ -.-1 U U
N ~ N s=, U1 ~ O ~,' U1 r1O ~-1 O .~., 4-I c6 ,~,' U7 -1, U N O '~ S-I r-I U
-r1 (~ t17 r1 ~ .t~ Ul ~tR ~ ~'., O U cd cd .1-~ O ~ 'L'S ~,' r1 ~,' O
~' U7 .~ ~I
~
.ti U1 U .-) ~.,-r1 '~ U '~ 'Wrl -ri f=i ~", .J-1 ',~ cti ,-Q ?-I
N O ,~-i t57 O U1 N .I-~ r1~ U1 N O N '~ '~
~,' .U ~.,'' O N
x-1 cd ,5y -.-I N U .Nd, N rd (CS ',~ ~,' ~-1 '~ (CS ~I -I-~ ~i ~-I .!-~
r1 'O ~-1 N ~i Oa r-I J.-~ .I-~ U7r-I -~'', ~ O -.-I
U7 -rl t=,' W 5y U1 N cIS .I~
~ N O ,t-, N ~
.-I O O ''Cidi rti cd ' O ~ U ~
-s", ~ c~ ~~ .-I .~ .!~ c0 U7 ~ ~r ~ O ~' N
' ~ ~ U1 O
~ ~ 1 -'' h N -I ~ ~ . ~
O ~ l. .S
(a ~ -, - -1J ~ b) ~ U7 .-I 5 l L ~-1 S~ cIS
I O I ~1 1 WIS 1=' -I
' ICS
. r ~ N r. , - , ' ri, y f~ r . O ir., ~1 , ~ 4-I r1 U1 f~'' N ~ r-I O O U ~y4-I
U U -r1 N ' ~ ~ x'-.r-1 .!-1 yf Q~ r1 ~ ;3 U1 ',~' -.-I O
S-I ~ r-I
~'., ~,' ~ .l-I O U7 S~,U7 ~,' -r1 ~ O O
dS ctS -r-I U1 S-1 c~ r1 -r-1 r-1 N N
tT
U1 ttS U .t-~ O~ cIi -4~ .~,'.O S''., ~-rl -rl '~ U1 O ,.C; .U r1 ' ~-I cd U1 .1~
~ ~
~ ~ O ?i ~ ~; ~-.-I tR .!-> .!
,-4 ~ N N -~ -r1 ,.~ ~ ~ U
r~ N U S tn l.1. ~ ai U
O O b N ttf N f-I
~ rd ar ~
-N
l O ~ S~ f -r1 > >~ a r, ~ W cti >~' -I U7 U1r ''d cd H r1 ~; -rl -~
O O N cd U r1 -ri ~ ~ U O ~ U1 .4.~ O -.-i N ~'ZSO.1..~ U N N -rl 4-1 Cr 'Z'S U1 ~I O r1 H .1..1 -ri cIi cd U ~-I ;~ NU ~ r-I .-1 c>3 , ri c~ U7 ~ ~,'' I ~,'' >~' ''d Zi U
U ~ r1 O ~ cd O O N ~y ~y-rl ~,' N ~ ~,' O -r-I -rl r1 ~ '~ ~ -L~ ~Sa U ~ ,~ .1~ S~ ~ U
N N ,t,'' -rl b) S-I .-I
'd J.-I C-a ~
rd O ~ U1 O U O.t~ U U S-I O Ul ~,' ~ N ~.,'' di ~ ~-I r-I
~ ~-1 N W-I N ?-I ~-1N '~ N N -r1 ?-i cd .!.- N J.-~ N ~ ~C N N N cd r1 cd J-~
' 4-I r-1 4--I l1-1~''., r-1 U ~t-W -1 '~ ~i r-I .~i Ut G>a -rt .-t U N ~-I N .1J U
l ~ ~
i ~
O O
''i3 ~
~ di cd O Itf rd~ r ., ZS N ~ '~ -r '-d O
~y ~I U I .-I ,s..,-' U7 Z3 ~ I ~-I
f~ ~-I U I -~', -r1 -r1 ,~,' ,Q c>$
-.-I W G' cti ,5.~
s~ a~ tn a~ a~~I o 3 cd ~n a~ ~-I
-- .u ~, c~ ~u c~
c>3 ,E,~ c~ .u s~ -N .I~in cd ~I ~ .u ~ w is ca ~ r1 ~ ?~ ' U
.
~ ~a ca cart a~ .~ ~w ~s ~ ~
a~ w ~s tn o r1 s~ a~ o ~I ~s ca ~s ~, ' ' ' ' ' ' b7-r-Ir-I -rl r-I r1,T~ U ~ -rl r-I ~, S-I ,~ O r1 OU trf ca ri U1 U7 ~; r1 ~, !IS Jr r-I O UI O .!~ 3 ' O (I$
N r1 O I t~ ~., U 5=; cd .L~ i4 .~., .~', ~, ~, ' -r1 Ul (d U7 NLc~ ' U7 -rl .R U7 ~,' S-I CS ~.," N tip N U1 U tA N ~-1 O r1 N O
' ~
' ' " "
..~, -r-I -~-I -r-Itn N N ,Q .Q ~-1 b7 -r-I U cd ctS 1~ td U1 N
.S O r1 O ,~, O
., '~ ~-I
(d ~ ,5 f.2~ cd -L.) U1 ~.~' .-i U7 .-I U O (d ~i ~ .I~ .1~
t~ ,5..,'' O
-rl O ~ ~ ~C ~U F(,' ~
' ~ 0 ~ ~
U ~ '' ' ~
j R ~ U
Cj U -r (d ~--rl -I
" l ~-, U r ~ ~ s~
O S, -I S-I N cIS c~S
~ i - ~
-I .
N -II
-t -I ~ -''C5 'd -R ~' U
N .~ r . r '~ O ~
., ~ I ~ -rl + -I ~ ~ r O ''C3 b1 .
ca 2i l O 'd ~ ~
~ 1 H U ~-I
~
>~ . - t37r ~ ~ N
-r-I ~ . ~I f~ .!-I
-I t5~ r-I ca .-I
. to .!-~
tn r-I O
~ N
~I 5;.," ~', G:'CS 4-I -rl ~; N ri S-I O .t.1 -r-I ~: U '~y Cl .!~ G' N cti ~-1 ~; O
U1 W I (d .-1 r1N N ~': .~. a-I ri O f~ ?-I N O ?-I ~ S-1 N N O H
ca U7 ?-I U7 U1~ 'Ci ~-rl U1 ctS
.~ U r1 ~ ri ~y O CS f.~a .N ,~ r-I ~I N cIS -rl H
3 ~ ca ~ ~ ~-~I a~ .u ~I ~ ~
~ ~I ca U .u ~ ~ r1 ' ~ ' ' ca O '~ U1 J O td ~ f: N
'~ U1 '' '~Jy N U r1 U ~
' U ' 41 tv ' i-1 ' ~
N
' .1J O r-i ~ O NU U1 ~, 4-I N O ~ O r-I ~ N cd 'i3 f~' ~ ,5r ~ r-I -I td 1..1 S-1 G ~-I J
N I ri ~ O O r1 ~-I
~,' ~' O
J.-~
O .h N J.-) .1~.~. N ,L,' 1-1 r1 N aS -r1 f0 N .1-~ r1 ~ ~,' N c6 N N ri ~-I ~d ~1 .l.-~
r1 U l0 U .~.,UO ~-I .!~ ,.C,''U (A r-1 ~"., ,G 1.1 ,ii Ul N .I-1 O N
U N N N ~
' ' r;.h , ~ .!~ ~ .1~ ~t3 UI U7 .~ ~ ca U
O.!~ cd U~ f-I ?-I.i; -I
~ S-I (d ~' ~ ctf E-~ r1 ~I U ~,' (d O ~S (S ~' O W .~,' O
(a ~ -r1 ~r ~ h h -~I~ J.WI .1.~ -Vcd ~ r1 ,.~ .1.I ~
~ N ?-I ctf O O cd -.-I
U Cj U .O
of .1)-r-I U7 4-~ u1 U1S-I U7 .-. U7 cti O N ~-I -L.~ cd ri 'C3 ~
cIS
N ~.,' -~, GiUI .~'~ U7 ~' U ~
.1-) O ,~,' U1 ~' ~ ~ .l U
,~, N ~ '~ l b7 N
~ ~ l ~ N N
' 5 d ' ' -r1,si O .!-~ O cd Or .O -r X-I~ .1-I ~i UctS O G U 'd O
U7 U ~,' U U ?-I ( .1-1 E-~ B -rl ~ z -rl X11 !11 'C~ ~!~ N J-~ O ~'., (d O ri O .~'., U ,.C; cI3 Urt o w 3 ~ ~ cn .I~ o ~ r1 .u a~ ~ .u N s~ w -~I .u o s~
ca U1r1 fly r-1 U1 U7rtS S-I U J.-)U1 O U1 S-I t~ ~-I ctf cIS .~., 'LS ~-I N
U ' N
rtS
ON ~6 O ai cd-rt O N m W td I r1 f~.R u7 U O N ~ ~ N .~2 cti ~ U1 aU 3 U ?,-~I3 w ~.~ ~ +~ ~ zi 3 ~I ~
o U ;~ -~I ~n ~
.~'.,~ U1 ''d 'T3 tR O U7 t(S U
N ~-1 -r1 ~ '-' ~ 'LS
' ~ i U1 N
> U N
t' O ~~ r-i ~' cd ~y O U7 .h ~ ., CS ~~..,, .- ~r N O ~ U2 rtf .1-N ~ O 7 ~ ~
~ H
~
~
~,'' -1 .~ ~O ~ r-I N ~ cd ~ N
cd O U1 -I -r ~-1 ~
UI ~ l ~
~ ~ N
ctS
~I.!-~ S-1 O ~-1 ~-IUl r1 r1 ~,' S-I M
O c~ O ~1 ~., Ul l~ -r1 N
N O .J.) -r-i r1 r1 N
S-i ,~n'S ~ r-I ,.5~ W-r1 r1 O (IS ~ d1 -I~
n-I J.J clj N ~-I J.-) ~C, U
U7 U1 ~I U1 .l~ 'Z'S .~ J.-I
.!-.-Ir-I .-I -~-1w1 r1~ ctS S: ,~ .-I cIi O O N O ~I -.-I O .1-I
.-i .-I ~-1 clS 5~ -~ >~ ~-I
O SC
~l4-I rl Ul rl ~lH b7 U .u +~ ~l ctS
U U ~ ~r ,~,' 1~ W W cd '~ '~ U ~', cd tt~ -r-1 N cd H
U U U~ U
H H ~ H
N HU
f.~ ~ S~W
M r1 r-1~-I N
O O OO O
,'J O DCH ',7 ' H~ x 7~ ~ f o ~ a w W ~ .,~ ~ ~ I o o ,n ~ ..~ on ~ c. ~ o v--i ~ W N O ~ ~.r M of I Pr ~ 'G ~ ~ i > t-n "Zs ~ ~ ~ ~ cd ~ O ~i N ~O ~ V7 O i~ V ,..NNr N ~p ~ U ~ ri > ~ N ~ ""' ~ o o ~ o II
,D ~ ~ ~ ~ N O ~ ~ ~ i~ ~ ~n 1-i V .U .~., W ~ w N bA O .'~~., I I ~, r i ,w; ~ o 04 ~ ~ ~ ~ ~ '~ 04 0 , '~ ~. d ',.' p., y 4-i ,.D ,.., ~ U ~ ~~ O ~. t-~
~w ~
W o ~i > W ~ o~, ~ ~ ~i w ~ g ~ ~ ~o U i.-;;
U
O ~ 00 ~ ~ U ~ ~ ' ' r, ~ t~ O~ op D
. ~ m ov z C7 ,-, o °' o °' ~ a r_. ~ ' '-' ~ N a~ ,-.
U U U ~ ~ °' °° "~ ~ °' '~ ~ ~ N ' a M b a~'.~
a ~ o " N ~ ~ :x ~ °' t~ G4 W ~ o o .~ ~ ~ x ,-.
U U U ~ ~ ~ ~ ~ ~s ~ o x W ~ ~r o i N ~. a, °~,''' °~,~''' d ~ ~ u'! °° ~'' 'h ~ "~
°° :x '° M $' ~ ° >
0 o U o ~ ~ M '~ vi ~ ~ N ~ ~ .~,°c o . ' ~~
w w ~ w ~ ~~ ~:~W~~ x b a, ~, p, >, m ' U ~ c~ os ~ c~ o is 0 0 ° o Gz!o:° ~v~~.E-,~ ~" U i~
o en ~' ~ ° ' ~ ~ '~ U
ix1 f~ ~ 0.1 ~ d' d 3 ~ o°', '~ ~ ~ i .°x ~ ~ ~ ' ~' ~ Q"
~o.~ od %~d x~ ~~~ ..c~~
--i cs: d d r~. d d c~ Z w Z ~ ~ d x d vi c~ U "~ c~ ... to Z
H
~ o ~ ~ ~ w U v, N _cC 4~ ~ ~ ~ b~A
'O .f", U .Ut'., '~ U .O ~ O N rUn ,b y ~ O ~ > .b ,~ b-0 ' ,~f.",~ SG cC C/1 ° N ~ cn w ~' p O p~ ~ '+~ ~ U c~ ~r ~ ~ ~ ~b ~ ~ cG
fr' ~d bA ~ ~ L~ U b ~ ~ G O ~' V m ~ '~ ai U
p ,.d ;b ~ ccs ~ t~ U ~ c~ ~,, ~ >,"
p" c0 .~ U ~ O °~'" U ~ V d m ~ ~ ,FCC, O ~' N vi cC (~ . ~ ~ ~ .f. (~ w ~ ~ ~ ~ ~ c'nG U
s.. ~ o .v °~ U ~ E-' Y
U ,~ ~ ~, '~ Y ~ w ~' i~ p o ~r w° a ~ o ~' ~ w .C a "G ~ c~
O ~ pp ~ U Pa ~ U O ~ ~ v~
m 4~ 0 U ~tU~- .~ ~,~UJ~~ ~'~'O~
O 'O N 'yn ~ C N cct ~ N ~ t-, U ~n O~ OU N ~~nUaf ~a3~4r ~O ~ .~.' U'bcUn N N cG . Y N ..O .~prr N v~ ~ > a~.yn . m O .f, .~ O G .~" a~ d ~R C .gyp'' ~"~ U N O ~ m p ~ ~,' ~ ~ O
cd c~ N tn 3 ~~ ~~' .y"'~, ~ .~ N 4a 7 o w ~ ~ ~ ~s "° " a p ,~
o 'Y ~ Y ~ 'Y o .~ ;o a ~ .n o ~ ~ .~ p;
p., w °
on '~ A ~~ ~'n ~° a .~ o ~ '~ ~ ~ ~ o ~ O ~ a o°n >~ ,~
s~ ~ w ~ o. Pa ~r ~ ~ P-. ~ ~r ~ c~ ~ a' p s. o -d o A d ~ d ~ d d ~ a ~ d '~ ~ ,°' ~ d ~ A w° '~ ~ :c a.
w .n w H
e~c ~ ~ E~ d W
w ~ ~ ~ ~ w U -o ~ ~°
o °' :~ °' ~D
O ~ '~ O ~j~' y ~.., y.., .~ ~ C7 ~ ~u H a" ~ 0 0 0 .c o ..~. U ~ ~p .-i i~r ~ ' G O ~ O N
w z ~~.~ ~~ ~ _ N .~T ~.j N ~"
Vj O by ~ ~ H ~ N ~
p ~ ~ ~ ~ .O O
~ O~ ~ ~ ~ Or, ~ p ~/ N
O ~ ~ ~ ~ O C~ W
~-o~ ~~ o~,~~f.~t~~ ~ .~~ ion o0 c H ~ ~ ~ ~ ~ ~~ ~ ~ ~ U _~ ~ o i ~ N ~ ~ ~ '~ ;~ o ~ o ~a; ~ ~ b ~ ~° ~ .x a~ ~ C7 v ~ ~ c~ o r; ~ ,.,_, a o v~ ~ ~ ov ~' a~ ~ P4 0 0 ~. .b V ~ .-. ~ ~'s°' w °~ b oo ~ cn . C7 P, ~., '. ~ o oho oho '~ CV ~ .~, ~ '~ p ~ ~. i~, cd p f-4 , ~ ~"'" U .~ dD Pn oW'~ ~~oo '~'' ~ o°°, ~~~ ouoi ~~~' ° ~p.'U
M ~ M .~ " y c~ cC '~ N ~ ~ ~ ~ ~O ,~ S''~ ~ ~ U ~ ~ N ~O n'~ N b ~ ~_. ~ U
N N FG ~ ..~-~ ~ .d d' oo ~ eC c'~ 'Gi M ~o P-~ M W '~~~ _~ y,°~'~
_~ ~ ~:
'-' W p cC N CL, N O ~ nj ~ N ~ N ~ _~ ~ O P-i N
N
~ > > ' ~' d o~"o a~ ~' ~c ~ ~ 3 ~ x U ~ ~ v~ ~' a~ ~ ~ y L7 .x due' .~ ~ '~ ~ E' ~ ~ ~ ai ~p o ~ ~ o ~ .~ .C ° ~
°O..° v ~
cn cn ~ G7 ~ 00 ~ F"'y--i y ~, ~y'i bA :--n p U i 4., ~ ;n ~,; ~ .~ ~ ~ :~ r,., ~ b a ~ i ~ ~ ~ r p ~ ~ a ; '~ ~' v ~ ~~°°z w~~ ~~~ ~~ ~ z°U wNa~
N ~ 'n o a~ ~ ~ '~ on ~ ° v U ~ ~, E"~ ,~, L~ N .b ~ p ccf p, 'O ~ GJ U .1"Ur U far T7 a"
W
y> ~I O Q. ~ ~ cct U .-~. O
O" ~ ~ b ~~ ,_., ~ R,a ~ . N ~ b 'gyp N
~F." ~ L~'. w U in b p ~ ~ C
'W n ~ V ~ O ~ b0 ~ ~ O
V ~ ,~ ~U ~ .Y ~ O m > ~
U ~ ~.. by b "~ y U '~ ?pG w ~3 .,t', ..'''', ~ U ~ ~~ b U ~,~ O
~, ~ U ~ O O ~ '~" ~ by '~ c~ ~" ~ -~. O P-i W v~ c~C ~ pr ~ .O ~ b-0 O O ~ ~ N ~
O ,~.~ ,.~ ~ s' ~ '~ ~ P. N .C O 'b n b cC~ Y~ ~~~~ ~> ~y 3U~ cdt~-ny V y a~ o~ y ~ ~ ~ ,~ ~ ~. ~ ~ o v~ .~ ~ b on 3 ~' '~ a~ can o ~ r~. a~ ou . a~ ~ ~ ~ a~
ayi ~ eu .r o 4. ~s ~
as ~ ~ ~ ~~ o ~ ~ '~: -~ ~ ,a ~ o ~ Pi :.-~ .~ ~N U :'' ,.C c~ ~ ~ ~ .D O ,~ U
'~ bOp cn b N C"» ~ ~ ~ G p, .fl by ~ ~ ~ '~ WJ ~ N
iG~C t'~d~ .C~~~ y~"y O~ ~w ~~'p O .i~.
.~r b ~ ~ P-i O ~ ~ b4 ~ 3 ~ s~. ~ ~ t3, ~ ~ p. cC
~ U o ~ ~ ~ ~ ~ d ~ -o d -d ca ~ ..c U
'C ø~ U ~ 4r m U
CL w P'~-. ~ U ~ ~ H
<110> INCYTE GENOMICS, INC.
THORNTON, Michael PATTERSON, Chandra LAL, Preeti BURFORD, Neil YUE, Henry GANDHI, Ameena R.
ELLIOTT, Vicki S.
RAMKUMAR, Jayalaxini BAUGHN, Mariah R.
KALLICK, Deborah A.
WALIA, Narinder K.
HAFALIA,April J.A.
YAO, Monic,~ue G.
LU, Yan TRIBOULEY, Catherine M.
POLICKY, Jennifer L.
KEARNEY, Liam GRAUL, Richard WARREN, Bridget LEE, Ernestine A.
DING, Li <120> G-PROTEIN COUPLED RECEPTORS
<130> PI-0176 PCT
<140> To Be Assigned <141> Herewith <150> 60/221,478; 60/223,268; 60/227,054; 60/231,121; 60/232,243;
60/232,691; 60/235,146 151> 2000-07-27; 2000-08-03; 2000-08-21; 2000-09-08; 2000-09-23;
2000-09-15; 2000-09-22 <160> 38 <170> PERL Program <210> 1 <211> 339 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474806CD1 <400> 1 Met Leu Ser Ile Leu Leu Pro Ser Arg Gly Ser Arg Ser Gly Ser Arg Arg Gly Ala Leu Leu Leu Glu Gly A1a Ser Arg Asp Met Glu Lys Va1 Asp Met Asn Thr Ser Gln Glu Gln Gly Leu Cys Gln Phe Ser Glu Lys Tyr Lys Gln Val Tyr Leu Ser Leu Ala Tyr Ser Ile Ile Phe Ile Leu Gly Leu Pro Leu Asn Gly Thr Val Leu Trp His Ser Trp Gly Gln Thr Lys Arg Trp Ser Cys Ala Thr Thr Tyr Leu Val Asn Leu Met Val Ala Asp Leu Leu Tyr Va1 Leu Leu Pro Phe Leu Ile Ile Thr Tyr Ser Leu Asp Asp Arg Trp Pro Phe Gly Glu Leu Leu Cys Lys Leu Val His Phe Leu Phe Tyr Ile Asn Leu Tyr Gly Ser Ile Leu Leu Leu Thr Cys Ile Ser Val His Gln Phe Leu Gly Val Trp His Pro Leu Cys Ser Leu Pro Tyr Arg Thr Arg Arg His Ala Trp Leu Gly Thr Ser Thr Thr Trp Ala Leu Va1 Val Leu Gln Leu Leu Pro Thr Leu A1a Phe Ser His Thr Asp Tyr Ile Asn Gly Gln Met Ile Trp Tyr Asp Met Thr Ser Gln Glu Asn Phe Asp Arg Leu Phe Ala Tyr Gly Ile Val Leu Thr Leu Ser Gly Phe Leu Ser Pro Ser Leu Val Ile Leu Val Cys Tyr Ser Leu Met Val Arg Ser Leu Ile Lys Pro Glu G1u Asn Leu Met Arg Thr Gly Asn Thr Ala Arg Ala Arg Ser Ile Arg Thr Ile Leu Leu Val Cys Gly Leu Phe Thr Leu Cys Phe Val Pro Phe His Ile Thr Arg Ser Phe Tyr Leu Thr Ile Cys Phe Leu Leu Ser Gln Asp Cys Gln Leu Leu Met Ala Pro Ser Val Ala Tyr Lys Ile Trp Arg Pro Leu Val Ser Val Ser Ser Cys Leu Asn Pro Val Leu Tyr Phe Leu Ser Arg Gly Ala Lys Ile Glu Ser Gly Ser Ser Arg Asn <210> 2 <211> 335 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474840CD1 <400> 2 Met Thr Pro G1y Gly Arg Ala Cys Ser Glu Met Arg Ser Cys His Cys Ala Pro Ala Trp Ala Thr Glu Arg Asp Ser Val Ser Lys Lys Lys Lys Asn Lys Lys Lys Asn Leu Phe Ser Gln Ala Thr Ile Gly Leu Leu Ala Asn Thr Phe Phe Leu Phe Phe Asn Ile Phe Ile Phe Leu Gln Asp Gln Lys Ser Lys Pro His Asp Leu Ile Ser Cys Asn Ser Ala Phe Ile His Val Val Met Phe Leu Thr Val Val Asp Ala Trp Pro Pro Asp Met Pro Glu Ser Leu His Leu Gly Asn Glu Phe Lys Phe Lys Ser Leu Ser Tyr Ile Asn Arg Val Arg Met Gly Leu Cys Ile Cys Asn Ile Cys Leu Leu Ser Ile His Gln Ala Asn Thr I1e Ser Pro Asn Asn Phe Cys Leu Ala Arg Leu Lys Gln Lys Phe Thr Asn Asn Ile Ile Met Ser Ser Phe Phe Ser Phe Phe Phe Trp Ser Ile Asn Leu Ser Phe Ser Tyr Asn Ile Va1 Phe Phe Thr Val Ala Ser Ser Asn Val Thr Gln Asn Ser Leu Pro Lys Gly Ser Asn Thr Val His Phe Leu Pro Met Lys Ser Phe Met Arg Lys Val Phe Phe Thr Leu Thr Leu Ser Arg Asp Val Phe Ile Ile Gly Ile Thr Leu His Ser Ile Ala His Met Val Ile Leu Val Ser Arg His Glu Thr Gln Ser Gln His Leu His Ser Ile Ser Ile Ser Pro Gln Ala Phe Pro Glu Lys Arg Ala Ala Gln Thr Ile Pro Leu Leu Val Ser Tyr Cys Leu Val Met Cys Trp Val Asp Leu Ile Ile Ser Ser Ser Ser Thr Leu Leu Trp Thr Cys Asn Pro Val Phe Leu Ser Met Gln Asn Leu Val Gly Asp Val Tyr Ala Thr Val Val Leu Leu Glu Gln Ile Ser Ser Asp Lys Asn Ile Val Asp Ile Leu Gln Asn Met Gln Ser Ala Ile Lys Leu <210> 3 <211> 428 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7475092CD1 <400> 3 Met Gln Arg Lys G1u Lys Ala Lys Cys Pro Gln Glu A1a Pro Ala Gly Arg Glu Pro Ser Thr Pro Gly Gly Gly Ser Gly G1y Gly Gly Ala Val Ala Ala A1a Ser Gly Ala Ala Val Pro Gly Ser Val Gln Leu Ala Leu Ser Val Leu His Ala Leu Leu Tyr Ala Ala Leu Phe Ala Phe Ala Tyr Leu Gln Leu Trp Arg Leu Leu Leu Tyr Arg Glu Arg Arg Leu Ser Tyr G1n Ser Leu Cys Leu Phe Leu Cys Leu Leu Trp Ala Ala Leu Arg Thr Thr Leu Phe Ser Ala Ala Phe Ser Leu Ser Gly Ser Leu Pro Leu Leu Arg Pro Pro Ala His Leu His Phe Phe Pro His Trp Leu Leu Tyr Cys Phe Pro Ser Cys Leu Gln Phe Ser Thr Leu Cys Leu Leu Asn Leu Tyr Leu Ala Glu Val Ile Cys Lys Val Arg Cys Ala Thr Glu Leu Asp Arg His Lys Ile Leu Leu His Leu Gly Phe Ile Met Ala Ser Leu Leu Phe Leu Val Val Asn Leu Thr Cys A1a Met Leu Val His Gly Asp Val Pro Glu Asn Gln Leu Lys Trp Thr Val Phe Val Arg Ala Leu Zle Asn Asp Ser Leu Phe Ile Leu Cys Ala Ile Ser Leu Val Cys Tyr Ile Cys Lys Ile 215 .220 225 Thr Lys Met Ser Ser Ala Asn Val Tyr Leu Glu Ser Lys Gly Met Ser Leu Cys Gln Thr Val Val Val Gly Ser Val Val Ile Leu Leu Tyr Ser Ser Arg Ala Cys Tyr Asn Leu Val Val Val Thr Ile Ser Gln Asp Thr Leu Glu Ser Pro Phe Asn Tyr G1y Trp Asp Asn Leu Ser Asp Lys Ala His Val Glu Asp Ile Ser Gly Glu Glu Tyr Ile Val Phe Gly Met Val Leu Phe Leu Trp Glu His Val Pro Ala Trp Ser Val Val Leu Phe Phe Arg Ala Gln Arg Leu Asn Gln Asn Leu Ala Pro Ala Gly Met I1e Asn Ser His Ser Tyr Ser Ser Arg Ala Tyr Phe Phe Asp Asn Pro Arg Arg Tyr Asp Ser Asp Asp Asp Leu Pro Arg Leu Gly Ser Ser Arg Glu Gly Ser Leu Pro Asn Ser G1n Ser Leu Gly Trp Tyr Gly Thr Met Thr Gly Cys G1y Ser Ser Ser Tyr Thr Val Thr Pro His Leu Asn Gly Pro Met Thr Asp Thr Ala Pro Leu Leu Phe Thr Cys Ser Asn Leu Asp Leu Asn Asn His His Ser Leu Tyr Val Thr Pro Gln Asn <210> 4 <211> 330 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7341260CD1 <400> 4 Met Thr Pro Asn Ser Thr G1y Glu Val Pro Ser Pro Ile Pro Lys Gly Ala Leu Gly Leu Ser Leu Ala Leu Ala Ser Leu Ile Ile Thr Ala Asn Leu Leu Leu Ala Leu Gly Ile Ala Trp Asp Arg Arg Leu Arg Ser Pro Pro Ala Gly Cys Phe Phe Leu Ser Leu Leu Leu Ala Gly Leu Leu Thr Gly Leu Ala Leu Pro Thr Leu Pro Gly Leu Trp Asn Gln Ser Arg Arg Gly Tyr Trp Ser Cys Leu Leu Val Tyr Leu Ala Pro Asn Phe Ser Phe Leu Ser Leu Leu Ala Asn Leu Leu Leu Va1 His Gly Glu Arg Tyr Met Ala Val Leu Arg Pro Leu Gln Pro Pro Gly Ser Ile Arg Leu Ala Leu Leu Leu Thr Trp Ala Gly Pro Leu Leu Phe A1a Ser Leu Pro Ala Leu Gly Trp Asn His Trp Thr Pro Gly Ala Asn Cys Ser Ser Gln Ala Ile Phe Pro Ala Pro Tyr Leu Tyr Leu Glu Val Tyr Gly Leu Leu Leu Pro Ala Val Gly Ala Ala Ala Phe Leu Ser Val Arg Val Leu Ala Thr Ala His Arg Gln Leu Gln Asp Ile Cys Arg Leu Glu Arg Ala Val Cys Arg Asp Glu Pro Ser Ala Leu Ala Arg Ala Leu Thr Trp Arg Gln Ala Arg Ala Gln Ala Gly Ala Met Leu Leu Phe Gly Leu Cys Trp Gly Pro Tyr Val Ala Thr Leu Leu Leu Ser Val Leu Ala Tyr Glu Gln Arg Pro Pro Leu Gly Pro Gly Thr Leu Leu Ser Leu Leu Ser Leu Gly Ser Ala Ser Ala Ala Ala Val Pro Va1 Ala Met Gly Leu Gly Asp Gln Arg Tyr Thr Ala Pro Trp Arg Ala Ala Ala Gln Arg Cys Leu Gln Gly Leu Trp Gly Arg Ala Ser Arg Asp Ser Pro Gly Pro Ser Ile Ala Tyr His Pro Ser Ser Gln Ser Ser Val Asp Leu Asp Leu Asn <210> 5 <211> 676 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7473911CD1 <400> 5 Met Asn Lys Asn Asn Lys Pro Ser Ser Phe Ile A1a Ile Arg Asn Ala Ala Phe Ser Glu Val Gly Ile Gly Ile Ser A1a Asn Ala Met Leu Leu Leu Phe His Ile Leu Thr Cys Leu Leu Lys His Arg Thr Lys Pro Ala Asp Leu Ile Val Cys His Val Ala Leu Ile His Ile Ile Leu Leu Leu Pro Thr Glu Phe Ile Ala Thr Asp Ile Phe Gly Ser Gln Asp Ser Glu Asp Asp Ile Lys His Lys Ser Val Ile Tyr Arg Arg Asn Arg Gln Ser Gln His Phe His Ser Thr Asn Leu Ser Pro Lys Ala Pro Pro Glu Lys Met Ala Thr Gln Thr Ile Leu Leu Leu Val Ser Cys Phe Val Ile Val Tyr Val Leu Asp Cys Val Val Ala Ser Cys Ser Gly Leu Val Trp Asn Ser Asp Pro Val Arg His Arg Val Gln Met Leu Val Asp Asn Gly Tyr Ala Thr Ile Ser Pro Ser Val Leu Pro Arg Leu Thr Ala Pro Asn Glu Trp Arg Ala Ser Val Tyr Leu Asn Asp Ser Leu Asn Lys Cys Ser Asn Gly Arg Leu Leu Cys Val Asp Arg Gly Leu Asp Glu Gly Pro Arg Ser Val Pro Lys Cys Ser Glu Ser Glu Thr Asp Glu Asp Tyr Ile Va1 Leu Arg Ala Pro Leu Arg Glu Asp Glu Pro Lys Asp Gly Gly Ser Val Gly Asn Ala Ala Leu Val Ser Pro Glu Ala Ser Ala Glu Glu Glu Glu Glu Arg Glu Glu Gly Gly Glu A1a Cys Gly Leu Glu Arg Thr Gly Ala Gly G1y Glu Gln Val Asp Leu Gly Glu Leu Pro Asp His Glu Glu Lys Ser Asn Gln Lys Val Ala Ala Ala Thr Leu Glu Asp Arg Thr Gln Asp Glu Pro Ala Glu Glu Ser Cys Gln Ile Val Leu Phe Gln Asn Asn Cys Met Asp Asn Phe Val Thr Ser Leu Thr Gly Ser 320 ~ 325 330 Pro Tyr Glu Phe Phe Pro Thr Lys Ser Thr Ser Phe Cys Arg Glu Ser Cys Ser Pro Phe Ser Glu Ser Val Lys Ser Leu Glu Ser Glu Gln Ala Pro Lys Leu Gly Leu Cys Ala Glu Glu Asp Pro Val Val Gly Ala Leu Cys Gly Gln His Gly Pro Leu Gln Asp Gly Val Ala Glu Gly Pro Thr Ala Pro Asp Val Val Val Leu Pro Lys Glu Glu Glu Lys Glu Glu Val Ile Val Asp Asp Met Leu Ala Asn Pro Tyr Val Met Gly Asp Glu Gly Glu Glu Glu Glu Glu Glu Phe Va1 Asp Asp Thr Leu Ala Asn Pro Tyr Val Met Gly Val Gly Leu Pro Gly Arg Gly Gly Glu Glu Glu Glu Glu Glu Glu Va1 Val Asp Asp Thr Leu Ala Ser Leu Tyr Lys Met Gly Glu Glu His Arg His Lys Gly Leu Ala Pro Leu Trp Glu Gly Gly Gln Lys Pro Ser Gln Lys Leu Pro Pro Lys Lys Pro Asp Leu Arg Gln Val Pro Gln Pro Leu Ala Ser Glu Val Pro Gln Arg Arg Gln Glu Arg Ala Val Val Thr Glu Gly Arg Pro Leu Glu Ala Ser Arg Ala Leu Pro Ala Lys Pro Arg Ala Phe Thr Leu Tyr Pro Arg Ser Phe Ser Val Glu Gly Gln Glu I1e Pro Val Ser Ile Ser Val Tyr Trp Glu Pro Glu Gly Ser Gly Leu Asp Asp His Arg Ile Lys Arg Lys Glu Glu His Leu Ser Val Val Ser Gly Ser Phe Ser Gln Arg Asn His Leu Pro Ser Ser Gly Thr Ser Thr Pro Ser Ser Met Val Asp Ile Pro Pro Pro Phe Asp Leu Ala Cys Ile Thr Lys Lys Pro Ile Thr Lys Ser Ser Pro Ser Leu Leu Ile Asp Ser Asp Ser Pro Asp Lys Tyr Lys Lys Lys Lys Ser Ser Phe Lys Arg Phe Leu Ala Leu Met Phe Asn Lys Met Glu 650 655 ~ 660 Arg Pro Gly Thr Met Ala His Ala Cys His Pro Ser Thr Leu Gly Ser <210> 6 <211> 372 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474767CD1 <400> 6 Met Glu His Thr His Ala His Leu Ala Ala Asn Ser Ser Leu Ser Trp Trp Ser Pro Gly Ser Ala Cys Gly Leu Gly Phe Val Pro Val Val Tyr Tyr Ser Leu Leu Leu Cys Leu Gly Leu Pro Ala Asn Ile Leu Thr Val Ile Ile Leu Ser Gln Leu Val Ala Arg Arg Gln Lys Ser Ser Tyr Asn Tyr Leu Leu Ala Leu Ala Ala Ala Asp Ile Leu Val Leu Phe Phe Ile Val Phe Va1 Asp Phe Leu Leu Glu Asp Phe Ile Leu Asn Met Gln Met Pro Gln Val Pro Asp Lys Ile Ile Glu Val Leu Glu Phe Ser Ser I1e His Thr Ser Ile Trp Ile Thr Val Pro Leu Thr Ile Asp Arg Tyr Ile Ala Val Cys His Pro Leu Lys Tyr His Thr Val Ser Tyr Pro Ala Arg Thr Arg Lys Val Ile Val Ser Val Tyr Ile Thr Cys Phe Leu Thr Ser Ile Pro Tyr Tyr Trp Trp Pro Asn Ile Trp Thr Glu Asp Tyr Ile Ser Thr Ser Val His His Val Leu Ile Trp Ile His Cys Phe Thr Val Tyr Leu Val Pro Cys Ser Ile Phe Phe Ile Leu Asn Ser Ile Ile Val Tyr Lys Leu Arg Arg Lys Ser Asn Phe Arg Leu Arg Gly Tyr Ser Thr Gly Lys Thr Thr Ala Ile Leu Phe Thr Ile Thr Ser Ile Phe Ala Thr Leu Trp Ala Pro Arg Ile Ile Met Ile Leu Tyr His Leu Tyr Gly Ala Pro Ile Gln Asn Arg Trp Leu Val His Ile Met Ser Asp Ile Ala Asn Met Leu Ala Leu Leu Asn Thr Ala Ile Asn Phe Phe Leu Tyr Cys Phe Ile Ser Lys Arg Phe Arg Thr Met Ala Ala Ala Thr Leu Lys Ala Phe Phe Lys Cys Gln Lys Gln Pro Val Gln Phe Tyr Thr Asn His Asn Phe Ser Ile Thr Ser Ser Pro Trp Ile Ser Pro Ala Asn Ser His Cys Ile Lys Met Leu Val Tyr Gln Tyr Asp Lys Asn Gly Lys Pro I1e Lys Ser Arg Asn Asp Ser Lys Ser Ser Tyr Gln Phe Glu Asp Ala Ile Gly Ala Cys Val Ile Ile Leu <210> 7 <211> 271 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7475815CD1 <400> 7 Met Asn Lys Asn Asn Lys Pro Ser Ser Phe Ile Ala Ile Arg Asn Ala Ala Phe Ser Glu Val G1y Ile Gly Ile Ser Ala Asn A1a Met Leu Leu Leu Phe His Ile Leu Thr Cys Leu Leu Lys His Arg Thr Lys Pro Ala Asp Leu Ile Val Cys His Val Ala Leu Ile His Ile Ile Leu Leu Leu Pro Thr Glu Phe Ile Ala Thr Asp Ile Phe Gly Ser Gln Asp Ser Glu Asp Asp Tle Lys His Lys Ser Val Ile Tyr Arg Tyr Arg Leu Met Arg Gly Leu Ser Ile Ser Thr Thr Cys Leu Leu Ser Ile Leu Pro Ala Ile Thr Cys Ser Pro Arg Ser Ser Cys Leu Ala Val Phe Lys Asp Ser His Ile Thr Asn His Val Ala Phe Ser Ser Val Phe His Ile Ser Ile Ser Asp Ser Phe Leu Val Ser Thr Leu Pro Ile Lys Asn Leu Ala Ser Asn Ser Leu Thr Phe Val Thr Gln Ser Cys Ser Ala Gly Tle Gly Ser Arg Pro Pro Ser Ser Gly Tyr Met Val Ile Leu Leu Ser Arg Arg Asn Arg Gln Ser Gln His Phe His Ser Thr Asn Leu Ser Pro Lys Ala Pro Pro Glu Lys Met Ala Thr Gln Thr Ile Leu Leu Leu Val Ser Cys Phe Val Ile Val Tyr Val Leu Asp Cys Va1 Val Ala Ser Cys Ser Gly Leu Val Trp Asn Ser Asp Pro Va1 Arg His Arg Val Gln Met Leu Val Asp Asn Gly Tyr Ala Thr Ile Ser Pro Ser Val Leu Va1 Ser Thr Glu Lys <210> 8 <211> 611 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 60263275CD1 <400> 8 Met Gln Gly Pro Leu Leu Leu Pro Gly Leu Cys Phe Leu Leu Ser Leu Phe Gly Ala Val Thr Gln Lys Thr Lys Asn Ile Asn Glu Cys Thr Pro Pro Tyr Ser Val Tyr Cys Gly Phe Asn Ala Val Cys Tyr Asn Val Glu Gly Ser Phe Tyr Cys Gln Cys Val Pro Gly Tyr Arg Leu His Ser Gly Asn Glu Gln Phe Ser Asn Ser Asn Glu Asn Thr Cys Gln Asp Thr Thr Ser Ser Lys Thr Thr Gln Gly Arg Lys Glu Leu Gln Lys Ile Val Asp Lys Phe Glu Ser Leu Leu Thr Asn Gln Thr Leu Trp Arg Thr Glu Gly Arg Gln Glu Ile Ser Ser Thr Ala 1l0 115 120 Thr Thr Ile Leu Arg Asp Val Glu Ser Lys Val Leu Glu Thr Ala 125 130 l35 Leu Lys Asp Pro Glu Gln Lys Val Leu Lys Ile Gln Asn Asp Ser Val Ala Ile Glu Thr Gln Ala Ile Thr Asp Asn Cys Ser Glu Glu Arg Lys Thr Phe Asn Leu Asn Val Gln Met Asn Ser Met Asp Ile Arg Cys Ser Asp Ile Ile Gln Gly Asp Thr Gln Gly Pro Ser Ala Ile Ala Phe Ile Ser Tyr Ser Ser Leu Gly Asn Ile Ile Asn Ala Thr Phe Phe Glu Glu Met Asp Lys Lys Asp Gln Val Tyr Leu Asn Ser Gln Val Val Ser Ala Ala Ile G1y Pro Lys Arg Asn Val Ser Leu Ser Lys Ser Val Thr Leu Thr Phe Gln His Val Lys Met Thr Pro Ser Thr Lys Lys Val Phe Cys Val Tyr Trp Lys Ser Thr Gly Gln Gly Ser Gln Trp Ser Arg Asp Gly Cys Phe Leu Ile His Val Asn Lys Ser His Thr Met Cys Asn Cys Ser His Leu Ser Ser Phe Ala Val Leu Met Ala Leu Thr Ser Gln Glu Glu Asp Pro Val Leu Thr Val Ile Thr Tyr Val Gly Leu Ser Val Ser Leu Leu Cys Leu Leu Leu Ala Ala Leu Thr Phe Leu Leu Cys Lys Ala Ile Gln Asn Thr Ser Thr Ser Leu His Leu Gln Leu Ser Leu Cys Leu Phe Leu Ala His Leu Leu Phe Leu Val Gly Ile Asp Arg Thr G1u Pro Lys Val Leu Cys Ser Ile Ile Ala Gly Ala Leu His Tyr Leu Tyr Leu Ala A1a Phe Thr Trp Met Leu Leu Glu Gly Val His Leu Phe Leu Thr Ala Arg Asn Leu Thr Va1 Val Asn Tyr Ser Ser Ile Asn Arg Leu Met Lys Trp Ile Met Phe Pro Val Gly Tyr Gly Val Pro Ala Val Thr Val Ala I1e Ser Ala Ala Ser Trp Pro His Leu Tyr Gly Thr A1a Asp Arg Cys Trp Leu His Leu Asp Gln Gly Phe Met Trp Ser Phe Leu Gly Pro Val Cys Ala Ile Phe Ser Ala Asn Leu Val Leu Phe Ile Leu Val Phe Trp Ile Leu Lys Arg Lys Leu Ser Ser Leu Asn Ser G1u Val Ser Thr Ile Gln Asn Thr Arg Met Leu A1a Phe Lys Ala Thr Ala Gln Leu Phe Ile Leu Gly Cys Thr Trp Cys Leu Gly Leu Leu Gln Val Gly Pro Ala A1a G1n Val Met Ala Tyr Leu Phe Thr Ile Ile Asn Ser Leu Gln Gly Phe Phe Ile Phe Leu Val Tyr Cys Leu Leu Ser Gln Gln Val Gln Lys Gln Tyr Gln Lys Trp Phe Arg Glu Ile Val Lys Ser Lys Ser Glu Ser Glu Thr Tyr Thr Leu Ser Ser Lys Met Gly Pro Asp Ser Lys Pro Ser Glu G1y Asp Val Phe Pro Gly Gln Val Lys Arg Lys Tyr <210> 9 <211> 1469 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 60203310CD1 <400> 9 Met Trp Pro Ser Gln Leu Leu Ile Phe Met Met Leu Leu Ala Pro Ile Ile His Ala Phe Ser Arg Ala Pro I1e Pro Met Ala Val Val Arg Arg Glu Leu Ser Cys Glu Ser Tyr Pro Ile G1u Leu Arg Cys Pro Gly Thr Asp Val Tle Met Ile Glu Ser Ala Asn Tyr Gly Arg Thr Asp Asp Lys Ile Cys Asp Ser Asp Pro Ala Gln Met Glu Asn Ile Arg Cys Tyr Leu Pro Asp Ala Tyr Lys Ile Met Ser Gln Arg Cys Asn Asn Arg Thr Gln Cys Ala Val Val Ala Gly Pro Asp Val Phe Pro Asp Pro Cys Pro G1y Thr Tyr Lys Tyr Leu Glu Val Gln Tyr G1u Cys Val Pro Tyr Lys Val Glu Gln Lys Val Phe Leu Cys Pro G1y Leu Leu Lys Gly Val Tyr Gln Ser Glu His Leu Phe Glu Ser Asp His Gln Ser Gly Ala Trp Cys Lys Asp Pro Leu Gln Ala Ser Asp Lys Ile Tyr Tyr Met Pro Trp Thr Pro Tyr Arg Thr Asp Thr Leu Thr Glu Tyr Ser Ser Lys Asp Asp Phe Ile Ala Gly Arg Pro Thr Thr Thr Tyr Lys Leu Pro His Arg Val Asp Gly Thr Gly Phe Val Val Tyr Asp Gly Ala Leu Phe Phe Asn Lys Glu Arg Thr Arg Asn Ile Val Lys Phe Asp Leu Arg Thr Arg Ile Lys Ser Gly Glu Ala Ile Ile Ala Asn Ala Asn Tyr His Asp Thr Ser Pro Tyr Arg Trp G1y G1y Lys Ser Asp Ile Asp Leu Ala Va1 Asp Glu Asn Gly Leu Trp Val Ile Tyr Ala Thr Glu Gln Asn Asn Gly Lys Ile Thr A1a Asp Arg Cys Trp Leu His Leu Asp Gln Gly Phe Val Ile Ser G1n Leu Asn Pro Tyr Thr Leu Arg Ile Glu Gly Thr Trp Asp Thr Ala Tyr Asp Lys Arg Ser Ala Ser Asn Ala Phe Met Ile Cys Gly Ile Leu Tyr Val Val Lys Ser Val Tyr Glu Asp Asp Asp Asn Glu Ala Thr Gly Asn Lys Ile Asp Tyr Ile Tyr Asn Thr Asp Gln Ser Lys Asp Ser Leu Val Asp Val Pro Phe Pro Asn Ser Tyr Gln Tyr Ile Ala Ala Val Asp Tyr Asn Pro Arg Asp Asn Leu Leu Tyr Val Trp Asn Asn Tyr His Va1 Val Lys Tyr Ser Leu Asp Phe Gly Pro Leu Asp Ser Arg Ser Gly Gln A1a His His Gly Gln Val Ser Tyr Ile Ser Pro Pro Ile $is Leu Asp Ser Glu Leu Glu Arg Pro Ser Val Lys Asp Ile Ser Thr Thr Gly Pro Leu Gly Met Gly Ser Thr Thr Thr Ser Thr Thr Leu Arg Thr Thr Thr Leu Ser Pro Gly Arg Ser Thr Thr Pro Ser Val Ser Gly Arg Arg Asn Arg Ser Thr Ser Thr Pro Ser Pro Ala Va1 Glu Val Leu Asp Asp Met Thr Thr His Leu Pro Ser Ala Ser Ser Gln Ile Pro Ala Leu Glu Glu Ser Cys Glu Ala Val Glu Ala Arg Glu I1e Met Trp Phe Lys Thr Arg Gln Gly Gln Ile Ala Lys Gln Pro Cys Pro Ala Gly Thr I1e Gly Val Ser Thr Tyr Leu Cys Leu Ala Pro Asp Gly Ile Trp Asp Pro Gln Gly Pro Asp Leu Ser Asn Cys Ser Ser Pro Trp Val Asn His Ile Thr Gln Lys Leu Lys Ser Gly Glu Thr Ala Ala Asn Ile Ala Arg Glu Leu Ala Glu Gln Thr Arg Asn His Leu Asn Ala 575 . 580 585 Gly Asp Ile Thr Tyr Ser Val Arg Ala Met Asp Gln Leu Val G1y Leu Leu Asp Val Gln Leu Arg Asn Leu Thr Pro Gly Gly Lys Asp Ser Ala Ala Arg Ser Leu Asn Lys Leu Gln Lys Arg Glu Arg Ser Cys Arg Ala Tyr Val Gln Ala Met Val Glu Thr Val Asn Asn Leu Leu Gln Pro Gln Ala Leu Asn Ala Trp Arg Asp Leu Thr Thr Ser Asp Gln Leu Arg Ala A1a Thr Met Leu Leu Ha.s Thr Val Glu Glu Ser A1a Phe Val Leu Ala Asp Asn Leu Leu Lys Thr Asp Ile Val Arg Glu Asn Thr Asp Asn Ile Lys Leu Glu Va1 Ala Arg Leu Ser Thr Glu Gly Asn Leu Glu Asp Leu Lys Phe Pro Glu Asn Met Gly His G1y Ser Thr Ile Gln Leu Ser Ala Asn Thr Leu Lys Gln Asn Gly Arg Asn Gly Glu Ile Arg Val Ala Phe Val Leu Tyr Asn Asn Leu Gly Pro Tyr Leu Ser Thr Glu Asn Ala Ser Met Lys Leu Gly Thr Glu Ala Leu Ser Thr Asn His Ser Val Ile Val Asn Ser Pro Val Ile Thr Ala Ala Ile Asn Lys Glu Phe Ser Asn Lys Val Tyr Leu Ala Asp Pro Val Val Phe Thr Val Lys His Ile Lys Gln Ser Glu Glu Asn Phe Asn Pro Asn Cys Ser Phe Trp Ser Tyr Ser Lys Arg Thr Met Thr G1y Tyr Trp Ser Thr Gln Gly Cys Arg Leu Leu Thr Thr Asn Lys Thr His Thr Thr Cys Ser Cys Asn His Leu Thr Asn Phe Ala Val Leu Met Ala His Val Glu Val Lys His Ser Asp Ala Val His Asp Leu Leu Leu Asp Val Ile Thr Trp Val Gly Ile Leu Leu Ser Leu Val Cys Leu Leu I1e Cys Ile Phe Thr Phe Cys Phe Phe Arg Gly Leu Gln Ser Asp Arg Asn Thr Ile His Lys Asn Leu Cys Ile Ser Leu Phe Val Ala Glu Leu Leu Phe Leu Ile Gly Ile Asn Arg Thr Asp Gln Pro Ile Ala Cys Ala Val Phe Ala Ala Leu Leu His Phe Phe Phe Leu Ala Ala Phe Thr Trp Met Phe Leu Glu Gly Val Gln Leu Tyr Ile Met Leu Val Glu Val Phe Glu Ser Glu His Ser Arg Arg Lys Tyr Phe Tyr Leu Val Gly Tyr Gly Met Pro Ala Leu Ile Val Ala Val Ser Ala Ala Val Asp Tyr Arg Ser Tyr Gly Thr Asp Lys Val Cys Trp Leu Arg Leu Asp Thr Tyr Phe Ile Trp Ser Phe Ile Gly Pro Ala Thr Leu Ile Ile Met Leu Asn Val Ile Phe Leu Gly Ile Ala Leu Tyr Lys Met Val His His Thr A1a Ile Leu Lys Pro Glu Ser Gly Cys Leu Asp Asn Ile Asn Tyr Glu Asp Asn Arg Pro Phe Ile Lys Ser Trp Val Ile Gly Ala Ile Ala Leu Leu Cys Leu Leu Gly Leu Thr Trp Ala Phe Gly Leu Met Tyr Ile Asn Glu Ser Thr Val Ile Met Ala Tyr Leu Phe Thr Ile Phe Asn Ser Leu Gln Gly Met Phe Ile Phe Ile Phe His Cys Val Leu Gln Lys Lys Val Arg Lys Glu Tyr Gly Lys Cys Leu Arg Thr His Cys Cys Ser Gly Lys Ser Thr Glu Ser Ser Ile Gly Ser Gly Lys Thr Ser G1y Ser Arg Thr Pro Gly Arg Tyr Ser Thr Gly Ser G1n Ser Arg Ile Arg Arg Met Trp Asn Asp Thr Val Arg Lys Gln Ser Glu Ser Ser Phe Ile Thr Gly Asp Ile Asn Ser Ser Ala Ser Leu Asn Arg Glu Gly Leu Leu Asn Asn Ala Arg Asp Thr Ser Val Met Asp Thr Leu Pro Leu Asn Gly Asn His Gly Asn Ser Tyr Ser Ile Ala Ser Gly Glu Tyr Leu Ser Asn Cys Val Gln Ile Ile Asp Arg Gly Tyr Asn His Asn Glu Thr Ala Leu Glu Lys Lys Ile Leu Lys Glu Leu Thr Ser Asn Tyr Ile Pro Ser Tyr Leu Asn Asn His 1265 1270 .1275 Glu Arg Ser Ser Glu Gln Asn Arg Asn Leu Met Asn Lys Leu Val Asn Asn Leu Gly Ser Gly Arg Glu Asp Asp Ala Ile Va1 Leu Asp Asp Ala Thr Ser Phe Asn His Glu Glu Ser Leu Gly Leu Glu Leu Ile His Glu Glu Ser Asp Ala Pro Leu Leu Pro Pro Arg Val Tyr Ser Thr Glu Asn His Gln Pro His His Tyr Thr Arg Arg Arg Ile Pro Gln Asp His Ser Glu Ser Phe Phi Pro Leu Leu Thr Asn Glu His Thr Glu Asp Leu Gln Ser Pro His Arg Asp Ser Leu Tyr Thr Ser Met Pro Thr Leu Ala Gly Val Ala Ala Thr Glu Ser Val Thr Thr Ser Thr Gln Thr Glu Pro Pro Pro Ala Lys Cys G1y Asp Ala Glu Asp Val Tyr Tyr Lys Ser Met Pro Asn Leu Gly Ser Arg Asn His Val His Gln Leu His Thr Tyr Tyr Gln Leu Gly Arg Gly Ser Ser Asp Gly Phe Ile Val Pro Pro Asn Lys Asp Gly Thr Pro Pro Glu Gly Ser Ser Lys Gly Pro Ala His Leu Val Thr Ser Leu <210> 10 <211> 469 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No~: 7477349CD1 <400> 10 Met Asp Pro Ser Val Val Ser Asn Glu Tyr Tyr Asp Val Ala His Gly Ala Lys Asp Pro Val Val Pro Thr Ser Leu Gln Asp Ile Thr Ala Val Leu Gly Thr Glu Ala Tyr Thr Glu Glu Asp Lys Ser Met Val Ser His Ala G1n Lys Ser Gln His Ser Cys Leu Ser His Ser Arg Trp Leu Arg Ser Pro Gln Va1 Thr Gly Gly Ser Trp Asp Leu Arg Ile Arg Pro Ser Lys Asp Ser Ser Ser Phe Arg Gln Ala Gln Cys Leu Arg Lys Asp Pro Gly Ala Asn Asn His Leu Glu Ser Gln Gly Val Arg Gly Thr Ala Gly Asp Ala Asp Arg Glu Leu Arg Gly Pro Ser Glu Lys Ala Thr Ala Gly Gln Pro Arg Val Thr Leu Leu Pro Thr Pro Asn Val Ser Gly Leu Ser Gln Glu Phe Glu Ser His Trp Pro Glu Ile Ala Glu Arg Ser Pro Cys Val A1a Gly Val I1e Pro Val Ile Tyr Tyr Ser Val Leu Leu Gly Leu Gly Leu Pro Val Ser Leu Leu Thr Ala Val Ala Leu A1a Arg Leu Ala Thr Arg Thr Arg Arg Pro Ser Tyr Tyr Tyr Leu Leu Ala Leu Thr Ala Ser Asp Ile Ile Ile Gln Val Val Ile Val Phe Ala Gly Phe Leu Leu G1n Gly Ala Val Leu Ala Arg Gln Val Pro Gln Ala Val Val Arg Thr Ala Asn Ile Leu Glu Phe Ala Ala Asn His Ala Ser Va1 Trp Ile Ala Ile Leu Leu Thr Val Asp Arg Tyr Thr Ala Leu Cys His Pro Leu His His Arg Ala Ala Ser Ser Pro Gly Arg Thr Arg Arg Ala Ile Ala Ala Va1 Leu Ser A1a Ala Leu Leu Thr Gly Ile Pro Phe Tyr Trp Trp Leu Asp Met Trp Arg Asp Thr Asp Ser Pro Arg Thr Leu Asp Glu Va1 Leu Lys Trp Ala His Cys Leu Thr Val Tyr Phe Ile Pro Cys Gly Val Phe Leu Val Thr Asn Ser Ala Ile Ile His Arg Leu Arg Arg Arg Gly Arg Ser Gly Leu Gln Pro Arg Val Gly Lys Ser Thr Ala Ile Leu Leu Gly Ile Thr Thr Leu Phe Thr Leu Leu Trp A1a Pro Arg Val Phe Val Met Leu Tyr His Met Tyr Val Ala Pro Val His Arg Asp Trp Arg Val His Leu Ala Leu Asp Val Ala Asn Met Val Ala Met Leu His Thr Ala Ala Asn Phe Gly Leu Tyr Cys Phe Val Ser Lys Thr Phe Arg Ala Thr Val Arg Gln Val Ile His Asp Ala Tyr Leu Pro Cys Thr Leu Ala Ser Gln Pro Glu Gly Met Ala Ala Lys Pro Val Met Glu Pro Pro Gly Leu Pro Thr Gly Ala Glu Val <210> 11 <211> 335 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 55002225CD1 <400> 11 Met Asn Pro Phe His Ala Ser Cys Trp Asn Thr Ser Ala Glu Leu Leu Asn Lys Ser Trp Asn Lys Glu Phe Ala Tyr Gln Thr A1a Ser Val Val Asp Thr Val Ile Leu Pro Ser Met Ile Gly Ile Ile Cys Ser Thr Gly Leu Val Gly Asn Ile Leu Ile Val Phe Thr Ile I1e Arg Ser Arg Lys Lys Thr Val Pro Asp Ile Tyr Ile Cys Asn Leu Ala Val Ala Asp Leu Val His Ile Val Gly Met Pro Phe Leu Ile His Gln Trp Ala Arg Gly Gly Glu Trp Val Phe Gly Gly Pro Leu Cys Thr Ile Ile Thr Ser Leu Asp Thr Cys Asn Gln Phe Ala Cys Ser Ala Ile Met Thr Val Met Ser Val Asp Arg Tyr Phe Ala Leu Val Gln Pro Phe Arg Leu Thr Arg Trp Arg Thr Arg Tyr Lys Thr Ile Arg Ile Asn Leu Gly Leu Trp Ala Ala Ser Phe Ile Leu Ala Leu Pro Val Trp Val Tyr Ser Lys Val Ile Lys Phe Lys Asp Gly Val Glu Ser Cys Ala Phe Asp Leu Thr Ser Pro Asp Asp Val Leu Trp Tyr Thr Leu Tyr Leu Thr Ile Thr Thr Phe Phe Phe Pro Leu Pro Leu Ile Leu Val Cys Tyr Ile Leu Ile Leu Cys Tyr Thr Trp Glu Met Tyr Gln Gln Asn Lys Asp Ala Arg Cys Cys Asn Pro Ser Val Pro Lys Gln Arg Val Met Lys Leu Thr Lys Met Val Leu Val Leu Val Va1 Val Phe Ile Leu Ser Ala Ala Pro Tyr His Val Ile Gln Leu Val Asn Leu Gln Met Glu Gln Pro Thr Leu Ala Phe Tyr Val Gly Tyr Tyr Leu Ser Ile Cys Leu Ser Tyr Ala Ser Ser Ser Ile Asn Pro Phe Leu Tyr Ile Leu Leu Ser Gly Thr Pro G1n I1e 305 3l0 315 Gln Arg Arg Ala Thr Glu Lys Glu Ile Asn Asn Met Gly Asn Thr Leu Lys Ser His Phe <210> 12 <211> 630 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7475686CD1 <400> 12 Met Arg Leu Gly Pro Va1 Pro Ala Arg Ala Arg Ala Leu Leu Ser Trp Val Arg Gly Leu Glu Ser Arg Gly Gly Glu Trp Thr Lys Cys Ile Val Gln Leu Gly His Leu Leu Ala Thr Gln His Pro Ala Ala Pro Thr Cys Gly Val Val Ser Ser Ala Leu Val Met His Ser Thr Asp Val Cys Leu Ala Pro Thr Met His Gln Ala Leu Asp Trp Ala Ala Gly Ile Trp Phe Thr Gly Arg Leu Gly Leu Arg Glu His Lys Ser Leu Ala Gln Gly Asp Ser Val Cys Pro Cys Glu Ser Glu Leu Gly Asp Phe Gln Val Tyr Gly Leu Val Ser Thr Glu G1y Val Va1 Ser Cys Phe Gly Glu Lys Thr Pro Gln His Pro Gly Pro Pro Ala Ser Leu Ser Leu Ala Asn Arg Cys His Asn Val Val Thr Ala Va1 Gly Ala Trp Pro Ala His Gly Ser I1e Leu Gly Asn Val Pro Glu Ala Pro Val Gly Ala Asp Val Leu Gly Ala Gly Gly Cys Asp Trp Ala Asp Lys Glu Ala Leu Ala Pro Gly Gln Arg Ala Lys Val His Ile Leu Leu Glu Ser Ser Gly Gln Ser Asp Pro Ser Tyr Ala Va1 Leu Pro Asp Ser Trp Ala Ala Thr G1u G1y Phe Pro Thr Tyr Arg Ser Gln Val Ser Ser Pro Arg Ile Pro Gly Ser Ser Ile Trp Leu Gly Ser Gly Ser Gly Trp Pro Ile Leu Gly Glu Leu Arg Glu Cys Asp Gln Met Phe Ser Cys Met Leu Pro Thr Gly Cys Ala Ser Phe Gln Asp Pro Gly Arg Tyr Gly Asp Tyr Asp Leu Pro Met Asp Glu Asp Glu Asp Met Thr Lys Thr Arg Thr Phe Phe Ala Ala Lys Ile Val Ile Gly Ile Ala Leu Ala Gly Ile Met Leu Val Cys Gly Ile Gly Asn Phe Val Phe Ile Ala Ala Leu Thr Arg Tyr Lys Lys Leu Arg Asn Leu Thr Asn Leu Leu Ile Ala Asn Leu Ala Ile Ser Asp Phe Leu Val Ala Ile Ile Cys Cys Pro Phe Glu Met Asp Tyr Tyr Val Val Arg Gln Leu Ser Trp Glu His Gly His Val Leu Cys Ala Ser Val Asn Tyr Leu Arg Thr Val Ser Leu Tyr Val Ser Thr Asn Ala Leu Leu Ala Ile Ala I1e Asp Arg Tyr Leu Ala Ile Val His Pro Leu Lys Pro Arg Met Asn Tyr Gln Thr Ala Ser Phe Leu Ile Ala Leu Val Trp Met Val Ser Ile Leu Ile A1a Ile Pro Ser Ala Tyr Phe Ala Thr Glu Thr Va1 Leu Phe Ile Val Lys Ser Gln Glu Lys I1e Phe Cys Gly Gln I1e Trp Pro Val Asp Gln G1n Leu Tyr Tyr Lys Ser Tyr Phe Leu Phe Ile Phe Gly Val Glu Phe Val Gly Pro Val Val Thr Met Thr Leu Cys Tyr Ala Arg Ile Ser Arg Glu Leu Trp Phe Lys Ala Val Pro Gly Phe Gln Thr Glu Gln I1e Arg Lys Arg Leu Arg Cys Arg Arg Lys Thr Val Leu Val Leu Met Cys Ile Leu Thr Ala Tyr Val Leu Cys Trp Ala Pro Phe Tyr Gly Phe Thr Ile Val Arg Asp Phe Phe Pro Thr Val Phe Val Lys Glu Lys His Tyr Leu Thr Ala Phe Tyr Val Val Glu Cys I1e Ala Met Ser Asn Ser Met Ile Asn Thr Val Cys Phe Val Thr Val Lys Asn Asn Thr Met Lys Tyr Phe Lys Lys Met Met Leu Leu His Trp Arg Pro Ser Gln Arg Gly Ser Lys Ser Ser Ala Asp Leu Asp Leu Arg Thr Asn Gly Val Pro Thr Thr Glu Glu Val Asp Cys Ile Arg Leu Lys <210> 13 <211> 695 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7482007CD1 <400> 13 Met Lys Met Lys Ser Gln A1a Thr Met Ile Cys Cys Leu Val Phe Phe Leu Ser Thr Glu Cys Ser His Tyr Arg Ser Lys Ile His Leu Lys Ala Gly Asp Lys Leu G1n Ser Pro Glu Gly Lys Pro Lys Thr Gly Arg Ile Gln Glu Lys Cys Glu Gly Pro Cys Ile Ser Ser Ser Asn Cys Ser Gln Pro Cys Ala Lys Asp Phe His Gly Glu Ile Gly Phe Thr Cys Asn .Gln Lys Lys Trp Gln Lys Ser Ala Glu Thr Cys Thr Ser Leu Ser Val Glu Lys Leu Phe Lys Asp Ser Thr Gly Ala Ser Arg Leu Ser Val Ala A1a Pro Ser Ile Pro Leu His Ile Leu Asp Phe Arg Ala Pro Glu Thr Ile G1u Ser Val A1a Gln Gly Ile Arg Lys Asn Cys Pro Phe Asp Tyr Ala Cys Ile Thr Asp Met Val Lys Ser Ser Glu Thr Thr Ser Gly Asn Ile Ala Phe Ile Val Glu Leu Leu Lys Asn Ile Ser Thr Asp Leu Ser Asp Asn Va1 Thr Arg Glu Lys Met Lys Ser Tyr Ser Glu Val Ala Asn His Ile Leu Asp Thr Ala Ala Ile Ser Asn Trp Ala Phe Ile Pro Asn Lys Asn Ala Ser Ser Asp Leu Leu Gln Ser Val Asn Leu Phe Ala Arg Gln Leu His Ile His Asn Asn Ser G1u Asn Ile Val Asn Glu Leu Phe Ile Gln Thr Lys G1y Phe His I1e Asn His Asn Thr Ser Glu Lys Ser Leu Asn Phe Ser Met Ser Met Asn Asn Thr Thr Glu Asp Ile Leu Gly Met Val Gln Ile Pro Arg Gln Glu Leu Arg Lys Leu Trp Pro Asn Ala Ser Gln Ala Ile Ser Ile Ala Phe Pro Thr Leu Gly Ala Ile Leu Arg Glu Ala His Leu Gln Asn Val Ser Leu Pro Arg Gln Val Asn Gly Leu Val Leu Ser Val Val Leu Pro Glu Arg Leu Gln Glu Ile Ile Leu Thr Phe Glu Lys Ile Asn Lys Thr Arg Asn Ala Arg Ala Gln Cys Val Gly Trp His Ser Lys Lys Arg Arg Trp Asp Glu Lys Ala Cys Gln Met Met Leu Asp Ile Arg Asn Glu Val Lys Cys Arg Cys Asn Tyr Thr Ser Val Val Met Ser Phe Ser Ile Leu Met Ser Ser Lys Ser Met Thr Asp Lys Val Leu Asp Tyr Ile Thr Cys Ile Gly Leu Ser Val Ser Ile Leu Ser Leu Val Leu Cys Leu Ile Ile Glu Ala Thr Val Trp Ser Arg Val Val Val Thr G1u Ile Ser Tyr Met Arg His Val Cys Ile Val Asn Ile Ala Val Ser Leu Leu Thr Ala Asn Val Trp Phe Ile Ile Gly Ser His Phe Asn Ile Lys Ala Gln Asp Tyr Asn Met Cys Val Ala Val Thr Phe Phe Ser His Phe Phe Tyr Leu Ser Leu Phe Phe Trp Ile Leu Phe Lys Ala Leu Leu Ile I1e Tyr Gly Ile Leu Val Ile Phe Arg Arg Met Met Lys Ser Arg Met Met Val Ile Gly Phe Ala Ile Gly Tyr Gly Cys Pro Leu Ile Ile Ala Val Thr Thr Val Ala Ile Thr Gly Pro Val Lys Gly Tyr Met Arg Pro Glu Ala Cys Trp Leu Asn Trp Asp Asn Thr Lys Ala Leu Leu A1a Phe Ala Ile Pro Ala Phe Val Ile Val Ala Val Asn Leu Ile Val Val Leu Val Val Ala Val Asn Thr Gln Arg Pro Ser I1e Gly Ser Ser Lys Ser Gln Asp Val Val Ile Ile Met Arg Ile Ser Lys Asn Val Ala Ile Leu Thr Pro Leu Leu Gly Leu Thr Trp G1y Phe Gly Ile Ala Thr Leu Ile Glu Gly Thr Ser Leu Thr Phe His Ile Ile Phe Ala Leu Leu Asn Ala Phe Gln Gly Phe Phe Ile Leu Leu Phe Gly Thr Ile Met Asp His Lys Ile Arg Asp Ala Leu Arg Met Arg Met Ser Ser Leu Lys Gly Lys Ser Arg Ala Ala Glu Asn Ala Ser Leu Gly Pro Thr Asn Gly Ser Lys Leu Met Asn Arg Gln Gly <210> 14 <211> 633 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 6769042CD1 <400> 14 Met Tyr Phe Thr Ala Ala Ile Gly Lys His Ala Leu Leu Ser Ser Thr Leu Pro Ser Leu Phe Met Thr Ser Thr Ala Ser Pro Val Met Pro Thr Asp Ala Tyr His Pro Ile Ile Thr Asn Leu Thr Glu Glu Arg Lys Thr Phe Gln Ser Pro Gly Val Ile Leu Ser Tyr Leu Gln Asn Val Ser Leu Ser Leu Pro Ser Lys Ser Leu Ser Glu Gln Thr Ala Leu Asn Leu Thr Lys Thr Phe Leu Lys Ala Val Gly Glu Ile Leu Leu Leu Pro Gly Trp Ile Ala Leu Ser Glu Asp Ser Ala Val Val Leu Ser Leu Ile Asp Thr Ile Asp Thr Val Met Gly His Val Ser Ser Asn Leu His Gly Ser Thr Pro Gln Val Thr Val G1u Gly Ser Ser Ala Met A1a Glu Phe Ser Val Ala Lys Ile Leu Pro Lys Thr Val Asn Ser Ser His Tyr Arg Phe Pro Ala His Gly Gln Ser Phe Ile Gln Ile Pro His Glu Ala Phe His Arg His Ala Trp Ser 170 175 7.80 Thr Val Val Gly Leu Leu Tyr His Ser Met His Tyr Tyr Leu Asn Asn Ile Trp Pro Ala His Thr Lys Ile Ala Glu Ala Met His His Gln Asp Cys Leu Leu Phe Ala Thr Ser His Leu Ile Ser Leu Glu Val Ser Pro Pro Pro Thr Leu Ser Gln Asn Leu Ser Gly Ser Pro Leu Ile Thr Val His Leu Lys His Arg Leu Thr Arg Lys Gln His Ser Glu Ala Thr Asn Ser Ser Asn Arg Val Phe Val Tyr Cys Ala Phe Leu Asp Phe Ser Ser Gly Glu Gly Val Trp Ser Asn His Gly Cys Ala Leu Thr Arg Gly Asn Leu Thr Tyr Ser Val Cys Arg Cys Thr His Leu Thr Asn Phe Ala Ile Leu Met Gln Val Val Pro Leu Glu Leu Ala Arg G1y His G1n Val Ala Leu Ser Ser Ile Ser Tyr Val Gly Cys Ser Leu Ser Val Leu Cys Leu Val Ala Thr Leu Val Thr Phe Ala Val Leu Ser Ser Val Ser Thr Ile Arg Asn Gln Arg Tyr His Ile His Ala Asn Leu Ser Phe Ala Val Leu Val Ala Gln Va1 Leu Leu Leu Ile Ser Phe Arg Leu Glu Pro Gly Thr Thr Pro Cys Gln Val Met Ala Val Leu Leu His Tyr Phe Phe Leu Ser Ala Phe Ala Trp Met Leu Val Glu Gly Leu His Leu Tyr Ser Met Val Ile Lys Val Phe Gly Ser Glu Asp Ser Lys His Arg Tyr Tyr Tyr Gly Met Gly Trp Gly Phe Pro Leu Leu Ile Cys Ile Ile Ser Leu Ser Phe Ala Met Asp Ser Tyr Gly Thr Ser Asn Asn Cys Trp Leu Ser Leu Ala Ser Gly Ala Ile Trp Ala Phe Val Ala Pro Ala Leu Phe Val Ile Val Val Asn Ile Gly Ile Leu Ile Ala Val Thr Arg Val Ile Ser Gln Ile Ser A1a Asp Asn Tyr Lys Ile His G1y Asp Pro Ser Ala Phe Lys Leu Thr Ala Lys Ala Val Ala Val Leu Leu Pro Ile Leu Gly Thr Ser Trp Val Phe Gly Val Leu Ala Val Asn Gly Cys Ala Val Val Phe Gln Tyr Met Phe Ala Thr Leu Asn Ser Leu Gln Gly Leu Phe Ile Phe Leu Phe His Cys Leu Leu Asn Ser Glu Val Arg Ala Ala Phe Lys His Lys Ile Lys Val Trp Ser Leu Thr Ser Ser Ser Ala Arg Thr Ser Asn Ala Lys Pro Phe His Ser Asp Leu Met Asn Gly Thr Arg Pro Gly Met Ala Ser Thr Lys Leu Ser Pro Trp Asp Lys Ser Ser His Ser Ala His Arg Val Asp Leu Ser Ala Val <210> 15 <211> 370 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7476053CD1 <400> 15 Met Glu Ala Ala Ser Leu Ser Val Ala Thr Ala Gly Val Ala Leu 1 5 l0 15 Ala Leu Gly Pro Glu Thr Ser Ser Gly Thr Pro Ser Pro Arg Gly Ile Leu Gly Ser Thr Pro Ser Gly Ala Val Leu Pro Gly Arg Gly Pro Pro Phe Ser Val Phe Thr Val Leu Val Val Thr Leu Leu Val Leu Leu Ile Ala Ala Thr Phe Leu Trp Asn Leu Leu Val Pro Val Thr Ile Pro Arg Val Arg Ala Phe His Arg Val Pro His Asn Leu Val Ala Ser Thr Ala Val Ser Asp Glu Leu Val Ala Ala Leu Ala Met Pro Pro Ser Leu Ala Ser G1u Leu Ser Thr Gly Arg Arg Arg Leu Leu Gly Arg Ser Leu Cys His Val Trp Ile Ser Phe Asp Ala Leu Cys Cys Pro Ala Gly Leu Gly Asn Val Ala Ala Ile Ala Leu Gly Arg Asp Gly A1a Ile Thr Arg His Leu Gln His Thr Leu Arg Thr Arg Ser Arg Ala Ser Leu Leu Met Ile Ala Leu Ala Arg Val Pro Ser Ala Leu Ile Ala Leu Ala Pro Leu Leu Phe Gly Arg Gly Glu Va1 Cys Asp Ala Arg Leu Gln Arg Cys Gln Val Ser Arg Glu Pro Ser Tyr Ala Ala Phe Ser Thr Arg Gly Ala Phe His Leu Pro 20!37 Leu Gly Val Val Pro Phe Val Tyr Arg Lys Ile Tyr Glu Ala Ala Lys Phe Arg Phe Gly Arg Arg Arg Arg Ala Val Leu Pro Leu Pro Ala Thr Met G1n Val Lys Glu Ala Pro Asp Glu Ala Glu Val Val Phe Thr Ala His Cys Lys Ala Thr Val Ser Phe Gln Val Ser G1y Asp Ser Trp Arg Glu Gln Lys Glu Arg Arg Ala Ala Met Met Val Gly Ile Leu Ile Gly Val Phe Val Leu Cys Trp Ile Pro Phe Phe Leu Thr Glu Leu Ile Ser Pro Leu Cys Ala Cys Ser Leu Pro Pro Ile Trp Lys Ser Ile Phe Leu Trp Leu Gly Tyr Ser Asn Ser Phe Phe Asn Pro Leu Ile Tyr Thr Ala Phe Asn Lys Asn Tyr Asn Asn Ala Phe Lys Ser Leu Phe Thr Lys Gln Arg <210> 16 <211> 324 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7480410CD1 <400> 26 Met Gly Met Glu Gly Leu Leu Gln Asn Ser Thr Asn Phe Val Leu Thr Gly Leu Ile Thr His Pro Ala Phe Pro Gly Leu Leu Phe Ala Ile Val Phe Ser Ile Phe Val Val Ala Ile Thr Ala Asn Leu Val Met Ile Leu Leu Ile His Met Asp Ser Arg Leu His Thr Pro Met Tyr Phe Leu Leu Ser Gln Leu Ser Ile Met Asp Thr Ile Tyr Ile Cys Ile Thr Val Pro Lys Met Leu Gln Asp Leu Leu Ser Lys Asp Lys Thr Ile Ser Phe Leu Gly Cys A1a Va1 Gln Ile Phe Leu Tyr Leu Thr Leu Tle Gly Gly Glu Phe Phe Leu Leu G1y Leu Met Ala Tyr Asp Arg Tyr Val Ala Val Cys Asn Pro Leu Arg Tyr Pro Leu Leu Met Asn Arg Arg Val Cys Leu Phe Met Val Val Gly Ser Trp Val Gly Gly Ser Leu Asp Gly Phe Met Leu Thr Pro Val Thr Met Ser Phe Pro Phe Cys Arg Ser Arg Glu Ile Asn His Phe Phe Cys Glu Ile Pro Ala Val Leu Lys Leu Ser Cys Thr Asp Thr Ser Leu Tyr Glu Thr Leu Met Tyr Ala Cys Cys Val Leu Met Leu Leu Ile Pro Leu Ser Val Ile Ser Val Ser Tyr Thr His Ile Leu Leu Thr Val His Arg Met Asn Ser Ala Glu Gly Arg Arg Lys Ala Phe Ala Thr Cys Ser Ser His Ile Met Val Val Ser Val Phe Tyr Gly Ala Ala Phe Tyr Thr Asn Val Leu Pro His Ser Tyr His Thr Pro Glu Lys Asp Lys Val Val Ser Ala Phe Tyr Thr Ile Leu Thr Pro Met Leu Asn Pro Leu Ile Tyr Ser Leu Arg Asn Lys Asp Val Ala Ala Ala Leu Arg Lys Val Leu Gly Arg Cys Gly Ser Ser G1n Ser Ile Arg Val Ala Thr Val Ile Arg Lys Gly <210> 17 <211> 315 <212> PRT
<213> Homo Sapiens <220>
<22l> misc_feature <223> Incyte ID No: 55036418CD1 <400> 17 Met Glu Thr Trp Val Asn Gln Ser Tyr Thr Asp Gly Phe Phe Leu Leu Gly I1e Phe Ser His Ser Thr Ala Asp Leu Val Leu Phe Ser Val Va1 Met Ala Val Phe Thr Val Ala Leu Cys Gly Asn Val Leu Leu Ile Phe Leu Ile Tyr Met Asp Pro His Leu His Thr Pro Met Tyr Phe Phe Leu Ser Gln Leu Ser Leu Met Asp Leu Met Leu Val Cys Thr Asn Val Pro Lys Met Ala Ala Asn Phe Leu Ser Gly Arg Lys Ser Ile Ser Phe Val Gly Cys Gly Ile Gln Ile Gly Leu Phe Val Cys Leu Val Gly Ser Glu G1y Leu Leu Leu Gly Leu Met Ala Tyr Asp Arg Tyr Val Ala Ile Ser His Pro Leu His Tyr Pro Ile Leu Met Asn Gln Arg Val Cys Leu Gln Ile Thr Gly Ser Ser Trp 140 l45 150 Ala Phe Gly Ile Ile Asp Gly Leu Ile Gln Met Val Val Val Met Asn Phe Pro Tyr Cys Gly Leu Arg Lys Val Asn His Phe Phe Cys Glu Met Leu Ser Leu Leu Lys Leu Ala Cys Val Asp Thr Ser Leu Phe Glu Lys Val Ile Phe Ala Cys Cys Val Phe Met Leu Leu Phe Pro Phe Ser Ile Ile Val Ala Ser Tyr A1a His Ile Leu Gly Thr Val Leu Gln Met His Ser Ala Gln Ala Trp Lys Lys Ala Leu Ala Thr Cys Ser Ser His Leu Thr Ala Val Thr Leu Phe Tyr Gly Ala Ala Met Phe I1e Tyr Leu Arg Pro Arg His Tyr Arg Ala Pro Ser His Asp Lys Val Ala Ser Ile Phe Tyr Thr Val Leu Thr Pro Met Leu Asn Pro Leu Ile Tyr Ser Leu Arg Asn Arg Glu Val Met Gly Ala Leu Arg Lys Gly Leu Asp Arg Cys Arg Ile Gly Ser Gln His <210> 18 <211> 324 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7481701CD1 <400> 18 Met Glu Ser Pro Asn Gln Thr Thr Ile Gln Glu Phe Ile Phe Ser Ala Phe Pro Tyr Ser Trp Val Lys Ser Val Val Cys Phe Val Pro Leu Leu Phe Ile Tyr Ala Phe Ile Val Val Gly Asn Leu Val Ile Ile Thr Val Val Gln Leu Asn Thr His Leu His Thr Pro Met Tyr Thr Phe Ile Ser Ala Leu Ser Phe Leu Glu Ile Trp Tyr Thr Thr Ala Thr Ile Pro Lys Met Leu Ser Ser Leu Leu Ser Glu Arg Ser I1e Ser Phe Asn Gly Cys Leu Leu Gln Met Tyr Phe Phe His Ser Thr G1y Ile Cys Glu Val Cys Leu Leu Thr Val Met Ala Phe Asp His Tyr Leu Ala Ile Cys Ser Pro Leu His Tyr Pro Ser Ile Met Thr Pro Lys Leu Cys Thr Gln Leu Thr Leu Ser Cys Cys Val Cys Gly Phe Ile Thr Pro Val Pro Glu Ile Ala Trp Ile Ser Thr Leu Pro Phe Cys Gly Ser Asn His Leu Glu His Ile Phe Cys Asp Phe Leu Pro Val Leu Arg Leu Ala Cys Thr Asp Thr Arg Ala Ile Val Met Ile Gln Val Val Asp Val Ile His Ala Val Glu Ile Ile Thr Ala Val Met Leu Ile Phe Met Ser Tyr Asp Gly Ile Val Ala Val Ile Leu Arg Ile His Ser Ala Gly G1y Arg Arg Thr Ala Phe Ser Thr Cys Val Ser His Phe Ile Val Phe Ser Leu Phe Phe Gly Ser Val Thr Leu Met Tyr Leu Arg Phe Ser Ala Thr Tyr Ser Leu Phe Trp Asp Ile Ala Ile Ala Leu Ala Phe Ala Val Leu Ser Pro Phe Phe Asn Pro Ile Ile Tyr Ser Leu Arg Asn Lys Glu Ile Lys Glu Ala Ile Lys Lys His Ile Gly Gln Ala Lys Ile Phe Phe Ser Val Arg Pro Gly Thr Ser Ser Lys Ile Phe <210> 19 <211> 312 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7481774CD1 <400> 19 Met Glu Pro Trp Gln His Pro Thr His Phe Ile Leu Leu Gly Phe Ser Asp Arg Pro His Leu Glu Arg IIe Leu Phe Val Val Ile Leu Ile Ala Tyr Leu Leu Thr Leu Val Gly Asn Thr Thr Ile Ile Leu Val Ser Arg Leu Asp Pro His Leu His Thr Pro Met Tyr Phe Phe Leu Ala His Leu Ser Phe Leu Asp Leu Ser Phe Thr Thr Ser Ser Ile Pro Gln Leu Leu Tyr Asn Leu Asn Gly Cys Asp Lys Thr Ile Ser Tyr Met Gly Cys Ala I1e Gln Leu Phe Leu Phe Leu Gly Leu Gly Gly Val Glu Cys Leu Leu Leu Ala Val Met Ala Tyr Asp Arg Cys Val Ala Ile Cys Lys Pro Leu His Tyr Met Val Ile Met Asn Pro Arg Leu Cys Arg Gly Leu Va1 Ser Val Thr Trp Gly Cys Gly Val Ala Asn Ser Leu Ala Met Ser Pro Val Thr Leu Arg Leu Pro Arg Cys Gly His His Glu Val Asp His Phe Leu Cys Glu Met Pro Ala Leu Ile Arg Met Ala Cys Ile Ser Thr Val Ala Ile Asp Gly Thr Val Phe Val Leu Ala Val Gly Val Val Leu Ser Pro Leu Val Phe Ile Leu Leu Ser Tyr Ser Tyr Ile Val Arg Ala Val Leu Gln Ile Arg Ser Ala Ser Gly Arg Gln Lys A1a Phe Gly Thr Cys Gly Ser His Leu Thr Va1 Val Ser Leu Phe Tyr Gly Asn Ile Ile Tyr Met Tyr Met Gln Pro Gly Ala Ser Ser Ser Gln Asp Gln Gly Lys Phe Leu Thr Leu Phe Tyr Asn Ile Val Thr Pro Leu Leu Asn Pro Leu Ile Tyr Thr Leu Arg Asn Arg Glu Val Lys Gly Ala Leu Gly Arg Leu Leu Leu Gly Lys Arg Glu Leu Gly Lys Glu <210> 20 <211> 1076 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474806CB1 <400> 20 caaagttgaa tgccgggttg gggcagaggc tgatgccgtg ctgaggtcat gatgttatgc 60 tgtccatttt gcttccttcc aggggaagca gaagcgggag ccgtcgtgga gctctgctcc 120 tggagggagc ctcccgggac atggagaagg tggacatgaa tacatcacag gaacaaggtc 180 tctgccagtt ctcagagaag tacaagcaag tctacctctc cctggcctac agtatcatct 240 ttatcctagg gctgccacta aatggcactg tcttgtggca ctcctggggc caaaccaagc 300 gctggagctg tgccaccacc tatctggtga acctgatggt ggccgacctg ctttatgtgc 360 tattgccctt cctcatcatc acctactcac tagatgacag gtggcccttc ggggagctgc 420 tctgcaagct ggtgcacttc ctgttctata tcaaccttta cggcagcatc ctgctgctga 480 cctgcatctc tgtgcaccag ttcctaggtg tgtggcaccc actgtgttcg ctgccctacc 540 ggacccgcag gcatgcctgg ctgggcacca gcaccacctg ggccctggtg gtcctccagc 600 tgctgcccac actggccttc tcccacacgg actacatcaa tggccagatg atctggtatg 660 acatgaccag ccaagagaat tttgatcggc tttttgccta cggcatagtt ctgacattgt 720 ctggctttct ttccccctcc ttggtcattt tggtgtgcta ttcactgatg gtcaggagcc 780 tgatcaagcc agaggagaac ctcatgagga caggcaacac agcccgagcc aggtccatcc 840 ggaccatcct actggtgtgt ggcctcttca ccctctgttt tgtgcccttc catatcactc 300 gCtCCttCta CCtCaCCatC tgCtttCtgC tttCtCagga ctgccagctc ttgatggcac 960 ccagtgtggc ctacaagata tggaggcctc tggtgagtgt gagcagctgc ctcaacccag 1020 tcctgtactt tctttcaagg ggggcaaaaa tagagtcagg ctcctccaga aactga 1076 <210> 21 <211> 1102 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474840CB1 <400> 21 ggaggctgag gcaggagaat ggcatgaccc caggaggcag agcttgcagt gagatgagat 60 catgccactg tgctccagcc tgggcaacag agcgagactc tgtctcaaaa aaaaaaaaaa 120 acaaaaaaaa aaaccttttt tcccaagcta ccattggact tttagccaac acctttttcc 180 ttttcttcaa catcttcata ttccttcagg atcagaaatc gaagccccat gacctcatca 240 gctgtaattc ggccttcatt catgtagtga tgttcctcac tgtggtggat gcttggcctc 300 cagatatgcc tgaatcactg cacttaggga atgagttcaa atttaagtcc ttgtcctaca 360 taaacagagt gaggatgggc ctatgtatct gtaacatctg tctcctgagt atacaccagg 420 ccaacaccat cagccccaac aacttctgtt tggcaaggct taaacagaaa ttcacaaata 480 acattatcat gtcatctttt ttttcttttt ttttttggtc catcaatttg tctttcagtt 540 ataacatagt attctttact gtggcttctt ctaatgtgac ccagaacagt ctacctaagg 600 gcagcaatac tgttcacttt ctccccatga agtccttcat gagaaaagta ttttttactc 660 tgacattatc cagggatgtc ttcattatag gaattacact gcattcaatt gcacacatgg 720 tgatccttgt gtccaggcat gagacgcaat ctcagcacct tcacagcatc agcatctctc 780 cacaagcctt cccagagaaa agggctgctc agaccatccc gctgttagtg agctactgtc 840 tggtcatgtg ctgggtggac ctcatcatct catcttcttc aaccctgctg tggacgtgta 900 acccagtctt cctgagtatg cagaaccttg tgggcgatgt ctatgccact gttgttctac 960 tggaacaaat cagctctgat aaaaatatag ttgacattct ccaaaatatg caaagtgcta 1020 taaagcttta acaagttggc gatggaaaac atttctaaaa aatagtcttc tcctatagtt 1080 caattgttca agtagccctg ga 1102 <210> 22 <211> 2529 <212> DNA ' <213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7475092CB1 <400> 22 ggctccggtg tttcccgccg ttcatgcagc gaaaagagaa agcaaaatgc cctcaggagg 60 ctccagccgg ccgcgagccc tccacgcccg gcgggggcag cggaggcgga ggcgccgtcg 120 ctgcagcctc aggcgccgcg gtgccgggct ccgtgcagtt ggcgctgagc gtcctgcacg 180 ccctgctcta cgccgcgctg ttcgcctttg cctacctgca gctgtggcgg ctgctcctgt 240 accgcgagcg gcggctgagt taccagagcc tctgcctctt cctctgtctc ctgtgggcag 300 cgctcaggac caccctcttc tccgccgcct tctcgctcag cggctccctg cccttgctcc 360 ggccgcccgc tcacctgcac ttcttccccc actggctgct ctactgcttc ccctcctgtc 420 tccagttctc cacgctctgt ctcctcaacc tctacctggc ggaggttata tgtaaagtca 480 gatgtgccac tgaacttgac agacacaaaa ttctactgca tttgggcttt ataatggcaa 540 gcctgctctt tttagtggtg aacttgactt gcgcaatgct agttcatgga gatgtcccag 600 aaaatcagtt gaagtggact gtgtttgttc gagcattaat taatgatagc ctgtttattc 660 tttgtgccat ctctttagtg tgttacatat gcaaaattac aaaaatgtca tcagctaatg 720 tctacctcga atcaaagggt atgtctctgt gccagactgt cgtcgtgggc tctgtagtca 780 ttcttctgta ctcttccaga gcttgttata atttggtggt ggtcaccata tctcaggata 840 cattagaaag tccatttaat tatggctggg ataatctttc agataaggct catgtagaag 900 acataagtgg agaagagtat atagtatttg gaatggtcct ctttctgtgg gaacatgtgc 960 cagcatggtc ggtggtactg tttttccggg cacagagatt aaaccagaat ttggcacctg 1020 ctggcatgat aaatagtcac agttatagtt ccagagctta ctttttcgac aatccaagac 1080 gatatgatag tgatgatgac ctgccaagac tgggaagttc aagagaagga agtttaccaa 1140 attcgcaaag tttgggctgg tatggcacca tgactgggtg tggcagcagc agttacacag 1200 tcactcccca cctgaatgga cctatgacag atactgctcc tttgctcttt acttgtagta 1260 atttagattt gaacaatcat catagcttat atgtgacacc acaaaactga cagcatcacc 1320 aagtcatgat tcttgagttg tttttcataa atgtgtatat tcaatgtgtt taaattccat 1380 ctacataaac attccattat ctgttgcaac tgaaaacaaa atctggaagt gtggctgtgt 1440 ttggtaaata acacagctat tatttttgac ctcttcatag taaaatgaag taaaatggaa 1500 agtttggagt aggagaaaag agagattaga tcttaaggca cttgatggcc tccaaaaatc 1560 ctgactttgg aacatcaaat gcatatgtgc acttttatct ttgttctgag tcactgcagt 1620 ccccaaagtc atatgccaat gttcacactg aaatactgta ttgtacacca aactggaagg 1680 caattttcct atgaaaatca aagccggtat attcattggt atgctctata cagatatctt 1740 aataaaaatt ttatagtgtg aacagtgcac agagttaagg cataaaaatg tatcattctt 1800 tataaaaatc tactgaaaat gtgtaatcat tgaagacagt tcttttaagc atgattttaa 2860 aatagcaact gaaattcaat cattttaaac aaatgatggt agtaatccat tagttatggc 1920 cagcagtgtt ctttggagag ccacaataat ttcaagagga aaatatacca gtgaaaattg 1980 tgtggctatt ttgagtagaa ttggtcagtt gattattttg tgtaattgag atatatgtag 2040 tagtttaagc atgattcttg aagaaagcaa tagtgacttt tgcataggga gattttggta 2100 gaaacttctt gggactaaac aagtttagag atgcatttaa gaattattca caaaatgtgt 2160 aattctaaat taaaacataa atatattttc aaaagcattt gatttctctg aagcatgata 2220 tagctggtct tacctagtga atcaggattg tcctcaggta aatgaaatca tgatacatta 2280 ttgcagtgaa ctcaagtgca atactttgta agacatataa ttcctatgat tttcacattt 2340 ttatatctta tatatgggaa aagccaaatt aaattgaatt cagattaatt ccagcattag 2400 actaaatgag caaacttaag taaatgtaca aactaggtaa gtataaaacc acaggttaac 2460 aatattggag tacttttaga attacattaa aactgtctta aatgtcctat cccaaatcta 2520 aaaaaaaaa 2529 <210> 23 <211> 1847 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7341260CB1 <400> 23 gggggaggca ggcctcccag ttgctgcagt ttggaatatg tcaggtccca ccctcccaga 60 ggcggggcca gggctgagtc ctgccagcct catttctcta tccctctgag aacccagacg 120 ggcagagcct gggtaggaga gcctggcccc gctgtcccca ctgggtggag acaccatgca 180 cttggtccac ttgtgctctt cagccaggac accagacatg gtccaaaccg ctgcagggct 240 ggctgcagca actccctgac actcaggaag gcccaggctg ggcaggcaat acctgctccc 300 aacagccatg catgccggct gccgctccag gactcccctg tccccaggac caagatgacg 360 cccaacagca ctggcgaggt gcccagcccc attcccaagg gggctttggg gctctccctg 420 gccctggcaa gcctcatcat caccgcgaac ctgctcctag ccctgggcat cgcctgggac 480 cgccgcctgc gcagcccacc tgctggctgc ttcttcctga gcctactgct ggctgggctg 540 ctcacgggtc tggcattgcc cacattgcca gggctgtgga accagagtcg ccggggttac 600 tggtcctgcc tCCtCgtCta CttggCtCCC aaCttCtCCt tCCtCtCCCt gCttgCCaaC 660 ctcttgctgg tgcacgggga gcgctacatg gcagtcctga ggccactcca gccccctggg 720 agcattcggc tggccctgct cctcacctgg gctggtcccc tgCtCtttgC CagtCtgCCC 780 gctctggggt ggaaccactg gacccctggt gccaactgca gctcccaggc tatcttccca 840 gccccctacc tgtacctcga agtctatggg ctcctgctgc ccgccgtggg tgctgctgcc 900 ttcctctctg tccgcgtgct ggccactgcc caccgccagc tgcaggacat ctgccggctg 960 gagcgggcag tgtgccgcga tgagccctcc gccctggccc gggcccttac ctggaggcag 1020 gcaagggcac aggctggagc catgctgctc ttcgggctgt gctgggggcc ctacgtggcc 1080 acactgctcc tctcagtcct ggcctatgag cagcgcccgc cactggggcc tgggacactg 1140 ttgtccctcc tctccctagg aagtgccagt gcagcggcag tgcccgtagc catggggctg 1200 ggcgatcagc gctacacagc cccctggagg gcagccgccc aaaggtgcct gcaggggctg 1260 tggggaagag cctcccggga cagtcccggc cccagcattg cctaccaccc aagcagccaa 1320 agcagtgtcg acctggactt gaactaaagg aagggcctct gctgactcct accagagcat 1380 ccgtccagct cagccatcca gcctgtctct actgggcccc acttctctgg atcagagacc 1440 ctgcctctgt ttgaccccgc actgactgaa taaagctcct ctggccgtta aaaaaaaaaa 1500 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaac aaacaaacag 1560 aaaaaaaaaa aaaagaacac acaaagaaca cagaacaaac caagcagcac accacacaca 1620 aaaacaatgc acacacagaa caagacacaa tcagagacag agagcacaca gcacggaccc 1680 cagccacgcc cccagcactg accaccacga cccgacacag aaacgaacac tgaagactca 1740 acgcacaaaa cgacaaccag accacaagcc aaccgcctca cgccccagca acgaacacac 1800 atacaaaacc aaaccgagac aacccacata cagccaaaca aaccaca 1847 <210> 24 <211> 2031 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7473911CB1 <400> 24 atgaataaaa acaacaaacc ttccagtttc atagccataa gaaatgctgc tttctctgaa 60 gtcggcattg ggatctctgc caatgccatg ctccttctct tccacatcct cacgtgcctt 120 ctcaagcaca ggaccaagcc cgctgacctg atcgtttgtc atgtggctct aatccatatc 180 atattgctgc tacccacaga gttcatagct acagatattt ttgggtctca ggattcagag 240 gatgacatca aacataagtc agttatctac aggcgtaaca ggcagtccca gcattttcac 300 agcaccaacc tttctccaaa agcaccccca gaaaaaatgg ccacgcagac cattcttctg 360 ctcgtgagtt gctttgtgat tgtgtatgtt ttggactgtg ttgtcgcctc ctgctcagga 420 ctggtgtgga acagtgatcc agtccgtcat cgagtccaga tgctggtgga caatggctat 480 gccaccatca gtccttcagt gctacccagg ctgactgccc caaacgagtg gagagccagt 540 gtgtacctga atgacagctt gaacaaatgc agcaacggac ggctgctctg tgtagacagg 600 gggcttgatg aggggccccg gtccgtccca aagtgctctg agtcagagac cgacgaggat 660 tacatcgtcc tcagggctcc gctgagggag gacgaaccca aggacggggg cagtgtgggg 720 aatgcagccc tggtgtctcc cgaggcctct gcagaagagg aagaggagcg tgaggaggga 780 ggcgaggcat gtggcctgga gaggacagga gctggtgggg agcaggttga ccttggtgaa 840 ctacctgacc atgaggagaa aagcaaccag aaagtggcag ctgccaccct ggaggaccgc 900 acacaggatg agcctgctga ggagagctgc cagatcgtcc ttttccagaa caactgcatg 960 gacaactttg tgacttccct cacaggaagc ccctacgagt tcttcccaac caagagcacc 1020 tctttttgca gggagagctg ttctcctttt tctgagtcag tgaaaagctt agaatcagag 1080 caggcaccaa agttggggct gtgtgcggag gaggaccccg tggttggggc tttgtgtggc 1140 cagcatggac ccttgcaaga tggagtggcg gagggtccca cagcccctga tgtggtggtc 1200 ctgccgaagg aggaggagaa ggaggaggtc attgtggatg acatgctggc caacccctat 1260 gtgatgggag atgaggggga ggaggaggag gaggagttcg tggatgacac actggccaac 1320 ccctatgtga tgggagtggg cctgccagga agaggagggg aggaggagga ggaggaggag 1380 gtcgtggatg acacgctggc cagcctctat aagatgggag aagaacatcg acacaagggc 1440 ctggccccac tctgggaagg tggccagaaa ccgtcccaga aactgccccc aaagaaacca 1500 gatctgaggc aggttcctca gcccctggca tcggaggtgc cgcagaggag gcaggaaaga 1560 gctgttgtca ctgaagggag gcccctggaa gccagcaggg ccttgccagc aaagcccagg 1620 gccttcactt tataccctcg gtcgttctcc gtggaaggcc aagagattcc tgtttccatc 1680 tctgtgtact gggagccaga agggtcgggg ttagatgacc acaggataaa gaggaaagag 1740 gaacatctct ctgtcgtgtc tgggagtttc tcccagagaa accaccttcc atccagcggc 1800 acctccacgc cttcttccat ggtcgacatc ccacctcctt tcgacctggc ctgcatcacc 1860 aagaagccca tcacaaagag ctctccctct ctcctgatcg acagcgactc cccggacaag 1920 tacaagaaga agaagtcatc ctttaagcgg ttcctggcgc tgatgtttaa caagatggag 1980 aggccaggca cgatggctca tgcctgtcat cccagcactt tgggaagctg a 2031 <210> 25 <211> 1130 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474767CB1 <400> 25 ggggcgcgct catggagcac acgcacgccc acctcgcagc caacagctcg ctgtcttggt 60 ggtcccccgg ctcggcctgc ggcttgggtt tcgtgcccgt ggtctactac agcctcttgc 120 tgtgcctcgg tttaccagca aatatcttga cagtgatcat cctctcccag ctggtggcaa 180 gaagacagaa gtcctcctac aactatctct tggcactcgc tgctgccgac atcttggtcc 240 tctttttcat agtgtttgtg gacttcctgt tggaagattt catcttgaac atgcagatgc 300 ctcaggtccc cgacaagatc atagaagtgc tggaattctc atccatccac acctccatat 360 ggattactgt accgttaacc attgacaggt atatcgctgt ctgccacccg ctcaagtacc 420 acacggtctc atacccagcc cgcacccgga aagtcattgt aagtgtttac atcacctgct 480 tcctgaccag catcccctat tactggtggc ccaacatctg gactgaagac tacatcagca 540 cctctgtgca tcacgtcctc atctggatcc actgcttcac cgtctacctg gtgccctgct 600 ccatcttctt catcttgaac tcaatcattg tgtacaagct caggaggaag agcaattttc 660 gtctccgtgg ctactccacg gggaagacca ccgccatctt gttcaccatt acctccatct 720 ttgccacact ttgggccccc cgcatcatca tgattcttta ccacctctat ggggcgccca 780 tccagaaccg ctggctggta cacatcatgt ccgacattgc caacatgcta gcccttctga 840 acacagccat caacttcttc ctctactgct tcatcagcaa gcggttccgc accatggcag 900 ccgccacgct caaggctttc ttcaagtgcc agaagcaacc tgtacagttc tacaccaatc 960 ataacttttc cataacaagt agcccctgga tctcgccggc aaactcacac tgcatcaaga 1020 tgctggtgta ccagtatgac aaaaatggaa aacctataaa aagtcgtaat gacagcaaaa 1080 gctcctacca gtttgaagat gccattggag cttgtgtcat catcctgtga 1130 <210> 26 <211> 1202 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7475815CB1 <400> 26 caggttctgc aatacaattg gaaacaactc attgctcctg cctatgaaga agtagaacta 60 tggtaaaaat aagaaaatgc cttcccaata atagggagtt gtactatgga agtaatatgg 120 aggcccagca atgggaatca tagtccagcc atgatggcat agtcatggga gaagagagag 180 ggtggggatg gcttccagga gggtgtgaag agggggtcca gtactgaagg gggaaaagat 240 gcatcagaat taattaatgt attttgatga tggcaatagt gttggttgag attggtgaag 300 gtagtaatat ttgtgatatt tttgttgctt ttctccctag acattaacta tgtgcttatt 360 ttccccataa gatgaataaa aacaacaaac cttccagttt catagccata agaaatgctg 420 ctttctctga agtcggcatt gggatctctg ccaatgccat gctccttctc ttccacatcc 480 tcacgtgcct tctcaagcac aggaccaagc ccgctgacct gatcgtttgt catgtggctc 540 taatccatat catattgctg ctacccacag agttcatagc tacagatatt tttgggtctc 600 aggattcaga ggatgacatc aaacataagt cagttatcta caggtacagg ttgatgagag 660 gCCtCtCCat ttCCaCCa.CC tgCCtgCtga gtatcctccc ggccatcacc tgcagcccca 720 gaagctcctg tttggcagtg ttcaaagatt ctcacatcac caaccacgtt gctttctctt 780 ccgtcttcca catatccatt agtgacagct tcttagtctc cactcttccc atcaaaaatc 840 tggcctcaaa tagccttaca tttgtcactc aatcctgctc tgctgggatc ggctcacggc 900 ccccctccag tggatacatg gtgattctct tgtccaggcg taacaggcag tcccagcatt 960 ttcacagcac caacctttct ccaaaagcac ccccagaaaa aatggccacg cagaccattc 1020 ttctgctcgt gagttgcttt gtgattgtgt atgttttgga ctgtgttgtc gcctcctgct 1080 caggactggt gtggaacagt gatccagtcc gtcatcgagt ccagatgctg gtggacaatg 1140 gctatgccac catcagtcct tcagtgctag tcagtactga aaaatgaatg atcaaagtct 1200 ga 1202 <210> 27 <211> 2079 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 60263275CB1 <400> 27 tacggcacag tagagagctt ccagggctgg ctggcgtggg atacccgtac cacagaaatg 60 cagggaccat tgcttcttcc aggcctctgc tttctgctga gcctctttgg agctgtgact 120 cagaaaacca aaaacattaa tgaatgtaca ccaccctata gtgtatattg tggatttaac 180 gctgtgtgtt acaatgtcga aggaagtttc tactgtcaat gtgtcccagg atatagactg 240 cattctggga atgaacaatt cagtaattcc aatgagaaca cctgtcagga caccacctcc 300 tcaaagacaa cccagggcag gaaagagctg caaaagattg tggacaaatt tgagtcactt 360 ctcaccaatc agactttatg gagaacagaa gggagacaag aaatctcatc cacagctacc 420 actattctcc gggatgtgga atcgaaagtt ctagaaactg ccttgaaaga tccagaacaa 480 aaagtcctga aaatccaaaa cgatagtgta gctattgaaa ctcaagcgat tacagacaat 540 tgctctgaag aaagaaagac attcaacttg aacgtccaaa tgaactcaat ggacatccgt 600 tgcagtgaca tcatccaggg agacacacaa ggtcccagtg ccattgcctt tatctcatat 660 tcttctcttg gaaacatcat aaatgcaact ttttttgaag agatggataa gaaagatcaa 720 gtgtatctga actctcaggt tgtgagtgct gctattggac ccaaaaggaa cgtgtctctc 780 tccaagtctg tgacgctgac tttccagcac gtgaagatga cccccagtac caaaaaggtc 840 ttctgtgtct actggaagag cacagggcag ggcagccagt ggtccaggga tggctgcttc 900 ctgatacacg tgaacaagag tcacaccatg tgtaattgca gtcacctgtc cagcttcgct 960 gtcctgatgg ccctgaccag ccaggaggag gatcccgtgc tgactgtcat cacctacgtg 1020 gggctgagcg tctctctgct gtgcctcctc ctggcggccc tcacttttct cctgtgtaaa 1080 gccatccaga acaccagcac ctcactgcat ctgcagctct cgctctgcct cttcctggcc 1140 cacctcctct tcctcgtggg gattgatcga actgaaccca aggtgctgtg ctccatcatc 1200 gccggtgctt tgcactatct ctacctggcc gccttcacct ggatgctgct ggagggtgtg 1260 cacctcttcc tcactgcacg gaacctgaca gtggtcaact actcaagcat caatagactc 1320 atgaagtgga tcatgttccc agtcggctat ggcgttcccg ctgtgactgt ggccatttct 1380 gcagcctcct ggcctcacct ttatggaact gctgatcgat gctggctcca cctggaccag 1440 ggattcatgt ggagtttcct tggcccagtc tgtgccattt tctctgcgaa tttagtattg 1500 tttatcttgg tcttttggat tttgaaaaga aaactttcct ccctcaatag tgaagtgtca 1560 accatccaga acacaaggat gctggctttc aaagcaacag ctcagctctt catcctgggc 1620 tgcacatggt gtctgggctt gctacaggtg ggtccagctg cccaggtcat ggcctacctc 1680 ttcaccatca tcaacagcct ccaaggcttc ttcatcttct tggtctactg cctcctcagc 1740 cagcaggtcc agaaacaata tcaaaagtgg tttagagaga tcgtaaaatc aaaatctgag 1800 tctgagacat acacactttc cagcaagatg ggtcctgact caaaacccag tgagggggat 1860 gtttttccag gacaagtgaa gagaaaatat taaaactaga atattcaact ccatatggaa 1920 aatcatatcc atggatctct ttggcattat gaagaatgaa gctaaggaaa agggaattca 1980 ttaaacatat catccttgga gaggaagtaa tcaaccttta cttcccaaac tgtttgttct 2040 ccacaatagg tctcaacaaa tgtgtggtaa attgcatta 2079 <210> 28 <211> 5324 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 60203310CB1 <400> 28 ggcggcagca gcagcagcaa gaggaggaga agcagcccca gctatgactg ccgcatgtta 60 atagctgccg ctgggtccct cggctgctgc tggagacaga gcctgactcc gaagttgtgc 120 aactgtggac tgggagagac atttgaaccc tcttttcttt tcgctcccct tttgccccct 180 tggggtgtgt gaagcgagga acgtaaagga aggcgaacat ttggctctct ttttccttcc 240 cctttctccg tggctgtgta gcggaagaaa gggaagagag actttttgtt gttgtttcct 300 tgactggggt ctccaccctc ctgctgcttt ctctgcgctt cgattctcgt tatttgccgc 360 gtgtJggttgg gggtgtctgc acaggggccg gccggtcttt tgccccgggc tcaatggctg 420 gattgtggaa actgcacccg ccttcaggtt gttgagcaac tgatgggacg atctcaggga 480 ccggcgttta cgaaaggttt cagatttggg atattggtgt ttctgttttg gagaaattat 540 tctttttctt tttaatttga agaaaaatca tcagtcttgg aatacagaag agaaactaga 600 aatatacgta ttttgtttca catttgaaca gtcattcttg aggaatactc catacctgag 660 tagacagcca tgtggccatc gcagctacta attttcatga tgctcttagc tccaataatt 720 catgetttca gccgtgcccc aattccaatg gctgtggtcc gcagagagct atcctgtgag 780 agctatccta tagagcttcg ctgtccagga acagacgtca tcatgataga aagtgccaac 840 tatggcagga ctgatgacaa aatttgtgac tctgaccctg ctcagatgga gaatatccga 900 tgttatctgc cagatgccta taagattatg tctcaaagat gcaataacag aacccagtgt 960 gcagtggtgg caggtcctga tgtttttcca gacccgtgtc caggaaccta taaatacctt 1020 gaagtgcagt atgaatgtgt cccttacaaa gtggaacaaa aagtttttct ttgtcctgga 1080 ctactaaaag gagtatacca gagtgaacat ttgtttgagt ccgaccacca atctggggcg 1140 tggtgcaaag accctctgca ggcatctgac aagatttatt atatgccctg gactccctac 1200 agaactgata ccctgactga gtattcatcc aaggatgact tcattgctgg aagaccaact 1260 acaacctaca agctccctca tagggtggat ggcacaggat ttgtagtgta tgatggagct 1320 ttgttcttca acaaagagcg caccaggaac atagtaaagt ttgatttgcg gactaggata 1380 aagagtggag aggctatcat agcaaatgcc aattaccatg atacctcccc ttaccgatgg 1440 ggaggcaaat ctgacataga cctggcagta gatgagaatg ggctatgggt aatctatgca 150'0 acagaacaaa acaatggtaa aattgtcatt agtcaattga acccttacac cctacggatc 1560 gaaggaacat gggatactgc atatgataaa aggtcagctt ccaatgcctt tatgatttgt 1620 ggaattctgt atgtggtcaa atctgtatat gaggatgatg acaatgaggc tactggaaat 1680 aagattgact acatttacaa cactgaccaa agcaaggata gtttggtgga tgtacccttt 1740 cctaattcat accagtacat tgcagctgtg gattacaacc ccagggacaa cctactttat 1800 gtatggaata actatcacgt cgtgaaatat tctttggatt ttggacctct ggatagtaga 1860 tcagggcagg cacatcatgg acaagtttca tacatttctc cgccaattca ccttgactct 1920 gagctagaaa gaccctctgt taaagatatc tctaccacag gacctcttgg catgggaagc 1980 actaccacca gtaccaccct tcggaccaca actttgagcc caggaaggag taccaccccg 2040 tcagtgtcag gaagaagaaa ccggagtact agtaccccat ctccagctgt cgaggtactt 2100 gatgacatga ccacacacct tccatcagca tcgtcccaaa tcccagctct cgaagagagc 2160 tgtgaggctg tggaagcccg agaaatcatg tggtttaaga ctcgtcaagg acagatagca 2220 aagcagccat gccctgcagg aactataggt gtatcaactt atctatgcct tgctcctgat 2280 ggaatttggg atccccaagg tccagatctc agcaactgtt cttctccttg ggtcaatcat 2340 ataacacaga agttgaaatc tggtgaaaca gctgccaaca ttgctagaga gctggctgaa 2400 cagacaagaa atcacttgaa tgctggggac atcacctact ctgtccgggc catggaccag 2460 ctggtaggcc tcctagatgt acagcttcgg aacttgaccc caggtggaaa agatagtgct 2520 gcccggagtt tgaacaagct tcagaaaaga gagcgctctt gcagagccta tgtccaggca 2580.
atggtcgaga cagttaacaa cctccttcag ccacaagctt tgaatgcatg gagagacctg 2640 actacgagtg atcagctgcg tgcggccacc atgttgcttc atactgtgga ggaaagtgct 2700 tttgtgctgg ctgataacct tttgaagact gacattgtca gggagaacac agacaatatt 2760 aaattggaag ttgcaagact gagcacagaa ggaaacttag aagacctaaa atttccagaa 2820 aacatgggcc atggaagcac tatccagctg tctgcaaata ccttaaagca aaatggccga 2880 aatggagaga tcagagtggc ctttgtcctg tataacaact tgggtcctta tttatccacg 2940 gagaatgcca gtatgaagtt gggaacggaa gctttgtcca caaatcattc tgttattgtc 3000 aattcccctg ttattacggc agcaataaac aaagagttca gtaacaaggt ttatttggct 3060 gatcctgtgg tatttactgt taaacatatc aagcagtcag aggaaaattt caaccctaac 3120 tgttcatttt ggagctactc caagcgtaca atgacaggtt attggtcaac acaaggctgt 3180 cggctcctga caacaaataa gacacatact acatgctctt gtaaccacct aacaaatttt 3240 gcagtactga tggcacatgt ggaagttaag cacagtgatg cggtccatga cctccttctg 3300 gatgtgatca cgtgggttgg aattttgctg tcccttgttt gtctcctgat ttgcatcttc 3360 acattttgct ttttccgcgg gctccagagt gaccgtaaca ccatccacaa gaacctctgc 3420 atcagtctct ttgtagcaga gctgctcttc ctgattggga tcaaccgaac tgaccaaccg 3480 attgcctgtg ctgttttcgc tgccctgtta catttcttct tcttggctgc cttcacctgg 3540 atgttccttg agggggtgca gctttatatc atgctggtgg aggtttttga gagtgaacat 3600 tcacgtagga aatactttta tctggtcggc tatgggatgc ctgcactcat tgtggctgtg 3660 tcagctgcag tagactacag gagttatgga acagataaag tatgttggct ccgacttgac 3720 acctacttca tttggagttt tataggacca gcaactttga taattatgct taatgtaatc 3780 ttccttggga ttgctttata taaaatggtt catcatactg ctatactgaa acctgaatca 3840 ggctgtcttg ataacatcaa ctatgaggat aacagaccct tcatcaagtc atgggttata 3900 ggtgcaatag ctcttctctg cctattagga ttgacctggg cctttggact catgtatatt 3960 aatgaaagca cagtcatcat ggcctatctc ttcaccattt tcaattctct acagggaatg 4020 tttatattta ttttccattg tgtcctacag aagaaggtac gaaaagagta tgggaaatgc 4080 ctgcgaacac attgctgtag tggcaaaagt acagagagtt ccattggttc agggaaaaca 4140 tctggttctc gaactcctgg acgctactcc acaggctcac agagccgaat ccgtagaatg 4200 tggaatgaca cggttcgaaa gcagtcagag tcttccttta ttactggaga cataaacagt 4260 tcagcgtcac tcaacagaga ggggcttctg aacaatgcca gggatacaag tgtcatggat 4320 actctaccac tgaatggtaa ccatggcaat agttacagca ttgccagcgg cgaatacctg 4380 agcaactgtg tgcaaatcat agaccgtggc tataaccata acgagaccgc cctagagaaa 4440 aagattctga aggaactcac ttccaactat atcccttctt acctgaacaa ccatgagcgc 4500 tccagtgaac agaacaggaa tctgatgaac aagctggtga ataaccttgg cagtggaagg 4560 gaagatgatg ccattgtcct ggatgatgcc acctcgttta accacgagga gagtttgggc 4620 ctggaactca ttcatgagga atctgatgct cctttgctgc ccccaagagt atactccacc 4680 gagaaccacc agccacacca ttataccaga aggcggatcc cccaagacca cagtgagagc,4740 tttttccctt tgctaaccaa cgagcacaca gaagatctcc agtcacccca tagagactct 4800 ctctatacca gcatgccgac actggctggt gtggccgcca cagagagtgt taccaccagc 4860 acccagaccg aacccccacc ggccaaatgt ggtgatgccg aagatgttta ctacaaaagc 4920 atgccaaacc taggctccag aaaccacgtc catcagctgc atacttacta ccagctaggt 4980 cgcggcagca gtgatggatt tatagttcct ccaaacaaag atgggacccc tcccgaggga 5040 agttcaaaag gaccggctca tttggtcact agtctataga agatgacaca gaaattggaa 5100 ccaacaaaac tgctaacacc ttgttgactg ttctgagttg atataagcag tggtaataat 5160 gtgtgtactc ctaaatcttt atgctgtcct ctaaagacaa acacaaactc tcagactttt 5220 ttttttcaac tgggatttaa ggtcagccca ggggagaaag ataactgcta aaattcccct 5280 gtaccccatc ctttcttgtc ctttccccct tcagatggag actt 5324 <210> 29 <211> 1962 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7477349CB1 <400> 29 atggatccca gcgttgttag caatgagtat tatgatgttg cccatggagc aaaagatcca 60 gtggtcccca cttccctgca ggacatcact gctgtcctgg gtacagaagc atatactgag 120 gaagacaaat caatggtgtc ccatgcacag aaaagccagc attcttgtct cagccattcc 180 aggtggctga ggtctccaca ggtcacaggg ggaagctggg acctccgaat aaggccatcc 240 aaggactcca gCagtttccg~ccaggctcag tgtctgcgta aggatcctgg ggcaaacaac 300 cacttggaga gccaaggggt gagaggtaca gctggcgatg ctgacaggga gctgcgggga 360 ccctcagaaa aagccacagc tggccagcca cgagtgaccc tgctgcccac gcccaacgtc 420 agcgggctga gccaggagtt tgaaagccac tggccagaga tcgcagagag gtccccgtgt 480 gtggctggcg tcatccctgt catctactac agtgtcctgc tgggcttggg gctgcctgtc 540 agcctcctga ccgcagtggc cctggcgcgc cttgccacca ggaccaggag gccctcctac 600 tactaccttc tggcgctcac agcctcggat atcatcatcc aggtggtcat cgtgttcgcg 660 ggcttcctcc tgcagggagc agtgctggcc cgccaggtgc cccaggctgt ggtgcgcacg 720 gccaacatcc tggagtttgc tgccaaccac gcctcagtct ggatcgccat cctgctcacg 78O
gttgaccgct acactgccct gtgccacccc ctgcaccatc gggccgcctc gtccccaggc 840 cggacccgcc gggccattgc tgctgtcctg agtgctgccc tgttgaccgg catccccttc 900 tactggtggc tggacatgtg gagagacacc gactcaccca gaacactgga cgaggtcctc 960 aagtgggctc actgtctcac tgtctatttc atcccttgtg gcgtgttcct ggtcaccaac 1020 tcggccatca tccaccggct acggaggagg ggccggagtg ggctgcagcc ccgggtgggc 1080 aagagcacag ccatcctcct gggcatcacc acactgttca ccctcctgtg ggcgccccgg 1140 gtcttcgtca tgctctacca catgtacgtg gcccctgtcc accgggactg gagggtccac 1200 ctggccttgg atgtggccaa catggtggcc atgctccaca cggcagccaa cttcggcctc 1260 tactgctttg tcagcaagac tttccgggcc actgtccgac aggtcatcca cgatgcctac 1320 ctgccctgca ctttggcatc acagccagag ggcatggcgg cgaagcctgt gatggagcct 1380 ccgggactcc ccacaggggc agaagtgtag aggagggggc ccagctaggg agctcagggt 1440 ggctcatggc cacatgtact ggggcctttg aggttgtacc caaaacacgt ttatcaacag 1500 cttgctttcc ttgggtgggg gtggaggctc ctcctttggg tgtggctccc aggtagagag 1560 gaggacaact tagccagctc ttatgtttgc ttcaccagca atccctattt cctgggaaga 1620 tgaaagggca ctgccaggca caggctaata gcatcagtgc tgtgggcatt cctttgcggg 180 gggcattttg cctggctcat cgtgaatgcc agattaatgt tggttgaatg gatagaaaaa 1740 cggcctctca ttttcgtaac tgaggcagga gaatcgcttg aacccaggag acggaggttg 1800 cagcgagctg agatcgcgcc atagaaacac catggaactc caacctgggc aacaagagtg 1860 aaacttcgac tcaaaaaaaa aagagaaaaa acacattagg taacagtttc tttttagcat 1920 ttgtgtaacc tttaataaaa taaagtgata atcaaaaaaa as 1962 <210> 30 <211> 1558 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 55002225CB1 <400> 30 attttattcg cgaaggcacc ccacgctcct agaaaagagc acgacgcacc cgatgctcgg 60 attggatgaa gtggcaaagc tttaatccct ggaaagtcca cgaacaatga atccatttca 120 tgcatcttgt tggaacacct ctgccgaact tttaaacaaa tcctggaata aagagtttgc 180 ttatcaaact gccagtgtgg tagatacagt catcctccct tccatgattg ggattatctg 240 ttcaacaggg ctggttggca acatcctcat tgtattcact ataataagat ccaggaaaaa 300 aacagtccct gacatctata tctgcaacct ggctgtggct gatttggtcc acatagttgg 360 aatgcctttt cttattcacc aatgggcccg agggggagag tgggtgtttg gggggcctct 420 ctgcaccatc atcacatccc tggatacttg taaccaattt gcctgtagtg ccatcatgac 480 tgtaatgagt gtggacaggt actttgccct cgtccaacca tttcgactga cacgttggag 540 aacaaggtac aagaccatcc ggatcaattt gggcctttgg gcagcttcct ttatcctggc 600 attgcctgtc tgggtctact cgaaggtcat caaatttaaa gacggtgttg agagttgtgc 660 ttttgatttg acatcccctg acgatgtact ctggtataca ctttatttga cgataacaac 720 tttttttttc cctctaccct tgattttggt gtgctatatt ttaattttat gctatacttg 780 ggagatgtat caacagaata aggatgccag atgctgcaat cccagtgtac caaaacagag 840 agtgatgaag ttgacaaaga tggtgctggt gctggtggta gtctttatcc tgagtgctgc 900 cccttatcat gtgatacaac tggtgaactt acagatggaa cagcccacac tggccttcta 960 tgtgggttat tacctctcca tctgtctcag ctatgccagc agcagcatta acccttttct 1020 ctacatcctg ctgagtggaa cgcctcaaat ccaaagaaga gcgactgaga aggaaatcaa 1080 caatatggga aacactctga aatcacactt ttaggaaagt acatggatca ccatgagtct 1140 agacatgatt gtctatctta ctggtattat tagaaagggc aggtgtaccg atatgtttat 1200 gcccattctt cttgtgtact tgtgactctt agcagcatgg aagagaagtg taaccatgca 1260 aatacaatga gcttaatatg ctaactttag caagatgtaa aatgttgatc tatattgtgg 1320 gtagggaatg ggatagtctg agatacccag gcttcatgat ggtgtatatt atttcagcat 1380 attataaact agtcactaat gaaaatggcc atccatgacc attgactcaa aactcaccaa 1440 ggaacctgac cttgccctcc acactgcggc ctcactgtaa cagtttcctc aaggttccta 1500 ggagggtatc accttagagt gaagtctaaa atttggctat tttttatcta ttaaaaat 1558 <210> 31 <211> 2304 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7475686CB1 <400> 31 atgcggctgg gacctgtccc agcccgggcg cgcgccctct tgtcttgggt tagggggctg 60 gaaagccgag gaggggagtg gaccaaatgc attgttcagc tgggtcatct ccttgctacc 120 cagcatcccg cggcgcccac atgtggagtc gtttccagcg ccctggtcat gcactcaaca 180 gatgtctgtc tagcccccac tatgcaccag gcactggact gggcagcagg aatttggttt 240 acaggaagat taggactcag agagcataaa tcactggccc agggtgactc agtctgtcca 300 tgtgaaagtg aacttggtga tttccaagtc tatggcttgg tcagtacaga aggagtggtg 360 tcctgctttg gagagaagac cccgcagcat cctggccctc ctgcttcatt gtccctggcc 420 aacaggtgcc acaacgttgt gacagctgta ggagcctggc cagctcatgg gagcatcctt 480 ggaaatgttc cagaagcccc tgtgggagct gatgtgttgg gggctggagg atgtgactgg 540 gcagacaaag aggccctggc ccctgggcaa agggcaaagg tgcacattct tcttgagagt 600 tctggacagt ctgatccatc ctatgctgtc cttcctgaca gctgggcagc cacggagggt 660 ttcccaactt acagatctca ggtctcctct ccccgcatcc cgggtagttc catctggtta 720 ggcagtgggt ctggttggcc tatacttggg gaactcaggg aatgtgacca gatgttctcc 780 tgcatgttgc ccactggttg tgcctccttc caggatccag gacgttatgg tgattatgac 840 ctccctatgg atgaggatga ggacatgacc aagacccgga ccttcttcgc agccaagatc 900 gtcattggca ttgcactggc aggcatcatg ctggtctgcg gcatcggtaa ctttgtcttt 960 atcgctgccc tcacccgcta taagaagttg cgcaacctca ccaatctgct cattgccaac 1020 ctggccatct ccgacttcct ggtggccatc atctgctgcc ccttcgagat ggactactac 1080 gtggtacggc agctctcctg ggagcatggc cacgtgctct gtgcctccgt caactacctg 1140 cgcaccgtct ccctctacgt ctccaccaat gccttgctgg ccattgccat tgacaggtat 1200 ctcgccatcg ttcacccctt gaaaccacgg atgaattatc aaacggcctc cttcctgatc 1260 gccttggtct ggatggtgtc cattctcatt gccatcccat cggcttactt tgcaacagaa 1320 acggtcctct ttattgtcaa gagccaggag aagatcttct gtggccagat ctggcctgtg 1380 gatcagcagc tctactacaa gtcctacttc ctcttcatct ttggtgtcga gttcgtgggc 1440 cctgtggtca ccatgaccct gtgctatgcc aggatctccc gggagctctg gttcaaggca 1500 gtccctgggt tccagacgga gcagattcgc aagcggctgc gctgccgcag gaagacggtc 1560 ctggtgctca tgtgcattct cacggcctat gtgctgtgct gggcaccctt,ctacggtttc 1620 accatcgttc gtgacttctt ccccactgtg ttcgtgaagg aaaagcacta cctcactgcc 1680 ttctacgtgg tcgagtgcat cgccatgagc aacagcatga tcaacaccgt gtgcttcgtg 1740 acggtcaaga acaacaccat gaagtacttc aagaagatga tgctgctgca ctggcgtccc 1800 tcccagcggg ggagcaagtc cagtgctgac cttgacctca gaaccaacgg ggtgcccacc 1860 acagaagagg tggactgtat caggctgaag tgacccactg gtgtcacaca attgaaaacc 1920 ccagtccagt actcagagca tcacccacca tcaaccaagt tcataggctg catgggaaat 1980 gacatctgtg ttcatgcctc ccccgtgccc tcaagaagcc gaatgctgca aagtcgtaac 2040 atacaatgag actagacatg aaccaaatca gctgacattt actgatatcc gctcgacacc 2100 tactgtgtcc acaatcccaa caaggagatt agacacaagg agcagcaact gacatggact 2160 gaacatgtac tgtgtgcaag ccaaaccaat gagattaaca gggacagcag gagctgaatt 2220 atcttactat gtatcaaacc tgttgttcac aaattaaact acagtccaac ttgggtcaca 2280 tcgttttatt tcccattcat tttt 2304 <210> 32 <211> 2322 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature ' <223> Incyte ID No: 7482007CB1 <400> 32 cccatttcaa aaatggagaa gacagatcac tgccactgac caggaccgtg ggaggtgcca 60 cgtgatggtg aggcatcatg ctagggagct gagctctgac cttcctgctg ggtgattctc 120 cacctctggg ctgctagatc tacttcctgg atgccgtgaa gatcctcatg tatgaaaatg 180 aagtcccagg caaccatgat ttgctgctta gtgttctttc tgtccacaga atgttcccac 240 tatagatcca agattcacct aaaagctgga gataaacttc aaagccctga agggaaaccc 300 aagactggaa ggatccaaga gaaatgcgaa ggaccttgta tttcttcttc caactgcagc 360 cagccctgtg ctaaggactt tcatggagaa ataggattta catgtaatca aaaaaagtgg 420 caaaaatcag ctgaaacatg tacaagcctt tctgtggaaa aactctttaa ggactcaact 480 ggtgcatctc gcctttctgt agcagcacca tctatacctc tgcatattct agactttcga 540 gctccagaga ccattgagag tgtagctcaa ggaatccgta agaactgccc ctttgattat 600 gcctgcatca ctgacatggt gaaatcatca gaaacaacat ctggaaatat tgcatttata 660 gtggagttat taaaaaatat ttctacagac ttgtctgata atgttactcg agagaaaatg 720 aagagctata gtgaagtggc Caaccacatc ctcgacacag cagccatttc aaactgggct 780 ttcattccca acaaaaatgc cagctcggat ttgttgcagt cagtgaattt gtttgccaga 840 caactccaca tccacaataa ttctgagaac attgtgaatg aactcttcat tcagacaaaa 900 gggtttcaca tcaaccataa tacctcagag aaaagcctca atttctccat gagcatgaac 960 aataccacag aagatatctt aggaatggta cagattccca ggcaagagct aaggaagctg 1020 tggccaaatg catcccaagc cattagcata gctttcccaa ccttgggggc tatcctgaga 1080 gaagcccact tgcaaaatgt gagtcttccc agacaggtaa atggtctggt gctatcagtg 1140 gttttaccag aaaggttgca agaaatcata ctcaccttcg aaaagatcaa taaaacccgc 1200 aatgccagag cccagtgtgt tggctggcac tccaagaaaa ggagatggga tgagaaagcg 1260 tgccaaatga tgttggatat caggaacgaa gtgaaatgcc gctgtaacta caccagtgtg 1320 gtgatgtctt tttccattct catgtcctcc aaatcgatga ccgacaaagt tctggactac 1380 atcacctgca ttgggctcag cgtctcaatc ctaagcttgg ttctttgcct gatcattgaa 1440 gccacagtgt ggtcccgggt ggttgtgacg gagatatcat acatgcgtca cgtgtgcatc 1500 gtgaatatag cagtgtccct tctgactgcc aatgtgtggt ttatcatagg ctctcacttt 1560 aacattaagg cccaggacta caacatgtgt gttgcagtga catttttcag ccactttttc 1620 tacctctctc tgtttttctg gattctcttc aaagcattgc tcatcattta tggaatattg 1680 gtcattttcc gtaggatgat gaagtcccga atgatggtca ttggctttgc cattggctat 1740 gggtgcccat tgatcattgc tgtcactaca gttgctatca cagggccagt gaaaggctac 1800 atgagacctg aggcctgttg gcttaactgg gacaatacca aagccctttt agcatttgcc 1860 atcccggcgt tcgtcattgt ggctgtaaat ctgattgtgg ttttggttgt tgctgtcaac 1920 actcagaggc cctctattgg cagttccaag tctcaggatg tggtcataat tatgaggatc 1980 agcaaaaatg ttgccatcct cactccactg ctgggactga cctggggttt tggaatagcc 2040 actctcatag aaggcacttc cttgacgttc catataattt ttgccttgct caatgctttc 2100 cagggttttt tcatcctgct gtttggaacc attatggatc acaagataag agatgctttg 2160 aggatgagga tgtcttcact gaaggggaaa tcgagggcag ctgagaatgc atcactaggc 2220 ccaaccaatg gatctaaatt aatgaatcgt caaggatgaa atgctgcccc atttctcatg 2280 gatgtcctga gaccaagagg ggagatccag gagaaagagg cc 2322 <210> 33 <211> 2366 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 6769042CB1 <400> 33 atttaggtga cactatagaa gagcccagtg tgctggaaag gagatcgcca tgtacttcac 60 tgctgccatt ggaaagcatg ctttattgtc ttcaacgctg ccaagcctct tcatgacatc 120 cacagcaagc cccgtgatgc ccacagatgc ctaccatccc atcataacca acctgacaga 180 agagagaaaa accttccaaa gtcccggagt gatactgagt tacctccaaa atgtatccct 240 cagcttaccc agtaagtccc tctcggagca gacagccttg aatctcacca agaccttctt 300 aaaagccgtg ggagagatcc ttctactgcc tggttggatt gctctgtcag aggacagcgc 360 cgtggtactg agtctcatcg acactattga caccgtcatg iggccatgtat cctccaacct 420 gcacggcagc acgccccagg tcaccgtgga gggctcctct gccatggcag agttttccgt 480 ggccaaaatc ctgcccaaga ccgtgaattc ctcccattac cgcttcccgg cccacgggca 540 gagcttcatc cagatccccc acgaggcctt ccacaggcac gcctggagca ccgtcgtggg 600 tctgctgtac cacagcatgc actactacct gaacaacatc tggcccgccc acaccaagat 660 cgcggaggcc atgcatcacc aggactgcct gctgttcgcc accagccacc tgatttccct 720 ggaggtgtcc ccaccaccca ccctgtctca gaacctgtcg ggctctccac tcattacggt 780 ccacctcaag cacagattga cacgtaagca gcacagtgag gccaccaaca gcagcaaccg 840 agtcttcgtg tactgcgcct tcctggactt cagctccgga gaaggggtct ggtcgaacca 900 cggctgtgcg ctcacgagag gaaacctcac ctactccgtc tgccgctgca ctcacctcac 960 caactttgcc atcctcatgc aggtggtccc gctggagctt gcacgcggac accaggtggc 1020 gctgtcgtct atcagctatg tgggctgctc cctctccgtg ctctgcctgg tggccacgct 1080 ggtcaccttc gccgtgctgt cctccgtgag caccatccgg aaccagcgct accacatcca 1140 cgccaacctg tccttcgccg tgctggtggc ccaggtcctg ctgctcatta gtttccgcct 1200 cgagccaggc acgaccccct gccaagtgat ggccgtgctc ctacactact tcttcctgag 1260 tgccttcgca tggatgctgg tggaggggct gcacctctac agcatggtga tcaaggtctt 1320 tgggtcggag gacagcaagc accgttacta ctatgggatg ggatggggtt ttcctcttct 1380 gatctgcatc atttcactgt catttgccat ggacagttac ggaacaagca acaattgctg 1440 gctgtcgttg gcgagtggcg ccatctgggc ctttgtagcc cctgccctgt ttgtcatcgt 1500 ggtcaacatt ggcatcctca tcgctgtgac cagagtcatc tcacagatca gcgccgacaa 1560 ctacaagatc catggagacc ccagtgcctt caagttgacg gccaaggcag tggccgtgct 1620 gctgcccatc ctgggtacct cgtgggtctt tggcgtgctt gctgtcaacg gttgtgctgt 1680 ggttttccag tacatgtttg ccacgctcaa ctccctgcag ggactgttca tattcctctt 1740 tcattgtctc ctgaattcag aggtgagagc cgccttcaag cacaaaatca aggtctggtc 1800 gctcacgagc agctccgccc gcacctccaa cgcgaagccc ttccactcgg acctcatgaa 1860 tgggacccgg ccaggcatgg cctccaccaa gctcagccct tgggacaaga gcagccactc 1920 tgcccaccgc gtcgacctgt cagccgtgtg agccgggagg ctgccaacca ggccaggctg 1980 cgctcagaac acaccccccc aaacagaatg aaatgcccca cctttgccca tggaccctct 2040 ccttgctgct gtctggacat gggtgttgtg gccccgagac agctgtcctc ccctgtgact 2100 ctggctgtcg gagcacactg CtCagCCCag cagcctgatg cccaggccag cgtgggccct 2160 cctgccttgc atccacccgt gggctgagtg acttcctcgg gggattccca ggacacagtg 2220 gcctgacttg tgatggtgcc cttgagcctc ccttcatcac tcagcatcag accagcgagg 2280 cagggcatcg gggccggtcc cgcagcccgg agggatgtca gctctgtgct ggggggttgg 2340 ggcccgccCC aagtgtcagg ccccgc 2366 <210> 34 <211> 1458 <212> DNA
<213> Homo Sapiens <220>
34!37 <221> misc_feature <223> Incyte ID No: 7476053CB1 <400> 34 atggaggccg ctagcctttc agtggccacc gccggcgttg cccttgccct gggacccgag 60 accagcagcg ggaccccaag cccgagaggg atactcggtt cgaccccgag cggcgccgtc 120 ctgccgggcc gagggccgcc cttctctgtc ttcacggtcc tggtggtgac gctgctagtg 180 ctgctgatcg ctgccacttt cctgtggaac ctgctggttc cggtcaccat cccgcgggtc 240 CgtgCCttCC aCCgCgtgCC gcataacttg gtggcctcga cggccgtctc ggacgaacta 300 gtggcagcgc tggcgatgcc accgagcctg gcgagtgagc tgtcgaccgg gcgacgtcgg 360 ctgctgggcc ggagcctgtg ccacgtgtgg atctccttcg acgccctgtg CtgCCCCgCC 420 ggcctcggga acgtggcggc catcgccctg ggccgcgacg gggccatcac acggcacctg 480 cagcacacgc tgcgcacccg cagccgcgcc tcgttgctca tgatcgcgct cgcccgggtg 540 ccgtcggcgc tcatcgccct cgcgccgctg ctctttggcc ggggcgaggt gtgcgacgct 600 CggCtCCagC gctgccaggt gagccgggaa ccctcctatg CCgCCttCtC CdCCCgCggC 660 gccttccacc tgccgcttgg cgtggtgccg tttgtctacc ggaagatcta cgaggcggcc 720 aagtttcgtt tcggccgccg ccggagagct gtgctgccgt tgccggccac catgcaggtg 780 aaggaagcac ctgatgaggc tgaagtggtg ttcacggcac attgcaaagc aacggtgtcc 840 ttccaggtga gcggggactc ctggcgggag cagaaggaga ggcgagcagc catgatggtg 900 ggaattctga ttggcgtgtt tgtgctgtgc tggatcccct tcttcctgac ggaactcatc 960 agcccactct gtgcctgcag cctgcccccc atctggaaaa gcatatttct gtggcttggc 1020 tactccaatt ctttcttcaa ccccctgatt tacacagctt ttaacaagaa ctacaacaat 1080 gccttcaaga gcctctttac taagcagaga tgaacacagg ggttagagag acatgggtag 1140 attttaagga ggaaggaact tggacttttt cgtcagtgat ctgagattct tccctccaca 1200 gctgagtgct aatgctgtat tgagagttat accattgggc ctggactgta gaagcagcag 1260 agccaaggtt ctcaagaaag acagcaaagg tctggcagat gttgtaacta tgccttcttc 1320 ccatgtgcat ggcagacatt gccaattggt catggcttgg ctccccactg agcaggaact 1380 tggtctcaga atcctttcca ggacagcacc ctaggcagct actgttgatt atttaaaatt 1440 gatgcaagac ttgaaaaa 1458 <210> 35 <211> 975 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte zD No: 7480410CB1 <400> 35 atgggcatgg agggtcttct ccagaactcc actaacttcg tcctcacagg cctcatcacc 60 CatCCtgCCt tCCCCgggCt tCtCtttgCa atagtCttCt ccatctttgt ggtggctata 120 acagccaact tggtcatgat tctgctcatc Cacatggact cccgcctcca cactcccatg 180 tacttcttgc tcagccagct ctccatcatg gataccatct acatctgtat cactgtcccc 240 aagatgctcc aggacctcct gtccaaggac aagaccattt ccttcctggg ctgtgcagtt 300 cagatcttcc tctacctgac cctgattgga ggggaattct tcctgctggg tctcatggcc 360 tatgaccgct atgtggctgt gtgcaaccct ctacggtacc ctctcctcat gaaccgcagg 420 gtttgcttat tcatggtggt cggctcctgg gttggtggtt ccttggatgg gttcatgctg 480 actcctgtca ctatgagttt ccccttctgt agatcccgag agatcaatca ctttttctgt 540 gagatcccag ccgtgctgaa gttgtcttgc acagacacgt cactctatga gaccctgatg 600 tatgcctgct gcgtgctgat gctgcttatc cctctatctg tcatctctgt ctcctacacg 660 cacatcctcc tgactgtcca caggatgaac tctgctgagg gccggcgcaa agcctttgct 720 acgtgttcct cccacattat ggtggtgagc gttttctacg gggcagcctt ctacaccaac 780 gtgctgcccc actcctacca cactccagag aaagataaag tggtgtctgc cttctacacc 840 atcctcaccc ccatgctcaa cccactcatc tacagcttga ggaataaaga tgtggctgca 900 gctctgagga aagtactagg gagatgtggt tcctcccaga gcatcagggt ggcgactgtg 960 atcaggaagg gctag 975 <210> 36 <211> 948 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 55036418CB1 <400> 36 atggagacgt gggtgaacca gtcctacaca gatggcttct tcctcttagg catcttctcc 60 cacagtactg ctgaccttgt cctcttctcc gtggttatgg cggtcttcac agtggccctc 120 tgtgggaatg tcctcctcat cttcctcatc tacatggacc ctcaccttca cacccccatg 180 tacttcttcc tcagccagct ctccctcatg gacctcatgt tggtctgtac caatgtgcca 240 aagatggcag ccaacttcct gtctggcagg aagtccatct cctttgtggg ctgtggcata 300 caaattggcc tctttgtctg tcttgtggga tctgaggggc tcttgctggg actcatggct 360 tatgaccgct atgtggccat tagccaccca cttcactatc ccatcctcat gaatcagagg 420 gtctgtctcc agattactgg gagctcctgg gcctttggga taatcgatgg cttgatccag 480 atggtggtag taatgaattt cccctactgt ggcttgagga aggtgaacca tttcttctgt 540 gagatgctat ccttgttgaa gctggcctgt gtagacacat ccctgtttga gaaggtgata 600 tttgcttgct gtgtcttcat gcttctcttc ccattctcca tcatcgtggc ctcctatgct 660 cacattctag ggactgtgct gcaaatgcac tctgctcagg cctggaaaaa ggccctggcc 720 acctgctcct cccacctgac agctgtcacc ctcttctatg gggcagccat gttcatctac 780 ctgaggccta ggcactaccg ggcccccagc catgacaagg tggcctctat cttctacacg 840 gtccttactc ccatgctcaa ccccctcatt tacagcttga ggaacaggga ggtgatgggg 900 gcactgagga aggggctgga ccgctgcagg atcggcagcc agcactga 948 <210> 37 <211> 1086 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature .
<223> Incyte ID No: 7481701CB1 <400> 37 ggctctattc agacgctggc ttcttgtaag tgtattcctt tatccaatag tagatgcctc 60 ctagaaggct tgagtgcact ggaaattgaa actctcactt tcaacttgga gatggagagc 120 cccaatcaaa ccaccattca ggagtttatc ttctccgctt tcccttattc ctgggttaag 180 tctgttgtct gctttgttcc actgctcttc atctatgctt tcattgttgt tggaaacctg 240 gtcatcatca cagtggtcca gttgaatact cacctccaca ctcccatgta tacttttatc 300 agtgctcttt cttttctgga gatttggtat accacagcca caatcccaaa gatgctgtct 360 agcctgctta gtgagaggag catttccttc aatggttgtc tcctgcagat gtatttcttc 420 cattccaccg gcatctgtga ggtgtgtctc ttgacagtta tggcctttga ccactacctg 480 gccatatgca gccctcttca ttatccctct atcatgaccc ccaagctatg tacccaactg 540 actttaagtt gctgtgtttg tggctttatc acacccgttc ctgagattgc ctggatctct 600 acactgccat tttgtggttc gaatcacctt gaacatatct tctgtgactt cctcccagtg 660 ctgcgtctgg cctgcacaga cacacgagcc atcgtcatga ttcaggtagt ggatgtcatt 720 catgcagtgg agattattac agctgtgatg Ctcatcttca tgtcctacga tggtattgtg 780 gctgtaattc tacgtattca ttcagctgga ggccgccgca cagcattttc cacgtgtgtc 840 tctcacttca ttgtcttttc gctcttcttt ggcagtgtga ctctcatgta cctacgcttc 900 tctgccacct actctttgtt ctgggatata gccattgctc tggcctttgc agttttgtct 960 cccttcttca accccattat ctatagcctg aggaataaag aaataaaaga agctataaaa 1020 aagcacatag gtcaagctaa gatatttttt tccgtaagac cagggacctc aagtaagata 1080 ttttag 1086 <210> 38 <211> 1529 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7481774CB1 <400> 38 aagggagacc acagtgagag ggagccctga gcagaagtaa ggctgtcaca aggctggaag 60 cagagaacat ccccatggaa ctgaagacag catgctgcat ccctgggagg agggagctct 120 taaggaagtt ccaaggattg atatttctgt tcagctgcag tagagatgga tggaaccatg 180 gcagcaccca acccatttca tcctactggg attctctgac cgaccccatc tggagaggat 240 cctctttgtg gtcatcctga tcgcgtacct cctgaccctc gtaggcaaca ccaccatcat 300 cctggtgtcc cggctggacc cccacctcca cacccccatg tacttcttcc tcgcccacct 360 ttccttcctg gacctcagtt tcaccaccag CtCCatCCCC CagCtgCtCt acaaccttaa 420 tggatgtgac aagaccatca gctacatggg ctgtgccatc cagctcttcc tgttcctggg 480 tctgggtggt gtggagtgcc tgcttctggc tgtcatggcc tatgaccggt gtgtggctat 540 ctgcaagccc ctgcactaca tggtgatcat gaaccccagg ctctgccggg gcttggtgtc 600 agtgacctgg ggctgtgggg tggccaactc cttggccatg tctcctgtga ccctgcgctt 660 accccgctgt gggcaccacg aggtggacca cttcctgtgt gagatgcccg ccctgatccg 720 gatggcctgc atcagcactg tggccatcga cggcaccgtc tttgtcctgg cggtgggtgt 780 tgtgctgtcc cccttggtgt ttatcctgct ctcttacagc tacattgtga gggctgtgtt 840 acaaattcgg tcagcatcag gaaggcagaa ggccttcggc acctgcggct cccatctcac 900 tgtggtctcc cttttctatg gaaacatcat ctacatgtac atgcagccag gagccagttc 960 ttcccaggac cagggcaagt tcctcacgct cttctacaac attgtcaccc ccctcctcaa 1020 tcctctcatc tacaccctca gaaacagaga ggtgaagggg gcactgggaa ggttgcttct 1080 ggggaagaga gagctaggaa aggagtaaag gcatctccac ctgacttcac ctccatccag 1140 ggccactggc agcatctgga acggctgaat tccagctgat attagcccac gactcccaac 1200 ttgccttttt ctggactttt gtgaggctgt ttcagttctg acattatgtg tttttgttgt 1260 tgctcttaaa attgagacgg ggtctcactc tgtcacctag ggtggagtgc agtggtgcca 2320 ccatagctcc ttcgactatt gggcttaagc gatcctcccc cacctcagcc ttccaagtaa 1380 ctgggactac aggtgtgcat cactggcagt gggaattgtg gcttttctgt cttctatgga 1440 gacggggtct tgctgtgttg accaggctgg tcccaaactc ctggcctcat gtgatcctcc 1500 tgccatggcc tcctaaagtt ctgggatta
Claims (82)
1. An isolated polypeptide selected from the group consisting of:
a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19.
a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19.
2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-19.
3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide encoding a polypeptide of claim 2.
5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID
NO:20-38.
NO:20-38.
6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
7. A cell transformed with a recombinant polynucleotide of claim 6.
8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
9. A method for producing a polypeptide of claim 1, the method comprising:
a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and b) recovering the polypeptide so expressed.
a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and b) recovering the polypeptide so expressed.
10. An isolated antibody which specifically binds to a polypeptide of claim 1.
11. An isolated polynucleotide selected from the group consisting of:
a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:20-38, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90%
identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:20-38, c) a polynucleotide complementary to a polynucleotide of a), d) a polynucleotide complementary to a polynucleotide of b), and e) an RNA equivalent of a)-d).
a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:20-38, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90%
identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:20-38, c) a polynucleotide complementary to a polynucleotide of a), d) a polynucleotide complementary to a polynucleotide of b), and e) an RNA equivalent of a)-d).
12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.
13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.
15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
16. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.
17. A composition of claim 16, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-19.
18. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition of claim 16.
19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting agonist activity in the sample.
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting agonist activity in the sample.
20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.
21. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 20.
22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting antagonist activity in the sample.
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting antagonist activity in the sample.
23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.
24. A method for treating a disease or condition associated with overexpression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 23.
25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:
a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.
a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.
26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:
a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1, b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.
a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1, b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.
27. A method for screening a compound fox effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:
a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
28. A method for assessing toxicity of a test compound, said method comprising:
a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
29. A diagnostic test for a condition or disease associated with the expression of GCREC in a biological sample comprising the steps of:
a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
30. The antibody of claim 10, wherein the antibody is:
a) a chimeric antibody, b) a single chain antibody, c) a Fab fragment, d) a F(ab')2 fragment, or e) a humanized antibody.
a) a chimeric antibody, b) a single chain antibody, c) a Fab fragment, d) a F(ab')2 fragment, or e) a humanized antibody.
31. A composition comprising an antibody of claim 10 and an acceptable excipient.
32. A method of diagnosing a condition or disease associated with the expression of GCREC
in a subject, comprising administering to said subject an effective amount of the composition of claim 31.
in a subject, comprising administering to said subject an effective amount of the composition of claim 31.
33. A composition of claim 31, wherein the antibody is labeled.
34. A method of diagnosing a condition or disease associated with the expression of GCREC
in a subject, comprising administering to said subject an effective amount of the composition of claim 33.
in a subject, comprising administering to said subject an effective amount of the composition of claim 33.
35. A method of preparing a polyclonal antibody with the specificity of the antibody of claim comprising:
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
b) isolating antibodies from said animal; and c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19.
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
b) isolating antibodies from said animal; and c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19.
36. An antibody produced by a method of claim 35.
37. A composition comprising the antibody of claim 36 and a suitable carrier.
38. A method of making a monoclonal antibody with the specificity of the antibody of claim comprising:
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
b) isolating antibody producing cells from the animal;
c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
d) culturing the hybridoma cells; and e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID
NO:1-19.
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
b) isolating antibody producing cells from the animal;
c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
d) culturing the hybridoma cells; and e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID
NO:1-19.
39. A monoclonal antibody produced by a method of claim 38.
40. A composition comprising the antibody of claim 39 and a suitable carrier.
41. The antibody of claim 10, wherein the antibody is produced by screening a Fab expression library.
42. The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.
43. A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19 in a sample, comprising the steps of:
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19 in the sample.
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19 in the sample.
44. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19 from a sample, the method comprising:
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19.
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19.
45. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:1.
NO:1.
46. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:2.
NO:2.
47. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:3.
NO:3.
48. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:4.
NO:4.
49. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:5.
NO:5.
50. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:6.
NO:6.
51. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:7.
NO:7.
52. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:8.
NO:8.
53. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:9.
NO:9.
54. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:10.
NO:10.
55. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:11.
NO:11.
56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:12.
NO:12.
57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:13.
NO:13.
58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:14.
NO:14.
59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:15.
NO:15.
60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:16.
NO:16.
61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:17.
NO:17.
62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:18.
NO:18.
63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:19.
NO:19.
64. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:20.
NO:20.
65. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:21.
NO:21.
66. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:22.
NO:22.
67. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:23.
NO:23.
68. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:24.
NO:24.
69. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:25.
NO:25.
70. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:26.
NO:26.
71. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:27.
NO:27.
72. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:28.
NO:28.
73. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:29.
NO:29.
74. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:30.
NO:30.
75. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:31.
NO:31.
76. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:32.
NO:32.
77. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:33.
NO:33.
78. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:34.
NO:34.
79. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:35.
NO:35.
80. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:36.
NO:36.
81. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:37.
NO:37.
82. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:38.
NO:38.
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22147800P | 2000-07-27 | 2000-07-27 | |
US60/221,478 | 2000-07-27 | ||
US22326800P | 2000-08-03 | 2000-08-03 | |
US60/223,268 | 2000-08-03 | ||
US22705400P | 2000-08-21 | 2000-08-21 | |
US60/227,054 | 2000-08-21 | ||
US23112100P | 2000-09-08 | 2000-09-08 | |
US60/231,121 | 2000-09-08 | ||
US23224300P | 2000-09-13 | 2000-09-13 | |
US60/232,243 | 2000-09-13 | ||
US23269100P | 2000-09-15 | 2000-09-15 | |
US60/232,691 | 2000-09-15 | ||
US23514600P | 2000-09-22 | 2000-09-22 | |
US60/235,146 | 2000-09-22 | ||
PCT/US2001/023433 WO2002010387A2 (en) | 2000-07-27 | 2001-07-25 | G-protein coupled receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2417195A1 true CA2417195A1 (en) | 2002-02-07 |
Family
ID=27569369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002417195A Abandoned CA2417195A1 (en) | 2000-07-27 | 2001-07-25 | G-protein coupled receptors |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2004516817A (en) |
AU (1) | AU2001280785A1 (en) |
CA (1) | CA2417195A1 (en) |
WO (1) | WO2002010387A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1232266A2 (en) * | 2000-03-20 | 2002-08-21 | Curagen Corporation | Polypeptides and nucleic acids encoding same |
US7510845B2 (en) | 2000-05-04 | 2009-03-31 | California Institute Of Technology | Assay employing G protein-coupled receptor expressed in dorsal root ganglia |
US20030092035A1 (en) | 2000-05-04 | 2003-05-15 | Anderson David J. | Pain signaling molecules |
GB2371546A (en) * | 2000-09-12 | 2002-07-31 | Smithkline Beecham Corp | G protein coupled receptor AXOR 109 |
AU2002212309A1 (en) * | 2000-10-06 | 2002-04-15 | Bayer Aktiengesellschaft | Regulation of human secretin receptor-like gpcr |
US20060141453A9 (en) | 2000-11-03 | 2006-06-29 | Qun-Yong Zhou | Prokineticin polypeptides, related compositions and methods |
GB0027537D0 (en) * | 2000-11-10 | 2000-12-27 | Glaxo Group Ltd | New polypeptide |
WO2002040669A1 (en) | 2000-11-17 | 2002-05-23 | Banyu Pharmaceutical Co., Ltd. | Novel guanosine triphosphate (gtp) binding protein-coupled receptor protein, bg37 |
US20040076985A1 (en) * | 2000-12-14 | 2004-04-22 | Alex Smolyar | Regulation of human chemokine-like receptor |
AU2002258780A1 (en) | 2001-04-11 | 2002-10-28 | Bristol-Myers Squibb Company | Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof |
WO2002088355A1 (en) * | 2001-04-25 | 2002-11-07 | Fujisawa Pharmaceutical Co., Ltd. | Novel guanosine triphosphate-binding protein-coupled recepotr place 6002312 and its gene and production and use of the same |
US20030143668A1 (en) * | 2001-06-18 | 2003-07-31 | National Institute Of Advanced Industrial | Guanosine triphosphate-binding protein coupled receptors |
JPWO2003027142A1 (en) * | 2001-09-21 | 2005-01-06 | 山之内製薬株式会社 | Novel G protein coupled receptor |
GB0208407D0 (en) * | 2001-10-01 | 2002-05-22 | Aventis Pharma Inc | A novel G protein-coupled receptor, GAVE10 |
AU2002364149A1 (en) * | 2001-12-06 | 2003-06-23 | Bristol-Myers Squibb Company | Novel human g-protein coupled receptor, hgprbmy34, and variants and methods of use thereof |
AU2003275986A1 (en) * | 2002-09-25 | 2004-04-19 | Bayer Healthcare Ag | Regulation of human calcium-independent alpha-latrotoxin receptor homolog 3 |
WO2004042407A1 (en) * | 2002-11-04 | 2004-05-21 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 73a (gpr73a) |
WO2005059550A1 (en) * | 2003-10-06 | 2005-06-30 | H. Lundbeck A/S | Dna encoding snorf138 and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9801455D0 (en) * | 1998-04-24 | 1998-04-24 | Astra Pharma Inc | New receptor |
AU784543B2 (en) * | 1999-11-16 | 2006-04-27 | Pharmacia & Upjohn Company | Novel G protein-coupled receptors |
WO2001048188A1 (en) * | 1999-12-28 | 2001-07-05 | Helix Research Institute | Novel guanosine triphosphate-binding protein-coupled receptors, genes thereof and production and use of the same |
EP1265925A2 (en) * | 2000-02-23 | 2002-12-18 | PHARMACIA & UPJOHN COMPANY | G protein-coupled receptors |
EP1261710A2 (en) * | 2000-03-08 | 2002-12-04 | PHARMACIA & UPJOHN COMPANY | G protein-coupled receptors |
EP1282707A2 (en) * | 2000-05-11 | 2003-02-12 | Bayer Aktiengesellschaft | Regulation of human p2y-like g protein-coupled receptor |
-
2001
- 2001-07-25 CA CA002417195A patent/CA2417195A1/en not_active Abandoned
- 2001-07-25 WO PCT/US2001/023433 patent/WO2002010387A2/en not_active Application Discontinuation
- 2001-07-25 AU AU2001280785A patent/AU2001280785A1/en not_active Abandoned
- 2001-07-25 JP JP2002516303A patent/JP2004516817A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2004516817A (en) | 2004-06-10 |
WO2002010387A2 (en) | 2002-02-07 |
WO2002010387A3 (en) | 2003-01-03 |
AU2001280785A1 (en) | 2002-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080241158A1 (en) | Human taste-specific receptor TIR3 | |
CA2409776A1 (en) | G-protein coupled receptors | |
CA2392961A1 (en) | G-protein coupled receptors | |
CA2417195A1 (en) | G-protein coupled receptors | |
US20030138818A1 (en) | G-protein coupled receptors | |
CA2399982A1 (en) | G-protein coupled receptors | |
CA2374911A1 (en) | G-protein coupled receptors | |
CA2408140A1 (en) | G-protein coupled receptors | |
CA2423704A1 (en) | G-protein coupled receptors | |
CA2401454A1 (en) | G-protein coupled receptors | |
CA2437717A1 (en) | G-protein coupled receptors | |
US20040023252A1 (en) | G-protein coupled receptors | |
CA2425269A1 (en) | G-protein coupled receptors | |
EP1339748A2 (en) | G-protein coupled receptors | |
CA2450925A1 (en) | G-protein coupled receptors | |
US20040023268A1 (en) | G-protein coupled receptors | |
US20040059092A1 (en) | G-protein coupled receptors | |
US20030220477A1 (en) | G-protein coupled receptors | |
CA2445338A1 (en) | G-protein coupled receptors | |
EP1366152A2 (en) | G-protein coupled receptors | |
EP1303609A2 (en) | G-protein coupled receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |